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It is our great pleasure to welcome delegates to Perth, Western Australia for the 20th Annual ASHM
Conference to be held from Wednesday 17 to Saturday 20 September 2008.
The ASHM Conference is Australasia’s premier conference in the HIV, hepatitis and related diseases
sector. It brings together the range of disciplines involved in HIV and hepatitis management, including
basic science, clinical medicine, community programs, education, epidemiology, Indigenous health,
international and regional issues, nursing and allied health, policy, primary care, public health and
prevention, and social research.
We are pleased to announce that the 2008 ASHM Conference will again be run back-to-back with the
Australasian Sexual Health Conference with one full day of overlap on Wednesday 17 September.
The Annual Consensus Conference is this year incorporated into the clinical stream of the main ASHM
Conference program. The Australian Antiretroviral Guidelines sessions will be held on the afternoons
of Thursday 18 and Friday 19 September. These sessions include evidence-based presentations from
international and local experts on the latest research and developments in HIV treatment and provide
the opportunity for discussion.
Take this opportunity to explore Perth. The conference venue is the Perth Convention Centre, within
Perth CBD.
Levinia Crooks, Chief Executive Officer
Australasian Society for HIV Medicine

welcome letter

Dear ASHM Members, friends and colleagues,

NATIONAL PROGRAM COMMITTEE
Convenor: John Dyer

Francine Eades

Fremantle Hospital

Aboriginal Health Council of WA

Lisa Bastian

Jeffrey Grierson

WA Health

Scott Bowden

Victorian Infectious Diseases Reference
Laboratory

Peter Canavan

National Association of People Living with
HIV/AIDS

Tony Cunningham

Australian Centre for HIV and Hepatitis
Virology Research

Australian Research Centre in Sex, Health
and Society (ARCSHS)

Darrel O’Donnell

New South Wales Health – AIDS and
Infectious Diseases Branch

Heather Worth

National Centre in HIV Social Research

Andrew Grulich

Tim Wotton

National Centre in HIV Epidemiology and
Clinical Research (NCHECR)

Australian Government Department of
Health and Ageing

Vickie Knight

Levinia Crooks, Marina Carman,
Nadine Giatras, Daliah Szwarc,
Nicole Robertson

Sydney Sexual Health Centre

Johnson Mak

Australasian Society for HIV Medicine

MacFarlane Burnet Institute

Lewis Marshall

Fremantle Hospital – Sexual Health Clinic
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SECTORAL PARTNERS

The following organisations support the aims of the conference and encourage their members and
associates to attend:
 AusAID
 Australasian Chapter of Sexual Health Medicine
 Australian Centre in HIV and Hepatitis
Virology Research
 Australian Federation of AIDS Organisations
 Australian Government Department of Health
and Ageing
 Australian Haemophilia Foundation
 Australian Research Centre in Sex, Health
and Society
 Family Planning NSW

 Macfarlane Burnet Institute
 National Association of People Living with HIV/AIDS
 National Centre in HIV Epidemiology and
Clinical Research
 National Centre in HIV Social Research
 NSW Health
 New Zealand AIDS Foundation
 Nossal Institute for Global Health
 Sexually Transmitted Infections Research Centre
 VicHealth

Many other organisations also contribute to the success of the ASHM conferences; we appreciate their
support.

environment policy
 ASHM implements a waste-reduction policy that addresses – Reduce, Reuse, Recycle. This is done before,
during and after each conference
 ASHM reduces the number of printed materials by using electronic communication means wherever possible,
including the website, email, online registration and abstract submission
 ASHM monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
Where possible, ASHM will organise leftover food to be picked up by local charities to distribute accordingly
 ASHM aims to research and prioritise purchasing items and equipment that support the use of recycled
materials or can be recycled after use
 ASHM will aim to ensure that recycling bins are available onsite at all events
 ASHM will endeavour to minimise travel through the use of teleconferences instead of face-to-face meetings
and holding meetings only when necessary
 ASHM encourages all conference stakeholders to consider the environment by suggesting the following:
reduction in printing requirements; recycling conference materials; and reusing conference merchandise.
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Program
at a glance

7.30am

Registration Opens

8.00am
- 9.00am

Arrival Coffee/Tea in Pavillion 1

8.30am 10.30am
10.30am
11.00am

ASHM Opening Ceremony and Plenary 1

9.00am
- 10.30am

Riverside Theatre/Auditorium

Meeting Room 1,2,3

Morning Tea in Exhibition & Poster Area in Pavilion 1

Women Risk HIV 11.00am - International
11.00am ACH2 Bench to Bed: 1
12.30pm
- 12.30pm
Riverside Theatre/Auditorium
Meeting Room 8
12.30pm
- 1.30pm

Sexual Health Plenary 5:
A Mixed Bag of Jewels

program at a glance

WEDNESDAY 17 SEPTEMBER

11.00am
- 12.30pm

Sexual Health Plenary 6:
Drugs and Sex
Meeting Room 1,2,3

Lunch in Exhibition & Poster Area in Pavilion 1

Launch of the Annual Surveillance Report and the Annual Report of Trends in Behaviour from the National Centre
12.45pm in HIV Epidemiology and Clinical Research
- 1.15pm
Meeting Room 8; Lunch will be provided there for attendees from 12.30pm

1.30pm
- 3.00pm

IDU - Domestic
Riverside Theatre/Auditorium

1.30pm
- 3.00pm

ACH2 Bench to Bed: 2
Meeting Room 8

1.30pm
- 3.00pm

Sexual Health Plenary 7:
Out of Sight Out of Mind
Meeting Room 1,2,3

3.00pm
Afternoon Tea in Exhibition & Poster Area in Pavilion 1
- 3.30pm

Riverside Theatre/Auditorium

5.15pm
- 6.15pm

Circumcision: Crown Jewels
Riverside Theatre/Auditorium

3.30pm
- 5.00pm

Planning Requires
Economic and Quality
Review

3.30pm
- 5.00pm

Meeting Room 8

Sexual Health Conference
Closing
Meeting Room 1,2,3

5.15pm
- 6.15pm

Diagnostics and Assay
Development
Meeting Room 1,2,3

Joint Conference Dinner, ‘Diamonds are Forever’ - Bellevue Ballroom, Perth Convention Centre
7.30pm 11.30pm

Sponsored by the Australian Government Department of Health and Ageing, WA Health, Gilead, GlaxoSmithKline,
Boehringer Ingelheim and Merck Sharp & Dohme

17-20 september 2008 @ Perth Convention Centre, Western Australia 				

		

WEDNESDAY 17 SEPTEMBER 2008

3.30pm
- 5.00pm

Virology/Immunology
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program at a glance

THURSDAY 18 SEPTEMBER
7.00am

Registration Opens

7.30am
- 8.45am

Breakfast Session - ‘Meet the Experts’ - Clinical

8.00am
- 9.00am
9.00am10.30am

Riverview 4

8.00am
- 8.45am

Oral Poster Session - Social Research, International,
Community, Indigenous Health
Meeting Room 1,2,3

Arrival Coffee/Tea in Exhibition & Poster Area in Pavilion 1
HIV and Ageing
Riverside Theatre/Auditorium

10.30am
Morning Tea in Exhibition & Poster Area in Pavilion 1
- 11.00am

11.00am 12.30pm

Hot Topics: Top
Papers of 2008

11.00am
- 12.30pm

Riverside
Theatre/
Auditorium

International: Global
HIV Initiatives vs
11.00am - Local Response
12.30pm

Riverview 4

Lunch in Exhibition & Poster Area in Pavilion 1

12.30pm
- 1.30pm

ASHM AGM in Meeting Room 6; Lunch will be provided here to attendees
Australian
Antiretroviral
Guidelines:
Consensus
Session

1.30pm
- 3.00pm

Riverside
Theatre/
Auditorium
3.00pm
- 3.30pm

3.30pm
- 4.55pm

1.30pm
- 3.00pm

AusAID Session
- Indonesia

Meeting Room 8

HIV Immunology
1.30pm
- 3.00pm

Meeting Room 1,2,3

Meeting Room 8

CALD Media

Prevention and
Treatment Issues
for Older Gay Men
- Sponsored by
NSW Health and
ACON

Afternoon Tea in Exhibition & Poster Area in Pavilion 1
Ian Thompson
Memorial
Session
- Clinical Anti
Retroviral
Therapy

3.30pm
- 5.00pm

Epidemiology
- Morbidity and
Mortality

3.30pm
- 5.00pm

Riverview 4

Policy: Australia’s Response to HIV in Asia
and the Pacific: New Partnerships and
Collaborations
Riverside Theatre/Auditorium

6.30pm
- 7.00pm

Social Research
- Desire

Riverview 4

Riverside
Theatre/
Auditorium

5.00pm
- 6.30pm

Margaret
Macdonald
Memorial Session
11.00am - - Epidemiology
12.30pm Population

Meeting Room 1,2,3

12.30pm
- 1.30pm

1.30pm
- 3.00pm

THURSDAY 18 SEPTEMBER 2008

Community
Research into
Practice

5.00pm
- 6.30pm

3.30pm
- 5.00pm
Meeting Room 1,2,3

Meeting Room 8

Response and
Predictions in ART

Adherence to
Antiretroviral
Therapy

5.00pm
- 6.30pm

Riverview 4

Meeting Room
1,2,3

Launch of the Prison Entrants’ Blood Borne Virus Report in Riverside Theatre/Auditorium
Sponsored by WA Health on behalf of the National Drug Research Institute

Free Evening
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7.00am
7.00am 8.45am
8.00am 9.00am

9.00am10.30am

10.30am
11.00am

11.00am
12.30pm

Registration
Case Presentation Breakfast

7.45am
- 8.45am

Riverview 4

Oral Poster Session - Public Health and
Epidemiology
Meeting Room 1,2,3

Arrival coffee/tea in Exhibition & Poster Area in Pavilion 1

program at a glance

FRIDAY 19 SEPTEMBER

Plenary - Prevention
Riverside Theatre/Auditorium

Morning Tea in Exhibition & Poster Area in Pavilion 1

Peter Meese
Memorial
Session - Clinical
- Associated
Conditions
Complications

Indigenous
11.00am - Health
12.30pm

Riverside Theatre/
Auditorium

Epidemiology
- Transmission/
11.00am - Acquisition
11.00am 12.30pm
12.30pm

Riverview 4

International:
Where to for Testing
and Counselling
in Resource-Poor
Settings?

Meeting Room
1,2,3

Meeting Room 8

International:
PNG

Phillip Medcalf
Memorial Session
- Community,
Health Choices and
Communication

12.30pm
Lunch in Exhibition & Poster Area in Pavilion 1
- 1.30pm
Australian
Antiretroviral
Guidelines:
1.30pm - Consensus
3.00pm
Session

1.30pm 3.00pm

Riverside Theatre/
Auditorium

Social Research
- Sexual Risk in
Space and Time

1.30pm 3.00pm

1.30pm
- 3.00pm

Meeting Room
1,2,3

Riverview 4

Meeting Room 8

3.00pm Afternoon Tea in Exhibition & Poster Area in Pavilion 1
3.30pm

3.30pm 5.00pm

Exhibition Closes

Clinical - Toxicity

3.30pm 5.00pm

Riverside Theatre/
Auditorium

5.15pm - Swiss Statement
6.30pm
Riverside Theatre/Auditorium

Network Sex

3.30pm 5.00pm

International
- Harm
Reduction in
Asia

3.30pm
- 5.00pm

Meeting Room
1,2,3

Riverview 4

5.15pm 6.30pm

Social Research Lives Worth Living
Meeting Room 8

Media Event - HIV Epidemiology and Public Health
Response in WA
Meeting Room 1,2,3

Free Evening

17-20 september 2008 @ Perth Convention Centre, Western Australia 				
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3.30pm
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program at a glance

SATURDAY 20 SEPTEMBER
7.00am
7.30am
- 8.45am

Registration
Breakfast Session - ‘Meet the Experts’ - Basic
Science/Immunology
Riverview 4

7.45am
- 8.45am
8.00am
- 9.00am

9.00am10.30am

9.00am10.30am
Riverside
Theatre/
Auditorium

11.00am
- 12.45pm

Meeting Room 1,2,3

Arrival coffee/tea in Foyer, Level 2

Clinical
Epidemiology

10.30am
- 11.00am

Oral Poster Session - Clinical, Allied Health and
Basic Science

Social Research
- Listen Up:
International
Perspective on
Young People and
HIV Risk

9.00am10.30am

BloodBorne
Viruses: CoInfection
9.00am10.30am
Meeting
Room 1,2,3

Riverview 4

Program Delivery

Meeting Room 8

Morning Tea in Foyer, Level 2

Plenary - HIV AND TB Coinfection and Conference Closing
Riverside Theatre/Auditorium
Lunch in Foyer, Level 2

1.45pm

Conference Close

SATURDAY 20 SEPTEMBER 2008

12.45pm
- 1.45pm
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ACON Presents:

Prevention and Treatment Issues for Older Gay Men.
A sponsored ASHM conference session on differences in risk,
behaviour and health promotion need in men over 40

Chairs:

Stevie Clayton
ACON

Geoff Honnor
NSW Health

Panellists:

Garrett Prestage
NCHECR

John Imrie
NCHSR

Dermot Ryan
ACON

Russell Westacott
ACON

Rob Lake

Positive Life NSW

Thursday 18 September 3.30pm – 5.00pm Meeting Room 8
The average age of seroconversions is
increasing; people with HIV are living longer
and more men in their 40s and 50s are
becoming HIV positive. This 90 minute session
brings together a range of researchers,
service delivery and health promotion
professionals to explore appropriate HIV
prevention and health promotion responses
for older gay men.

The session will include an examination
of available data - both nationally and
internationally - that highlight issues in
relation to risk behaviour impacting on
seroconversions amongst this group.
Additionally, the session will explore aspects
of sex cultures and the framing of prevention
messages, specific interventions targeted to
older HIV positive men, as well as explore the
implications for an ageing GLBT community,
including workforce development needs in the
medical and aged care sectors.
Supported by a funding grant from:

invited speakers

Martyn French
Clinical Professor of Pathology and Laboratory
Medicine at the University of Western Australia and
a Clinical Immunologist at Royal Perth Hospital and
PathWest Laboratory Medicine, Perth, Australia.
Martyn French has been interested in the
management of patients with acquired and
primary immunodeficiency disorders since 1980
and has conducted research on the immunology
of HIV infection since 1986. He is currently a
member of INSIGHT Network Immunology Group.
He has participated in the Australian HIV clinical
trials program since the late 1980s and is currently
Chair of the Antiretroviral Working Group of
The National Centre in HIV Epidemiology and
Clinical Research. His particular area of expertise
is disorders of immune reconstitution in HIV
patients receiving antiretroviral therapy and he
first described immune restoration disease in
1992. He is an author of over 170 publications
and a member of the editorial boards of AIDS and
Clinical Immunology.

invited speakers

Chris Burrell
After graduation, Prof Burrell trained at Prince
Henry and Prince of Wales Hospitals in Sydney
and completed a PhD on virus replication at ANU.
He then spent 8 years as Lecturer in Bacteriology
at Edinburgh University and the Royal Infirmary,
Edinburgh, where he led a research laboratory
on hepatitis B and trained in clinical virology. He
moved to IMVS in 1979, and since 1990 has been
Professor of Virology in the University of Adelaide
and concurrently head of the Infectious Diseases
Laboratories, IMVS. His research interests have
included the molecular biology and pathogenesis
of virus infections, particularly hepatitis B, HIV
and papillomavirus; diagnostic virology; virus
epidemiology and prevention. He has been active
in NHMRC since 1980’s, and has been member
or chair of various advisory committees in the
Government and private sector.

Paul Gorry
Head, HIV Molecular Pathogenesis Laboratory,
Burnet Principal Fellow, Macfarlane Burnet Institute
for Medical Research & Public Health. Associate
Professor of Medicine, Monash University,
Melbourne

Paul Gorry completed his PhD in 1998, which
examined mechanisms controlling HIV replication
in brain astrocytes. From 1999 to 2002 he undertook
postdoctoral studies at the Dana-Farber Cancer
Institute at Harvard Medical School in Boston,
where he researched mechanisms contributing
to neurotropism and neurovirulence of HIV and
host factors contributing to HIV transmission and
persistence. In 2002 he returned to the Burnet
Institute to head the HIV Molecular Pathogenesis
Laboratory. Paul is presently Principal Fellow of the
Burnet Institute Faculty, Associate Professor in the
Department of Medicine at Monash University,
and Associate Professor in the Department of
Microbiology and Immunology at the University
of Melbourne. His major research interests are
pathogenesis of CCR5-restricted HIV variants,
structure-function relationships of the HIV Env
glycoproteins, and HIV neuropathogenesis.
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invited speakers

Roy Gulick
Professor of Medicine at Weill Medical College
of Cornell University, Director of the Cornell HIV
Clinical Trials Unit of the Division of International
Medicine and Infectious Diseases, and Attending
Physician at the New York Presbyterian Hospital in
New York City
Dr Gulick is Director of the Cornell HIV Clinical Trials
Unit and Professor of Medicine at Weill Medical
College of Cornell University in New York City. His
research interests include designing, conducting
and analysing clinical trials to refine antiretroviral
therapy strategies and assess antiretroviral drugs
with new mechanisms of action. He currently
serves as Principal Investigator of the Cornell Clinical
Trials Unit and as Chairman of the Optimization
of Antiretroviral Therapy Committee of the AIDS
Clinical Trials Group (ACTG), sponsored by the
National Institutes of Health. He also serves as a
board member of the International AIDS SocietyUSA and as a member of the Panel on Clinical
Practices for Treatment of HIV Infection of the US.
Department of Health and Human Services. He
is a member of the American Society of Clinical
Investigation and the International AIDS Society
and has presented at national and international
meetings and published widely in the field of HIV/
AIDS.
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Adeeba Kamarulzaman
Head, Infectious Diseases Unit, Department
of Medicine, University of Malaya Medical Centre,
Malaysia
Professor Adeeba Kamarulzaman is presently
the Head and Professor of Infectious Diseases
at the University of Malaya where she oversees
the running of an HIV/AIDS tertiary referral and
research centre in Kuala Lumpur.
In addition to her clinical and academic
commitments, she has been actively involved
in the community response to HIV/AIDS in
Malaysia. As convenor of the Malaysian Harm
Reduction Working Group of the Malaysian AIDS
Council, she successfully led the advocacy for the
implementation of harm reduction, including oral
substitution therapy and needle syringe programs
in Malaysia in 2005. In January 2006 she was
elected President of the Malaysian AIDS Council,
the umbrella organization for all AIDS NGOs in
Malaysia. In this capacity, she has been further
involved in advocating for and overseeing the
implementation of community-based HIV/AIDS
programmes across the country. She is presently
the Chair of the TREAT Asia Steering Committee,
and is a member of the Executive Committee
and Advisory Boards of the International Harm
Reduction Association and the International
Harm Reduction Development, as well as the
American Foundation for AIDS Research (amfAR).
Additionally, she is an Executive Committee
member of the United Nations Regional Task
Force on HIV Prevention Amongst Drug Users, and
a member of the United Nations Reference Group
on HIV and Injecting Drug Use.

17-20 september 2008 @ Perth Convention Centre, Western Australia

Over the last 16 years Professor Kelleher has
conducted extensive clinical and laboratory- based
research into the immunopathogenesis of HIVinfection, particularly with regards CD4 and CD8 Tcell responses during primary infection and in longterm non-progressors. He has conducted studies
describing the impact of various therapeutic
interventions on these responses. These studies
complement his interest in the impact of immune
responses on viral evolution and escape. He has
been responsible for the conduct of several trials of
immunotherapeutics and has been involved with
each of the prophylactic HIV vaccine trials so far
conducted in Australia. He works collaboratively
with other Australian and international groups
in the USA, Europe and Thailand. This work has
resulted in a large number of peer-reviewed
publications. In 2007 he was awarded a National
Health and Medical Research Council Practitioner
Fellowship.

Simon Mallal
Director of the Institute for Immunology and
Infectious Diseases at Murdoch University and
Royal Perth Hospital, Western Australia.

invited speakers

Anthony Kelleher 
Associate Professor of Medicine at the University
of New South Wales and Group Head of the
Immunovirology and Pathogenesis Program of the
National Centre in HIV and Epidemiology Clinical
Research. He is also a Clinical Immunologist and
Immunopathologist at Saint Vincent’s Hospital, n
Sydney, Australia.

Simon Mallal studied medicine at the University of
Western Australia and has managed patients with
HIV, auto-immune and allergic disease in Perth
since 1987, and supervises the associated routine
diagnostic immunology and molecular biology
laboratory. He is a Clinical Immunologist trained in
Internal Medicine and Pathology and completed a
Post-Doctoral Fellowship in Infectious Diseases at
the Johns Hopkins School of Medicine, Baltimore,
Maryland.
He has had a longstanding research interest in
the genes which influence the outcomes of HIV
and other diseases. More recently, he has focused
on the way viruses adapt to the immune system
of the patient and the implications of this for
HIV vaccine design and other newly emerging
infectious disease threats. His group also studies
the genetics and mechanisms by which drugs
may cause severe side effects. Their discovery of a
genetic test to predict those patients predisposed
to develop a potentially life-threatening reaction
to the important anti-HIV drug abacavir has been
taken up globally and represents one of the first
successful implementations of personalised
medicine.
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invited speakers

Gita Ramjee
Medical Research Council HIV/AIDS Lead
Programme and HIV Prevention Research Unit
Durban, South Africa
Gita Ramjee is the Director of the South African
Medical Research Council’s HIV Prevention Research
Unit and Director of the HIV/AIDS lead program.
She was awarded distinguished visiting professor
by Tamil Nadu Medical University in Chennai, India.
In 1988, she joined the Department of Pediatrics
at the University of Kwazulu Natal to complete
a masters degree, studying fungal diseases in
malnourished children. She then completed her
PhD in kidney diseases of childhood. In the early
1990s, she joined the Medical Research Council
to work on HIV/AIDS, and in particular womeninitiated HIV prevention options. She is well known
for her work on HIV prevention trials. Her unit is the
only one worldwide which conducted 4 Phase III
and 1 Phase IIB trial of women-initiated prevention
methods consecutively. She has authored over
50 peer-reviewed publications and serves as
a reviewer for many international journals and
research organisations. In 2006, she was a finalist
in the science category of the Woman of the Year
award in South Africa. She is an invited member of
several societies in recognition of her contribution
to the field of HIV prevention.
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Sarah Rowland-Jones
Human Immunology Unit, John Radcliffe Hospital,
Oxford, United Kingdom
Sarah Rowland-Jones qualified in medicine from
the universities of Cambridge and Oxford, and
trained in Infectious Diseases in London and
Oxford. She began her research career in Oxford
with Professor Andrew McMichael on the role of
cellular immune responses to viral infections. Since
1995 she has led a research group in the Medical
Research Council (MRC) Human Immunology Unit
in Oxford, studying the role played by cytotoxic Tcells in determining the outcome of HIV infection,
as well as dengue and influenza virus infections. A
key focus of the work has been the study of immune
responses to HIV in people with an unusually good
outcome of their exposure to the virus. Since 2004
she has worked as Director of Research in the MRC
laboratories in the Gambia, the UK’s oldest and
largest overseas research unit, which has led to a
shift in her research focus towards understanding
the pathogenesis of and immune response to HIV2 infection in West Africa.
Bruno Spire
Social Researcher, Marseilles, France
Bruno Spire got his MD degree in 1985 and his
PhD in virology in 1990. In the early 1980s he
worked in the laboratory at the Institut Pasteur
with Françoise Barré-Sinoussi and participated in
the first studies aimed at characterising HIV. In the
1990s he worked in HIV molecular virology on the
role of the vif accessory gene. In 1999, he switched
to social sciences and public health issues and
focused on adherence to antiretroviral treatment,
quality of life and risky behaviours of people living
with HIV/AIDS. He has a permanent position at
the French National Research Institute for Medical
Research and leads his own group in the field of
public health applied to HIV. Dr Spire is openly
HIV-positive and is the new president of AIDES, the
French community-based NGO.
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David has worked in the field of HIV prevention for
over 20 years as an academic and practitioner. He is
currently Acting Director and Lead Health Specialist
in the Global HIV/AIDS Program of the World Bank.
He holds an adjunct professorial position at the
Centre for International Health at Curtin University
of Technology in Perth, Western Australia. He has
worked in over 50 countries in Africa, Asia, Eastern
Europe, the Middle East and the Caribbean. He
has also consulted on HIV prevention for several
international agencies, including AusAID, DFID,
EU, USAID, UNAIDS, UNICEF, USAID and the World
Bank. His major research and applied interests are
in the use of surveillance systems to characterise
HIV epidemics, understand critical HIV/AIDS
transmission dynamics and intervention priorities
and to promote HIV prevention responses that are
grounded in a thorough understanding of national
and local HIV epidemics – an understanding of the
“last 1,000 infections in a given context.
Pietro Vernazza
Division of Infectious Diseases of a tertiary hospital
in Eastern Switzerland, St. Gallen and President of
the Swiss Federal Commission on AIDS

Robin Wood
Director of the Desmond Tutu HIV Centre Institute
of Infectious Disease and Molecular Medicine,
University of Cape Town Faculty of Health Sciences
Observatory, South Africa

invited speakers

David Wilson
Senior Lecturer, Curtin University of Technology,
Perth

Professor
Robin Wood
completed
his
undergraduate training at the universities of
Oxford and London and carried out post-graduate
training in internal medicine at the University of
Cape Town, and infectious diseases training at
Stanford Medical School, California. Since 1993
he supervised the first dedicated HIV clinic in the
Western Cape at Somerset Hospital (Cape Town,
South Africa). He has overseen the development
of HIV care services within the public sector
at secondary hospital, community health and
primary health clinic levels.
Professor Wood is currently the Director of the
Desmond Tutu HIV Centre. He supervises the largest
community ART clinic in the Western Cape and the
TB/HIV Research programme in Masiphumelele, a
local township.His major research interests are in
the fields of infectious diseases and HIV. He has
published widely in the areas of HIV management,
tuberculosis interaction with HIV and new drug
development.

Pietro Vernazza trained in internal medicine and
infectious diseases in St.Gallen, Switzerland and
at the University of North Carolina at Chapel
Hill. Since the early 1990s he focused his clinical
research on co-factors of sexual transmission of HIV
and in the past six years has begun to investigate
options for simplified maintenance treatment
with PI monotherapy for HIV. Dr Vernazza is
a member of the Swiss HIV Cohort where he
chaired the Scientific Board from 2001 to 2007.
Since 2000 he has been head of the Division of
Infectious Diseases of a tertiary hospital in Eastern
Switzerland, St. Gallen. He is currently president of
the Swiss Federal Commission on AIDS.
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MEMORIAL SESSIONS

MEMORIAL SESSIONS
ASHM has a commitment to ensure that at each annual ASHM Conference we honour the memory
of those people who have contributed greatly to the sector. Four memorial sessions are held each
year. These include: an Epidemiology Session on behalf of Margaret MacDonald; a Community Session
on behalf of Phillip Medcalf; a Primary Care Session on behalf of Peter Meese; and a Clinical Medicine
Session on behalf of Ian Thompson.

Margaret MacDonald
Dr Margaret MacDonald, a Senior Lecturer at the
National Centre for Epidemiology and Clinical
Research, died on 29 September 2003 after a
very brief illness. She had made a substantial
contribution to Australia’s remarkable response
to the threat of an HIV epidemic. Dr MacDonald
was a nurse before developing her career as
a public health researcher. She devised and
established a series of inexpensive, timely and
effective epidemiological monitoring techniques,
especially for populations of injecting drug
users. Her influence extended beyond Australia
through this work. Dr MacDonald is best known
for developing in 1995 an annual survey of
demographic characteristics, drug consumption,
risk behaviour, and hepatitis C and HIV serology.
She had recently contributed substantially to the
official evaluation of the Medically Supervised
Injecting Centre in Kings Cross, Sydney. Despite
her considerable contribution and international
reputation, Dr MacDonald remained the same
unassuming and self-effacing figure. Her work was
influenced by a strong concern for social justice.
Dr MacDonald had a wide range of interests and
enjoyed many pursuits.

Phillip Medcalf 
Phillip Medcalf, President of NAPWA, died on 22
February 2003. In the Australia Day Awards of 2003,
Phillip James Medcalf (deceased) was awarded
the Medal of the Order of Australia for service to
the community as a supporter and promoter of
the interests of people living with HIV/AIDS. Phillip
had been a volunteer in the sector since he retired
from full-time work as the General Manager at
Sydney Sexual Health Centre in 1996. From 1996,
Phillip had state-based roles in PLWH/A (NSW), The
AIDS Council of NSW and the Bobby Goldsmith
Foundation as representative on the boards and
committee membership of the NSW HIV Agencies
Forum, and the NSW Rural HIV Conferences. In
May 1999 Phillip joined the National Association
of People living with HIV/AIDS (NAPWA) Executive
Committee, nominating for Vice President after
several years as a PLWH/A (NSW) representative
to the national body. In 2001 Phillip became
President of NAPWA, a position he held until
his death. Over this period he also represented
in a variety of national positions, including the
Commonwealth World AIDS Day Committee, the
NAPWA nominee on the Board of Governors of
the AIDS Trust of Australia (ATA), and the Board
of Directors of the Australian Federation of AIDS
Organisations (AFAO).
He was also working in a part-time capacity at the
Australasian Society for HIV Medicine (ASHM) from
August 2000 to March 2002. In a year when he was
the Executive Assistant to the Executive Officer of
ASHM, he was also the NAPWA President and was
invited to be part of the opening session of the
2001 ASHM Conference. Phillip leaves behind a
legacy that was valued and appreciated by people
all around Australia.
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Peter was a dedicated GP. His gifts of optimism,
empathy and intelligence were available to all who
consulted him. His patients had every confidence in
him. Peter also worked very hard for advancement
in his profession. He was affiliated with many
medical organisations, but worked particularly
hard in the pursuit of excellence in the field of HIV
and Sexual Health and was a very active HIV/STI
clinician and ASHM Member. Peter was a Senior
Fellow of the Australasian College of Sexual Health
Physicians, contributing articles and being involved
in the examination process of its doctors. He was
one of the editors of the Management Guidelines
for Sexually Transmissible Infections. Peter was a
long-term committee member and past chairman
of the Venereology Society of Victoria and a past
president of the National Venereology Council of
Australia. He taught and examined the students
of the Diploma of Venereology, and was always
contributing to furthering the knowledge in the
field of STIs. He was also an examiner for the Royal
Australian College of General Practitioners.
Peter had worked in the Infectious Diseases Unit
of the Alfred Hospital for almost a decade. He was
instrumental in ASHM and the National Centre in
HIV Epidemiology and Clinical Research. He was
always involved in clinical trials - for the benefit of
his patients. He made an invaluable contribution
to this field of medicine.

Ian Thompson
Dr Ian Lyall Thompson FRCP FRACP, consultant
physician and haematologist, died in Sydney in
August 1989 at the age of 59. He was educated at
Scots College, Sydney and the Faculty of Medicine
of the University of Sydney. He became a member
of the Royal College of Physicians in 1959 and
subsequently a Fellow of the Royal College of
Physicians and the Royal Australasian College of
Physicians. In Sydney, his main appointments were
consultant physician at Sydney Hospital, Crown
Street Women’s Hospital, St Luke’s Hospital and later
at St Vincent’s Hospital, Darlinghurst, where he was
consultant physician to the Haematology and HIV
Medicine Units. Dr Thompson was known by all for
his enormous breadth and depth of knowledge,
his rapier-sharp wit and his ever-present sense of
humour. A compassionate and disciplined man,
he was dedicated to the care of his patients and
as a diagnostician he was unsurpassed. He was
a much-loved teacher of medical students and
of physician trainees. He devoted an enormous
amount of time to and unending support for his
younger colleagues, encouraging them in the
pursuit of their careers in medicine. But it is not
only within medicine that he will be remembered
- his great knowledge covered the fields of art,
literature, music and travel. He was a consummate
conversationalist and entertainer. His enthusiasm
for life itself made him a truly remarkable man, for
which he will always be remembered.
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Peter Meese
Dr Peter Meese, a physician in the Infectious
Diseases Unit of the Alfred Hospital, Melbourne,
died on 23 February 2000. He graduated from the
University of Melbourne and began working at
Middle Park Clinic in 1976.
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'ILEAD RECOGNIZES THE
URGENT NEED FOR ACCESS
TO HEALTHCARE CAPACITY
AS WELL AS ()6 MEDICATIONS
WORLDWIDE PARTICULARLY
IN DEVELOPING COUNTRIES
WHERE THE !)$3 EPIDEMIC
IS DEVASTATING COMMUNITIES
7E BELIEVE THAT THE
MEDICINES WE DEVELOP
SHOULD BE ACCESSIBLE TO
ALL PATIENTS WHO NEED
THEM WORLDWIDE REGARDLESS
OF INCOME OR LOCATION

Our heart
is in the right place.
We are undertaking the following initiatives locally and globally to help further expand
access to our medicines and build healthcare capacity in resource-limited settings:
Gilead Access Program – to provide Viread® (tenofovir disoproxil fumarate) and Truvada®
(emtricitabine/tenofovir disoproxil fumarate) at substantially reduced prices in many low
and middle income countries. This has been ongoing since 2003.
Partnerships with Generic Manufacturers – Gilead has signed non-exclusive
licenses with multiple Indian generic manufactures to provide low cost high-quality
generic versions of Viread® in 95 resource-limited countries, which are home to
95% of the world’s HIV infected people.
The Gilead Foundation – focused on improving health infrastructure
in the developing world.
A member of the Collaboration for Health in Papua New Guinea (CHPNG)*
– to create sustainability and capacity in HIV management in PNG and meet the
needs identified by our primary stakeholders and partners – ASHM and NAPWA.
*Gilead, Boehringer Ingelheim, Merck Sharpe & Dohme, GSK, Pfizer Australia.

Advancing Therapeutics. Improving Lives.

general
information

Exhibition
An exhibition will be held in Pavilion 1 of the Perth
Convention Centre.

Venue
Perth Convention Centre
21 Mounts Bay Road, Perth
Western Australia 6000
PO Box 7451, Cloisters Square, Perth
Western Australia 6850
ph:
+61 8 9338 0300
fax:
+61 8 9338 0309

Wednesday 17 September 2008: 8.00am – 5.00pm
Thursday 18 September 2008:
8.00am – 5.00pm
Friday 19 September 2008:
8.00am – 3.30pm

The venue will host the conference sessions, poster
presentations, the breakfast session, conference
day catering, the trade exhibition and the Gala
Dinner.
Registration Desk
All enquiries should be directed to the registration
desk, located on Level 2 of the Perth Convention
and Exhibition Centre. The desk will be open at
the following times:
Wednesday 17 September 2008:
Thursday 18 September 2008:
Friday 19 September 2008:
Saturday 20 September 2008:

7.30am to 6.30pm
7.00am to 6.30pm
7.00am to 6.30pm
7.00am to 2.00pm

Speaker Preparation Room
A speaker preparation room will be located in
Meeting Room 12. This room will be open at the
following times:
Tuesday 16 September 2008:
Wednesday 17 September:
Thursday 18 September 2008:
Friday 19 September 2008:
Saturday 20 September 2008:

3.30pm to 6.00pm
7.30am to 6.00pm
7.00am to 6.00pm
7.00am to 6.00pm
7.00am to 12.00pm

General information

Disclaimer
All information disclosed in the Conference
Program is correct at the time of printing. The
Conference Secretariat reserves the right to
alter the Conference Program in the event of
unforeseen circumstances. All speakers were
invited to contribute abstracts for inclusion in
the Conference Handbook. Unfortunately, not
all speakers were able to provide us with their
abstracts at the time of printing. The Conference
Secretariat accepts no responsibility for errors,
misprints or other issues with abstracts contained
in this handbook.

The Australasian Sexual Health Conference
exhibition concludes on Wednesday 17 September
at 5.00pm.

The exhibition will open for the ASHM Conference
on Wednesday 17 September 2008 at 8.00am and
conclude on Friday 19 September at 3.30pm.
The exhibition will be open during the following
hours:

Poster Display
Posters will be displayed, grouped in their
disciplines, for the duration of the exhibition in
Pavilion 1 of the Perth Convention Centre.

There are dedicated poster viewing times for each
theme area. These are:
• Wednesday 17 September at 12.30pm - 1.30pm:
Basic Science, Clinical Medicine, Community
Program and Education Posters.
• Thursday 18 September at 12.30pm - 1.30pm:
Epidemiology, Indigenous Health and International
& Regional Issues Posters.
• Friday 19 September at 12.30pm - 1.30pm:
Nursing & Allied Health, Primary Care, Public Health
& Prevention and Social Research Posters.
Internet Café
The Internet café, proudly sponsored by JanssenCilag Tibotec will be available in Pavilion 1, at
Booths 31 and 32. This will be available from
Wednesday 17 September 2008 at 8.00am until
Friday 19 September 2008 at 3.30pm.

Juice Bar
A Juice Bar, proudly sponsored by Boehringer
Ingelheim, will be available in Pavilion 1, at Booths
3 and 4. This will be available from Wednesday 17
September at 8.30am until Friday 19 September
2008 at 3.30pm.

All speakers must take their presentation to the
speaker preparation room a minimum of four
hours prior to their presentation or the day before
if presenting at a breakfast or morning session.
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general information

INFORMATION HUB
The Information Hub will be located on Level 2
next to the registration desk. Three computers will
be available for:
• Completing an online conference evaluation
survey
• Printing a certificate of attendance
• Viewing the Australasian Chapter of Sexual Health
Medicine Mock Exit Assessment Presentation
• Viewing the abstract search database
• Viewing delegate lists
HIV Prescriber CME Points
HIV s100 prescribers who are accredited in NSW/
ACT/VIC will receive 5 Prescriber CME points for
their attendance at the conference.

DELEGATE LIST
A delegate list will be viewable at the Information
Hub.
Liability/Insurance
In the event of industrial disruptions or natural
disasters ASHM cannot accept responsibility for
any financial or other losses incurred by delegates.
Nor can the Secretariat take responsibility for
injury or damage to property or persons occurring
during the conference or associated activities.
Insurance is the responsibility of the individual
delegate.

RACGP/RACP/AChSHM:
CME & MOPS Points
Application has been made to have attendance
recognised for Quality Assurance & Continuing
Professional Development. If you wish to claim
CME points please ensure that you sign the
attendance sheet at the Information Hub. You will
be able to print a certificate of attendance at the
Information Hub.
Smoking
This conference has a no smoking policy.
Mobile Phones/Beepers
As a courtesy to all delegates and speakers, please
switch off, or set to silent, your mobile phones and
beepers during all sessions.
Name Badges
For security purposes, all attendees must wear their
name badge at all times while in the conference
venue. Entrance to the exhibition will be limited
to badge-holders only. If you misplace your name
badge, please advise staff at the registration desk.
Personal Mail
The conference organisers do not accept
responsibility for personal mail. Please have all
mail sent to your accommodation address.
evaluation surveys
Evaluation Surveys will be available on-line at
the Information Hub. We ask that all delegates
complete this survey electronically to go into
a prize draw to win two tickets for the Sydney
Harbour Bridge Climb.
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location map

Hotels
Perth
Convention
Centre

Parmelia
Hilton Perth

Perth Convention Centre

Sullivans Hotel

Medina
Grand
Perth
Rydges Perth

Mounts
Bay Waters
Apartments

Duxton Hotel Perth
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Bellevue Ballroom, Level 3
The Perth Convention Exhibition Centre

The theme of the dinner is ‘Diamonds are Forever’.
Tickets will be required for entry to all associated
events. All tickets will be given out on registration.
No tickets for the Conference Gala Dinner are
available on-site.
The dinner is supported by the Australian
Government Department of Health and Ageing,
WA Health, Gilead, GlaxoSmithKline, Boehringer
Ingelheim and Merck Sharp & Dohme.
Case Presentation Breakfast

Friday 19 September 2008: 7.00am

Riverview 4, Level 2
The Perth Convention Exhibition Centre
Case presentations will be supported by brief
literature reviews and open to audience questions.
Breakfast will be served during this session. The
best case presentation will be awarded a cash
prize.
Tickets will be required for entry to all associated
events. All tickets will be given out on registration.
If you would like to purchase tickets to the Case
Presentation Breakfast you may do so up until
12 noon on Wednesday 17 September at the
registration desk.
The Case Presentation Breakfast is optional and is
not included in any of the registration fees.
Ticket cost: A$22.00 for all registrants.
Tickets to Associated Events
Tickets will be required for entry to all associated
events. All tickets will be given out on registration.
A no-refund policy operates for cancellation of
function tickets.

Media Event:
HIV Epidemiology and Public Health
Response in WA
Friday 19 September 2008:

5.00pm to 6.30pm

associated events

Conference Gala Dinner

Wednesday 17 September 2008: 7.30pm to 11.30pm

ASHM will be holding a media event in conjunction
with the Western Australian Department of Health,
exploring the impact of the Western Australian
economic boom on HIV infection rates among
WA’s heterosexual population. This session will be
held Friday 19 September 2008.
The session will feature a panel including:
Paul Van Buynder, WA Public Health Division; Trish
Langdon, WA AIDS Council; Don Baxter, Australian
Federation of AIDS Organisations; and Darren
Russell, Cairns Sexual Health.
Open to all delegates.

Consensus Conference
The Perth Convention Exhibition Centre
The Annual Consensus Conference is this year
incorporated into the clinical stream of the main
ASHM 08 Conference program. Previously, the
Annual Consensus Conference has been held on
the Saturday afternoon immediately following the
close of the ASHM Conference. Feedback from
previous years has suggested that attendance and
participation would be maximised if the Australian
Antiretroviral Guideline sessions were moved into
the ASHM program.
This year, the Australian Antiretroviral Guidelines
sessions will be held on the afternoons of
Thursday 18 and Friday 19 September. These
sessions include evidence-based presentations
from international and local experts on the latest
research and developments in HIV treatment and
provide the opportunity for discussion.

Dr Roy Gulick is a member of the US Department
of Health and Human Services (DHSS) Panel on
Antiretroviral Guidelines for Adults and Adolescents
and will represent DHHS at these sessions. The
DHSS Guidelines for the Use of Antiretroviral Agents
HIV-1 Infected Adults and Adolescents have been
endorsed by Australia and form the basis on which
the Australian commentary is developed. The
Australian commentary to the latest Guidelines for
the Use of Antiretroviral Agents in HIV-1 Infected
Adults and Adolescents is available at: http://www.
ashm.org.au/aust-guidelines/.
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CD-Rom Handbook Sponsor

exhibitor
directory

Booth Number

Abbott............................................................................................................................................................................

24,25

Australasian Chapter of Sexual Health Medicine .......................................................................................

6

Australasian Society for HIV Medicine ............................................................................................................

11,12

Boehringer Ingelheim ............................................................................................................................................

3,4

Bristol-Myers Squibb ............................................................................................................................................... 19,20,21,22
CaraData ....................................................................................................................................................................... 5
Gilead.............................................................................................................................................................................

15,16,17, 18

GlaxoSmithKline .......................................................................................................................................................

7,8,9,10

HIV & HCV Education Projects, The University of QLD............................................................................... 28
HIV Consortium ......................................................................................................................................................... 41
iNova ..............................................................................................................................................................................

35,36,37,38

International congress on AIDS in Asia and the Pacific (Thurs 18 to Fri 19 Sep only) .......................

45

Janssen-Cilag Tibotec ............................................................................................................................................. 31, 32
Merck Sharp & Dohme...........................................................................................................................................

29,30

National Association of People Lliving with HIV/AIDS ............................................................................. 44
National Centre in HIV Social Research/ARCSHS......................................................................................... 34
Novartis ........................................................................................................................................................................

13,14

Pfizer Australia ...........................................................................................................................................................

27

Schering-Plough ....................................................................................................................................................... 42
The UnderView Collection - Glen Cowans .................................................................................................... 33
WA Health ...................................................................................................................................................................

23

exhibition booth listing

Company Name

The following organisations are exhibiting during the Sexual Health Conference and will be available to visit on
Wednesday 17 September only.
CSL Biotherapies..............................................................................................................................................................................................................
Marie Stopes International........................................................................................................................................................................................
Qiagen....................................................................................................................................................................................................................................
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Australasian Chapter of Sexual Health Medicine

Australasian Chapter of Sexual 
Health Medicine (6)
The Australasian Chapter of Sexual Health
Medicine is the professional body responsible for
the education and training of doctors wishing
to specialise in sexual health. It contributes to
the professional development of other health
professionals through its training courses, and the
development and dissemination of guidelines
and other educational products. It provides expert
advice to government and other agencies on
sexual health matters and its Fellows contribute to
policy development at state and national level.
Australasian Chapter of
Sexual Health Medicine
145 Macquarie Street
Sydney NSW 2000
Australia
Ph:
(+61 2) 9256 9643
Fax:
(+61 2) 9256 9693
Email: sexualhealthmed@racp.edu.au

exhibitor directory

Abbott (24, 25)
We are a global health care company devoted to
discovering new medicines, new technologies
and new ways to manage health. Our products
span the continuum of care, from nutritional
products and laboratory diagnostics through
medical devices and pharmaceutical therapies
including Kaletra, Humira and Reductil.
Throughout our 100+ year history, Abbott people
have been driven by a constant goal: to advance
medical science to help people live healthier lives.
It’s part of our heritage. And, it continues to drive
our work. Today, 65,000 Abbott employees around
the world share the passion for “ Turning Science
Into Caring.”

Australasian Society for HIV Medicine 
(11,12)
The Australasian Society for HIV Medicine (ASHM)
is a peak representative professional body for
medical practitioners and other health care workers
in Australasia who work in HIV, viral hepatitis and
related disease areas.

It was formed in 1988 (as the Australian Society
of AIDS Physicians). It changed its name in 1989
to reflect a broader membership base and was
incorporated in New South Wales in 1990. ASHM
became a registered charity in 2003.

ASHM is a key partner in the Australasian and
regional response to HIV, viral hepatitis and
related diseases. It works closely with government,
advisory bodies, community agencies and other
professional organisations in Australia and the
Asia Pacific region. It conducts broad education
programs in HIV and viral hepatitis for medical
practitioners, health care providers and allied
health workers and manages programs of
continuing medical education.
ASHM is governed by an elected voluntary board
and managed by a secretariat. It receives support
from the Australian Government Department of
Health and Ageing, the Australian Government’s
Agency for International Development (AusAID),
State and Territory Departments of Health and
the private sector, and has established the ASHM
Foundation which raises funds in support of
educational activities. ASHM works on a range of
issues affecting its members, including education
and training, resources, HIV treatment, viral
hepatitis, international/development issues and
professional affairs. ASHM conducts an annual
medical scientific conference. In addition, the
ASHM conference division provides professional
conference organisation to third parties.
Australasian Society for HIV Medicine (ASHM)
LMB 5057
DARLINGHURST NSW 1300
Australia
Ph:
61 2 8204 0700
Fax:
61 2 9212 2382
Email: ashm@ashm.org.au
Web:
www.ashm.org.au
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Boehringer Ingelheim (3, 4)
Boehringer Ingelheim is committed to active
involvement and practical answers for people
living with HIV. The fight against HIV/AIDS extends
to resource-poor settings. where Viramune®
(nevirapine) has been donated to treat more
than 1,000,000 mother-child pairs through 162
programmes in 59 countries through the Viramune
Donation Programme.
Boehringer Ingelheim is also proud to be a member
of the Collaboration for Health in PNG (CHPNG).
The CHPNG is the initiative of a group of Australian
pharmaceutical companies who are dedicated
to making a philanthropic contribution towards
improving the health and wellbeing, and political
and social stability of Australia’s nearest neighbour
and is currently working with its partners to provide
education and support to health care workers in
PNG.
Contact:
PO Box 1969
Macquarie Centre
NORTH RYDE NSW 2113
Phone: 61 2 8875 8833
Fax:
61 2 8875 8712

Caradata (5)
CaraData is a successful Queensland based
technology company that specialises in the
development of health informatics software
for use in the management and surveillance of
sexual health, communicable diseases, HIV/AIDS,
Hepatitis C and Family Planning clinics. CaraData’s
core product is SHIP – Sexual Health Information
Program. SHIP has been designed to reduce the
workload for Medical, Administration, Nursing and
Laboratory staff and to support the transition to a
full electronic patient record. SHIP is user friendly,
flexible and adaptable to meet minimum data set
requirements. In 2004 CaraData took over from
Dickson Computer Services (DCS) where SHIP was
first developed by CEO Bridget Dickson in 1992.
Since then SHIP is now installed in more then 68
clinics throughout the world including Malaysia,
New Zealand, Barbados, Ireland and six states
in Australia – Queensland, New South Wales,
Australian Capital Territory, Tasmania, Northern
Territory and Western Australia. In 2005 CaraData
established another branch over in Dublin, Ireland.
Through this CaraData is able to provide 24/7
support to all its clients.
Contact Details:
Email: info@caradata.com
Ph: +61 7 5594 9328
		
Fax: +61 7 5571 5376
		
Web: www.caradata.com

Bristol-Myers Squibb  (19, 22)
Bristol-Myers Squibb is a global biopharmaceutical
company with a mission to extend and enhance
human life.
Operating in Australia since 1930, Bristol-Myers
Squibb is dedicated to discovering and developing
innovative
and
cost-effective
medicines
addressing significant unmet medical needs.
The Bristol-Myers Squibb R&D organisation is
working on treatments for cancer, atherosclerosis/
thrombosis, diabetes, obesity, psychiatric
disorders, Alzheimer’s disease, hepatitis, HIV/AIDS,
rheumatoid arthritis, and solid organ transplant
rejection.
For many years Bristol-Myers Squibb has been
a leader in the area of HIV/AIDS and currently
provides Reyataz® (atazanavir sulfate) to thousands
of Australians.
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Gilead  (15-18)
Gilead’s mission is to advance patient care by
developing ground-breaking therapeutics to
treat life-threatening infectious diseases. We apply
the best of biopharmaceutical science to create
innovative medicines that bring new hope in
the battles against HIV/AIDS (Truvada®, Emtriva®,
Viread®), chronic hepatitis B (Hepsera®), and
serious bacterial and systemic fungal infections
(AmBisome®).
Company name: Gilead Sciences
Address: Level 1, 128 Jolimont Road, East
Melbourne, Victoria, 3002, Australia
Phone: +61 (0)3 9272 4400
Fax:  	 +61 (0)3 9272 4411
We look forward to seeing you at the Gilead
Sciences booth at Sexual Health & ASHM.

GlaxoSmithKline (7-10)
GSK Australia (GSK) is one of the largest research
based pharmaceutical companies in Australia.
GSK’s vision is to “help people to do more, feel
better and live longer”.
The company’s product portfolio is closely aligned
with the country’s key health priorities of asthma,
immunisation, depression, diabetes, oncology,
indigenous health and infectious diseases. GSK
also supplies 25% of the world’s medicinal opiate
needs from its Australian operations.

HIV & HCV Education Projects The 
University of QLD  (28)
The HIV & HCV Education Projects is based
within the School of Medicine, The University of
Queensland and has been operating since the
beginning of 1998. It is recognised at a state
level, nationally and internationally as a centre
of expertise in clinical education, facilitation,
monitoring and evaluation, and resourcing.
Originally, the primary responsibility of the
projects was to design, develop, implement and
evaluate courses for medical practitioners who
wished to prescribe HIV antiretroviral therapies
in Queensland, Australia. This remains a core
component of the organisation. By 2003, the HIV
& HCV Education Projects was providing clinical
education, facilitation, monitoring and evaluation,
and resourcing in its three core domains of HIV,
Sexual Health and Viral Hepatitis across a range of
health disciplines, including medical practitioners,
nurses, dentists, allied health and community
health workers. By 2006 this expanded to include
other domains.
School of MedicineThe University of Queensland
288 Herston Road
HERSTON QLD 4006
Australia
Ph:
07 3346 4813
Fax:
07 3346 4757
Email: hivandhcvprojects@uq.edu.au

GSK invests more than $35 million a year in
Australian research and development, confirming
the company’s place as one of the largest and
most active innovators in the country.
Through a series of cooperative partnerships - with
government, the scientific research sector and the
broader Australian community – GSK makes a
substantial contribution to important economic,
social and health initiatives.
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HIV CONSORTIUM
For Capacity Building in Asia and the Pacific

HIV CONSORTIUM (41)
The HIV Consortium for Capacity Building in
Asia and the Pacific is funded by AusAID to
strengthen the capacity of organisations and
individuals to respond effectively to HIV by
fostering strategic partnerships and linkages in
the health care, research and community sectors.
Membership includes:
Albion Street Centre
Australasian Society for HIV Medicine
Australian Federation of AIDS Organisations
Australian Injecting and Illicit Drug Users League
Australian Research Centre in Sex, Health and
Society
National Serology Reference Laboratory
National Centre in HIV Epidemiology and Clinical
Research
National Centre in HIV Social Research
Scarlet Alliance, Australian Sex Workers
Association

Janssen-Cilag Tibotec (31, 32)
Tibotec, a division of Janssen-Cilag, is at the
forefront of human immunodeficiency virus (HIV)
research. With several active discovery programs
in HIV, hepatitis C and other life-threatening
infectious diseases, Tibotec’s mission is to be a
world leader in the discovery and development of
innovative HIV/AIDS drugs and anti-infectives for
diseases of high unmet medical need. PREZISTAÒ
(darunavir) gained PBS approval in December
2007.
Tibotec, a division of Janssen-Cilag Pty Ltd
1 - 5 Khartoum Road, North Ryde,
NSW 2113 Australia
Ph:
61 2 8875 3333
Toll Free 1800 800806

www.hivconsortium.org
02 8204 0751

iNova Pharmaceuticals (35-38)
iNova Pharmaceuticals develops and markets
a range of over-the-counter and prescription
medicines to Australasia, Asia-Pacific, South Africa,
the Americas and other international markets
directly and also through other pharmaceutical
companies and agents. These include prescription
medicines in the areas of weight management,
dermatology, heart conditions, asthma and pain
management.

Merck Sharp & Dohme (29, 30)
Merck Sharp & Dohme (MSD) Australia is a
research based pharmaceutical company and
has been looking after the health of Australians
since 1952, a history of which MSD is extremely
proud. MSD invests a considerable amount into
Australian research and development. Over 90%
of MSD products are manufactured and packaged
in Australia, which leads to new investment
and infrastructure opportunities. The ongoing
commitment of MSD in Australia is evidenced
by its achievement in becoming the largest
pharmaceutical exporter in the country, exporting
to more than 16 countries throughout the world.

To learn more about iNova Pharmaceuticals, go to
http://www.inovapharma.com
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National association of people living 
with Hiv/aids (44)
The National Association of People Living with
HIV/AIDS is Australia’s peak
non-government organisation representing
community-based groups of people living
with HIV. NAPWA provides advocacy, policy,
education and outreach on a national
level.
We work across a range of health and education
initiatives to promote the highest quality standard
of care for HIV positive people and contribute
to clinical and social research into the causes
and prevention of HIV. We strive to minimise
the adverse personal and social effects of HIV by
championing the participation of positive people
at all levels.

National Centre in HIV Social 
Research/ARCSHS (34)
The National Centre in HIV Social Research
(NCHSR) was established in 1990 with funding
from the Commonwealth Department of Health
and Ageing, Australia. We are located within the
Faculty of Arts and Social Sciences at The University
of New South Wales, Sydney.
NCHSR is internationally recognised for its
contribution to the Australian response to HIV
and hepatitis C. While the core of its work has
been in social aspects of HIV, particularly in regard
to sexual practice, in recent years the NCHSR
research program has expanded to include social
research related to hepatitis C, injecting and illicit
drug use, sexual health, Aboriginal health and the
Asia-Pacific region.
NCHSR is highly regarded for its multidisciplinary
approach, quality and range of work, timeliness
of research findings, and engagement with
those communities most affected by HIV, STIs
and hepatitis C. NCHSR’s core-funded strategic
research has been strengthened by its location
within an academic environment and the
attendant scholarship and culture that entails. This
has ensured research that is intellectually rigorous
and valued by key decision makers.

ARCSHS

The Australian Research Centre in Sex, Health and
Society was established in 1993 as an independent
unit within the Faculty of Health Sciences at
La Trobe University. It has a multi-disciplinary
team of staff with qualifications and expertise in
psychology, anthropology, sociology, public health,
health promotion, methodology, epidemiology,
education, women’s health, consumer advocacy
and health policy. The Centre is dedicated to the
advancement of knowledge and applied skills in
sexual health; locally, nationally and internationally.
Through our research, teaching and community
activities we strive to develop and sustain a direct
and organic link with the wider community. The
Centre has had since its inception a dedicated
Community Liaison and Education Unit to ensure
the research is disseminated widely and informs
policy and practice.

Novartis (13, 14)  
Novartis is a world leader in the research,
development and supply of products to protect
and improve health and well-being.
Novartis Pharmaceuticals researches and supplies
a broad range of innovative and effective
prescription medicines to treat patients in both
general and specialist practice and hospitals.
Created in 1996 from the merger of Swiss
companies, Ciba and Sandoz, Novartis has a history
in Australia going back over fifty years. Novartis
employs about 98 000 people and operates in
over 140 countries around the world.
In Australia the company now employs more
than 600 people, and invests over AUD $30million
annually in local research. This research not only
assures the effectiveness of the company’s current
range of treatments, but also secures the promise
of improving health for the future.
Novartis medicines treat some of the most
serious health conditions confronting healthcare
professionals and their patients. The company’s
work is spread across many diseases in the areas
of Primary Care, Oncology, Transplantation, and
Ophthalmics.
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Pfizer Australia (27)
With a history dating back to 1886, Pfizer Australia
has grown to become the nation’s leading
provider of prescription medicines. Pfizer Australia
exports $600 million worth of product around
the region annually from three manufacturing
plants across the nation. Our researchers are
part of the world’s largest private sector medical
research program with more than 580 projects in
discovery and development. In Australia, we spent
more than $45 million in 2006 on local research
and development across our business, helping to
keep some of the nation’s leading researchers here
in Australia working on conditions that have the
potential to impact every Australian family.

Schering Plough (42)
Schering-Plough is an innovation-driven,
science-centred global health care company.
Through its own biopharmaceutical research and
collaborations with partners, Schering-Plough
creates therapies that help save and improve lives
around the world. Schering-Plough applies its
research-and-development platform to human
prescription and consumer products as well as
to animal health products. Schering-Plough’s
vision is to “Earn Trust, Every Day” with the doctors,
patients, customers and other stakeholders served
by its colleagues around the world.
As part of its long-term commitment to working
with doctors to support patients with hepatitis,
Schering-Plough’s PEGATRON is now the first and
only pegylated interferon approved for retreatment
of chronic hepatitis C.
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The UnderView Collection - Glen 
Cowans (33)
Glen Cowans is a unique and passionate
photographer. His inspiration is our ocean. His
subjects are the beautiful life forms that live there.
Born in Western Australia, Cowans developed his
passion for the ocean while snorkelling at the age
of ten. In 1995 he began his pursuit of underwater
photography, and in 2005 left his trade as an
electrician to become a full-time photographer.
With over 13 years’ experience in underwater
photography --- ranging through all the mediums
of film, transparency and digital ---, Cowans has
had more than 26 exhibitions. His work has found
favour with collectors across Australia and around
the world. Cowans’ takes photography to a new
level by bridging the gap between photography
and art. His philosophy is to allow nature to be the
artist and let the shapes, colours and life forms of
the ocean create the masterpiece. Cowans’ work
offers viewers a rare experience, one where they
can contemplate the wondrous life found in the
underwater world.

WA Health (23)
Using a partnership approach, the Sexual Health
and Blood-borne Virus Program of the WA
Department of Health directs and coordinates the
prevention and control of sexually transmitted
infections, human immunodeficiency virus
and blood-borne viruses (STI/HIV/BBV) for the
population of WA. Priority populations within WA
include: young people; Aboriginal people; people
who inject drugs; gay and other homosexually
active men; sex workers (including opportunistic
sex workers) and clients of sex workers; people
living with HIV/AIDS and hepatitis C; and health
care workers.
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UNDERGRADUATE
AWARDS

Leon Botes

Leon is a Sexual Health Nurse who has worked in Sexual
Health and HIV/AIDs in South Africa, New Zealand and
Australia. He has also worked for the National Centre in
HIV Epidemiology and Clinical Research and completed
his Masters in Health Science (Sexual Health) at the
University of Sydney in 2005. Since then, Leon has been
a tutor on the online learning Postgraduate Program
in Sexual Health. Leon was awarded the Novartis 2008
Scholarship for Sexual Health Research, offered through
the Royal College of Physicians. This scholarship has
enabled him to begin his PhD project focused on Anal
Squamous Intraepithelial Lesions (ASILs).
Poster Number 121

Ming Liang Chan

Ming Liang Chan’s research is focused on understanding
the homeostatic control of CD4+ T cell numbers in
chronic HIV infection. In HIV and in experimental models
of SIV in rhesus macaques, chronic infection is associated
with progressive CD4+ T cell depletion. However, in
natural infection of some species, described as natural
hosts, infection is largely asymptomatic. Ming Liang’s
current research involves the use of mathematical and
statistical tools to study viral pathogenesis in SIV and
gain a deeper understanding about the lack of disease
progression in natural hosts. In his latest work, he used a
model to explain how the non-pathogenic SIV infection
of natural hosts can be caused by lower levels of CD4+
T lymphocyte activation. This dynamic understanding of
infection provides valuable insights into the pathogenesis
of AIDS in HIV-infected individuals.

undergraduate awards

UNDERGRADUATE AND JUNIOR
RESEARCHER IN HIV
AND VIRAL HEPATITIS AWARDS
PROGRAM 2008

Heidi Coupland

Heidi is a PhD candidate in the National Centre in HIV
Epidemiology and Clinical Research, University of New
South Wales. Her supervisors are Associate Professor
Lisa Maher and Dr Carolyn Day. Few studies have
explored cultural differences in injecting drug users’
(IDUs) vulnerability to hepatitis C (HCV) infection and
barriers to accessing services for HCV-related issues.
This ethnographic study explored Indo-Chinese IDUs’
explanatory models of HCV prevention and management
and examined their influence on health-seeking behaviour,
in particular, access to HCV treatment. Field work and
in-depth interviews were conducted with Cambodian,
Lao and Vietnamese-background IDUs (n=72) in South
Western Sydney. Twenty-three were involved in a pilot
of a culturally-informed brief intervention regarding HCV
treatment. Following a baseline interview and provision of
the brief intervention, participants were offered facilitated
referral to a tertiary liver clinic and were followed up and
interviewed again at three and six months. Preliminary
results indicate that explanatory models of HCV influence
decision-making and patterns of service access in relation
to hepatitis C testing and treatment. However, cultural
meanings of injecting drug use and notions of family
obligations, particularly in the context of immigration
and resettlement, also shape responses to HCV among
this group.
Oral Presentation: Wednesday 17 September: ASHM IDU:
Domestic; 2.45pm - 3.00pm
Poster Number 151

Benjamin Cowie

Dr Ben Cowie is an Infectious Diseases Physician from
Melbourne. He is writing his Doctoral Thesis through the
University of Melbourne on the seroepidemiology of
hepatitis B virus infection in Victoria and the development
of a mathematical model of HBV infection in Australia,
research which was conducted at VIDRL in Melbourne. A
serosurvey of a randomised, age-structured sample
of over 3200 serum specimens stored at VIDRL from
1995-2005 has enabled examination of the changing
prevalence of infection and vaccination uptake over
time, and analysis by age-group and geographic area
has been undertaken. Both simple linear regression
and complex deterministic models of HBV infection in
Australia have been constructed, allowing an assessment
of the impact of existing control strategies and describing
the evolution of the burden of HBV infection in Australia
to date and into the future.
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Ashley Freeman

Ashley Freeman is an undergraduate student of Dental
Surgery at the University of Adelaide, completing a
concurrent honours degree in dental science. His
research investigates the oral health and treatment
needs of patients at a specialised dental institution for
individuals with HIV. The introduction of highly-active
anti-retroviral therapy (HAART) has allowed HIV positive
individuals to experience a greater life expectancy but
with the potential for an increased risk of medical comorbidities including non-HIV related oral conditions.
Little data is available describing prevalence and severity
of oral manifestations and little evidence available for
appropriate dental management in a post-HAART
cohort of patients. This retrospective study of patient
case records from 2001 to 2008 aims to describe the oral
health needs and oral manifestations of HIV amongst
a South Australia population. Emphasis is placed on
changes in the prevalence of HIV-related oral lesions since
the introduction of highly active anti-retroviral therapy
(HAART) in the late 1990s. The increase life expectancy
of HIV patients as a result of HAART has also led to the
increase prevalence of medical comorbidities. The nature
and severity of these problems, as they relate to the
prevalence of any oral lesions and necessity for dental
care will also be assessed. Information provided will help
establish the current oral health needs for people with HIV.
These findings provide information on the prevalence of
oral conditions and demonstrate the need to identify and
address oral health needs for people with HIV.
Poster Number 126

Suzanne Polis

Suzanne Polis is working full time as a Clinical Nurse
Consultant in HIV/ Hepatitis at St George Hospital, and
a part time PhD student at University of Technology
Sydney, Faculty of Nursing, Midwifery & Family Health.
Suzanne’s research focuses on individual’s adherence
to HIV and hepatitis B virus (HBV) medications. Initial
studies aim to identify factors that are associated with
non-adherence in intellectually challenged HIV positive
people having clinical evidence of non-adherence and
virological resistance to antiviral therapies. Factors that
are found to be associated with non-adherence will be
used to implement individualized, and developmentally
appropriate, adherence strategies, and to develop
educational tools and written information. Future
quantitative and qualitative studies are planned to
investigate adherence to HBV medications within the
general population. Anecdotal evidence suggests
that patients have limited knowledge and understanding
of chronic HBV treatments, treatment adherence, and the
development of drug resistance, and that they risk long
term liver sequelae including hepatocellular carcinoma.
Study findings aim to improve anti-viral medication
adherence and long term health outcomes within these
population groups.
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Sharmila Reddy

Eliciting broadly neutralizing antibodies (nab) against HIV1 has been a major limiting factor in the development of
successful vaccines against HIV-1. The HIV-1 envelope
glycoprotein is the sole viral protein available for nab
to target and hence would be an ideal candidate for
vaccine development. However variations in envelope
protein sequences driven by high error rate of HIV1 reverse transcriptase during the course of infection
can mediate escape from humoral immune responses.
Studies show that protein sequences of transmitting
strains are consistently different from those derived after
seroconversion, have structural variations which lead to
greater exposure of conserved domains and are highly
sensitive to neutralization. Hence studying the envelope
protein of viral isolates derived from patients prior to
seroconversion may allow identification of envelope
proteins with well exposed neutralization-sensitive
epitopes - potentially useful information for developing
vaccine candidates. Samples from preseroconversion
cohort were selected, envelope region cloned and
sequences were analyzed. The clones will be used for
immunogenicity trials in animals and the neutralization
activity of the resulting sera will be assessed. The aim is
to induce high titers of broadly neutralizing antibodies
capable of blocking HIV-1 transmission and to assess
the relative contribution of different epitopes to virus
neutralization.
Oral Poster Presentation: Saturday 20 September; Oral
Poster Session: Clinical, Allied Health and Basic Science;
8.45am - 8.50am. Poster Number 109

Ruby Uddin

Ruby Uddin is a Sexual Health Registrar, who has been
training in Sydney with a particular interest in the clinical
care for women living with HIV and the challenges they
face. The rising rate of HIV infection in women in Australia,
will heighten the need for HIV/Sexual Health services
to focus further on developing a specific approach for
management of HIV in women, particularly with emphasis
on reproductive and maternal health. Notified cases
of newly diagnosed HIV infection in females resident
in NSW increased from 31 of 391 (7.9%) in 2005, to 45
of 369 (12.1%) in 2006, and a corresponding significant
national increase has been observed from 5.8% to 14.3%,
in 2005 and 2006, respectively. During her Sexual Health
training at the Short Street Sexual Health Service, St
George Hospital, Kogarah, where increasing numbers of
HIV positive women are being seen, Ruby was able to
document and investigate specific issues pertaining to
management of HIV in women, particularly in relation to
disclosure to partners, contraception, access to care and
HIV management in pregnancy. Results of the study
could be helpful in developing local service policy to
optimise provision of services for HIV positive women.
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ASHM UNDERGRADUATE AND JUNIOR RESEARCHER SUPPORT AWARDS IN HIV
AND viral HEPATITIS 2009
ASHM is offering up to eight support awards in 2009.
The awards are available to promote research interest
in HIV and viral hepatitis. Applications should be made
in writing via the application form on the reverse of
this flyer, and must be received in the ASHM Office by
COB 1 February 2009. Please attach your abstract and a
photocopy of your most recent academic transcript.
THE AWARDS WILL COMPRISE:
 Annual ASHM associate membership for 2009
 Linkages between the student and ASHM members
in the designated area of research interest
 Access to the ASHM website to allow students to
place information about their research project
 Participation in relevant ASHM Committees
 Access to ASHM library, resources and archives
 First option to take on part-time research assistant
positions offered by ASHM
 Registration at the 21st Annual ASHM Conference, to
be held in Brisbane in September 2009, or registration
at the 2010 Viral Hepatitis
Australasian Conference
 Presentation of a poster following abstract
submission to the chosen conference in a special
poster session (required)
 Scholarship for recipients requiring travel and/or
accommodation to assist with attendance at the
Conference to a value of A$400
 Publication of a short report on the research initiative
in an edition of ASHMNews

THE APPLICATION PROCESS:
Applications are invited from all relevant disciplines,
with priority given to medicine, nursing, dentistry and
allied health, and must relate to a degree, diploma
or award program at the undergraduate level (not
available for post-doctoral programs). Applications
can be received for residents of Australia and New
Zealand only and can be for new work or work in
progress. The awards program is funded by ASHM and
the ASHM Tax Deductible Domestic Gift Fund. The
Australian Government Department of Health and
Ageing provides support for the administration of this
program.
Abstracts of no more than 350 words should be
submitted in writing along with the application form
overleaf. Please note that applications which reflect the
national priority action areas for research as outlined
in the National HIV/AIDS Strategy and the National
Hepatitis C Strategy will be given precedence. These
research areas can be found on the Commonwealth
Health website at www.health.gov.au or via the ASHM
website at www.ashm.org.au. A Sub-Committee of the
ASHM Board will review the applications and applicants
will be notified of the outcome of their application by
20 March 2009.
For further information please review the website or
contact Scott Chambers at scott.chambers@ashm.org.au.
Tel: 02 8204 0704.
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ASHM UNDERGRADUATE AND JUNIOR RESEARCHER
SUPPORT AWARDS IN HIV & VIRAL HEPATITIS 2009

APPLICATION FORM

Please attach your abstract (max. 350 words) and a photocopy of your most recent academic transcript.
You may attach any extra notes or supporting documentation.

APPLICANT:
Name:
Postal address:

Phone: 	Email:
Course in which you are enrolled:
Department/faculty:

Institution:

Supervisor contact details:
Name:
Postal address:

Phone: 	Email:

Please describe your area of research interest (and attach abstract):

What do you hope to achieve?

What is your interest in HIV or viral hepatitis?

How could ASHM assist you?

Supervisor’s signature:

Date:

Applicant’s signature:

Date:

Form deadline:
COB 1 February 2009

Post to: ASHM Office, LMB 5057, DARLINGHURST NSW 1300
Fax: 02 9212 2382 or register online at: www.ashm.org.au

full conference
program

7.30am

Registration

8.00am
- 9.00am

Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1
Sexual Health Plenary 5:
A Mixed Bag of Jewels

ASHM Opening Ceremony and Plenary 1
8.30am
- 10.30am

9.00am
- 10.30am

Riverside Theatre/Auditorium

Chairs: John Chuah and
Alexandra Marceglia

Chairs: John Dyer and Levinia Crooks
8.35am
- 8.40am
8.40am
- 8.45am
8.45am
- 8.50am

Welcome to Country by Janet Hayden
Welcome by Jonathan Anderson - President, Australasian Society for HIV
Medicine, Australia
9.00am
- 9.30am
Government Representative

8.50am
- 8.55am

Welcome by Graham Brown - President, Australian Federation of AIDS
Organisations, Australia

8.55am
- 9.00am

Welcome by Robert Mitchell - President, National Association of People
Living with HIV/AIDS, Australia
9.30am
- 10.00am

9.00am
- 9.45am

Gita Ramjee - Director, South African Medical Research Council
HIV/AIDS Lead Programme, South Africa
HIV Prevention: Hypothesis to Facts

9.45am
- 10.30am
10.30am
- 11.00am

Sarah Rowland-Jones - Human Immunology Unit, John Radcliffe
Hospital, Oxford, United Kingdom

10.00am
- 10.30am

Towards a HIV Vaccine - What is Protective Immunity Against HIV
Infection?

Matthew Law - Head Biostatics
and Database, National Centre
in HIV Epidemiology and
Clinical Research, Sydney, New
South Wales, Australia
Should we be Vaccinating Boys
as well as Girls with the HPV
Vaccine?
Kathleen Mazzella - Founder,
Gynaecological Awareness
Information Network, Western
Australia
A Woman’s Personal Perspective
and Experience of what is
Missing in Sexual Health and
Society, the Vulva
David Speers – Infectious
Diseases Physician, Sir Charles
Gairdner Hospital, Western
Australia
Sexual Transmission of Hepatitis
B and C

Morning Tea in Exhibition and Poster Area in Pavilion 1
Women Risk HIV
- International

11.00am
- 12.30pm

Meeting Room 1,2,3

full conference program

WEDNESDAY 17 SEPTEMBER

Riverside Theatre/
Auditorium

11.00am
- 12.30pm

Meeting Room 8
Chairs: Tony Cunningham
and Scott Bowden

11.00am
- 12.30pm

Meeting Room 1,2,3
Chairs: Fraser Drummond
and Richard Teague

WEDNESDAY 17 SEPTEMBER 2008

Chairs: Susan Kippax
and Gita Ramjee

Sexual Health Plenary 6:
Drugs and Sex

ACH2 Bench to Bed: 1
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full conference program

11.00am
- 11.15am

11.15am
- 11.30am

Holmes W - A Novel
Approach to Antenatal
Risk Assessment in Very
Low HIV Prevalence
Settings in ResourcePoor Countries

Damian Purcell - Senior
Lecturer, Virology, Department
of Microbiology and
Immunology, University
of Melbourne, Melbourne,
Victoria, Australia

Towards Vaccines Eliciting
Broad Neutralising Antibody
Responses by Selecting for
HIV-1 ENV Immunogens
that Prominently Expose
Conserved Neutralisation
Epitopes

Ofasia E - Addressing
Gender-Based Violence
in Settlement Areas of
Port Moresby
11.20am
- 11.40am

11.30am
- 11.45am

WEDNESDAY 17 SEPTEMBER 2008

11.45am
- 12.00pm

12.00pm
- 12.15pm

Kupul M - Tribal
Fighting, Violence
Against Women and
Girls and HIV in Papua
New Guinea

Patricia Price - University
Academic, School Of
Pathology And Laboratory
Medicine, University of
Western Australia, Perth,
Western Australia

Fawkes J - Enabling HIV
Prevention Outcomes
for Sex Workers, Papua
New Guinea

Sex, Drugs and Disease
Transmission

12.00pm
- 12.20pm

Kate Cherry - Physician and
Senior Research Fellow, Alfred
Hospital and Burnet Institute,
Melbourne, Victoria, Australia
Joel Palefsky - Professor
of Medicine, University of
California, San Francisco, USA
Predicting Neuropathy Risk
Before Stavudine Prescription:
An Algorithm For Minimizing
Neurotoxicity In ResourceLimited Settings

Nitin Saksena - Chief Scientist,
Head of the Retroviral
Genetics Division, Westmead
Millennium Institute, and
Senior Research Fellow,
University of Sydney, New
South Wales, Australia
Biological Characterisation of a
Novel Anti-HIV Activity

12.15pm
- 12.30pm

11.00am
- 11.45am

Understanding Susceptibility
to CMV Immune
Restoration Disease and the
Immunological Consequences
of Extreme Immunodeficiency

Rawstorne P - Female
Sex Workers in Sri Lanka:
Why are Women who
Work on the Street More 11.40am
Likely to use Condoms
- 12.00pm
Compared with Women
who Work in other
Locations?

Ghaly S - Alcohol
Consumption, HIV
Transmission and
Implications for Women
in South Africa

Jeffrey Klausner - Director,
Sexually Transmitted Disease
Prevention and Control
Services, San Francisco, USA

11.00am
- 11.20am

12.20pm
- 12.30pm

56 						

11.45am
- 12.30pm

Natural History of HPV in the
Anal Canal

Discussion
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Launch of the Annual Surveillance Report, Aboriginal and Torres Strait Islander Surveillance Report and the Annual
Report of Trends in Behaviour from the NCHECR and NCHSR
Meeting Room 8; Lunch will be provided there for attendees from 12.30pm

IDU - Domestic
1.30pm
- 3.00pm

1.30pm
- 1.45pm

Riverside Theatre/
Auditorium

1.30pm
- 3.00pm

Meeting Room 1,2,3
Chairs: Katrina Allen and
David Smith

Prestage G - Illicit Drug
Use and Risk of HIV
Seroconversion among
Gay Men in Sydney: Data
from the Him Cohort

Paul Gorry - Head, HIV
Molecular Pathogenesis
Laboratory, Burnet Principal
Fellow, Macfarlane Burnet
Institute for Medical Research
& Public Health, Melbourne,
Victoria, Australia

Elizabeth Phillips - Clinical
Pharmacologist and Infectious
Disease Physician, Royal
Perth Hospital and Sir Charles
Gairdner Hospital, Perth,
Western Australia

1.30pm
- 1.50pm

2.00pm
- 2.15pm

Kwon AJS - Continued
Increases in Syringe
Distribution are
Required to Restrain Viral 1.50pm
Transmissions among
- 2.10pm
Injecting Drug Users in
Australia: Results from a
Modelling Study

2.45pm
- 3.00pm

1.30pm
- 3.00pm

Chairs: Damian Purcell and
Nitin Saksena

Deacon RM - Results
from the 2008 Periodic
Survey of NSW Needle
and Syringe Program
Attendees

2.30pm
-2.45pm

Meeting Room 8

Chairs: Ingrid Van Beek
and Tamara Speed

1.45pm
- 2.00pm

2.15pm
- 2.30pm

Sexual Health Plenary 7:
Out of Sight Out of Mind

ACH2 Bench to Bed: 2

Tissue-Specific Adaptive
Changes in V3 of gp120 Enable
Persistence of MaravirocSensitive R5X4 HIV-1 in Brain

Spooner C - The Role
of Needle Syringe
2.10pm
Programs in Preventing
- 2.30pm
Transmission to Injecting
by Young People

Gahan G - A Gap
Analysis of People with
a History of Injecting
Drug Use who are not
Currently Accessing
HIV and Sexual Health
Services in South
Eastern Sydney Illawarra
Area Health

1.30pm
- 2.00pm

2.30pm
-2.50pm

Coupland H Increasing Hepatitis C
Treatment Uptake by
Injecting Drug Users
2.50pm
from Culturally and
- 3.00pm
Linguistically Diverse
Backgrounds: Outcomes
of a Pilot Study of
Indochinese Injectors

Management of Penicillin
Allergy in the Syphilitic Patient

Bin Wang - Research Fellow,
Retroviral Genetics Division,
Westmead Millennium
Institute, Sydney, New South
Wales, Australia

Richard Hillman - Senior
Lecturer, Sexually Transmitted
Infections Research Centre,
The University of Sydney,
Sydney, New South Wales,
Australia

Genomic and Proteomic
Characterisation of Novel AntiHIV Activity
Jillian Carr - Senior Research
Officer, South Australia
Pathology, Adelaide, South
Australia, Australia

full conference program

12.45pm
- 1.15pm

Lunch in Exhibition and Poster Area in Pavilion 1

2.00pm
- 2.30pm

Anal Dysplasia and Cancer. An
Australian Experience

HIV DNA Levels in PBMC
Decline in Patients
Receiving Integrase Inhibitor
Combination Therapy
Anthony Cunningham
- Director, Australian Centre
for HIV and Hepatitis Virology
Research, Sydney, New South
Wales, Australia
Inhibition of HIV Binding to
Langerin on Langerhan’s Cells
as a Strategy for Microbicide
Development

Discussion

Basil Donovan - Professor of
Sexual Health, National Centre
in HIV Epidemiology and
Clinical Research, Sydney, New
South Wales, Australia
2.30pm
- 3.00pm

It’s only a cold sore, Love....”
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3.00pm
- 3.30pm

Planning Requires Economic
and Quality Review

Virology/Immunology
3.30pm
- 5.00pm

3.30pm
- 3.45pm

WEDNESDAY 17 SEPTEMBER 2008

Afternoon Tea in Exhibition and Poster Area in Pavilion 1

Riverside Theatre/
Auditorium

3.30pm
- 5.00pm

Meeting Room 8

Sexual Health Conference
Closing
3.30pm
- 5.00pm

Meeting Room 1,2,3

Chairs: Patricia Price
and Rosemary Ffrench

Chairs: Jim Hyde and Lisa
Bastian

Chairs: Jenny McCloskey and
David Jardine

Keane NM - An HLAC*0702 Restricted T-Cell
Response Directed
Against an Immune
Escaped HIV NEF KY11
Epitope Exhibits Higher
Functional Avidity but
Lesser Cytolytic Activity
when Compared with
the Anti-Wild Type
Response

Anderson J - A Critical
Analysis of the Quality
and Transferability of
Economic Evaluations of HIV
Interventions for Australian
Decision-Making

Basil Donovan - Professor of
Sexual Health, National Centre
in HIV Epidemiology and
Clinical Research, Sydney, New
South Wales, Australia

3.30pm
- 3.45pm

3.30pm
- 4.00pm

3.45pm
- 4.00pm

Stratov I - Robust NK-Cell
Mediated HIV-Specific
3.45pm
Antibody-Dependent
- 4.00pm
Responses in HIVInfected Subjects

Hillman R - Cost Effectiveness
of Screening for Anal Cancer in
HIV-Positive MSM

LASH Study - Law and
Sexworker Health

4.00pm
- 4.15pm

Fernandez S - CMVSpecific Effector
Memory CD4+ T-Cells
in HIV Patients on
Long-Term Art are
Predominantly ‘CD28
Null’ Immunosenescent
Cells

4.00pm
- 4.15pm

Bernard D - Effective
Partnership and Adequate
Investment Underpin a
Successful Response: Key
Factors in Dealing with HIV
Increases

Peter Leone - Associate
Professor of Medicine,
University of North Carolina,
and Director, North Carolina
HIV/STD Prevention and Control
Branch, USA

4.15pm
- 4.30pm

Lim A - Phenotypic
Analyses of FOXP3Expressing CD4+ And
CD8+ T Cells in HIVInfected Patients

4.15pm
- 4.30pm

4.30pm
- 4.45pm

Seddiki N - Identification
of Human Antigen4.30pm
Specific Regulatory T
- 4.45pm
Cells, Phenotyping and
Functional Analysis

4.45pm
- 5.00pm

Seddiki N - Regulatory
T Cell Abnormalities
are Associated with
Aberrant CD4+
4.45pm
T-Cell Responses in
- 5.00pm
Patients with Immune
Inflammatory Syndrome
(IRIS)

4.00pm
- 4.30pm

Savage J - Models of Access
and Clinical Service Delivery in
Australia Today

Anderson J - Measuring
Quality of Life for Economic
Evaluation in HIV

Discussion

Acute HIV and STDs: Screening
and Co-infection

4.30pm
- 4.50pm

Prize Presentations and Closing
Remarks by Darren Russell
- President of the Australasian
Chapter of Sexual Health
Medicine Committee

4.50pm
- 5.00pm

Presentation of Next Year’s
Conference by David Jardine
- Committee Convenor, 2009
Australasian Sexual Health
Conference, Brisbane
Diagnostics and Assay
Development

Circumcision: Crown Jewels
5.15pm
- 6.15pm

5.15pm
- 5.30pm

5.15pm
- 6.15pm

Riverside Theatre/Auditorium

Meeting Room 1,2,3

Chairs: Graham Brown and Andrew Grulich

Chairs: Elizabeth Dax and
Andrew Lloyd

Templeton D - Reduced Risk of HIV Seroconversion Among Circumcised
5.15pm
Homosexual Men who Report a Preference for the Insertive Role in Anal
- 5.30pm
Intercourse

Guy R - The Accuracy of HIV
Incidence Assays in Estimating
the Population Rate of New
Infections: A Systematic Review
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5.45pm
- 6.00pm

6.00pm
- 6.15pm

5.30pm
- 5.45pm

Gold J - Sensitivity and
Specificity of HIV Incidence
Assays: A Systematic Review

Anderson J - Cost-effectiveness of Circumcision for the Prevention of HIV 5.45pm
in Gay Men in Australia
- 6.00pm

Plate M - Evaluation of the New
Version 3 Cavidi Exavir™ Load
Quantitative HIV RT Load Kit as
an Alternative HIV Viral Load
Monitoring Assay for use in
Both Resource-Constrained and
Developed Countries

Donohue S - Promoting Circumcision within the Australian HIV
Prevention Response

Zaunders J - Persistence of High
Levels of HIV Antigen-Specific
CD4+ T Cells in Untreated
Chronic Infection, Detected by
a Novel Flow Cytometric Assay

6.00pm
- 6.15pm

Joint Conference Dinner, ‘Diamonds are Forever’ - Bellevue Ballroom, Level 3, Perth Convention Centre
Sponsored by the Australian Government Department of Health and Ageing, WA Health, Gilead,
GlaxoSmithKline, Boehringer Ingelheim, and Merck Sharp & Dohme

WEDNESDAY 17 SEPTEMBER 2008

7.30pm
- 11.30pm

Londish G - Small Population Health Benefits on HIV by Circumcising
Men who have Sex with Men

full conference program

5.30pm
- 5.45pm
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full conference program

THURSDAY 18 SEPTEMBER
7.00am

Registration
Breakfast Session - ‘Meet the Experts’ - Clinical

7.30am 8.45am

7.30am
- 7.40am

7.40am
- 7.50am

7.50am
- 8.00am

8.00am
- 8.10am

8.10am
- 8.45am

8.00am
- 9.00am

8.00am 8.45am

Riverview 4

Oral Poster Session - Social Research,
International, Community, Indigenous Health
Meeting Room 1,2,3

Chairs: Miles Beaman and Martyn French

Chairs: Jeffrey Grierson and Francine Eades

Martyn French - Clinical Professor, Pathology and
Laboratory Medicine, University of Western Australia,
Perth, Western Australia
8.00am
- 8.05am
Life-threatening Immune Reconstitution Inflammatory
Disease

Scott-Visser B - Enhanced Primary Care (EPC) and
Care Coordination as a Cooperative Model

Roy Gulick - Professor of Medicine, Weill Medical
College of Cornell University, USA

8.05am
- 8.10am

McGowan A - ‘We have Infections Zapped!’ Offering
Testing for Chlamydia and Gonorrhoea in Targeted
Youth Settings

8.10am
- 8.15am

Reeders D - User-Centred Design in a Resource for
Positive Travellers

David Nolan - Royal Perth Hospital and Murdoch
University, Western Australia

8.15am
- 8.20am

Brown G - Evaluation of a Health Promotion Short
Course for the HIV Community Sector

Prevention and Management Strategies for Metabolic
Syndrome and Cardiovascular Risk in Patients Taking
Antiretroviral Therapy

8.20am
- 8.25am

Brown G - Netreach: Online Peer Outreach to Virtual
Communities Across Australia

8.25am
- 8.30am

Lake R - Are Hospitals Biohazards for People with
HIV?

8.30am
- 8.35am

Clayton S - Sero-Sorting: What is the Impact on HIV
Transmission in Gay Men and How Do We Reduce
it?

8.35am
- 8.40am

Sarangapany J - Potential Difficulties and Barriers:
Findings from a Knowledge, Attitudes and Practice
Survey in Papua New Guinea

8.35am
- 8.45am

Discussion

Contemporary Approach to Management of
Antiretroviral Treatment Failure or Toxicity
Robin Wood - Director, Desmond Tutu HIV-Research
Centre, South Africa
Management of Late Presenting Patients with Severe
Opportunistic Infection

Questions and Panel Discussion

Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1

THURSDAY 18 SEPTEMBER 2008

HIV and Ageing
9.00am
- 10.30am Riverside Theatre/Auditorium
Chairs: Bill Whittaker and Patti Martinez
9.00am
- 9.20am

9.20am
- 9.40am

9.40am
- 10.00am

Bruce Brew - Head, Department of Neurology, St Vincents Hospital, Sydney, New South Wales, Australia  
Neurodegeneration and Ageing in the HAART Era
Marian Pitts, Director, Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne,
Victoria, Australia
Growing Old Disgracefully with HIV
Andrew Grulich - Professor, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales,
Australia
HIV, Cancer, and Immune Deficiency
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HIV Infection and Healthy Ageing: Is There a Need For HIV-Specific Management Guidelines for the Protection of Hearts,
Bones, Minds and More?
Morning Tea in Exhibition and Poster Area in Pavilion 1

Community
Research into
Practice

Hot Topics: Top
Papers of 2008

11.00am 11.00am 12.30pm Riverside Theatre/ 12.30pm
Riverview 4
Auditorium
Chairs: Susan
Kippax and Chris
Birch

11.00am 11.15am

11.00am 11.30am

11.30am 12.00pm

Martyn French
- Clinical Professor,
Pathology and
Laboratory
Medicine,
University of
Western Australia,
Perth, Western
Australia

Margaret
Macdonald
Memorial
Session Epidemiology
Population

International:
Global HIV
Initiatives vs Local
Response
11.00am 12.30pm Meeting Room
1,2,3

11.00am
12.30pm Meeting Room 8

Chairs: Jo Watson
and Marian Pitts

Chairs: John
Milan and Marina
Carman

Chairs: Andrew
Grulich and
Margaret
Hellard

Bruno Spire
- Communities
11.00am and Research: The
11.15am
Necessity for Dialogue

Wilson D - Tailoring
Global Responses
to Local Epidemics

Mcdonald A
- Trends in Newly
11.00am - Acquired HIV
11.15am Infection in
Australia, 1994
– 2007
Wand H Increasing HIV
Transmission
through Male
Homosexual and
Heterosexual
Contact in
Australia: Results
from an Extended
Back-Projection
Approach

11.15am11.30am

Canavan P - The Shock
11.15amof Ethical Community
11.30am
Research

Priohutomo S
- Impact of the
Global Fund in
Indonesia

11.30am 11.45am

Imrie J - The Feasibility
of a National Gay
Men’s InternetBased Cohort
11.30am and Prospective
11.45am
Behavioural
Surveillance Platform
in Australia -What are
the Issues?

Ward J - How is
the Aboriginal
and Torres
Worth H - Exploring
Strait Islander
the Links between
11.30am - Population Faring
HIV and Poverty:
11.45am in the Australian
Are the Analyses
HIV Epidemic?
Correct?
- An Analysis of
Data from 19932007

11.45am 12.00pm

Whittaker B - Special
Access Schemes - An
Analysis of the Last
Four Programs

Bebbington M
- Capacity Building
through Long-term
Partnerships

Mary Crewe
- Director, Centre
for the Study of
AIDS, University
of Pretoria, South
Africa

11.45am 12.00pm
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10.30am 11.00am

David Nolan - Senior Clinical Research Fellow, Centre for Clinical Immunology and Biomedical Statistics, Royal Perth
Hospital and Murdoch University, Perth, Western Australia

11.15am11.30am

Horyniak D
- The Impact of
11.45am - Migration on
12.00pm the Burden of
HIV Infection in
Victoria, Australia
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10.00am 10.30am
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full conference program

12.00pm 12.30pm

John Kaldor Deputy Director,
National Centre In
HIV Epidemiology
and Clinical
Research, Sydney,
New South Wales,
Australia

12.00pm 12.15pm

12.15pm 12.30pm

Ogier A - Towards
more Equitable
Access to HIV Clinical
Trials

12.00pm 12.15pm

Discussion

12.15pm 12.30pm

Menon A - Building
Clinical Capacity
to Manage Human
Immunodeficiency
Virus (HIV) Infection
in Resource
12.00pm Constrained
12.15pm
Environments:
Reflections from
Experience with
Clinical Mentoring
in Papua New
Guinea (PNG)

Discussion

12.30pm
- 1.30pm

Lunch in Exhibition and Poster Area in Pavilion 1

12.30pm
- 1.30pm

ASHM AGM in Meeting Room 6; Lunch will be provided at Meeting Room 6 for attendees

1.30pm 3.00pm

Australian
Antiretroviral
Guidelines:
Consensus
Session

1.30pm Riverside Theatre/ 3.00pm
Auditorium

Riverview 4
Chairs: Diana
Bernard and
Anthony Smith

Ryan CE - The
Molecular
12.15pm Characterization
12.30pm
of the HIV-1
Epidemic in Fiji

AusAID Session
- Indonesia
1.30pm 3.00pm

Meeting Room
1,2,3
Chairs: Murray
Proctor and David
Wilson

HIV
Immunology
1.30pm 3.00pm

Meeting Room 8
Chairs: Stephen
Kent and
Michael Boyle

THURSDAY 18 SEPTEMBER 2008

Chairs: Alan Street
and Ron McCoy

Social Research Desire

Manopaiboon C
- Unexpectedly
High HIV
Prevalence
Among Thai
Sex Workers in
a RespondentDriven Sampling
Survey
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1.30pm
- 1.45pm

1.30pm
- 1.50pm

Report on the
Integrated Bio
Behavioural
Surveillance ( IBBS)
Study for at Risk
Populations in
Indonesia

1.30pm
- 2.15pm
Tim Mackay, Head,
HIV Co-operation
Program Indonesia
1.45pm
- 2.00pm

Triffit KA - Sex Pigs
- A Rough Guide to
Dirty Sex

2.00pm
- 2.15pm

Prestage G - Gay
Men who Engage
in Group Sex are at
Increased Risk of HIV
2.00pm
Infection and Onward - 2.15pm
Transmission: Data
from the Three or
More Study

1.45pm
- 2.00pm

Ms Wulan Sekar
Sari, Director,
Stigma Foundation,
Indonesia

Harm Reduction in
Indonesia

Heterogeneity in
Primary R5 HIV-1
gp120 Structures
Affecting CD4
and CCR5
Interactions
and Exposure
of Neutralising
Antibody
Epitopes

Simon Mallal
- Clinical
Immunologist,
Royal Perth
Hospital - Clinical
Immunology
Department,
Perth, Western
Australia

How Might
Understanding of
the Co-Evolution
Of HLA and
Viruses Inform
Contemporary
Clinical Issues

THURSDAY 18 SEPTEMBER 2008

How to Use the
Newer Agents in
the TreatmentExperienced Patient
and What Drugs
Are in the Pipeline

AusAID Indonesia
HIV Program
Support,
Responsiveness and
Building Capacity
1.50pm
- 2.10pm

full conference program

Roy Gulick
–   Professor of
1.30pm
Medicine, Weill
- 1.45pm
Medical College,
Cornell University,
New York

De Wit J - Increasing
the Contribution
of Social Research
to HIV Prevention:
Developing and
Testing a TheoryDriven Intervention
to Reduce
Unpremeditated RiskTaking in MSM

Sigit Priohutomo,
Head HIV/AIDS
Program Ministry of
Health, Republic of
Indonesia

Paul Gorry - Head,
HIV Molecular
Pathogenesis
Laboratory,
Burnet Principal
Fellow,
Macfarlane
Burnet Institute
for Medical
Research &
Public Health,
Melbourne,
Victoria, Australia

17-20 september 2008 @ Perth Convention Centre, Western Australia 				

		

63

full conference program

Tim Read - Sexual
Health Physician,
Melbourne Sexual
Health Centre
and Victorian
infectious
Diseases Service
(Royal Melbourne
Hospital),
Melbourne,
2.15pm
Victoria, Australia -2.30pm
Catriona Ooi Director of Sexual
Health, Hunter
New England Area
Health, Newcastle,
New South Wales,
Australia

Carolyn Thomas
- Supervisor,
Spiritia Foundation,
Indonesia
Grierson J - Walking
after Midnight:
Trajectories of Sex on
Premises Visits

2.15pm
-2.30pm

2.10pm 2.30pm
Delivering
Community
Support Across
Different Epidemics
and Settings

Innate Immunity
in HIV Disease:
Friend or Foe

2.15pm
- 3.00pm
The Guidelines in
Action - Treatment
Dilemmas in
Clinical Practice
2.30pm
- 2.45pm

Adam PCG - Sexual
Desires, Sexual
Control and Sexual
Risk-Taking in Men
who have Sex with
Men.

Case 1: Managing
Suspected Early
Virologic Failure
Case 2: Juggling
Antiretroviral
Therapy and
Cardiovascular Risk
3.00pm
- 3.30pm

2.45pm
- 3.00pm

THURSDAY 18 SEPTEMBER 2008

What Do T Cell
Responses Mean:
A Post Step
Perspective

Discussion

Holt M - Medicine,
Risk Factor, Pleasure
Enhancer or Safe
Sex Aid? The Use
of Viagra and other
Sexuopharmaceuticals
by Gay Men

Tony Kelleher
- Associate
Professor,
National Centre in
HIV Epidemiology
& Clinical
Research, Sydney,
New South Wales,
Australia

2.50pm 3.00pm

Discussion

Afternoon Tea in Exhibition and Poster Area in Pavilion 1

Ian Thompson
Memorial Session
- Clinical Anti
Retroviral Therapy
3.30pm 5.00pm

2.30pm 2.50pm

2.30pm
- 3.00pm

Two case based
presentations:

Alan Landay
- Professor
and Chairman,
Department of
Immunology/
Microbiology,
Rush University
Medical Center,
Chicago , USA

Riverside Theatre/
Auditorium

Epidemiology
- Morbidity and
Mortality
3.30pm 5.00pm

Chairs: Elizabeth
Phillips and Greg
Dore
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3.30pm 5.00pm

Working
with CALD
Communities /
Working with
Media

Riverview 4

Meeting Room
1,2,3

Chairs: John Kaldor
and Sue Laing

Chairs: Trish
Langdon and Lisa
Bastian

Prevention
and Treatment
Issues for
Older Gay Men
- Sponsored by
NSW Health and
3.30pm - ACON
5.00pm
Meeting Room 8
Chairs: Stevie
Clayton and
Geoff Honnor
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3.35pm
- 3.45pm

3.45pm
-4.00pm

4.00pm
- 4.15pm

Read T - Efavirenz
(EFV) Plasma
Concentrations in
Patients Stopping
Therapy after
at Least One
Month due to
Neuropsychiatric
Disturbances: An
Initio Substudy

Seneviratne N ESPRIT (Evaluation
Of Subcutaneous
Proleukin® In
A Randomised
International
Trial): Factors
Associated with
Ongoing Cycling
with Recombinant
Interleukin-2 (RIL-2)

3.45pm
-4.00pm

4.00pm
- 4.15pm

3.30pm
- 3.45pm

An Overview
of Risk and
Behaviour in
Older Gay Men

Petoumenos K
- Predictors of LongTerm Changes in
Mean CD4 Cell Counts
3.45pm
Amongst HIV Infected
-4.00pm
Patients from the AsiaPacific Region During
Active Combination
Antiretroviral Therapy

McDonald A - Who
gets AIDS in the
HAART Era?

Crawford G - Safe
Sex No Regrets:
3.30pm
Sexual Health in the
- 3.45pm
Mainstream Media
in WA

full conference program

Pett S - Changes
3.30pm
in Circulating
- 3.45pm
CCR5+ T-Cells and
Antigen-Specific
CD4+ T-Cells during
Monotherapy with
a Small Molecule
CCR5 Antagonist
Sch532706,
compared with
Combination
Antiretroviral
Therapy (CART)

Murray JM - A Faster
Decrease in CD4+
T Cell Counts after
HIV Infection for
Older Individuals
Contributes
to Levels of
Immunosuppression
at HIV Diagnosis

Garrett Prestage
- Senior Lecturer,
National Centre in
HIV Epidemiology
& Clinical
Research, Sydney,
New South Wales,
Australia

4.00pm
- 4.15pm

Shaw MJ - Different
Communities,
Different Needs:
Shaping HIV/AIDS
Messages for
Six New South
Wales Culturally
and Linguistically
Diverse
Communities

Newman CE - The
Making of HIV as
a Public Concern:
Three Themes in
the Contemporary
Australian News
Media Coverage
of HIV
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John Imrie
- Associate
Professor,
National Centre
in HIV Social
Research,
University of New
South Wales,
Sydney, New
South Wales,
Australia
3.45pm
- 4.00pm

4.00pm 4.15pm

Risk, Realities
and HIV
Seroconversions
in Old Gay Men:
Qualitative
Results from an
Investigation of
Seroconversions
in Gay Men
Who HIV Test in
England (Insight
Study)
Dermot Ryan
- Acting Director,
Community
Health, AIDS
Council of New
South Wales,
Sydney, New
South Wales,
Australia

Prevention Issues
and Responses

		

THURSDAY 18 SEPTEMBER 2008

3.30pm
- 3.35pm

Introduction by
David Cooper,
Director, National
Centre in HIV
Epidemiology and
Clinical Research,
Sydney, New South
Wales, Australia

65
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4.15pm
- 4.30pm

Zhou J - Deferred
Modification of
Antiretroviral
Regimen Following
Treatment Failure
in Asia: Results
from the Treat Asia
HIV Observational
Database (TAHOD)

4.15pm
- 4.30pm

4.30pm
- 4.35pm

Oral Poster:
McLellan D
- Efavirenz and
Positive Urinary
Drug Screen for
Cannabinoids

4.35pm
- 4.40pm

Oral Poster:
Byakwaga H
- HIV Disease
Progression in HIV-1
Patients Initiating
Combination
Antiretroviral
4.30pm
Therapy with
- 4.45pm
Advanced Disease
in the Asia-Pacific
Region: Results
from the Treat Asia
HIV Observational
Database (TAHOD)

4.40pm
- 4.45pm

Oral Poster: Bloch
M - Triple Class
HIV Antiretroviral
(ARV) Failure in an
Australian Primary
Care Setting

4.45pm
- 4.50pm

Oral Poster: Chibo
- Resistance to the
HIV-1 Integrase
Inhibitor Raltegravir: 4.45pm
- 5.00pm
A Case Study

4.50pm
- 5.00pm

Discussion

Grebely J - High
Mortality Associated
with HIV Infection
Among Illicit Drug
Users in the HAART
Era

4.15pm
- 4.30pm

Van Leeuwen MT
- Cancer and HIV
in Australia: A
Comparison Across
Early and Late HAART
Periods

4.30pm
- 4.45pm

Katsaros E Reflections on
Improving Health
Outcomes

4.30pm 4.45pm

Rob Lake - Chief
Executive Officer,
Positive Life NSW,
Sydney, New
South Wales,
Australia

Treatment Issues
and Responses

Gelgor L - Update of
the Australian LongTerm Non-Progressor
(LTNP) Cohort

Riverside Theatre/Auditorium

4.45pm
- 5.00pm

O’Connor CC
- Acculturation,
Sexual Behaviour,
Risk And
Knowledge In
Vietnamese
Men Living In
Metropolitan
Sydney
Response and
Predictions in ART

5.00pm
- 6.15pm

Chairs: Levinia Crooks and Dr Bagus Widjaja
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4.15pm 4.30pm

Ageing GLBT
Populations

Policy: Australia’s Response to HIV in Asia and the
Pacific: New Partnerships and Collaborations
5.00pm
- 6.30pm

Sabri W - Radio
Dramas, HIV/AIDS
& the Vietnamese
Community in
Sydney

Russell Westacott
- Director, Client
Services, AIDS
Council of New
South Wales,
Sydney, New
South Wales,
Australia

Riverview 4
Chairs: Gail
Matthews and Jill
Carr

4.45pm 5.00pm

Discussion

Adherence to
Antiretroviral
Therapy
Meeting Room
5.00pm
1,2,3
- 6.30pm
Chairs: Angela
Kelly and Ric
Chaney
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Kerr SJ - Assessing
Adherence in Thai
Patients Taking
HAART

5.15pm
- 5.30pm

Chew C SN Characterisation
of TNF Block
Haplotypes
and Genotypes
that Predict an
Individual’s Risk
of StavudineAssociated Sensory
Neuropathy

Herrmann S - Side
Effects, Dosing
Schedules, Pill
Burden and
Perceived Stress:
Interaction
and Influence
on Medication
Adherence

5.30pm
- 5.45pm

Tschochner M Naturally Occurring
Polymorphisms in
HIV-1 Integrase:
5.30pm
Relationship to HIV
- 5.45pm
Subtype, Integrase
Inhibitor Resistance
and Immune
Selection

Baker D
- Improved
Treatment
Adherence
Associated
with Treatment
Simplification

5.45pm
- 6.00pm

Grey P - Patient
Characteristics and
Predictors of Time
to Commence
Antiretroviral
Treatment in a
5.45pm
Prospective Cohort - 6.00pm
Identified at Primary
HIV Infection (PHI).
(The Phaedra
Collaborative
Cohort)

O’Connor MB
- Adherence to
Anti-Retroviral
Therapy Among
Patients in
Bangalore, India

A New Aid Policy on HIV/AIDS: Issues for Consideration

Dr Tarun Weeramanthri - Executive Director, Public
Health Division, WA Health, Perth, Western Australia
5.15pm
- 5.30pm
How to Overcome PIF (Policy Implementation Fatigue)

James Ward - Program Manager, Aboriginal and
Torres Strait Islander Health, National Centre in HIV
Epidemiology and Clinical Research, Sydney, New
South Wales, Australia

5.30pm
- 5.40pm

Is it Luck or Persistence on the Ground? - Aboriginal and
Torres Strait Islander Australians and HIV. What Should
a Future Policy Response Look Like for Indigenous
Australia?
David Cooper - Director, National Centre in HIV
Epidemiology and Clinical Research, Sydney, New
South Wales, Australia
5.40pm
- 5.50pm
New Policies for Clinical and Operations Research in
Resource Limited Settings

5.15pm
- 5.30pm

6.00pm
- 6.15pm

Ibrahim D AIDS Dementia
Complex (ADC)
and Mental
Illness: The Role
of the NSW
Mental Health
Act in Managing
Compliance with
Highly Active Anti
Retroviral Therapy
(HAART)

6.15pm
- 6.30pm

Discussion

Don Baxter - Executive Director, Australian
Federation of AIDS Organisations, Sydney, New
South Wales, Australia
5.50pm
- 6.00pm

6.00pm
- 6.15pm

Discussion

Re-shaping Australia’s Response to Emerging Trends in
the HIV Epidemic in Asia and the Pacific
6.00pm
- 6.30pm
6.30pm
- 7.00pm

Discussion
Launch of the Prison Entrants’ Blood Borne Virus Report in Meeting Room 6
Sponsored by WA Health on behalf of the National Drug Research Institute

Free Evening
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full conference program

5.00pm
- 5.15pm

THURSDAY 18 SEPTEMBER 2008

5.00pm
- 5.15pm

Warner MS
- Evaluation of
the Relationship
between HLAB*5701 Status
5.00pm
and HIV Reverse
- 5.15pm
Transcriptase
Codon 245
Variation in South
Australian HIVInfected Individuals

Bob McMullan, MP - Parliamentary Secretary for
International Development Assistance, Braddon,
Australian Capital Territory, Australia
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FRIDAY 19 SEPTEMBER
7.00am

Registration Opens
Case Presentation Breakfast

7.00am
- 8.45am

Oral Poster Session - Public Health and Epidemiology
7.45am
- 8.45am

Riverview 4
Chairs: Tony Allworth and Pietro Vernazza

7.30am
- 7.45am

7.45am
- 8.00am

8.00am
- 8.15am

8.15am
- 8.30am

8.30am
- 8.45am
8.00am
- 9.00am

Sherry N - Autoimmune Haemolytic Anaemia: An
Unusual Presentation of HIV Seroconversion

Peel T - Steroid-Dependent Cryptococcal Immune
Restoration Disease in a HIV-Positive Patient

Barber B - A Case of Tenofovir-Associated Renal
Tubular Acidosis with Neurological Impairment

Rogers B - Three’s a Crowd: The Relationship
between CA-MRSA, HIV and MSM

Chang C - Fatal Acute Varicella-Zoster Virus
Haemorrhagic Meningomyelitis with Necrotising
Vasculitis in an HIV-Infected Patient

Meeting Room 1,2,3
Chairs: Fengyi Jin and Barry Combs

7.45am
- 7.50am

Introduction to Session

7.50am
- 7.55am

Roth N - A Comparative Study of Syphilis & HIV from a
Melbourne General Practice Perspective

7.55am
- 8.00am

Stoove M - Local HIV Information Testing and Support
(HITS) Pilot Program: Improving the Capacity of General
Practitioners

8.00am
- 8.05am

Allison W - Clinical Features Associated with HIV Infection
in Children at Port Moresby General Hospital - Interim
Analysis of a Prospective Study to Ascertain Predictors of
HIV Infection

8.05am
- 8.10am

Hsu D - Combination Antiretroviral Therapy in HIV
Patients at a Sydney Sexual Health Clinic

8.10am
- 8.15am

Jin F- Renewing the Seroconversion Study

8.15am
- 8.20am

Pedrana A - Estimating HIV Prevalence of HIV among
Men who have Sex with Men (MSM); A Review of
Methodological Options

8.20am
- 8.25am

O’Connor M - A Comparative Study of Human
Immunodeficiency Virus Antibody-Positive Patients in
Ireland and Australia

8.25am
- 8.30am

Prihaswan P - Sexo Latino. Sexo Caliente. Sexo Seguro. A
Safe Sex Campaign for Spanish Speaking Gay Men

8.30am
- 8.35am

Connelly C - The Effect of Introducing Specialist Blood
-Borne Virus Nurses into Prison Health Centres

8.35am
- 8.45am

Discussion

Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1
Plenary - Prevention

9.00am10.30am

Riverside Theatre/Auditorium

friday 19 SEPTEMBER 2008

Chairs: Gita Ramjee and John De Wit
9.00am
- 9.25am

9.25am
- 9.50am

Bruno Spire - President, French NGO AIDES, Public Health and Social Science in Clinical Research, Marseilles, France
Public Health and Social Science in Clinical Research: The Interest of a Multdisciplinary Approach
Sarah Rowland-Jones - Human Immunology Unit, John Radcliffe Hospital, Oxford, United Kingdom  
The Role of T-cells in HIV Immunity: Lessons from China and West Africa
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10.30am
- 11.00am

Understanding Our Last 1,000 Infections - Knowing our Epidemics for more Effective Programming
Pietro Vernazza - Head, Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, St Gallen,
Switzerland
Biological Factors of Sexual Transmission of HIV
Morning Tea in Exhibition and Poster Area in Pavilion 1
Peter Meese
Memorial
Session - Clinical
- Associated
Conditions
Complications

11.00am 12.30pm Riverside Theatre/
Auditorium

Epidemiology
- Transmission/
Acquisition

Indigenous
Health
11.00am
- 12.30pm

Riverview 4

11.00am 12.30pm

Meeting Room 1,2,3

11.00am
- 12.30pm

International:
Where to for
Testing and
Counselling in
Resource-Poor
Settings?
Meeting Room 8

Chairs: Moira
Wilson and David
Shaw

Chairs:
Heather
D’Antoine and
Ted Wilkes

Chairs: Andrew
Grulich and
Margaret Hellard

11.00am
- 11.15am

Kidd M - Primary
11.00am
Healthcare and HIV
- 11.15am
as a Chronic Disease

Huang R
- Managing
Data to Guide
a Long-Term
STI Control
Response in
some Remote
Central
Australian
Aboriginal
Communities

11.00am
- 11.15am

Pierce AB - Rates of
HIV Seroconversion
in Patients who have
Previously used
NPEP: Data Linkage
of the Victorian NPEP
Service Database
with the Victorian HIV
Surveillance Registry

11.00am
- 11.15am

Ankus J - Minimum
Standards for HIV
Counselling and
Testing for the
Pacific

11.15am11.30am

Agarwal U - Profile
of HIV Associated
Tuberculosis in the
Setting of Free AntiRetroviral Therapy
at a Tuberculosis
Hospital in India

11.15am11.30am

Slater A
- Barriers to
Hepatitis
C Services
for Rural
Aboriginal
People

11.15am11.30am

Jin F - Risk
Reduction Patterns
of Unprotected
Anal Intercourse:
Relative Risk for HIV
Acquisition in the
Health in Men (HIM)
Study

11.15am
- 11.30am

Sri Kartika A - VCT,
lessons learnt from
Indonesia after ‘3x5’

11.30am
- 11.45am

Newman C General Practitioner
Descriptions of
Challenges in the
Management of
Depression in Gay
Men and Men with
HIV

11.30am
- 11.45am

Webb D - A
Cultural World
AIDS Day in
the Aboriginal
Community

11.30am
- 11.45am

Jin F - Sexual
Partners’ Age as a
Risk Factor for HIV
11.30am
Seroconversion in the - 11.45am
Health in Men (HIM)
Study

Kelly A - Policing
Women’s Bodies: Are
we Ready to Move
Beyond Critiquing
PICT Yet?

11.45am
- 12.00pm

Wilson DP
- Importance
of Promoting
HIV Testing for
Preventing Secondary
11.45am
Transmissions:
- 12.00pm
Modelling the
Australian HIV
Epidemic Among
Men who have Sex
with Men

Poolsawat M
- Providing HIV
Services to Prisoners
in Thailand: Peer
Outreach Voluntary
Counselling and
Testing (VCT) and
Linkages to Care

11.45am
- 12.00pm

Carey C Determination of
the Underlying
Cause of Death in
Three Multicentre
International HIV
Clinical Trials

11.45am
- 12.00pm

Smith M
- Berrima
Women’s
Project

full conference program

10.10am
- 10.30am

David Wilson - Lead Health Specialist, the World Bank and Adjunct Professor, Centre for International Health,
Curtin University of Technology, Perth, Western Australia  

Chairs: Edward
Reis and Sigit
Priohutomo
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12.00pm
- 12.15pm

12.15pm
- 12.23pm

Oral Poster: Rotty
J - Incidence and
Characteristics of
HIV-Associated
Lymphoma in the
Era of HAART at Four 12.15pm
- 12.30pm
Major Australian
Treatment Centres

12.23pm
- 12.30pm

Oral Poster: Furner V
- Complications: The
TB + HIV Connection

12.30pm
- 1.30pm

Lunch in Exhibition and Poster Area in Pavilion 1
Australian
Antiretroviral
Guidelines:
Consensus Session

1.30pm
- 3.00pm

Riverside Theatre/
Auditorium

1.30pm
- 3.00pm

Chairs: Jenny
Hoy and Fraser
Drummond

1.30pm
- 2.00pm

friday 19 SEPTEMBER 2008

Gilles M
- Willingness
to Pay: What is
the True Cost
of Providing
12.00pm
Equitable
- 12.15pm
Health
Care in a
Disadvantaged
Community?

Hoy J - Re-Initiation
of Antiretroviral
Therapy (ART) in the
CD4 Cell-Guided
12.00pm
ART Interruption
- 12.15pm
Group in the Smart
Study Lowers Risk
of Opportunistic
Disease or Death

Dr. Sarah Pett Infectious Diseases
Physician and
Lecturer, National
Centre for HIV
1.30pm
Epidemiology &
- 1.45pm
Clinical Research,
Sydney, New South
Wales, Australia
Initiation of
Combination
Antiretroviral
Therapy in Adults
with HIV-1-infection,
What CD4 Threshold 1.45pm
- 2.00pm
to Use - Overview
of Clinical Trial Data
2008
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Cain A - The
Process of
Managing an
HIV-Positive
Indigenous
Woman with
a Chaotic
Lifestyle in a
Rural Setting

Social
Research:
Sexual Risk
in Space and
Time
Riverview 4

12.15pm
- 12.30pm

1.30pm
- 3.00pm

Chairs: Jeffrey
Grierson and
John Imrie

Smith A - I Met
Him at the
Candy Store:
Community
Attitudes
to Sex on
Premises
Venues and
their Patrons

Reynolds R
- HIV/AIDS
and Australian
Gay Life: A
Generational
Overview

Wilson DP - The
Paradoxical Effects
12.00pm
of using Antiretroviral- 12.15pm
Based Microbicides to
Control HIV Epidemics

Dax E - Proposed
Appraisal of HIV
Testing Strategies
Employing Simple/
Rapid Tests

Sirivongrangson P
- HIV Risk Behaviour
Among HIV-Infected 12.15pm
Men who have Sex
- 12.30pm
with Men in Bangkok,
Thailand

Allison WE - Use of
Dry Blood Spots
(DBS) to Aid Human
Immunodeficiency
Virus (HIV) Diagnosis
in Children in the
Absence of Local
Nucleic Acid Testing
Laboratory Capacity

International: PNG

Phillip Medcalf
Memorial Session
- Community,
Health
Choices and
Communication

Meeting Room 1,2,3

1.30pm
- 3.00pm

Chairs: Robert
Mitchell and John
Daye

Chairs: Joachim
Pantumari and Goa
Tau

1.30pm
- 1.45pm

Presenter To be
advised

1.45pm
- 2.00pm

Kitur I - Human
Immunodeficiency
Virus (HIV) and
Sexually Transmitted
Infections (STI)
Surveillance in Papua
New Guinea

Meeting Room 8

1.30pm
- 1.45pm

Martinez C - Life
Coaching - Mission
Not Impossible

1.45pm
- 2.00pm

Niggl M - HIVPositive Speakers
Bureaux a Model for
Sustainability and
Relevance in 2008
and Beyond

17-20 september 2008 @ Perth Convention Centre, Western Australia

2.15pm
-2.30pm

Lee J - Sex
Between Men
in Timor-Leste:
What does it
Mean?

2.15pm
-2.30pm

Dala M - The
Development,
Delivery and
Outcome of Patient
Care for Individuals
with HIV/AIDS
attending MAC from
2004 to 2008

Jeffrey Post
- Infectious
Diseases Physician,
Prince of Wales
Hospital, Sydney,
New South Wales,
Australia                 
and                     
Alan Street,
Deputy Director
2.30pm
and Head, HIV
- 2.45pm
Service, Victorian
Infectious Diseases
Service,
Royal Melbourne
Hospital, and
Visiting Physician,
Infectious
Diseases Unit, The
Alfred Hospital,
Melbourne,
Victoria, Australia

Holt M - ‘1 Msg
Then Sex’:
Temporality,
Spatiality,
Safety and Risk
In Gay and
Bisexual Men’s
Accounts of
Online SexSeeking

2.30pm
- 2.45pm

2.00pm
- 2.30pm
Emerging Issues
about Potency
and Toxicity of the
Preferred Agents for
Initial Therapy

2.30pm
- 3.00pm

Testing for Latent TB
2.45pm
in HIV Patients - The
- 3.00pm
Old or the New?

Discussion

2.45pm
- 3.00pm

3.00pm
- 3.30pm

Afternoon Tea in Exhibition and Poster Area in Pavilion 1

3.30pm

Exhibition Closes
Clinical - Toxicity

3.30pm
- 5.00pm

Riverside Theatre/
Auditorium
Chairs: Ronan
Murray and
Andrew Carr

Network Sex
3.30pm
- 5.00pm

Riverview 4
Chairs: Basil
Donovan and
Kate Ward

3.30pm
- 5.00pm

2.00pm
- 2.15pm

Green C - Treatment
Questions? Answers
by Internet and SMS
in Indonesia

2.15pm
-2.30pm

DeMaere K - The
Treataware Infoline:
A National HIV
Treatment Health
Promotion Service
for People Living
with HIV

Rondopali R and
Gaudentia Sr
- HIV/AIDS Awareness
and Access to
2.30pm
Antiretroviral Therapy
- 2.45pm
(ART) Makes a
Difference in People’s
Lives in Southern
Highlands, PNG

Sabri W - Dance,
Theatre Drama, HIV/
AIDS & the African
Communities in
Sydney

2.45pm
- 3.00pm

Triffitt K - Getting
on with it again
- Responding to the
Needs of People
Living Longer with
HIV

Discussion

International
-  Harm Reduction
in Asia

Social Research Lives Worth Living

3.30pm
Meeting Room 1,2,3 - 5.00pm

Meeting Room 8

Chairs: Nick
Medland and
Catherine Spooner

Chairs: Peter
Canavan and
Marian Pitts
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Gideon N and
Sawiya G - Education
Sessions Support
Adherence and
Improve Clinical
Outcome, Heduru
Clinic Port Moresby,
PNG

friday 19 SEPTEMBER 2008

2.00pm
- 2.15pm

Prestage G Age and Sexual
Behaviour
2.00pm
Among Gay
- 2.15pm
Men in Sydney,
Melbourne and
Brisbane

Roy Gulick
- Professor of
Medicine, Weill
Medical College,
Cornell University,
New York
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3.30pm
- 3.45pm

friday 19 SEPTEMBER 2008

3.45pm
-4.00pm

Drummond F
- Elevated Levels
of Interleukin-6
and D-Dimer are
Associated with an
Increased Risk of
Death in Patients
with HIV

Bloch M
- Cardiovascular
Disease (CVD) Risk
in the STEAL Study
Cohort

3.30pm
- 3.45pm

Laing SC
- Impact
of a NonOccupational
Post-Exposure
Prophylaxis
Program for
HIV in Western
Australia

3.30pm
- 3.45pm

Kamarulzaman A
- Harm Reduction
in Asia - A Clinician’s
Perspective

3.30pm
- 3.45pm

Herrmann S
- Development
of a New HealthRelated Quality of
Life Questionnaire
Specific to HIV/AIDS:
An International
and Cross-Cultural
Initiative

3.45pm
-4.00pm

Kaye MB
- Extensive
Transmission
Links amongst
Newly HIVInfected
Patients
Contribute
Significantly to
the Incidence
of HIV-1
Infection in
Melbourne

3.45pm
-4.00pm

Sari SW - Seeing Harm
3.45pm
Reduction from a
-4.00pm
Gender Perspective

Bavinton B and Gray
J - Assessing the
Needs of Younger
HIV-Positive Men

4.00pm
- 4.15pm

Poynten
IM - NonOccupational
Post Exposure
Prophylaxis
Against HIV
4.00pm
(NPEP) and
- 4.15pm
Subsequent
HIV Infection
in Homosexual
Men: Final Data
from the HIM
Cohort

Kab V - Risk Lifestyle
of Drug Users
in Phnom Penh,
Cambodia

4.00pm
- 4.15pm

Grierson J - Being
HIV Positive in
Aotearoa /New
Zealand: A Two
Study Comparison
2001-2007

4.00pm
- 4.15pm

Carey D - Poly-LLactic Acid for HIV-1
Facial Lipoatrophy:
48-Week Follow-Up

4.15pm
- 4.25pm

Oral Poster: Knox
D - A Public Access
Program of Sculptra® 4.15pm
Polylactic Therapy
- 4.30pm
to Treat People with
Facial Lipoatrophy

4.25pm
- 4.35pm

Oral Poster: Mackie
K - Interaction
Between Inhaled
Corticosteroids and
Protease Inhibitors
(PI) in HIV-Infected
Individuals
- Which is the
Preferred Inhaled
Corticosteroid?

4.35pm
- 4.45pm

4.30pm
- 4.45pm

Oral Poster: Hooker
D - Monitoring and
Understanding
Apoptosis in
HIV Patients by
Ligation-Mediated
Polymerase Chain
Reaction
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Langdon
PA - ‘Sex in
Other Cities’
- Responding
to Increases
in Overseas
Acquired HIV
Diagnoses in
WA

4.15pm
- 4.30pm

Crofts N - Harm
Reduction in Asia
– Australia’s Role

4.15pm
- 4.30pm

Zablotska IB
- Current Care and
Support Needs of
HIV-Positive Gay
Men: What Factors
Limit Access to
Available Services?

Harper RE
and Russell
D - North
Queensland
Travellers
Project:
Heterosexual
HIV Cluster

4.30pm
- 4.45pm

Speed T - This is the
Real World - Not as
We Know It

4.30pm
- 4.45pm

Murphy D - Viral
Families: Analysing
Kinship Discourse in
HIV Transmission

17-20 september 2008 @ Perth Convention Centre, Western Australia

5.15pm
- 6.30pm

5.15pm
- 5.35pm

5.35pm
- 5.50pm

Discussion

Discussion

4.45pm
- 5.00pm

Fawkes J - National
Needs Assessment
of Sex Workers who
Live with HIV 2008

Swiss Statement

Media Event - HIV Epidemiology and Public Health
Response in WA

Riverside Theatre/Auditorium

Meeting Room 1,2,3

Chairs: Geoff Honnor and Jonathan Anderson

Chairs: Paul Van Buynder and Trish Langdon

Pietro Vernazza - President, Swiss Federal
Commission on AIDS, St. Gallen, Switzerland
Background and Rationale - Normalising Sex in
Stable Serodiscordant Relationships
David Wilson - Mathematical Modelling Expert,
The National Centre in HIV Epidemiology and
Clinical Research, Sydney, New South Wales,
Australia
Modelling of Data on Viral Load and Transmission

5.50pm
- 6.05pm

4.45pm
- 5.00pm

full conference program

4.45pm
- 4.55pm

Oral Poster: Russell
D - Transient Sick
Sinus Syndrome
4.45pm
Related to Lopinavir- - 5.00pm
Ritonavir in a Patient
with AIDS

5.15pm
- 6.30pm

Susan Kippax, Professorial Research Fellow,
National Centre in HIV Social Research, Sydney,
New South Wales, Australia
Understandings of Viral Load in Negotiating
Unprotected Sex

6.05pm
- 6.20pm

Simon Donohoe - Manager, Education Team,
Australian Federation of AIDS Organisations,
Sydney, New South Wales, Australia
Implications for HIV Education and Health
Promotion

6.20pm
- 6.30pm

Debate

friday 19 SEPTEMBER 2008

Free Evening
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SATURDAY 20 SEPTEMBER
7.00am

7.30am
- 8.45am

Registration
Breakfast Session - ‘Meet the Experts’ - Basic
Science/Immunology
Riverview 4
Chairs: Scott Bowden and Tony Cunningham

7.30am
- 7.40am

Paul Gorry - Head, HIV Molecular
Pathogenesis Laboratory, Burnet Principal
Fellow, Macfarlane Burnet Institute
for Medical Research & Public Health,
Melbourne, Victoria, Australia
Oral Poster Session - Clinical, Allied Health and
Basic Science

Adaptive Changes in CCR5-Restricted HIV-1
Affecting Entry Inhibitor Potency

7.40am
- 7.50am

Chris Burrell - Head, Infectious Diseases
Laboratories, Institute of Medical and
Veterinary Science, Adelaide, South
Australia

7.45am
- 8.45am

Chairs: Lewis Marshall and Christopher Fairley

Natural History of Hepatitis B Infection

7.50am
- 8.00am

Anthony Cunningham - Director, Australian
Centre for HIV and Hepatitis Virology
Research, Sydney, New South Wales,
Australia

7.50am
- 7.55am

Purnomo J - Reduced Energy and Increased Saturated
Fat Intake in a Cohort of HIV-Positive Clients in Sydney

HIV Microbicides and Vaccines

7.55am
- 8.00am

Crooks L - The Support Focus is on Independent Living!

Mina John - Clinical Immunologist, Clinical
Immunology Department, Royal Perth
Hospital, Western Australia

8.00am
- 8.05am

Di Guilmi A - Validating an Abridged Symptoms Distress
Questionnaire in an HIV-Positive Population to Facilitate
Dietetic Referral and Improve Nutrition Outcomes

Genetic Factors and HIV & Hepatitis C

8.05am
- 8.10am

Di Guilmi A - Validating a Two-Question Depression
Screening Tool in an HIV-Positive Population to Use in
Improving Nutrition Outcomes and Prognosis

8.10am
- 8.15am

Earle M - Complex Psychological Factors Contributing
to Sexual Risk Behaviour Among HIV Negative Men
who have Sex with Men (MSM): Informing Sexual RiskReduction Initiatives for the Future

8.15am
- 8.20am

Emori R - Physical and Social Benefits of Antiretroviral
Therapy (ART) on the Lives of People Living with HIV
and AIDS (PLWHA) in Papua New Guinea (PNG)

8.20am
- 8.25am

Hoare A - Modelling the Emergence of Drug-Resistant
HIV in Bangkok

8.25am
- 8.30am

Tan D - Do Natural Killer Cells Compensate for Impaired
CD4+ T-Cell Responses to CMV in HIV Patients
Responding to Antiretroviral Therapy?

8.30am
- 8.35am

Reddy S - Molecular Cloning and Characterisation of
Envelope from HIV-1 Pre-Seroconversion Strains

8.35am
-8.40am

Gorton C - HIV in the Tropics: An Analysis of New HIV
Infections in Far North Queensland December 2006
- March 2008

8.00am
- 8.10am

saturday 20 SEPTEMBER 2008

8.10am
- 8.45am

8.00am
- 9.00am

Meeting Room 1,2,3

Questions and Panel Discussion

Arrival Coffee/Tea in Foyer, Level 2
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9.00am10.30am

Riverside
Theatre/
Auditorium

9.00am10.30am

Riverview 4

Blood-Borne Viruses:
Co-Infection

9.00am10.30am

Meeting Room 1,2,3

Program
Delivery

9.00am10.30am

Meeting Room
8

Chairs: Chris
Bourne and
Lisa Bastian

Chairs:
Heather Worth
and Patrick
Rawstorne

Chairs: Gail Matthews
and Scott Bowden

Chairs: Sam
Libertino
and Suzanne
Hermann

Goller Jl - HIV,
Syphilis and
Chlamydia in
MSM in Victoria:
9.00am
Risk Behaviour
- 9.15am
and Prevalence
at Clinic Sentinel
Surveillance
Sites

Power R
- Zimbabwe,
Adolescent
9.00am
Sexual Health
- 9.20am
and the Power of
Narratives

Matthews G - HIV/
9.00am
Hepatitis B Co-Infection - 9.15am

Ward K - Who is
Diagnosing HIV
in NSW?

9.15am
- 9.30am

Higgins N
- Rise in Syphilis
9.15am
Notifications in
- 9.30am
Victoria - A Case
Series Study

McMillan KE
- Pacific Specific:
Young People
and Condom
Use in Tonga
and Vanuatu

9.20am
- 9.35am

Oliver BG Immunopathogenesis
of Hepatic Flare in
HIV-Hepatitis B Virus
(HBV) Co-Infected
Individuals Following
Initiation of HBV-Active
Antiretroviral Therapy

9.15am
- 9.30am

Boddy G Queensland HIV
Models of Care
Project 2008

9.30am
- 9.45am

Srirajalingam
MSeroprevalence
and Incidence
of HSV-1 and
HSV-2 in an HIV
Seropositive
Cohort

Akuani F
- Adequate
Supply of Food
and its Impact
9.35am
on Adherence to - 9.50am
ART Treatment
in Papua New
Guinea

Matthews G - Tenofovir
Based HAART is
Associated with High
Rates of HBV DNA
Suppression and
HBEAG Seroconversion
in Thai HIV-HBV
Coinfected Patients

9.30am
- 9.45am

Cain A
- The Western
Australian Rural
and Remote
HIV Program:
A 10-Year
Experience

9.45am
- 10.00am

Bradstreet
B - Clinical
Outcome of
a Community
9.45am
Based Response
- 10.00am
to a Syphilis
Outbreak
Among Gay
Men in WA

9.45am
- 10.00am

Chuah J
- Comparison
of Clinical HIV
Performance
Indicators
(Post-HAART)
between AHOD
and a Regional
Sexual Health
Clinic 19962007

9.00am
- 9.15am

9.30am
- 9.45am

Walizopa L - The
Role of Comfort
in Young People
Talking and
Learning about
Sex and HIV
in Papua New
Guinea

9.50am
- 10.05am

Lo G - Screening
for Hepatocellular
Carcinoma (HCC)
in Hepatitis/HIV
Co-Infection using
Ultrasound Imaging
and Alfa-Feto Protein
Levels
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Clinical
Epidemiology

saturday 20 SEPTEMBER 2008

Social Research
- Listen Up:
International
Perspective on
Young People
and HIV Risk
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10.00am
- 10.15am

10.15am
- 10.30am

Moyer J - The
Role of the
Nurse in Syphilis
(and Other STI)
Risk Assessment
10.00am
in a Subacute
- 10.15am
Inpatient
Setting at the
Alfred Hospital,
Melbourne,
Victoria

Discussion

10.15am
- 10.30am

Regmi K
- Adolescence
Sexual Behaviour
and Risks of
Contracting
Sexually
Transmitted
Infections: A
Cross-Sectional 10.05am
- 10.20am
Study in Nepal

11.00am
- 12.45pm

10.10am
- 10.20am

Oral Poster:
Lienert TM
- Living Long
Term with HIV
in the Rainbow
Region

10.20am
- 10.30am

Discussion

Jung S - GBV-C vs. HIV-1
Several GBV-C Proteins
Inhibit Different HIV
Replication Steps

Discussion

10.20am
- 10.30am
10.30am
- 11.00am

10.00am
- 10.10am

Oral Poster:
Saloner KL
- Enhancing
the GP’s
Primary Care:
Acon Sydney’s
Enhanced
Primary Care
Project

Riley R - HIV and
Hepatitis C CoInfection: From Patient
to Educator

Morning Tea in Foyer, Level 2
Plenary - HIV and TB Co-infection and Conference Closing
Riverside Theatre/Auditorium
Chairs: Debbie Marriott and Jonathon Anderson

11.00am
- 11.30am

Robin Wood - Principal Investigator, Desmond Tutu HIV-Research Centre, Institute of Infectious Disease and
Molecular Medicine, Faculty Of Health Sciences Observatory, University of Cape Town, South Africa
HIV AND TB Co-infection

11.30am
- 12.00pm

12.00pm
- 12.30pm

saturday 20 SEPTEMBER 2008

12.30pm
- 12.45pm

Martyn French - Clinical Professor, Pathology and Laboratory Medicine, University of Western Australia, Perth,
Western Australia
Restoration of Immune Responses to M.tuberculosis in Patients with HIV and M.tuberculosis Infection is a DoubleEdged Sword
Adeeba Kamarulzaman - Head, Infectious Diseases Unit, Department of Medicine, University of Malaya
Medical Centre, Malaysia
Opportunistic Infections in Asia – The Unmet Needs
Levinia Crooks - Chief Executive Officer, Australasian Society for HIV Medicine, Sydney, New South Wales,
Australia
Closing Remarks, Prize Announcements and Future Conferences

12.45pm
- 1.45pm

Lunch in Foyer, Level 2

1.45pm

Conference Close
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Oral
Presentation
abstracts
wednesday 17 september 2008

HIV Prevention Research
Gita Ramjee
South African Medical Research Council HIV/AIDS Lead
Programme
The HIV Prevention field has faced a number of set backs
in the past year. Currently we have the ABC option of
abstinence, being faithful and condomize (male and
female), behavioural change and treatment of sexually
transmitted infections. More recently, three randomized
control trials showed that male circumcision is likely to
reduce the risk of female to male transmission of HIV
by up to 60%. With the rising infection rates in many
countries, the current efforts for HIV prevention are clearly
not adequate.

Sarah Rowland-Jones, Nuffield Department of Medicine,
Oxford University, John Radcliffe Hospital, Oxford OX3
9DU, UK
Following the disappointment experienced after the
failure of the STEP HIV phase II vaccine trial last year,
questions have bee raised about whether or not an
effective vaccine to prevent HIV-1 infection can ever be
achieved. Some have contended that the trial should
be seen as a product failure rather than a failure of the
entire T-cell vaccine concept, and that clinical vaccine
studies should continue on an empirical basis. Others
have suggested that there needs to be a return to basic
science in order to define genuine correlates of protective
immunity against HIV-1 infection. This presentation
will review the current efforts towards HIV vaccines
and discuss our understanding of the requirements
for a successful HIV-1 vaccine. Relevant studies of HIV
resistance or control of infection from studies in Kenya
and West Africa will be presented to provide support for
the concept of protective immunity.

wednesday 17 september 2008:  8.30am – 10.30am

Our recent efforts to expand HIV prevention options
through a variety of technologies (microbicides, vaccines,
HSV2 suppressive therapy, and vaginal diaphragm) have
had no success and in some cases there was a potential
of the intervention to increase the risk of HIV acquisition.
One of the challenges in the field has been in that the
theoretical concepts that have been scientifically sound
with adequate support from observational studies for
many of these novel intervention technologies, are not
supported by the same outcomes in randomized control
trials. With growing infection rates in many parts of the
world especially subSharan Africa, scientists in the HIV
prevention field need to come together to strategies and
ascertain why theoretical concepts and observational
studies are not proven effective in randomized control
trials, giving up on HIV prevention is not an option.

Towards an HIV vaccine - what is 
protective immunity against HIV
infection?

ASHM Opening Ceremony and Plenary 1

ASHM Opening Ceremony
and Plenary 1
8.30am – 10.30am
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Women Risk HIV – International 

ADDRESSING GENDER-BASED VIOLENCE IN
SETTLEMENT AREAS OF PORT MORESBY

Women Risk HIV – International
11.00am – 12.30pm
A NOVEL APPROACH TO ANTENATAL RISK
ASSESSMENT IN VERY LOW HIV PREVALENCE
SETTINGS IN RESOURCE-POOR COUNTRIES
Holmes WR, Centre for International Health, Burnet
Institute, Melbourne, VIC, Australia
In very low HIV prevalence settings in resource-poor
countries the relative cost-effectiveness of routine
provider-initiated offer of HIV testing for all pregnant
women is low. A strategy of offering the test to pregnant
women who may be more vulnerable to HIV infection
is problematic because it is difficult to identify pregnant
women at greater risk. Women at risk because of their
partner’s behaviour are often unaware of their risk,
and undertaking risk assessment is a sensitive task for
busy antenatal care staff to conduct in a confidential,
inoffensive and non-stigmatising manner.

wednesday 17 september 2008:  11.00am – 12.30pm

However, there are often opportunities to reach
expectant fathers with information and risk assessment.
These opportunities may include pre-conception couple
visits, antenatal couple visits, and ‘parentcraft’ classes for
pregnant women and expectant fathers.
We have developed a novel risk assessment quiz for
expectant fathers in the entertaining style typical of
women’s magazine personality quizzes. Because the
men do not need to fill in a checklist or questionnaire
they can be completely honest in their answers because
no one will know the result except themselves. The quiz
includes ‘comments’ for each risk category. Those in the
‘low or no exposure risk category’ are congratulated and
encouraged to continue their safe behaviours to protect
themselves and their families. Those in higher exposure
risk categories are informed that if they find they are HIV
positive it is possible to protect their wife from infection if
she is not yet infected, and that if she is already infected
the risk of transmission to their baby can be greatly
reduced. This provides a strong motivation for the father
to request a confidential HIV test. A commitment to
disclose a positive result to his wife would be obtained
during the pre-test counselling.
It is planned to evaluate the risk assessment quiz for
expectant fathers in Sri Lanka, where HIV prevalence
remains very low.
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Ofasia E1, Duffy SM2
1
World Vision Pacific Development Group; 2World Vision
Australia
Gender-based violence (GBV) is prioritised in Papua New
Guinea’s (PNG) National Gender Policy and Plan on HIV/
AIDS 2006-2010. Various studies indicate an association
between GBV and Human Immunodeficiency Virus
(HIV). High incidence of GBV in PNG is associated with
rapid social, cultural and economic change, social
dislocation and erosion of the wantok system, especially
in Port Moresby’s informal settlement areas. Victims of
physical and sexual violence exhibit higher rates of HIV
and sexually transmitted infections. The National AIDS
Council estimates nearly 60% of new HIV infections
in adults in 2007 occurred in women. Alarming rates
of domestic abuse (two out of three married women)
and sexual violence (over 50% of women) have been
recorded in PNG. In addition to HIV transmission caused
directly by violent sexual contact, GBV is symptomatic
of disempowerment and denial of a woman’s right to
exercise control over sexuality, and to sustain safe sexual
practices.
In 2007 World Vision commenced implementation of
the Ol Meri Igat Numba project to reduce GBV and HIV
transmission in four settlement areas. The project takes
an appreciative, rights-based and collaborative approach,
encouraging positive attitudes and behaviours as well
as challenging abusive ones. Project strategies combine
behaviour change communication (BCC), engagement
with service providers, and community forums. BCC
activities include theatre, dance, media campaigns,
and information, education and communication (IEC)
materials developed in partnership with women and
men in settlement areas. BCC messages raise awareness
of HIV, safer sex, rights, health and welfare services,
and strategies for action against perpetrators of GBV.
Community forums provide opportunities for women to
express concerns about GBV to men, community leaders
and service providers. To lessen women’s economic
dependence, women receive training in vocational and
business skills.
Project methodology and early project results will be
discussed, including successes and challenges. Anecdotal
evidence indicates that real change has occurred in both
men’s and women’s attitudes, but suggest long-term
engagement is required for sustainable change.

17-20 september 2008 @ Perth Convention Centre, Western Australia

There are many drivers of the epidemic and in the
Highlands of PNG tribal fighting may be one. While killing
men, tribal fighting creates a breeding ground for many
form of violence against women and girls. Women and
children are forced to be refugees in other ethnic areas,
women and girls are exchanged for guns and/or forced
into marriage and are raped and murdered. Women and
children go without food, girls are denied education
because they are refugees and pregnant women are
deprived of antenatal care during pregnancy and labour.
In these contexts women and girls are more vulnerable
to HIV.
Concerned with such high rates of violence in Melanesia
and East Timor a research of best practices was
commissioned by AusAID and carried out by Program for
Appropriate Technology in Health (PATH) utilizing local
researchers. Drawn from the PNG country evaluation,
which using participatory research methods, this paper
addresses how two communities in Chimbu Province
effectively addressing violence against women and girls
by first combating tribal fighting.
The success of these communities indicates that in order
for social change to occur there must be the desire for
such change. There must also be ownership of the
problem and the solutions. These communities and
other which want to change must also be prepared AND
supported to challenge cultural norms including violence,
leadership and relationships within and between men
and women and across ethnic groups. Two community
organisations have initiated gender equity training,
community policing by both men and women, and the
involvement of women in decision making.
Where communities are working to help themselves,
efforts must be made to help make them sustainable.
To address violence against women and girls, gender
relations need not be the direct entry point. Addressing
other social issues such as tribal fighting can lead to
change in gender relations and a reduction in violence
against women and girls which in turn will make them
less vulnerable to HIV. Communities have the power to
transform themselves providing sanctuaries for women
and girl from both violence and HIV.

Rawstorne P, Worth H, Kippax S
National Centre in HIV Social Research, The University of
New South Wales, Sydney, New South Wales, Australia
Sri Lanka has a low-level HIV epidemic. The first large scale
behavioural surveillance survey (BSS) in Sri Lanka was
conducted in 2006/2007. More than 7,000 people were
sampled from six sub-population groups: female sex
workers; factory workers; drivers of three-wheel taxis; men
who have sex with men; ‘beach boys’; and drug users. This
paper is focussed on female sex workers.

Women Risk HIV – International 

Kupul M1, Mek A1, Kepa B1, Kelly A2
1
Papua New Guinea Institute of Medical Research,
Goroka, Papua New Guinea; 2National Centre in HIV Social
Research, UNSW, Australia

FEMALE SEX WORKERS IN SRI LANKA: WHY
ARE WOMEN WHO WORK ON THE SREET
MORE LIKELY TO USE CONDOMS COMPARED
WITH WOMEN WHO WORK IN OTHER
LOCATIONS?

Sampling female sex workers (FSW) was done according
to the type of work context: streets, brothels, massageparlours, casinos, and karaoke bars. There were exactly 900
FSW who had vaginal intercourse with a paying client in
the previous twelve months, 488 of whom were working
on the street. (Note: anal intercourse is not included in
these analyses as it was rarely practiced).
In comparison with all other categories of FSW, women
working on the streets were more likely to have always
used condoms for vaginal intercourse in the last twelve
months (82.0 % versus 62.3 %, p=.000) and on the last
occasion (95.1 % versus 85.0 %, p=.000). These findings
were contrary to expectation and prompted further
analyses to explore the possible reasons why streetbased FSW are more likely to use condoms for vaginal
intercourse.
Multiple logistic regression analyses were conducted to
examine the factors that distinguished FSW working on
the street from other FSW. The final model showed that
street FSW were more likely to: carry condoms with them;
have found out about HIV through government health
services; decide themselves how much the client pays
for sex; and accurately believe that people can protect
themselves from getting HIV sexually by using a condom
every time they have intercourse. Street FSW were less
likely than other FSW to: read and write; and to have
found out about HIV through television.
Although less educated, FSW working on the street are
better prepared to prevent HIV transmission by the use of
condoms. These women are accessing important health
information from government health services and appear
to be taking greater responsibility for their health. Why
these women have better access to government health
services requires further exploration.
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TRIBAL FIGHTING, VIOLENCE AGAINST
WOMEN AND GIRLS AND HIV IN PAPUA NEW
GUINEA
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Women Risk HIV – International 

ALCOHOL CONSUMPTION, HIV
TRANSMISSION AND IMPLICATIONS FOR
WOMEN IN SOUTH AFRICA

ENABLING HIV PREVENTION OUTCOMES
FOR SEX WORKERS, PAPUA NEW GUINEA
Janelle Fawkes, Chief Executive Officer, Scarlet Alliance,
Australian Sex Workers Association,

Ghaly, S
The aim of this paper is to examine the HIV epidemic
in South Africa and to explore the role that alcohol
consumption plays in HIV transmission. The paper will
include a critical appraisal of various interventions that
aim to reduce alcohol abuse and in so doing, reduce HIV
incidence.

wednesday 17 september 2008:  11.00am – 12.30pm

In several studies, alcohol consumption has shown to
negatively impact on HIV prevention and treatment
programs in South Africa. High levels of alcohol
consumption are often attributed to factors such
as unemployment, abuse and as resistance against
oppression. High alcohol consumption was found to be
one of the predominant causes of risky sexual behaviour,
and a correlate of increasing levels of violence. The
association between increased risky sexual behaviour
and high levels of alcohol consumption has been
demonstrated through studies conducted in South
Africa by the South African Community Epidemiological
Network on Drug Use (SACENDU).

When sex work is criminalised sex workers ability to
access justice and services are reduced including: HIV
prevention, testing, treatment and care; general sexual
health. Laws regulating sex work in Papua New Guinea
have been interpreted to mean sex work per se is illegal.
This paper reviews the Papua New Guinea laws and
reports on the impact of stigma and discrimination
on HIV prevention along with the direct impacts on
individuals. Anecdotal evidence collected during a three
year capacity development project working directly with
Papua New Guinea sex workers has identified the need
for enabling legal environments for the success of future
HIV prevention, testing, treatment and care services for
sex workers in Papua New Guinea.

After working with local HIV clinics in townships with
the Organisation Friends of Africa, it became evident
that underdevelopment, high unemployment, lack of
recreational activities and the access to illegal alcohol
outlets impacts on the risk of disease transmission, rape,
teenage pregnancies and other forms of violence against
women, all of which may contribute to increasing HIV
rates. Intervention strategies such as the 2003 National
Liquor Act have been established to reduce levels of
alcohol consumption, by including a liquor outlet policy;
regulating the physical availability of alcohol; and placing
restrictions on alcohol marketing. Increasing employment
opportunities and the availability of recreational activities
are strategies that can also aid in reducing alcohol misuse
and high risk sexual behaviour. However, many of these
strategies have not yet been implemented. Consequently
alcohol remains the highest abused substance causing
irreversible social and physical damage for people living
in South Africa.
This paper reports on the effects that the misuse of
alcohol can have on the increasing rates of HIV and the
fact that women are predominantly affected and provides
a critical appraisal on some of the current alcohol related
interventions aimed at reducing HIV/AIDS transmission in
South Africa.
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TOWARDS VACCINES ELICITING BROAD
NEUTRALISING ANTIBODY RESPONSES BY
SELECTING FOR HIV-1 ENV IMMUNOGENS
THAT PROMINENTLY EXPOSE CONSERVED
NEUTRALISATION EPITOPES

restricted, relatively neutralisation sensitive) strains. Env
from one brain-derived clone elicited antibodies that
neutralised reporter virus pseudotyped with heterotypic
B-clade AD8 and 89.6 Env, but surprisingly not NL4.3 Env.
The systematic screening of Env variants may provide
further useful Env candidates for evaluation as broad
NAb-eliciting vaccines in animals

ACH2 Bench to Bed: 1

ACH2 Bench to Bed: 1
11.00am – 12.30pm

Purcell DF1, Tan J1, Siebentritt C1, Sterjovski J2, Gray LR2,
Churchill MJ2, Reddy SM1, Ramsland PA3, Gorry PR2 and
Center RJ1
1
Department of Microbiology and Immunology,
University of Melbourne, Parkville VIC 3010; 2Macfarlane
Burnet Institute for Medical Research and Public
Health, Prahran VIC 3004; 3Structural Immunology
Laboratory, Macfarlane Burnet Institute for Medical
Research and Public Health, Heidelberg, VIC 3084
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The recent failure of HIV vaccines eliciting potent T-cell
responses in humans has highlighted the need to also
stimulate broadly neutralising antibodies against HIV-1
envelope protein (Env), but this has proven a difficult task.
While antibodies can be non-neutralising or enhancing
for HIV infection, the desired broad neutralising antibodies
bind conserved conformations such as the CD4 receptor
and chemokine coreceptor binding sites on Env
oligomers. We hypothesised that environments where
target cells display low levels of receptor/coreceptor and
negligible neutralising-antibody levels may select for
HIV isolates that highly expose neutralisation-sensitive
Env structures required for viral entry. We sought to
rationally screen a panel of oligomeric Env for candidate
neutralising-antibody immunogens by ranking them
for binding affinity for soluble CD4 receptor (sCD4) and
affinity for a reference panel of broadly neutralising
monoclonal antibodies (mNAb). We assessed Env from
two sources: 1) the brain, where antibody levels are
typically low and 2) blood from late-stage AIDS patients
when HIV-specific antibodies diminish. In general, Env
from brain-derived clones showed higher affinity for
mNAb and sCD4 than did Env from control clones derived
from matched patient spleen. While some Env variants
from late AIDS patients showed high affinity for sCD4 or
mNAb this was not consistently different compared to
Env derived from pre-symptomatic patients in the same
cohort. A group of 6 Env clones with higher affinity for
mNAb and/or sCD4 were selected for a DNA prime with a
recombinant soluble gp140 oligomeric Env protein boost
immunisation trial in mice. Most mice developed high
anti-Env specific antibody titres measured by ELISA. Sera
were pooled within groups and assessed for the ability to
neutralise virus pseudotyped with Env derived from the
AD8 (CCR5-restricted, relatively neutralisation resistant),
89.6 (dual CCR5/CXCR4 tropic) and NL4.3 (CXCR4		
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UNDERSTANDING SUSCEPTIBILITY TO CMV
Immune Restoration Disease and the 
immunological consequences of 
extreme immunodeficiency

Predicting neuropathy risk before 
stavudine prescription: an algorithm 
for minimizing neurotoxicity in 
resource-limited settings

Patricia Price; Pathology and Laboratory Medicine,
University of Western Australia

Cherry CL1, Affandi JS2, Imran D3, Yunihastuti E 3, Smyth K4,
Vanar S5, Price P2, Kamarulzaman A5

CMV disease is a common complication of late-stage
HIV disease and recurs as immune restoration disease
(IRD) in some patients. Here immunological and genetic
factors assayed by our group are used to profile patients
who experience CMV disease`. CD4 T-cell responses
were assessed by IFNγ ELISpot assay and antibody was
quantitated by ELISA using a whole CMV antigen.

1

wednesday 17 september 2008:  11.00am – 12.30pm

We tested all available samples from patients who had
begun ART with advanced immunodeficiency (nadir < 50
CD4 T-cells/µl) in Perth (1996-8) and achieved a sustained
virological and immunological response (n=50 patients).
These criteria imply selection of patients on the basis of
survival before ART and a favorable outcome thereafter.
Although CD4 T-cell counts increased during the first
year on ART, IFNγ responses to CMV were low before ART,
rose slowly and never reached levels seen with cells from
uninfected donors. Within this patient cohort, the lowest
nadir CD4 T-cell counts associated with persistently low
CD4 T cell IFNγ responses to CMV antigen, higher IFNγ
responses to an NK-cell target (K562) and characteristic
TNFA and IL12B genotypes. In a broader cohort, the TNFA
genotype and high numbers of activating KIR genes were
associated with a history of CMV as an AIDS–defining
illness.
Patients who developed CMV IRD (retinitis or encephalitis,
n=7) had a history of CMV-AIDS. Their CMV IRD paralleled
a rise in anti-CMV antibody and markers of immune
activation (eg: plasma IL-6). Longitudinal studies of IFNγ
responses were not possible, but responses were low 23 years after the IRD. CMV IRD patients all had very low
nadir CD4 T-cell counts and the characteristic TNFA /
IL12B and KIR genotypes. These genotypes may promote
extreme immunodeficiency and/or CMV-AIDS or may
allow patients to survive these conditions to experience
an IRD and join our study. Activating KIR may promote
an NK response able to compensate for poor CD4 T-cell
responses to CMV. A corollary of this model is that CMV
IRD may not be a T-cell cytokine storm, as implicated in
IRD associated with mycobacteria.
A different scenario emerges in Kuala Lumpur. Patients
beginning therapy with <200 CD4 T-cells all experienced
a rise in CMV antibody and CD4 T-cell IFNγ responses.
Associations with CMV IRD are now under investigation.
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Burnet Institute, Monash University, and The Alfred
Hospital, Melbourne, Victoria, Australia; 2Royal Perth
Hospital and University of Western Australia, Perth, Western
Australia, Australia; 3Pokdisus Clinic, Cipto Mangunkusumo
Hospital and University of Indonesia, Jakarta, Indonesia;
4
Australian National University, Canberra, ACT, Australia;
5
University of Malaya, Kuala Lumpur, Malaysia.
Sensory neuropathy (SN) is a common, disabling
complication of stavudine (d4T) therapy, with prevalence
rates >40% reported from d4T-treated cohorts of patients
with HIV. Despite its toxicity, d4T is an effective, relatively
inexpensive HIV treatment and remains important in
resource-limited centres. Methods of predicting SN risk
are needed to guide antiretroviral prescribing in countries
where some use of d4T remains an economic necessity.
We undertook SN screening programs in Melbourne
(low d4T use), Kuala Lumpur (intermediate d4T use)
and Jakarta (routine d4T use) in 2006 to describe SN
risk factors among HIV patients in our region. SN was
defined by the presence of symptom/s and sign/s on
the AIDS Clinical Trials Group Brief Peripheral Neuropathy
Screen. Patients’ height, age and weight were recorded
and demographic, laboratory and treatment data were
obtained from the medical file. Statistical analysis using
Stata 9.2 defined factors associated with SN. The role of
patient demographics in predicting SN was then assessed
in patients who had ever used d4T.
294 patients were assessed (100 Australians, 98 Malaysians
and 96 Indonesians). Prevalence rates of SN were 42%,
19% and 34% respectively and 32% overall. In addition
to treatment exposures, increasing age (p=0.002) and
height (p=0.001) were independently associated with SN
risk. Receiver operating characteristic analysis suggested
“cut offs” of ≥170cm and/or ≥40 years for predicting
patients at risk of SN. These were applied to the 181 d4Texposed patients, yielding an SN risk of 20% in younger,
shorter patients, 33% in younger but taller patients, 38%
in older but shorter patients, and 66% in those older than
40 years and taller than 170 cm.
Stavudine is infrequently prescribed in Australia due
to high rates of toxicity, but remains an important HIV
treatment in our region. Rates of SN, a common d4T
toxicity that impairs quality of life and may reduce
patients’ ability to work, vary with patient age and height.
These data support prioritizing patients taller than 170
cm and/or older than 40 years (factors measurable at no
extra cost) for access to antiretrovirals other than d4T.
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BIOLOGICAL CHARACTERIZATION OF NOVEL
HIV-SPECIFIC ACTIVITY
Nitin Saksena1, Maly Soedjono1, Wayne Dyer2, and John
Zaunders3 and Bin Wang1,
1
Retroviral Genetics Labs, Westmead Millennium Institute,
USYD, Westmead, Sydney; 2Australian RedCross, Clarence
Street, Sydney; 3Center For Immunology,Darlinghurst,
Sydney

wednesday 17 september 2008:  11.00am – 12.30pm

Human Immunodeficiency virus type-1 has led to global
AIDS pandemic. Currently, there are 40 million people
infected with HIV and with 14,000 new infections occurring
each day. Although there are several lines of anti-retroviral
drugs available in the market and have provided better life
standards to HIV-infected individuals, there are continuing
problems associated with these drugs-such as toxicity
and emergence of resistance. All HIV vaccines have failed
to date. Thus, fresh approaches and strategies are needed
for controlling HIV. Recently, we have discovered a novel
HIV-specific cellular differentiation activity in the soluble
factor secreted by the CD4+ T cells from a unique HIV+
elite controller. This cellular differentiation activity leads to
the induction of CD14+ monocytes to their differentiation
to antigen presenting cells displaying CD40, CD86, CD11b
and CD14 markers. This activity was observed to occur in
both autologous and non-autologous fashion. This new
approach has shown promise on cells from HIV+ positive
individuals with low viral loads, suggesting its possible
future use as a therapeutic vaccine in conjunction with
currently prescribed therapy. The biology of these findings
will be findings will be discussed in detail.
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IDU – Domestic

RESULTS FROM THE 2008 PERIODIC SURVEY
OF NSW NEEDLE AND SYRINGE PROGRAM
ATTENDEES

IDU – Domestic
1.30pm - 3.00pm
ILLICIT DRUG USE AND RISK OF HIV
SEROCONVERSION AMONG GAY MEN IN
SYDNEY: DATA FROM THE HIM COHORT

wednesday 17 september 2008:  1.30pm – 3.00pm

Prestage G1, Jin F1, Imrie J2, Zablotska I2, Kippax S2,
Kaldor J1, Grulich A1
1
National Centre in HIV Epidemiology & Clinical Research,
UNSW; 2National Centre in HIV Social Research, UNSW.
Background: Illicit drug use has been associated with risk
behaviour among gay men. We examined frequency of
use of illicit drugs as a risk factor for HIV seroconversion in
a community-based cohort of HIV negative homosexually
active men in Sydney, Australia.
Methods: From June 2001 to June 2007, participants
underwent annual HIV testing and were interviewed
twice a year. Detailed information about sexual, drugusing and other behaviour was collected.
Results: Among 1,427 participants enrolled, 53 HIV
seroconverters were identified by June 2007.
At baseline, 62.7% reported using illicit drugs in the
previous six months, including 10.7% who reported at
least weekly use. Illicit drug use was associated with
unprotected anal intercourse with casual partners
(UAIC) (p<.001). Use of illicit drugs was associated with
increased risk of HIV infection at a univariate level and
this risk increased with greater frequency of use. This was
also true of the use of Viagra. Use of methamphetamine,
amyl nitrite and Viagra were highly intercorrelated. Use
of each type of illicit drug was included in multivariate
analysis, but after including Viagra only amyl nitrite and
Viagra remained significant. After controlling for sexual
risk behaviours, only use of Viagra remained significant
(AOR=1.75, CI=1.31-2.33, p<0.001), although amyl nitrite
was borderline significant (AOR=1.26, CI=0.98-1.62,
p=0.074).
Conclusion: While drug use may not be a directly
causative factor for UAIC, in this cohort of HIV-negative
gay men frequent drug use is independently associated
with HIV seroconversion. Viagra, amyl nitrite and
methamphetamine are often used specifically, and
explicitly, to enhance sexual pleasure among gay men,
especially in the context of ‘partying’. The association
between these drugs and UAIC among gay men suggests
that intensive sex partying, where both these activities
often occur, is an appropriate priority in HIV-prevention
efforts in this population.
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Deacon RM1, Iversen J1, Mason R2, Maher L1,3
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney, NSW,
Australia; 2AIDS/Infectious Diseases Branch, NSW Health
Department, Sydney, NSW, Australia; 3School of Public
Health and Community Medicine, University of New
South Wales, Sydney, NSW, Australia
In April 2008, the NSW Department of Health requested
that staff at Needle and Syringe Programs (NSPs) collect
demographic and drug use data from clients of NSP
services. The National Centre in HIV Epidemiology
and Clinical Research (NCHECR) was commissioned to
analyse and report on the results. All clients attending
participating NSPs during a two week period were asked
to provide information on their gender, age, ethnicity,
age of first drug injection, last drug injected, frequency
of injecting, syringe disposal and where syringes were
obtained.
A total of 6047 data collection forms were returned from
the 52 NSPs who participated in the data collection. Of
these, 3197 were clients who had not previously attended
the NSP during the two week period. The number of repeat
clients was 2009 giving an overall repeat ratio of 1.6. The
median age of non-repeat clients was 36 years, 66% were
male, 5.9% were from a non-English speaking background
and 13% self-identified as Aboriginal and/or Torres Strait
Islanders. The median duration of injecting drug use was
15 years and the most common drug last injected was
heroin (33%), followed by methamphetamine (28%).
Approximately 41% of clients reported injecting daily or
more frequently.
This project provides an important snapshot of the NSW
NSP client base and a useful mechanism for comparing
the characteristics of clients across different geographic
areas in NSW, as well as guiding estimates of the total IDU
population in NSW for service coverage evaluation.
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Kwon AJS,Iverson J, Maher L, Law M, Wilson DP
National Centre in HIV Epidemiology and Clinical Research,
University of New South Wales, Sydney, Australia
Sharing syringes by injecting drug users (IDUs) is an
important mode of worldwide transmission of blood
borne viruses, such as HIV and HCV. In Australia, the
current coverage of sterile syringes is approximately
50% and annually there are ~30-40 HIV notifications and
~9,500 cases of HCV due to syringe sharing by IDUs.
We address the following research questions: (i) what
are the driving behavioural factors in differential HIV and
HCV incidence among IDUs in Australia? (ii) What impact
will changes in needle-syringe programs (NSPs) have on
HIV and HCV incidence? (iii) How much reduction in the
proportion of injections that are shared and number of
time a syringe is used before disposal is required in order
to theoretically eradicate HIV and HCV epidemics among
IDUs?
These questions are addressed through the development
of a novel mathematical model based on risk equations,
calibrated to the Australian population of IDUs. Differential
incidence rates for the two epidemics are due to
differences in transmission probabilities but also because
syringe sharing behaviour and syringe distribution in
Australia are at levels that sustain high levels of HCV
incidence but not HIV. We provide predictions of the
changes in incidence of both epidemics due to changes
in intervention strategies.

THE ROLE OF NEEDLE SYRINGE PROGRAMS
IN PREVENTING TRANSMISSION TO
INJECTING BY YOUNG PEOPLE
Spooner C1, Brenner L1, Treloar C1
1
National Centre for HIV Social Research, University of
NSW, Sydney, NSW, Australia

IDU – Domestic

CONTINUED INCREASES IN SYRINGE
DISTRIBUTION ARE REQUIRED TO RESTRAIN
VIRAL TRANSMISSIONS AMONG INJECTING
DRUG USERS IN AUSTRALIA: RESULTS FROM
A MODELLING STUDY

There is evidence that drug users in Australia are making
transitions to injecting at younger ages. Needle and
syringe programs (NSPs) play important roles in services
for injecting drug users (IDU), and have the potential to
assist in prevention of transition to injecting methods.
However, their potential to access young people at risk of
initiating injection is affected by the reluctance of young
people to use health services.
How can NSPs be better accessed by young people and
play a role in prevention? What are the issues around
young people accessing NSPs?
To answer these questions, a literature review and
key informant consultations were conducted. Using
this research, an overview of existing and potential
strategies and an outline the significant issues for NSPs
in implementing such strategies will be presented. Issues
include concerns about exposure of young people to
drug users, normalisation of drug use, and NSP workforce
capacity to work with young people and implement
interventions.
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If Australia had not implemented NSP from the late 1980s,
then HIV notifications could have increased substantially
and moderate increases in HCV would also have been
observed. We predict that interventions due to NSP are
very effective in reducing HIV and HCV. An increase of in
the coverage rate to 90% could theoretically eradicate
HCV transmission among IDUs. Alternatively, if the
proportion of injections that are shared decreased from
15% to 2.5% then the HCV epidemic among IDUs could
be eradicated. This research highlights the large benefits
of NSPs and recommends that increased coverage can
result in significant reductions in viral transmissions
among IDUs.
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A gap analysis of people with a 
history of injecting drug use who 
are not currently accessing HIV
and sexual health services in South 
Eastern Sydney Illawarra Area Health  

INCREASING HEPATITIS C TREATMENT
UPTAKE BY INJECTING DRUG USERS FROM
CULTURALLY AND LINGUISTICALLY DIVERSE
BACKGROUNDS: OUTCOMES OF A PILOT
STUDY OF INDOCHINESE INJECTORS

Gahan G1, Malcolm A2, Purchas J3, Darlison L4,
Narayanan P5
1
HIV/AIDS & Related Programs Unit, South Eastern Sydney
Illawarra Area Health; 2, 3, 4, 5 The Millar Group Public Health
Consultants, Sydney

Coupland H1, Levy, M2, Day, C3, & Maher L1
1
National Centre in HIV Epidemiology and Clinical
Research and School of Public Health and Community
Medicine, University of New South Wales; 2Sydney South
West Area Health Service; 3Drug Health Services, Faculty
of Medicine, University of Sydney

People with a history of injecting drug use are documented
as one of the priority groups in the NSW HIV/AIDS
Strategy 2006-2009 and receive special reference in the
NSW Sexually Transmitted Infection Strategy 2006-2009.
Despite this, access to specialist HIV and sexual health
services by people who inject drugs remains low.
This paper describes a gap analysis commissioned
by South Eastern Sydney Illawarra Health to identify
characteristics and needs of people with a history of
injecting drug use and who are not accessing HIV/AIDS
and STI services; and to Identify service support strategies
for how SESIH services can better target these populations
to improve access.
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The paper describes innovative strategies used to contact
key informants, the role of informatics in analysing service
utilisation data and the development of service reorientation processes to increase access to not only HIV
and sexual health promotion, screening, prevention and
testing services but also to treatment and care services.
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Background: There has been limited research exploring
hepatitis C (HCV) treatment- seeking from the perspective
of injecting drug users (IDUs), particularly those from
culturally and linguistically diverse backgrounds.
Methods: Between 2003 and 2007 ethnographic fieldwork
and in-depth interviews were conducted with IndoChinese IDUs in South Western Sydney (n=72) recruited
using theoretical and snowball sampling. Eligibility criteria
for the pilot study (n=23) included being aged 18 years
and over, ability to complete interviews in English, being
of Cambodian, Lao or Vietnamese cultural background
and having injected drugs in the last six months. Following
a baseline interview about HCV, a culturally-informed
brief intervention about HCV treatment was provided
and participants offered facilitated referral to a tertiary
liver clinic. Participants were followed up and interviewed
again at three and six months.
Results: At baseline, most participants were unclear about
what treatment involved and its potential outcomes.
Participants responded to the brief intervention with
numerous, detailed questions but while most expressed
interest in having treatment at some stage, few (n=3)
attended the clinic. Factors influencing treatmentseeking included the cultural significance of “curing” HCV,
perceived capacity to adhere to treatment in the event of
experiencing side effects, patterns of injecting drug use,
precarious personal circumstances and lack of support,
imprisonment and past experiences with health services.
Some participants experienced difficulties accessing
the liver clinic, particularly with the system for making
appointments. Those who accessed the clinic and
disclosed current drug use felt that they were discouraged
from initiating treatment until they stopped injecting
drugs. Cultural factors influenced interactions with clinic
staff, particularly disclosure of drug and treatment-related
concerns.
Conclusions: Findings suggest that the brief intervention
increased participants’ knowledge levels and interest in
seeking treatment at some stage in the future. However,
in addition to raising awareness of treatment, issues
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identified regarding the assessment process and options
for assistance and support during treatment, need to be
addressed to promote treatment uptake by this group.
Models of service delivery in tertiary settings need to
include staff capacity to address drug dependence
issues, streamlined referral and assessment processes and
mechanisms for linking clients with culturally-appropriate
support.
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GENOMIC AND PROTEOMIC
CHARACTERIZATION OF A NOVEL HIVSPECIFIC ACTIVIITY
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1.30pm – 3.00pm
Tissue-specific adaptive changes in 
V3 of gp120 enable persistence of 
Maraviroc-sensitive R5X4 HIV-1 in brain 
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Paul R. Gorry.
Centre for Virology, Macfarlane Burnet Institute for
Medical Research and Public Health, Melbourne, Victoria,
Australia.
Most neurotropic HIV-1 strains are CCR5-restricted, but
R5X4 variants have been identified infrequently in brain.
In this study, HIV-1 Envs were cloned from R5X4 primary
viruses isolated from brain (n=6) and spleen (n=6) of
subject MACS1. Single R5X4 Envs cloned from brain
and blood of another subject were included (aBR01,
aBL01). Envs were sequenced and structural modeling
was performed to analyze amino acid variants. Env
fusogenicity was tested in fusion assays with wild type
and mutant coreceptors. Sensitivity to inhibition by the
CCR5 and CXCR4 inhibitors, Maraviroc and AMD3100
respectively, was tested in single-round entry assays.
MACS1 brain (M1br) and the brain-derived aBR01 Envs
were more fusogenic than Envs from matched spleen
or blood in cells expressing CD4/CCR5, whereas MACS1
spleen (M1sp) and the blood-derived aBL01 Envs were
more fusogenic than Envs from matched brain in cells
expressing CD4/CXCR4. Entry assays showed brain/
spleen R5X4 Envs had preferential usage of CCR5/CXCR4
for entry, respectively. Studies with coreceptor mutants
showed that, compared to M1sp Envs, M1br Envs had
reduced dependence on residues in the CCR5 N-terminus
(Y15), ECL1 (H88), and ECL3 regions (E262, F264) for CCR5mediated fusion. Compared to M1br Envs, M1sp Envs had
reduced dependence on residues 4-36 in the CXCR4 Nterminus and R183 in the ECL2 region for CXCR4-mediated
fusion. Sequence analysis identified R306 in the V3 loop
of 6/6 M1sp Envs and S306 in 6/6 M1br Envs. Mutagenesis
studies showed R/S306 was solely responsible for the
spleen/brain phenotypes, respectively. Whilst entry of
spleen R5X4 Envs was not inhibited by the CCR5 inhibitor
Maraviroc, entry of brain R5X4 Envs was potently inhibited
by Maraviroc; a phenotype also conferred by R/S306.
Thus, tissue-specific adaptive changes resulting in altered
mode of coreceptor usage may enhance the tropism of
compartmentalized R5X4 strains for cells expressing CCR5
in brain and CXCR4 in lymphoid tissues. Furthermore,
the results suggest CCR5 inhibitors may be effective in
suppressing certain R5X4 HIV-1 variants.
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Bin Wang1, Maly Soedjono1, Wayne Dyer2, Amit Kapur3
and Nitin Saksena1
1
Retroviral Genetics Labs, Westmead Millennium Institute,
USYD, Westmead, Sydney
2
Australian RedCross, Clarence Street, Sydney
3
Australian Proteomic Facility, Macquarie University,
Sydney
Virus-specific CD4+T cells play a critical role in antiviral
immunity. HIV-1-specific CD4+T cells in chronicallyinfected adults are mostly composed of IFN-g secreting
cells and IL-2-secreting CD4+T cells, while in other HIVinfected progressors there appears to be a defect in IL2-secreting cells. The HIV-infected non-progressors differ
from other HIV+patients in displaying strong proliferative
responses to viral antigen, which are thought to be
highly protective. As discussed in the first talk, we have
identified a rare HIV-infected non-progressor, in whom
this proliferative response was coupled with strong
HIV-specific cellular differentiation activity, which has
not been observed before. This differentiation activity
was mediated by a soluble factor secreted by CD4+T
cells in response to HIV antigen. This soluble factor,
in vitro, induces a potent and rapid differentiation of
CD14+ monocytes to antigen presenting cells in both
autologous and non-autologous fashion. In this study,
using quantitative superarray, whole human genome
microarray (>47,000 genes) and mass spectrometry, we
have elucidated possible immunological mechanism of
this novel HIV-specific bioactivity.
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1
SA Pathology, Adelaide, SA, 5000; 2School of Molecular
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Anthony L. Cunningham
Centre for Virus Research, Westmead Millennium Institute,
Westmead NSW Sydney Australia 2145

HIV DNA can persist for years in circulating cells from
patients on successful anti-retroviral therapy and presents
a circulating latent reservoir of virus. New drugs to treat
HIV infection are targeted at the HIV integrase (IN) enzyme.
We assessed changes in HIV DNA in patients treated with
an IN inhibitor, to assess if these new drugs can clear this
circulating reservoir.
PBMC were isolated from patients recruited for Raltegravir
(Ral) combination therapy based on special access
guidelines, DNA extracted and HIV DNA quantitated (1).
IN DNA sequence was obtained by consensus sequence
analysis. HIV DNA was detected in all patients prior to
Ral therapy and declined to undetectable levels within 4
wks in 5/6 patients and 8 wks in the 6th patient. Patients
concurrently showed a rise in CD4+ cells and a decline
in circulating plasma viral load. The increase in CD4+
cells without accompanied increased HIV DNA, indicates
reconstitution with HIV negative cells and prevention
of further re-infection of these cells. Successful therapy
was maintained for at least 6 mths. A minor transient
viremia was observed in one patient with a brief
treatment intermission at 3 mth post-therapy which was
accompanied by an increase in HIV DNA. Ral-induced
drug resistance mutations in the IN gene were not
observed in either the circulating virus or PBMC DNA.
In conclusion, Ral combination therapy successfully
and rapidly reduced HIV viral load and cellular DNA and
increased CD4+ without drug resistance. Prevention of
HIV DNA integration may promote decay and clearance
of unintegrated latent HIV DNA forms, while the turn-over
of cells harbouring integrated DNA without re-population
of new infected cells may subsequently purge the HIV
DNA containing reservoir. Thus, IN inhibitor therapy may
reduce the circulating HIV reservoir above that seen with
traditional protease and RT inhibitor based combination
therapies.
This work was supported by funding from ACH2
(1) Carr, J.M., et al., (2007) J Clin Micro, 45(4): 1288-97

The interaction of HIV with immature Langerhans cells
(iLCs) in the female genital tract is of key importance for
sexual transmission, as these cells are the major cells able
to transport virus through epithelium to T cells in the
submucosa or lymph node. HIV binds initially to langerin
on iLCs. Then the virus is probably either endocytosed or
cause true infection. Therefore inhibition of HIV binding to
langerin is likely to be a successful strategy for prevention
of infection by microbicides (but probably requires
combination with an inhibitor of the HIV fusion receptor
(CCR5)).
To test this hypothesis we initially used skin/mucosa
derived immature (i)LCs but yields were too low for
screening inhibitors, only for final validation of results.
However with the model iLCs, Mutz 3 cells, derived from
acute myelomonocytic leukaemia (5) and cultured in
GM-CSF, TNFα, TGF-β, 99% expressed Langerin and <2%
DC-SIGN and mannose receptor (MR), after cell sorting
to deplete DC-SIGN/MR+ cells. 80-95% of these cells also
expressed CD4 and 25-30% expressed CCR5. They were
infectable by HIV at similar levels to iLCs.
Meanwhile parallel studies on the oligomeric status of
langerin on the surface of langerin transfected QT6 and
Mutz3 cells showed Langerin to equilibrate between
monomeric and tetrameric states and that HIV gp120
trimer bound more strongly to the tetramer. The first
inhibitors tested were the generic C Type Lectin Receptor
inhibitor, mannan, and also blocking monoclonal
antibodies to the carbohydrate recognition domain
(CRD) and/or full extracellular domain (ECD) of langerin.
All inhibited gp120 monomer/trimer binding to langerin
as a monomer but not as a tetramer, indicating the
need to develop inhibitors of gp120-langerin oligomer
imteractions, such as soluble langerins. The latter were
tested for toxicity to monocyte derived DCs, Mutz 3 cells
and keratinocytes and shown to be toxic only at high
concentrations of >25μg/ml, using trypan blue dye
exclusion or, for DCs in an antigen presentation assays.
We will now examine the efficacy of soluble langerins in
inhibiting binding of gp120 to langerin (oligomers) on
Mutz 3 cells and iLCs, infection of these cells and finally
transfer of HIV from these cells to CD4 lymphocytes.
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Inhibition of HIV binding to langerin 
on Langerhan’s Cells as a strategy 
for microbicide development
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HIV DNA LEVELS IN PBMC DECLINE IN
PATIENTS RECEIVING INTEGRASE INHIBITOR
COMBINATION THERAP
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AN HLA-C*0702 RESTRICTED T-CELL
RESPONSE DIRECTED AGAINST AN IMMUNE
ESCAPED HIV NEF KY11 EPITOPE EXHIBITS
HIGHER FUNCTIONAL AVIDITY BUT LESSER
CYTOLYTIC ACTIVITY WHEN COMPARED
WITH THE ANTI-WILD TYPE RESPONSE

for adaptation driving creation of epitopes. In addition,
preliminary data on CTL killing suggests lesser cytolytic
activity of the variant specific T-cell response would favour
persistence of the adapted virus. These data support the
possibility of HIV adapting to actively exploit rather than
simply evade T-cell responses and have implications for
epitope inclusion criteria in HIV vaccine design.

Keane NM, Laird R, Chopra A, Maiden T, Almeida C, Mallal
S, John M
HIV-1 mutational escape from a suppressive epitopespecific T-cell response has been well described. Analysis
of HLA allele associated HIV polymorphism in populationbased studies (n>800) suggests that HIV may also adapt to
favour induction of certain epitopes that actively enhance
viral replication. We therefore sought to investigate the
presence and functionality of the HLA-restricted T-cell
responses driving one such adaptation identified by the
genetic analysis (Nef D108E in the HLA-C*0702 restricted
Nef KY11 epitope).
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Cryopreserved PBMC samples from 32 HIV-infected
patients with HLA-C*0702 allele were assayed for IFN-γ
production upon stimulation with the adapted and nonadapted (‘wild type’) KY11 peptides by ELISpot assay.
The functional avidity of wild type and variant-specific
T-cell directed responses were compared using serial
peptide dilutions. Autologous epitope sequences were
determined from contemporaneous plasma samples in
patients with detectable HIV viral load (n=4). CTL killing of
peptide-pulsed EBV transformed B-cells was determined
using the Chromium release assay.
IFN-γ was detected in PBMC samples from all patients
after stimulation with anti-CD3 or CEF. IFN-γ responses to
the wild type or adapted KY11 epitopes were detected
in 13 patients. The adapted epitope induced IFN-γ
responses in 11 HLA-C*0702 patients (median-500,
range 150-1110 spots/million cells). In 3 samples from 2
cases, the adapted peptide-specific response had greater
functional avidity than the wild type peptide. Autologous
sequence contained the D108E adaptation in 1 patient
who concurrently demonstrated IFN-γ responses. In
initial assessments of T-cell killing, HLA-C*0702 B-cells
pulsed with wild type peptide were killed more readily by
adapted peptide CTLs than wild type peptide CTLs.
Despite modest levels of epitope-specific IFN-γresponses
overall in this treatment-experienced patient group, HLArestricted responses against an HLA-adapted epitope
were demonstrable, including with higher avidity than the
wild type form in 3 samples, suggesting a functional basis
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Antibody-dependent cellular cytotoxicity (ADCC) is
a potentially effective adaptive immune response to
HIV-infection. The study of ADCC responses has been
hampered by the lack of simple methods to quantify these
responses and map effective epitopes. We serendipitously
observed that standard intracellular cytokine assays
on fresh whole blood from a cohort of 26 HIV-infected
subjects identified non-T lymphocytes expressing IFN-γ
in response to overlapping linear peptides spanning HIV1 proteins. The effector cells were CD3-4-8-14-2+56+/- NK
lymphocytes and degranulated Granzyme B and Perforin
in response to antigen stimulation. Serum transfer assays
demonstrated that the specific response was mediated
by IgG. Fresh blood samples from half of the HIV-infected
cohort demonstrated robust HIV peptide-specific IFNγ expression by NK cells; predominately to Env, Pol and
Vpu HIV-1 proteins. Responses were readily mapped to
define minimal epitopes utilizing this assay. Antibodydependent, HIV-specific NK cell recognition, involving
components of both innate and adaptive immune
systems, represents a novel and potentially effective
immune responses to induce by vaccination.

Fernandez S, Price P, French MA
Department of Clinical Immunology and Immunogenetics,
Royal Perth Hospital and School of Pathology and
Laboratory Medicine, University of Western Australia.
Perth, WA, Australia
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CMV-SPECIFIC EFFECTOR MEMORY CD4+
T-CELLS IN HIV PATIENTS ON LONG-TERM
ART ARE PREDOMINANTLY ‘CD28 NULL’
IMMUNOSENESCENT CELLS

HIV-infected individuals who achieve a long-term
virological response to combination antiretroviral
therapy (ART) experience variable recovery of CD4+ T-cell
responses to the antigens of opportunistic pathogens.
This does not reflect current CD4+ T-cell numbers but is
particularly evident amongst individuals who had a low
nadir CD4+ T-cell count before ART. Using cytomegalovirus
(CMV) as an index antigen, we examined markers relevant
to the activation or regulation of CD4+ T-cell interferon
(IFN)-γ responses in HIV patients on ART.
Study groups comprised male, CMV-seropositive HIV
patients (n=18) and healthy controls (n=10). HIV patients
were selected to fit three criteria; (1) nadir CD4+ T-cell
counts <50 cells/µL, (2) at least 3 years on ART and (3)
plasma HIV RNA <50 copies/mL for at least 2 years. IFNγ responses to a crude CMV antigen were measured
by ELISpot and were shown to arise from CD4+ T-cells.
Flow cytometry was used to assess expression of CD57,
CD28, cytotoxic T-lymphocyte antigen (CTLA)-4 and
programmed death (PD)-1 on CD4+ T-cells.
Expression of CTLA-4 on CD4+ T-cells was higher overall
in HIV patients compared to controls (p=0.03) but was
not correlated with IFN-γ responses to CMV (r=-0.17).
The expression of PD-1 on CD4+ T-cells in HIV patients
extended over a wider range than controls (median
(range) 4.9% (0.2-13.1) vs 2.3% (0.4-4.5), respectively)
but was also not associated with IFN-γ responses to
CMV (r=0.26). The majority of CD4+ T-cells expressed
CD28 in both patients and controls (median of 90%
and 93%, respectively) and CD28 expression inversely
correlated with IFN-γ responses to CMV (r=-0.54, p=0.02)
in HIV patients. CD4+ T-cells that did not express CD28
expressed high levels of CD57. The proportion of CD57+
CD28- T-cells was directly correlated with IFN-γ responses
to CMV in HIV patients (r=0.56, p=0.01).
These data suggest that a substantial proportion of
CMV-specific effector memory T-cells in previously
immunodeficient HIV patients receiving long-term
effective ART are immunosenescent ‘CD28 null” CD4+
T-cells, a situation similar to some autoimmune diseases.
IFN-γ responses to CMV do not appear to be limited by
CTLA-4 or PD-1.
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ROBUST NK-CELL MEDIATED HIV-SPECIFIC
ANTIBODY-DEPENDENT RESPONSES IN HIVINFECTED SUBJECTS
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PHENOTYPIC ANALYSES OF FOXP3EXPRESSING CD4+ AND CD8+ T CELLS IN
HIV-INFECTED PATIENTS

Identification of human antigenspecific regulatory T cells,
phenotyping and functional analysis

Lim A1, French MA1,2, and Price P1,2
1
School of Pathology and Laboratory Medicine, University
of Western Australia, Nedlands, Western Australia,
Australia; 2Department of Clinical Immunology and
Immunogenetics, Royal Perth Hospital, Perth, Western
Australia, Australia.

Nabila Seddiki1,2, Kai Brown1,2, Chansavath Phetsouphanh1,2,
David Cooper1,2,3, John Zaunders1,3 and Anthony Kelleher1,2,3
1
Centre for Immunology, St Vincents Hospital, Darlinghurst,
NSW 2010, Australia; 2National Centre in HIV Epidemiology
and Clinical Research, University of NSW, Kensington, NSW
2052, Australia; 3HIV, Immunology and Infectious Diseases
Clinical Services Unit, St Vincents Hospital, Darlinghurst,
NSW 2010

Proportions of CD25+CD4+ regulatory T (Treg) cells are
increased in HIV-infected patients. In untreated HIV disease,
the proportion of CD4+ Treg cells in blood and tissue may
be associated with the level of immune activation driven
by HIV replication. Furthermore, populations of CD4–
CD8– and CD8+ cells expressing FoxP3 are increased in
the blood, particularly in patients with very low CD4+ T
cell counts.
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FoxP3+ cells have not been extensively phenotyped
in HIV-infected individuals. We assessed the expression
of various markers of activation and co-stimulatory
molecules on FoxP3+CD4+ and FoxP3+CD8+ cells by
flow cytometry, and compared the expression of these
markers between untreated and treated patients.
The proportion of CD4-negative FoxP3+ cells was greatest
in the most immunodeficient patients. This population
included CD8+ and CD4–CD8– double negative cells. A
greater proportion of FoxP3+ cells from untreated patients
(n=20; 5–1,400 CD4+ T cells/µL) exhibited the memory
(CD45RO+) or activated (HLA-DRHI or Ki-67+) phenotype
when compared with patients on ART (n=20; 50-1,250
CD4+ T cells/µL) and uninfected donors (n=14). When
FoxP3+CD4+ and FoxP3+CD8+ T cells were compared
in treated/untreated patients and uninfected donors,
expression of both CD28 and CTLA-4 was higher in the
CD4+ subset, whereas expression of PD-1 and CD57 was
higher in the CD8+ subset.

CD4+CD25+CD127lowFoxp3+ regulatory T cell (Tregs)
have a role in maintaining tolerance to self-antigens
and coordinating immune responses to pathogens.
More recently, there has been increased interest in
antigen-specific Tregs as they have potential as a
novel immunotherapeutic agent in the treatment of
autoimmune disease and cancer and may also have
therapeutic role in transplantation and vaccine regimes.
Using recall responses and a new gating strategy for
which includes Foxp3, CD134 and CD39, we aimed to
identify, phenotype and study the function of Tregs
responding to re-stimulation with epitopes from CMV
pp65. In healthy CMV+ donors we found that 1.41%
±0.37% (mean±SEM) of peripheral CD4+ T cells were
specific for pp65. Surprisingly, a majority of these cells
(70.80%±1.00%%) were bona-fide Foxp3+ antigenspecific Tregs. This subpopulation was isolated by FACS
and studied in suppression assays. Antigen-specific
CD39+Foxp3+ Tregs were found to be better suppressors
than CD39- Foxp3+Tregs. To determine the source of
these Tregs, the TCRVβ CDR3 region of these subsets
and other subsets of effector/memory cells is currently
being amplified for clonotypic analyses. The results will
determine whether antigen-specific Tregs are derived
or not from effector/memory cells, which then undergo
clonal expansion when encounter antigen.

The data demonstrate major phenotypic differences
between FoxP3+CD4+ cells and FoxP3+CD8+ cells.
Proportions of CD4+ Treg cells and the FoxP3+CD8+
phenotype are directly related to the level of immune
activation. A “re-balance” of FoxP3+ cells from the CD8+
to the CD4+ compartment may occur in treated patients
who are able to successfully reconstitute their CD4+ T cell
compartment and maintain virological control.
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Regulatory T cell abnormalities are 
associated with aberrant CD4+ T-cell 
responses in patients with immune 
inflammatory syndrome (IRIS)
Nabila Seddiki1,2, Chansavath Phetsouphanh1,2,
Kai Brown1,2, John Zaunders1,3, David Cooper1,2,3,
Anthony Kelleher1,2,3
1
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Up to 30% of patients with HIV commencing antiretroviral
therapy (ART) late in the disease, restore a pathogenspecific cellular immune response that is immunopathological and causes disease referred as immune
reconstitution inflammatory syndrome or IRIS. We report
that in HIV-infected patients who developed IRIS to
mycobacteria, a large expansion of CD4+ T-cells specific
for M. avium complex (MAC) antigens producing high
levels of IFN-g and IL-2 (P<0.01) was observed. Surprisingly,
we found an even larger proportion of expanded
CD127loFoxp3+CD25+Tregs in these patients compared
to healthy controls (17.8%±2.51% c/w 6.81%±0.35%,
p<0.05) or to HIV+ patients before commencing
(4.5%±2.12%, p<0.01) or 4 weeks after starting ART
(4.3%±1.61%, p<0.01). However, these Tregs are defective
in their ability to suppress effector T cell proliferation and
production of inflammatory cytokines (IL-6, TNF-α). This
may explain the aberrant immune responses observed
in these patients. To further investigate the suppressive
dysfunction, we assessed CD39 and CD73 expression and
function. These two ecto-enzymes have been reported
recently to play a major role in Tregs function. Interestingly
we found that, although CD39 expression was elevated
in IRIS patients compared to controls (12.48%±2.069%
c/w 2.67%±0.38%, p<0.05), CD73 expression was very
low or absent compared to controls (1.045%±0.18% c/
w 5.028%±1.18%, p<0.01). The imbalance in expression
of these 2 regulatory ecto-enzymes that normally work
in tandem may help explain the observed defect in
suppressive function of Tregs, allowing the excessive
proliferation and inflammation in IRIS. Experiments are in
progress attempting to delineate a possible role for CD73
dysfunction in the immuno-pathology of IRIS.

		

95

Planning Requires Economic and Quality Review

COST EFFECTIVENESS OF SCREENING FOR
ANAL CANCER IN HIV+ MSM

Planning Requires Economic and
Quality Review
3.30pm – 5.00pm
A critical analysis of the quality 
and transferability of economic 
evaluations of HIV interventions for 
Australian decision-making
Anderson JS1, Carter R2, ,Cooper DA1.
1National Centre in HIV Epidemiology and Clinical
Research, Darlinghurst NSW 2010.
2Health Economics, Deakin University, Burwood, Victoria.
There have been few economic evaluations of HIV
healthcare and prevention interventions in Australia.
Decision-makers developing guidelines may use existing
studies from the pre-HAART era or overseas. However
findings from these studies may not be valid or relevant
in an Australian population. This study aimed to examine
the published literature of economic evaluations in the
post-HAART era to assess their quality and transferability.

wednesday 17 september 2008:  3.30pm – 5.00pm

The peer-reviewed literature was searched using
standard methodologies for publications (post 1996)
related to economic evaluation of HIV interventions in
high income countries. A second stage filter was applied
which assessed the interventions on a number of criteria
including impact on health and costs; evidence-based;
on the policy agenda; options for incremental increase
or decrease in funding; clear program logic for the
intervention; temporal relevance. Finally the EURONHEED
consensus instrument, developed by health economists,
was used to score the quality and generalisability of the
studies.
123 peer-review articles were available (1996-2007). Over
90% were published from North American studies with one
published study from Australia. 58 related to healthcare
and 62 prevention (including biomedical prevention).
19 focused on the prevention of perinatal transmission
and 13 on the diagnosis, prevention and management of
opportunistic infections. Quality and transferability scores
ranged from 96% to less than 50%. Key issues in quality
and transferability were perspective, study population,
model design, measurement and valuation of benefit
and cost data, and statistical analyses.
While there is extensive published literature on economic
evaluations, most of it comes from North America and
some of the findings appear less relevant to clinical
management and policy making. Study populations
may differ from an Australian population and values for
costs and outcomes may not be valid for Australia in
2008. Decision makers need to consider both the internal
and external validity of economic evaluations of HIV
interventions in the post-HAART era.
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Hillman R, Botes L
Sexually Transmitted Infections Research
University of Sydney. Sydney, NSW, Australia

Centre,

Anal Squamous Cell Carcinoma (ASCC) occurs at rates
of approximately 30 - 92 cases/100,000 in HIV+ MSMs.
Despite surgery, chemotherapy and radiotherapy, the
2004 overall five year survival in Australia is 64% (lower
in HIV+). This compares to 2002 rates of cervical cancer
among the general Australian female population of 6.9
cases/100,000, and a five year survival of 74%.
Similarities exist between ASCC and cervical cancer. For
example, both cancers occur in transitional tissue, both
are caused by sexual transmission of certain genotypes of
Human Papilloma Virus and they have similar cytological
and histological features. Using cervical cancer screening
as a model, we therefore sought to compare the
estimated cost parameters of a theoretical anal Pap
smear intervention to detect anal cancer, with those of
the existing cervical Pap smear programme.
The total number of HIV+ MSM in Australia is approximately
12,700. It can therefore be estimated that 7.5 (range
3.6 - 11.7) cases of anal cancer will develop per year in
these men. Anal Pap smears are reported as being 81%
sensitive. Thus, if all 12,700 HIV+ MSM in Australia were
screened, 81% of 7.5 cases = 6 cases would be detected.
In this manner, each case of anal cancer would require
12,700/6 = 2,116 HIV+ MSM to be screened.
In comparison, the New South Wales Pap Register
recorded 681 306 cervical Pap smears in 2005, when the
incident cervical cancer rate was 238 cases per year. Thus
681,306/238= 2,862 Pap tests were performed on women
for each case of cervical cancer detected.
A U.S.A. paper in 1999 estimated the cost per QALY for
anal cancer screening in HIV+ MSM every 2 years was
$13,000. In comparison, the most recent Australian figures
indicate that the cost per QALY for cervical screening is
significantly higher, at $21,707.
Our preliminary calculations therefore suggest that an
intervention targeting HIV+MSM with anal Pap smears
to screen for anal cancer would be of comparable value
and costs to that of the existing cervical cancer screening
program. A number of assumptions were made in the
above calculations, and further work is required to refine
these figures.
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Background:
Australia has mounted an effective prevention response
to HIV/AIDS by investing in policy informed by evidence,
strong partnerships and adequate investment. Recently,
in response to increases in HIV in some Australian states,
the New South Wales (NSW) Department of Health set up
a ‘Think Tank’ to examine state-based differences.
Methods:
The National Centre in HIV Social Research (NCHSR)
undertook key informant interviews with major
stakeholders to complement behavioural/surveillance
data. It was hoped to identify how members of
the partnership (government, non government
organisations, researchers, gay community) in NSW
had collaborated to keep HIV notifications in NSW
stable compared with increases in Victoria and
Queensland. In parallel, the Australian Federation
of AIDS Organisations (AFAO) analysed the strategic
contexts, government responses and investments
in prevention of HIV in all jurisdictions in Australia.
Results:
There were significant differences between NSW,
Queensland and Victoria in the way the HIV partnership
functioned and was resourced. Whilst the strong
partnership in NSW enabled a planned, evidence-based
response, the response in Queensland was hampered
by competitive tendering that pitched partners against
each other. In Victoria diminished funding, the inability
of partners to work together, an inadequate strategic
framework and a more rigorous application of the
purchaser-provider model inhibited collaborative
planning and the optimal resource allocation necessary
for an effective response. Prevention campaigns in
Queensland and Victoria were also subject to greater
government censorship than NSW campaigns.

Dr Jan Savage, ASHM
Mr Peter Canavan NAPWA, Ms Jo Watson, NAPWA, Ms
Levinia Crooks ASHM
Determining the appropriate nature, level and mechanism
for delivering care to people living with HIV has been a
constant challenge in the Australian environment. Since
the early recognition of HIV and the management of
opportunistic infection through to the development
and delivery of very effective antiretroviral agents there
has been a shifting understanding of what is best, what
is appropriate, what is manageable and what is affordable
care.
In Australia much care is provided to PWHIV by general
practitioners in the community setting. But this care is
provided in the context of there being a very dispersed
HIV population nationally. At the same time our health
workforce is over stretched and asked to take on
increasing levels of complex management.

Planning Requires Economic and Quality Review

Diana Bernard1, Susan Kippax1, Don Baxter 2
1
National Centre for HIV Social research (NCHSR);
2
Australian Federation of AIDS Organisations (AFAO)

Models of Access and Clinical Service 
Delivery in Australia Today

The Models of Access and Clinical Service Delivery Project
is a joint initiative of NAPWA and ASHM. It is supported
by DoHA and the States and Territories via AHMAC
arrangements. The project is exploring the changing
needs of PLWHA, the range of service models available
generically to manage chronic care as well as the
changing nature of HIV management.
The presentation outlines the methodology undertaken
and presents preliminary data being collected as part
of the project. It will also act as a discussion point for
attendees to put forward issues which they see as
important in the delivery of services to PLWHA as we
enter the third decade of HIV management.
wednesday 17 september 2008:  3.30pm – 5.00pm

Effective partnership and adequate 
investment underpin a successful 
response: key factors in dealing with 
HIV increases

Conclusions:
Since the Australian strategic response to HIV/AIDS
has been one of the most successful in the world, an
understanding of Australian partnership arrangements
is highly relevant for other countries addressing the
challenge of HIV/AIDS. Any interpretation of, and response
to, increases in HIV notifications and unsafe sexual practice
needs to be cognisant of the crucial nature of strategic
partnerships and adequate resourcing for successful
prevention.
Keywords: HIV transmission, evidence based policy,
partnership
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Circumcision

Circumcision
5.15pm – 6.15pm
REDUCED RISK OF HIV SEROCONVERSION
AMONG CIRCUMCISED HOMOSEXUAL MEN
WHO REPORT A PREFERENCE FOR THE
INSERTIVE ROLE IN ANAL INTERCOURSE

preference for the insertive role in anal intercourse. As
most HIV infections in homosexual men occur after
receptive anal sex, circumcision is likely to have a limited
impact as an HIV prevention intervention in Australian
homosexual men. However, circumcision may have a
role in those men who are predominantly at risk of HIV
seroconversion through insertive rather than receptive
anal intercourse.

Templeton DJ1,2, Jin F1, Mao L3, Prestage GP1, Donovan B1,4,
Imrie J3, Kippax SC3,Kaldor JM1, Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney
NSW, Australia; 2RPA Sexual Health, Royal Prince Alfred
Hospital, Sydney NSW, Australia; 3National Centre in HIV
Social Research, The University of New South Wales,
Sydney NSW; 4Sydney Sexual Health Centre, Sydney
Hospital, Sydney NSW, Australia
Circumcision substantially lowers the risk of HIV acquisition
among heterosexual men in Africa, but there are few and
conflicting data addressing circumcision status as a risk
factor for HIV among homosexual men. We examined
circumcision status as an independent risk factor for HIV
seroconversion in the community-based Health in Men
(HIM) cohort of homosexual men in Sydney, Australia.

wednesday 17 september 2008:  5.15pm – 6.15pm

Between 2001 and 2004, 1,426 initially HIV-negative men
were enrolled. Circumcision status was self-reported at
baseline and was validated by clinical examination during
study visits in a sub-sample of participants. All participants
were tested annually for HIV. Demographic information
was collected at baseline and detailed information on
sexual risk behaviours was collected every 6 months.
At baseline, almost two thirds of participants reported
being circumcised; mostly as infants. There were 53 HIV
seroconversions in the HIM cohort, an incidence of 0.78 per
100PY. On multivariate analysis controlling for behavioural
risk factors, being circumcised was not associated with
HIV seroconversion (HR 0.76, 95% CI 0.41-1.41, p=0.381).
However, among those with a preference for the insertive
role in anal intercourse, being circumcised was associated
with a significant reduction in HIV incidence when
controlling for age and number of insertive unprotected
anal intercourse (UAI) acts with HIV positive or status
unknown (sero-nonconcordant) partners (HR 0.15, 95%
CI 0.03-0.80, p=0.026). In these men, a median 100% (IQR
92.1-100%) of UAI acts with sero-nonconcordant partners
were in the insertive position and reported preference for
the insertive role was remarkably constant over time.
Overall, circumcision was not associated with HIV
incidence in the HIM cohort. However, being circumcised
was associated with a significant reduction in HIV
incidence among those participants who reported a
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Cost-effectiveness of circumcision 
for the prevention of HIV in gay men in 
Australia

Londish GJ1, Templeton DJ2, Regan D2, Kaldor JM2,
Murray JM1,2
1
School of Mathematics, University of New South
Wales, Sydney, NSW, Australia; 2National Centre for HIV
Epidemiology and Clinical Research, Sydney, NSW,
Australia

Anderson J
This study aimed to examine the incremental costeffectiveness of a program of male circumcision in
Australian MSM.
We used a dynamic model with a hypothetical population
of 180,000 MSM around Australia with baseline HIV
prevalence according to age but homogenous sexual
mixing. Circumcision was assumed to have an efficacy
of 60% (range 30-82%) in preventing acquisition by an
insertive MSM. Baseline circumcision rates ranged from
50.3% (for <25 y.o.) to 82.6% (for >45 y.o.). The impact of
antiretroviral therapy, sero-positioning and condom use
was included. Cost per circumcision was $3,650 including
pre-operative counseling, assessment and testing,
operative care and post-operative follow-up. Relevant
costs and outcomes including quality-adjusted life-years
were discounted at 3%.
Three strategies for implementation of a circumcision
intervention were compared with the status quo:
circumcising all MSM at sexual debut, all insertive MSM
immediately, and all MSM now. For each strategy the
number of HIV infections prevented per year is shown in
the table.
HIV infections
prevented per year

10 years 25 years 50 years

sexual debut

11

37

72

Insertive

20

34

56

all MSM

37

57

80

All approaches were not cost-effective early postintervention but they became cost-effective after 7-14
years for circumcising just insertive MSM; after 12-27 years
for all MSM; and after 19-31 years for circumcising all at
sexual debut. Intervention costs ranged from $14m a year
for the sexual debut approach, to $196m in the first two
years for the all MSM approach.
Sensitivity analyses will be presented that explore changes
in risk behaviour, uptake and parameter uncertainty .
Targeting the intervention to insertive men would be
most efficient, but even in the best-case, the benefits of
an intervention based on male circumcision would not
be seen for at least a decade and would have significant
upfront costs.
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Men who have sex with men (MSM) suffer a
disproportionate burden of HIV in the developed
world. The recent success of circumcision in reducing
HIV acquisition among heterosexual African men has
prompted debate on whether circumcision could be
effective in reducing HIV acquisition amongst MSM in
developed countries. We developed a mathematical
model to estimate the impact of a male circumcision
intervention on HIV incidence and prevalence in a MSM
community in a developed country. The model provides
a simple relationship between the level of circumcision
and long-term HIV prevalence. The results indicate that
the decrease in HIV prevalence is much lower than that
experienced amongst heterosexual men, such that if a
MSM community initially had no circumcision and 10%
HIV prevalence, complete circumcision would reduce
this to 6%. However, it would require decades before a
substantial drop in HIV prevalence was achieved. HIV
incidence follows a similar pattern with a drop during
intervention and then gradual decline over decades.
Strategic positioning, another risk reduction strategy,
can provide a slight increase to the effectiveness of
circumcision reducing prevalence from 6% to 1%. These
results suggest that circumcision is not a viable option
to substantially reduce HIV prevalence amongst MSM in
developed countries.

Circumcision

SMALL POPULATION HEALTH BENEFITS ON
HIV BY CIRCUMCISING MEN WHO HAVE SEX 
WITH MEN
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Diagnostics and Assay Development
5.15pm – 6.15pm
THE ACCURACY OF HIV INCIDENCE ASSAYS
IN ESTIMATING THE POPULATION RATE OF
NEW INFECTIONS: A SYSTEMATIC REVIEW

consideration is given to the presence of longstanding
infections and people receiving HIV treatment, with
their potential to produce “false-recent” findings in the
population. A variety of validation methods were used,
highlighting the need for a standard and comprehensive
framework for the development of incidence assays.

Guy R1,2, Gold J2,3, García Calleja JM4, Kaldor J2 on behalf of
the WHO Working Group on HIV Incidence Assays
Centre for Epidemiology and Population Health Research,
Burnet Institute, Melbourne, VIC, Australia; 2National Centre
in HIV Epidemiology and Clinical Research, Sydney, NSW,
Australia; 3Department for Epidemiology and Preventive
Medicine, Monash University, Melbourne, VIC, Australia;
4
World Health Organization, Geneva, Switzerland.
1

Specialised HIV serological assays have been used in
many countries to distinguish recent from established
HIV infections in populations as a basis for estimating
incidence. However there is recent evidence that the
BED-CEIA assay overestimates HIV-1 incidence, due to
misclassification of cases with longstanding HIV infection
as recent infections, leading to a recommendation by
UNAIDS that the BED assay not be used for routine
surveillance, incidence estimates or monitoring incidence
trends at a population level.

wednesday 17 september 2008: 5.15pm – 6.15pm

A review was conducted to summarise validation findings
for all assays. Validation was defined to mean the process
of comparing estimates of HIV incidence derived from
use of an assay in a population, to concurrent estimates
of incidence in the same population obtained by an
alternative means that is believed to provide a reliable
measure of incidence (‘gold standard’). PubMed was
searched to the end of December 2007.
There were 22 papers identified, reporting 25 overall
incidence estimates. The most frequently used ‘gold
standard’ incidence method was a cohort study (13),
followed by a database of repeat HIV testers (four) and
mathematical modelling (3). The percentage difference
between the median assay-derived incidence and ‘gold
standard’ incidence was 10%. Twelve of the 25 overall
analyses were based on the comparison of assay-derived
incidence and ‘gold standard’ incidence on identical
samples; the median difference for these assessments was
7.3%, compared to 26% for the 13 validations conducted
using non-identical populations. The median difference
was -13.4% for five validations conducted among IDUs,
13.9% for eight validations in MSM increasing to 166.3%
for eight validations among heterosexuals from subSaharan Africa. The median difference was 10.3% for three
validations conducted using the 3A11-LS assay, 7.5% for
15 validations using the BED assay and 13.9% for the six
validations using the Vironostika assay.
The review showed incidence assays perform well in
providing estimates of HIV incidence and assays can be
reliably used to estimate HIV incidence, as long as due
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Gold J1,2, Guy R1,3, García Calleja JM4, Kaldor J3 on behalf of
the WHO Working Group on HIV Incidence Assays
1
Centre for Epidemiology and Population Health Research,
Burnet Institute, Melbourne, VIC, Australia; 2Department
for Epidemiology and Preventive Medicine, Monash
University, Melbourne, VIC, Australia; 3National Centre
in HIV Epidemiology and Clinical Research, Sydney,
NSW, Australia; 4World Health Organization, Geneva,
Switzerland

treatment. However the limited descriptions of sample
characteristics, and limited number of specimens from
individuals with longstanding infections and individuals
receiving antiretroviral treatment, indicates the need for
established, well-described specimens banks for sensitivity
and specificity testing during assay development, before
their application in the field.

Reduction in new HIV infections is one of the world’s
major public health objectives. Specialised serological
assays have been developed to measure HIV incidence
at a population level. Assays are developed to have
an associated ‘estimated window period’ indicating
the time in which an infection is considered recent. To
maximise utility, assays must have a high probability of
correctly detecting recent infections (sensitivity) and a
low probability of misclassifying established infections as
recent (specificity).

Diagnostics and Assay Development

SENSITIVITY AND SPECIFICITY OF HIV
INCIDENCE ASSAYS: A SYSTEMATIC REVIEW

Publications reporting on sensitivity and specificity of
assays measured against specimens of known time of
infection until the end of 2007 were reviewed. Infections
were classed as recent or established, as indicated by
seroconversion before or after the assay window period.
We also assessed specimens relating to individuals
(i) known to be HIV infected for one year or more
(longstanding infections), (ii) diagnosed with AIDS and
(iii) receiving antiretroviral treatment.

wednesday 17 september 2008: 5.15pm – 6.15pm

Thirty two reports related to 16 different assays were
identified. The 90 sample sets included in the reports were
most commonly derived from cohorts (47) and sourced
from the United States (27). Thirty six (40%) sample sets
specified the subtype of the specimens; 22 were subtype
B. The number of specimens assessed ranged widely
(median 123, range 7-2749).
The median sensitivity for recent infections was 88.8%
(n=30, range 42.3-100). The median specificity for
established infections was 93.3% (n=33, range 49.5-100)
compared to 98.0% for longstanding infections (n=8,
range 70.0-100) and 91.6% for AIDS cases (n=23, range
72.2-100). Median specificity for individuals receiving
antiretroviral treatment for one year was 95.5% (n=4,
range 91.0-100) and 76.3% for individuals treated for two
years (n=4, range 72.7-81.8).
The majority of sensitivity and specificity estimates
were above 85% for recent and established infections.
Specificity was lower for AIDS cases compared to
longstanding infections and specificity appeared
to decrease with increasing time on antiretroviral
17-20 september 2008 @ Perth Convention Centre, Western Australia 				
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Evaluation of the new version 3 Cavidi 
ExaVir™ Load quantitative HIV RT load 
kit as an alternative HIV viral load 
monitoring assay for use in both 
resource-constrained and developed 
countries
Greengrass V1, Plate M1, Steele P1, Denholm J2, Morris L1
and Crowe SM1,2
1
Clinical Research Laboratory, Macfarlane Burnet Institute
for Medical Research and Public Health, Melbourne,
Australia; 2Infectious Diseases Unit, Alfred Hospital,
Melbourne, Australia
There is an increasing need for inexpensive and simple
tests to monitor HIV disease progression in developed and
resource-constrained countries to facilitate appropriate
use of antiretroviral therapy. We have extensively
evaluated the new version 3 (v3) low cost manual reverse
transcriptase assay, ExaVirTM Load assay from Cavidi AB
(HIV RT) and compared it to the version 2 (v2) assay and
the commercially available Roche COBAS Amplicor HIV-1
Monitor assay version 1.5, which measures HIV RNA (ultrasensitive preparation; HIV RNA).

wednesday 17 september 2008: 5.15pm – 6.15pm

Frozen plasma samples from HIV-infected individuals with
previously quantified HIV RNA were also tested for HIV RT
activity using the v2 (n=411) and the v3 (n=265) assays.
The HIV RT v3 assay sensitivity has improved significantly
from v2 with 95% of all samples detectable with HIV
RNA ≥400 copies/ml compared to 85% with v2. A strong
positive association was observed between detectable
samples tested using the HIV RNA assay compared
to HIV RT v2 and v3 assays (r=0.88; n=176 and r=0.88;
n=223 respectively). Bland-Altman model was used for
measuring agreement between the HIV RNA assay and
the HIV RT v2 and v3 assays (mean difference: -0.19 log10
and -0.11 log10 respectively) and between the HIV RT v2
and v3 assays (mean difference: 0.01 log10).
The HIV RT v3 assay is more sensitive than the v2 assay.
Other improvements include faster turnaround time
and fewer consumables required. The HIV RT v3 assay is
suitable for use in monitoring HIV disease progression in
both resource-constrained and developed countries.
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PERSISTENCE OF HIGH LEVELS OF HIV
ANTIGEN-SPECIFIC CD4+ T CELLS IN
UNTREATED CHRONIC INFECTION,
DETECTED BY A NOVEL FLOW CYTOMETRIC
ASSAY
Zaunders J1, Bailey M2, Munier ML2, Seddiki N2, Kim M3,
Pett S2, Emery S2, Cunningham AL3, Cooper DA1,2 and
Kelleher AD1,2
Centre for Immunology, St Vincent’s Hospital,
Darlinghurst, NSW; 2National Centre in HIV Epidemiology
and Clinical Research, Darlinghurst, NSW; 3Westmead
Millenium Institute, Westmead, NSW
1

HIV antigen-specific CD4+ T cells are preferentially
targeted and deleted by cytopathic infection. In most
cases, HIV-1 antigen-specific CD4+ T cells are barely
detectable by proliferation assays, and at low levels by
interferon-γ production. We developed a novel assay of
antigen-specific CD4+ T cells, based on up-regulation
of CD25 and CD134 (OX40), and not reliant on either
proliferation or cytokine production, to reassess the
level of HIV-specific CD4+ T cells in untreated chronic
infection.
Samples of whole blood from 15 healthy adult controls
and 13 consecutive asymptomatic untreated subjects
with established HIV-1 infection (median: 158 CD4+ T
cells/µl; 4.7 log10 RNA copies/ ml) were incubated in vitro
for 40-44 hr with either culture medium alone or with
various recall antigens including lysates of CMV and M.
avium; UV-inactivated HSV-1; or a pool of overlapping 15mer peptides covering HIV-1 Gag. Cell surface CD25 and
CD134 were measured on CD4+ T cells by flow cytometry.
Results for subject groups were expressed as medians.
The background level of CD25+CD134+ CD4+ T cells
was very low, <0.03% of CD4+ T cells (mean + 3xSD). In
healthy adult controls, recall responses to CMV, M. avium
and HSV-1 were a median of 3.9%, 3.6% and 1.1% of CD4+
T cells, respectively and correlated with standard assays of
lymphoproliferation in 7-day cultures. In the cohort of HIVinfected subjects, responses to CMV, M. avium and HSV-1
were 4.7%, 5.2% and 2.3% of CD4+ T cells, respectively.
Responses to HIV-1 Gag peptides were a median of 0.1%
in healthy adult controls, but in the HIV-infected subjects
responding cells were a median 0.8% of CD4+ T cells
(*p<0.001 compared with controls), with 6/13 subjects
having much higher responses, ranging from 1.7 to 4.8%
of CD4+ T cells.
This novel assay has revealed relatively large populations
of antigen-specific CD4+ T cells that respond to recall
antigens, in both healthy adults and asymptomatic,
untreated chronically infected HIV-infected subjects. In
particular, we have discovered that there are 5-10 times
more HIV Gag-specific CD4+ T cells present in peripheral
blood than previously estimated by proliferation or IFN-γ
production.
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Oral
Presentation
abstracts
thursday 18 september 2008

This is intended to be an interactive session for practitioners
involved in the clinical care of HIV-infected patients. It
is assumed that participants will be experienced in the
assessment and treatment of HIV infection. Presentations
will elucidate practical and evidence-based clinical
approaches to the evaluation and management of
complex clinical scenarios, including

Oral Poster Session - Social Research,
International, Community, Indigenous
Health 8.00am - 8.45am
Scott-Visser B - see page 255
McGowan A - see page 254
Reeders D - see page 242
Brown G - see page 236
Brown G - see page 271
Lake R - see page 239
Clayton S - see page 271
Sarangapany J - see page 256

thursday 18 september 2008: 7.30am – 8.45am

· Life-threatening Immune Reconstitution Inflammatory
Disease (Prof Martyn French)
· Prevention and Management Strategies for Metabolic
Syndrome and Cardiovascular Risk in Patients Taking
Antiretroviral Therapy (Dr David Nolan)
· Management of Late Presenting Patients with Severe
Opportunistic Infection (Dr Robin Wood)
· Contemporary Approach to Management of
Antiretroviral Treatment Failure or Toxicity (Dr Roy Gulick)

Breakfast session – ‘Meet the Experts’ – Clinical

Breakfast session –
‘Meet the Experts’ – Clinical
7.30am – 8.45am
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HIV and Ageing

GROWING OLD DISGRACEFULLY WITH HIV

HIV and Ageing
9.00am – 10.30am

Pitts MK
Australian Research Centre in Sex, Health and Society,
LaTrobe University

NEURODEGENERATION AND AGEING IN THE
HAART ERA

Brew BJ
Departments of Neurology and HIV Medicine St
Vincent’s Hospital, Sydney Australia

thursday 18 september 2008: 9.00am – 10.30am

Neurodegeneration and the effects of ageing on the brain
in HAART treated patients are becoming of increasing
concern. Existing HIV infected patients are growing
older as a consequence of suppression of HIV replication
and the number of older patients newly acquiring HIV
infection is growing. There is evidence in some patients
for chronic immune activation and oxidative stress within
the central nervous system despite effective antiretroviral
therapy at least as measured in the cerebrospinal
fluid. Oxidative stress is the “final common pathway” in
the pathogenesis of a number of neurodegenerative
diseases. Furthermore, there are particular aspects of
HIV disease and its therapy that potentially contribute to
the development of ALzheimers disease or at least a like
illness. These include hyperlipidaemia, excess amyloid
production and inhibition of amyloid degradation.
Emerging evidence for the development of these
diseases from clinical and neuropathological studies will
be reviewed. The implications for the early introduction
of HAART with drugs that have good brain penetration
will be discussed.

The advent of HAART and improved clinical care means
that HIV positive people can now expect longevity
almost equivalent to HIV negative people. This change
has presented new challenges for positive people, those
who provide treatment, care and support and those
who research with them to understand better the lived
experience. Ageing brings with it new challenges that
may be related to the ageing process itself, to living
longer with the virus and living longer on treatments.
However, ageing is broader than simply facing these
challenges. We simply do not know what the effects of
HIV will be in the very long term, there is some evidence
of premature ageing associated with HIV, but there are
also indications that older HIV +ve people actually have
better well being, if not better health than their middle
aged counterparts. The relationship of identity, HIV status,
gender and sexuality may also change as one ages. This
talk will focus on the different ways in which people may
grow older with HIV, exploring the diversity of experience
and the highs as well as the lows of being old.
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Until recently, it was accepted that only a few specific
types of cancer were associated with the immune
deficiency associated with HIV infection. Although it is
known that a number of other cancers occur at increased
rates, most studies have concluded that these cancers
occur at increased rates because of lifestyle risk factors for
cancer in people with HIV, rather than a direct effect of
immune deficiency.
In the past year, this paradigm has been challenged by the
finding that solid organ transplant recipients have a profile
of increased cancer incidence that is strikingly similar to
people with HIV. As these two populations share little in
terms of lifestyle risks for cancer, it appears that immune
deficiency must underlie these increased risks. Most of
cancers occurring at increased incidence are those known
or suspected to be related to oncogenic infective agents
including Epstein-Barr virus (non-Hodgkin lymphoma
(NHL), Hodgkin lymphoma), human herpesvirus 8
(Kaposi’s sarcoma, KS), human papillomavirus (anogenital
and head and neck cancers), hepatitis B and C virus (liver
cancer), and helicobacter pylori (stomach cancer). Most
epithelial cancers common in the general population (eg
breast, prostate and ovarian) do not occur at increased
risk.
Although it is now clear that immune deficiency causes
increased incidence of many cancers, there remains
uncertainty about the level of immune function required
to prevent increased rates. In transplant recipients, rates
of many cancers rapidly return towards normal on
cessation of iatrogenic immune suppression. In people
with HIV, rates of NHL and KS have declined markedly
since the widespread use of combination anti-retroviral
therapy, but rates remain raised above population levels.
For Hodgkin lymphoma, it incidence is highest when
immune deficiency is moderate rather than profound.
For other cancers, there are few data on rates by level of
immune deficiency.
Describing cancer rates by level of immune function
is an important research priority among people with
HIV. If cancer incidence is raised even in the modestly
immune deficient, cancer risk may become an important
consideration in deciding when to start HIV therapy, and
in the setting of goals for optimal immune recovery.

HIV and Ageing

Grulich AE
National Centre in HIV Epidemiology and Clinical Research,
UNSW, Sydney, NSW, Australia

HIV INFECTION AND HEALTHY AGEING:
IS THERE A NEED FOR HIV-SPECIFIC
MANAGEMENT GUIDELINES FOR THE
PROTECTION OF HEARTS, BONES, MINDS
AND MORE?    
Nolan DA1,2
1
Centre for Clinical Immunology and Biomedical Statistics,
Murdoch University and Royal Perth Hospital, Perth,
Western Australia; 2Department of Clinical Immunology,
Royal Perth Hospital, Perth, Western Australia
The widespread availability of effective first-line and
salvage HIV treatment regimens has transformed HIV
infection into a chronic condition that is frequently
manageable into older age; including among those with
longstanding HIV infection who were originally given a
limited prognosis. Hence, long-term HIV treatment now
incorporates an increased awareness of age-associated
conditions such as cardiovascular and metabolic diseases,
osteoporosis, cognitive decline, and risk of malignancy
– in addition to providing optimally effective and safe
antiretroviral therapy.
In this context, several key questions are now directing
new avenues of clinical research. First, what is the impact
of HIV infection and associated immune deficiency on
age-associated diseases? There is now good evidence
that progressive immune deficiency is associated with
increased risk of atherogenic dyslipidemia, reduced
muscle mass and bone density, and ‘non-AIDS-related’
malignancies (eg. skin and lung cancer). The potential
effect of immune activation, irrespective of CD4 T
cell count, is also being explored as a risk factor for
cardiovascular disease, dyslipidemia and HIV-associated
dementia. These factors can inform clinical management
decisions with regard to patient assessment and
monitoring, and are fuelling a growing debate regarding
CD4-guided HIV treatment initiation.
Second, what is the impact of antiretroviral drug treatment
on age-associated diseases? Here, consideration of
individual drug toxicity profiles, rather than antiretroviral
‘class effects’, appears to be the most appropriate
approach. This is a growing area of interest, particularly in
light of recent studies suggesting associations between
NRTI choice and risk of diabetes (stavudine>zidovudine)
and cardiovascular disease (abacavir>didanosine).
Third - and perhaps most importantly at this stage - to
what extent are we able to assess disease risk, and apply
prevention and management strategies, using guidelines
that have been developed in the general population?
Here, an awareness of existing guidelines, and their
incorporation into routine clinical practice, will provide
a valuable platform for developing clinical experience
as well as guiding further research. These guidelines also
reinforce the potent contribution of ‘lifestyle’ factors (eg
smoking) to chronic disease risk.
These question will be explored, with the goal of
developing practical approaches to the management of
healthy ageing in HIV infection.
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This symposium is aimed at clinicians, epidemiologists,
public health practitioners and researchers. Three
presenters will summarise and place in broader context the
5-10 contributions in HIV basic, clinical, epidemiological
and social research published over the course of the past
year that they consider most important, with an emphasis
on those most likely to result in fundamental practice and
paradigm change.
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11.00am – 12.30pm
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Bruno Spire1,2, Jean-Marie-Legall1, Franck Barbier1, Christian
Andreo1 and Vincent Pelletier1
1
AIDES, Pantin, France; 2INSERM U912, Marseille, France
In France, AIDES is the largest community-based
association and contributes through social activism
both to improve the living conditions of PLWHA and to
influence policy makers in order to stem the HIV epidemic.
AIDES promotes a community based approach: “doing
with people, not for people” by adopting innovative
approaches and tailoring appropriate actions to meet
communities’ needs.
Since the introduction of ART, community activists and
public researchers have worked together in order to
answer research needs emerging from the community.
In the field of care and support, one such need is how
to face therapeutic failure by promoting salvage therapy
trials combining several new molecules. Another such
need is how to promote comprehensive care, including
adherence interventions, justified either by a theoretical
health psychology framework or on evidence-based
empirical data. Research needs were also identified in the
field of quality of life improvement, more particularly in the
domain of sexual and affective life. Community members
advocate to promote research on side-effects, including
those which are all too often neglected, and to take into
account the patient’s perspective as a possible outcome in
clinical trials. In the field of social sciences, research needs
identified by the community raise several questions: i:how
to influence the negative perception of PLWHA by the
general public, ii how to decrease stigmatisation which has
not been strongly impacted by the advent of ART, iii how
to overcome barriers to disclosure and determine which
interventions could help in creating greater acceptance
of PLWHA. Furthermore, research is urgently needed to
explore in which circumstances promoting “low risk” sex
practices may reduce the risk of HIV transmission. It is
also important to determine whether frequent, routine
testing for people who are often exposed to HIV may
reduce sexual risks in recently diagnosed HIV cases and
also reduce HIV incidence. In conclusion, scientists must
interact with community groups to better tailor research
issues to real needs. Scientific evidence is an indispensable
and efficient weapon to support action and lobbying.
The battle against AIDS can be won only if scientists, field
actors, community groups and civil society are mobilised
altogether.

Canavan P
National Association of People Living With HIV/AIDS
(NAPWA)
The history of the HIV community’s involvement in clinical
research has to date largely been driven from the start by
‘health shocks’. The greatest health shock of them all is to
be diagnosed with a life threatening disease and to have
that diagnosis shift to the shock of vulnerability, rapid
disease progression and death.
Health shocks associated with the HIV crisis have
necessitated giving priority to the initiation of HIV clinical
research agendas being driven by biomedical imperatives,
including the need for effective antiretroviral treatments
and management strategies.

Community Research and Practice

COMMUNITIES AND RESEARCH: THE
NECESSITY FOR DIALOGUE

THE SHOCK OF ETHICAL COMMUNITY
RESEARCH

Research influenced by needs which are foremost dealing
with ‘crisis avoidance’ present particular challenges
to communities and to their elected representatives
in remaining engaged to ensure research is evolving
in ethically robust, personally relevant, community
supported and sustainable ways.
This paper seeks to first challenge some of the traditional
ways community involvement in clinical research occurs
and in doing so open up discussion on current levels
of community engagement, discussing difficulties and
emerging limitations of a representative model.
The HIV crisis has now shifted to occupy centre stage in
the developing world and in doing so has introduced a
new ‘health shock risk’ to opportunities for meaningful
involvement by HIV positive communities in the
developed world in engaging a research ethic which
creates opportunities for a revitalized scientific research
agenda relevant to the needs of HIV positive communities
in the developed world today.
In seeking to reinvigorate a broad based community
engagement with clinical research, this paper proposes
that there is a concomitant opportunity to reexamine the
motivations and opportunities of clinical research agendas
to accommodate a multidisciplinary reflexive approach
– which embraces diversified and changing health
needs and perspectives, wider access arrangements,
strengthened communication processes and guaranteed
reporting of trial results.
Finally, ways forward are introduced to assist both
community and researchers to begin a serious discussion
on strengthening partnership processes and to avoid
tendencies of mechanistic engagement with either
clinical research or consumers.
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THE FEASIBILITY OF A NATIONAL GAY
MEN’S INTERNET-BASED COHORT AND
PROSPECTIVE BEHAVIOURAL SURVEILLANCE
PLATFORM IN AUSTRALIA – WHAT ARE THE
ISSUES?
Imrie J1, Prestage GP2,3, Pitts M3
1
National Centre in HIV Social Research, The University
of New South Wales, Sydney, NSW, Australia; 2National
Centre in HIV Epidemiology and Clinical Research, The
University of New South Wales, Sydney, NSW, Australia;
3
Australian Research Centre in Sex Health and Society, La
Trobe University, Melbourne, VIC, Australia
In Australia, concern about rising HIV-notifications,
diverging epidemics between jurisdictions and increasing
STIs among homosexually active men (MSM) have
prompted a re-think of behavioural surveillance research.
Current surveillance, while of high quality, has notable
shortcomings – limited coverage outside main cities and
among hard-to-reach groups, and capacity to evaluate
prevention effectiveness.
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We are investigating the feasibility of a national internetbased research platform that would support a longitudinal
cohort of HIV-positive and HIV-negative men (with data
linkage to national and state disease registers), and repeat
cross-sectional behavioural surveys (with monitoring of
repeat respondents over time).
A national internet-based platform combining both
longitudinal and repeat cross-sectional studies would
be unique. Added benefits of linkage to national and
state registers would be incidence data on HIV/STIs and
other health conditions (e.g. cancer, mental illness, etc),
and potentially, health, pharmaceutical and social care
service usage. Such a research platform would allow
comparisons between states/territories, and with the
general male population. Obvious challenges include
participant retention, stratified sampling and sample-size
in small states. But in this new territory there are also new
issues - multi-level inter-sectoral collaboration, evaluation
design, ethics, consent requirements, governance and
data management (e.g. confidentiality, handling and
ownership).
Innovations addressing limitations of current behavioural
surveillance and extending its usefulness are needed,
particularly in mature MSM HIV epidemics. Internet
platforms and data linkage offer potentially mechanisms
to do this, but at a national level, present a range of new
challenges to the field.
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National SAS programs – a review of 
the last 4 programs
Watson J, Whittaker B1, Brown D, Strum A, Paul A
1National Association of People Living with HIV/AIDS
(NAPWA), 2Janssen-Cilag Australia, 3Merck Sharp &
Dohme Australia, 4Pfizer Australia
NAPWA is the national peak body representing plwha
organisations in Australia. As part of its national advocacy
program, it is the organisation responsible for negotiations
with individual pharmaceutical companies for the
development and monitoring of Special Access Scheme
(SAS) programs for HIV antiretrovirals. NAPWA also
maintains monitoring of the programs with the individual
drug manufacturer’s, prior to each drug being submitted
and registered through the Australian regulatory process
for listing on the Pharmaceutical Benefits Scheme.
The national SAS programs have been a feature of
the Australian HIV community based response since
the early HIV activism movement which established
compassionate access to the experimental agent AZT,
in the early 90’s. Since then, there has been a program
developed for every HIV drug, and over the years there
has been significant changes to the way in which SAS
programs have been developed, and how they have
been utilised by doctors for their patients.
This presentation will review the last 4 programs which
have been run in Australia, up to the present time. This will
include a report of the individual program profiles, and
their specific patient criteria and enrollment numbers.
Some of the trends noted across state and territory
jurisdictions, and the changes which can be observed
across program timelines will be also addressed.
Discussion includes an analysis of the impacts of the
overlap of some of the programs across specific periods
of time, and their operation in parallel to several major
clinical studies in Australia targeting the same patient
population. The presentation will also cover the principles
behind the ongoing provision of SAS programs in Australia
today, and the analysis of trends observed in the patient
group which is being supported through this mechanism
for early access to the new agents.
Finally, some concluding remarks will be focused on the
potential for improving SAS program parameters in the
future, including better ways to learn from the “real life”
information which these programs can provide as part
of the experience of the patient and their doctors in
ongoing HIV clinical management developments.
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TOWARDS MORE EQUITABLE ACCESS TO HIV
CLINICAL TRIALS
Ogier, A
National Association of People living With HIV/AIDS
(NAPWA), Sydney, NSW, Australia
Access to optimal HIV treatments and services should
not be reserved for those living in key urban centres. But
where you live in Australia does limit the options of many
people with HIV.
The Treataware campaign (launched by NAPWA in May
2008) is an important new health promotion project,
providing a variety of formats in which all HIV positive
Australians can access specific HIV treatments information.
The project is promoted to people with HIV as well as
their aligned health workers and medical practitioners
to support a team approach to making informed choices
regarding HIV treatments.
A key objective of Treataware is to encourage people
with HIV to engage more with their medical practitioners
about treatment developments and to link them to
relevant clinical trials information regardless of their
geographic location.
People with HIV need to be better informed about HIV
and general health needs, but importantly they need to
work in partnership with their health providers to produce
clear, comprehensive and up to date plans for living well
with HIV.
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The Treataware clinical trials website incorporates the first
searchable public register of Australian HIV clinical trials,
providing clinical, technical and medical information
in a user-friendly format. This database is acting as a
centralised source of information for both people living
with HIV and their clinical care providers.
Adrian Ogier did a lot of different things for a lot of
different community organisations before achieving his
most long-winded tour de force coordinating ASHM’s
prescriber program and short courses in HIV medicine. He
now works for the National Association of People Living
with HIV/AIDS in the Health, Treatments and Research
Unit.
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TAILORING GLOBAL RESPONSES TO LOCAL
EPIDEMICS
David Wilson
Curtin University Of Technology And Lead Health
Specialist, The World Bank
The presentation will talk about tailoring global evidence
and interventions to an understanding of local HIV
transmission dynamics to ensure global approaches
tackle the sources of new infections in each local context
and the role of surveillance, research and good analysis in
bridging the gap between global policy and local action.

EXPLORING THE LINKS BETWEEN HIV AND
POVERTY: ARE THE ANALYSES CORRECT
Worth H
National Centre In HIV Social Research
In the developing world, HIV has been constantly
associated with poverty. Poor people are said to have
the greatest vulnerability to HIV and that the economic
impact epidemic will itself cause poverty to deepen
and indeed to engender state instability in places with
the highest prevalence. Yet, is this strictly true, or is the
picture much more complicated?
In this paper, using a number of case studies, I will argue
that it is not poverty per se that is the important association
with the spread of HIV; rather, it is the incorporation of
developing countries into the global world that creates
conditions where the virus rapidly spreads.
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International: Global HIV initiatives vs
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112 						

17-20 september 2008 @ Perth Convention Centre, Western Australia

Bebbington M; Carman M
The HIV Consortium for Capacity Building in Asia and
the Pacific is a collaboration of nine Australian HIV
organisations formed to implement the AusAID funded
Regional Capacity Building Program 2008-2011
The purpose of the Regional Capacity Building Program
is to foster strategic partnerships and linkages between
Australia and the Asia-Pacific region that will enable
sustained performance improvement for individuals
and organisations working in the HIV/AIDS health care,
research and community responses.
The Program aims to support a strategic, coordinated and
complementary use of the expertise and experience of
organisations which have played important roles in the
Australian response to HIV.
The Program seeks to build durable and long-standing
relationships between partners, which can change and
adjust as capacity develops. Sustainability is supported
because capacity building takes place in the context of
broader organisational development.

BUILDING CLINICAL CAPACITY TO MANAGE
HUMAN IMMUNODEFICIENCY VIRUS (HIV)
INFECTION IN RESOURCE CONSTRAINED
ENVIRONMENTS: Reflections from 
experience with clinical mentoring in 
Papua New Guinea (PNG)
Menon A1, Ankus J1, Reis E 1
Australasian Society for HIV Medicine (ASHM)
Since the announcement of the 3X5 initiative there
has been a scaling up of access to treatments for HIV
positive people in developing countries. Measures such
as development of appropriate policies, infrastructure,
reorientation and reorganization of the STI/HIV program,
recruitment of staff, and increased funding are necessary
prerequisites to this effort. Minimum standards, Standard
Operating Guidelines, training programs and materials
are widely available to enable clinical teams to deliver the
continuum of care for HIV positive people.
A key element to this effort is the role of clinical mentoring
in building clinical capacity within health services. This
presentation will reflect on successes, constraints and the
importance of ongoing support of services providing HIV
treatment and care, based on experience from PNG

International: Global HIV initiatives vs local response

CAPACITY BUILDING THROUGH LONG-TERM
PARTNERSHIPS
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This presentation will provide an overview of the HIV
Consortium’s work plan and outline the HIV Consortium’s
approach to capacity building and partnerships.
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Margaret Macdonald Memorial Session
– Epidemiology Population
11.00am – 12.30pm
TRENDS IN NEWLY ACQUIRED HIV
INFECTION IN AUSTRALIA, 1994 – 2007
McDonald A for the National BBV and STI Surveillance
Committee
National Centre in HIV Epidemiology and Clinical Research,
Sydney
Introduction: Recent analysis of trends in newly diagnosed
HIV infection in Australia indicated an increasing
population rate of HIV diagnosis in Queensland, South
Australia, Victoria and Western Australia and a stable
trend in NSW in 2000 – 2006, suggesting differences in
the extent of HIV transmission by State/Territory.
Methods: Cases of newly diagnosed HIV infection are
notifiable in each State/Territory health jurisdiction
in Australia. State/Territory health authorities forward
notifications to the National HIV Registry for national
collation and analysis. Information sought at national HIV
notification includes evidence of recent HIV acquisition.
Cases with a previous negative or indeterminate test
result or a diagnosis of primary HIV infection within 12
months of HIV diagnosis are defined as cases of newly
acquired HIV infection.
Results: In 1994 – 2007, 12 248 cases of newly diagnosed
HIV infection were notified to the National HIV Registry
including 3 120 (25.5%) with newly acquired HIV
infection. The age standardised rate of newly acquired
HIV infection in Australia increased steadily over time to
1.56 per 100 000 population in 2006. The percentage
of new HIV diagnoses with evidence of newly acquired
infection increased significantly from 21.7% in 1994
– 2000 to 29% in 2001 – 2007 (p<0.0001). Compared with
the percentage of diagnoses with newly acquired HIV
infection in 1994 – 2000, significant increases occurred
in 2001 – 2007 in NSW (p<0.0001), QLD (p<0.0001), VIC
(p=0.018) and WA (p=0.044). Median age at diagnosis
of newly acquired HIV infection increased significantly
among males and females from 34 and 29 years in 1994
– 2000 to 37 and 31 years, respectively, in 2001 – 2007.
Among homosexually active men, the percentage of new
HIV diagnoses with newly acquired infection increased
significantly from 26.8% in 1994 – 2000 to 37.1% in 2001
– 2007 (p<0.0001). Significant increases in the percentage
of diagnoses with newly acquired infection also occurred
among both males and females whose exposure was
attributed to heterosexual contact and among males
with an undetermined exposure.

INCREASING HIV TRANSMISSION THROUGH
MALE HOMOSEXUAL AND HETEROSEXUAL
CONTACT IN AUSTRALIA: RESULTS FROM AN
EXTENDED BACK-PROJECTION APPROACH
Handan Wand1, Ping Yan2, David Wilson1, Ann McDonald1,
Melanie Middleton1, John Kaldor1 and Matthew Law1
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, Australia; 2Center for Infectious
Disease Prevention and Control Population and Public
Health Branch, Canada
To reconstruct the HIV epidemic in Australia for selected
populations categorized by route of exposure, including
male homosexual transmission, transmission from
injecting drug use (IDU), and heterosexual transmission for
men and women in Australia. A modified statistical backprojection modelling technique was used to estimate
the expected historical HIV incidence. The method links
three sources of data from a surveillance system, namely,
(1) newly diagnosed HIV infection, (2) newly acquired HIV
infection and (3) AIDS diagnoses. We also ascertained
sensitivity to changes in various parameter assumptions.
These analyses estimated that to the end of 2006 a total
of 19,690, 1050 and 2610 people have been infected with
HIV through male homosexual contact (MHC), injecting
drug use (IDU) and heterosexual contact (HC) respectively.
Of those infected, 13%, 12% and 23% were estimated to
have not been diagnosed with their HIV infection. HIV
infections through IDU were estimated to be declining.
Sensitivity analyses demonstrated that the model was
robust to major parameter uncertainties. Our analyses
suggest that sexual transmission of HIV is increasing in
Australia. The estimated increase in HIV through HC was
also accompanied with a high estimated proportion
undiagnosed with their infection. These analyses suggest
that sexual transmission of HIV, and in particular HC,
should be the focus of renewed HIV prevention efforts.
The proportion of new infections attributable to injecting
drug use decreased since 2002; in contrast, the proportion
attributable to heterosexual exposure has increased
slightly. Thus this data provide useful information for
planning future prevention activities and health structures,
taking into account the increasing impact of the epidemic
for selected populations by exposure categories.

Discussion: The increasing population rate of diagnoses
of newly acquired HIV infection suggests increasing HIV
transmission in Australia, primarily among males with a
history of homosexual contact.
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For many Aboriginal and Torres Strait Islander communities
in Australia there are higher risks for acquiring HIV
infection than in the non-Indigenous population due to
substantially higher rates of bacterial sexually transmissible
infections (STI). Furthermore, Aboriginal and Torres Strait
Islander people have poorer access to health services
compared with non Indigenous people.
Nationally, information on Aboriginal and TSI status at
HIV/AIDS diagnosis was sought prospectively from 1995.
The pattern of newly diagnosed HIV infection in Australia
is described over the years 1993 – 1999 and 2000 - 2006,
by Aboriginal and/or TSI status.
In the Aboriginal and Torres Strait Islander population, 133
(28% female) and 138 (30% female) cases of HIV infection
were newly diagnosed in Australia in 1993 – 1999 and in
2000 – 2006, respectively, whereas 4,737 (8.5% female)
and 5,457 (10.9% female) were newly diagnosed in
the non-Indigenous population in each time period,
respectively. The declining trend in the age standardised
rate of newly diagnosed HIV infection in 1993 – 1999 and
the increasing trend in 2000 – 2006 was similar in the
Aboriginal and TSI population and the non-Indigenous
population. In the years 1993 – 1999 and 2000 – 2006,
median age at HIV diagnosis increased significantly in
both populations, from 29 to 33 years among Aboriginal
and Torres Strait Islander cases (p=0.004) and from 33 to
36 years among non-Indigenous cases (p<0.001). Among
the Aboriginal and Torres Strait Islander cases, exposure to
HIV was attributed to male homosexual contact, injecting
drug use, heterosexual contact or mother-to-child
transmission in 51.9%, 6%, 35.3% and less than 2% of cases
in 1993 – 1999 and to 44.9%, 19.6%, 32.6% and less than
1% in 2000 – 2006. In the non-Indigenous population, HIV
exposure was attributed to male homosexual contact,
injecting drug use, heterosexual contact and mother-tochild transmission in 72.5%, 3.3%, 15.3%, and less than 1%
in 1993 – 1999 and to 71.1%, 3.2%, 19.9% and less than
1% in 2000 – 2006.
Although the population rate of HIV/AIDS diagnosis by
Aboriginal and Torres Strait Islander status were similar the
risk of HIV transmission in both populations needs to be
minimized through diagnosis and treatment of bacterial
STI and adoption of safer sexual and injecting behaviour.

Horyniak D1, Stoové M1, Yohannes K1, Breschkin A²,
Tomnay J³, Carter T³, Hatch B³, Guy R1
1
Centre for Epidemiology and Population Health
Research, Burnet Institute, Melbourne, VIC, Australia.
²
Victorian Infectious Diseases Reference Laboratory,
North Melbourne, VIC, Australia. ³Department of Human
Services, Melbourne, VIC, Australia.
Accurate estimates of the number of people diagnosed
and living with HIV infection provide the basis for planning
of services. Case reporting of new diagnoses provides
an incomplete basis for planning, because it does not
account for migration into and out of a jurisdiction.
The Victorian passive surveillance system records HIV
diagnoses in Victoria, and distinguishes between new
Victorian diagnoses and cases previously diagnosed
interstate or overseas. Demographic and behavioural
characteristics are recorded for each case. In order to gain
an understanding of the impact of population movement
on the burden of HIV infection in Victoria, we compared
the characteristics of people first diagnosed with HIV in
Victoria with those previously diagnosed elsewhere.
Between 1994 and 2007 there were 3,111 HIV notifications
in Victoria, including 212 cases (6.8%) previously diagnosed
positive interstate and 124 (4.0%) diagnosed overseas. The
proportion of cases diagnosed outside Victoria increased
from 6.4% between 1994 and 2000 to 13.8% between
2001 and 2007. Most of the previous interstate diagnoses
were made in NSW (58.5%). Male-to-male sexual contact
was the most commonly reported HIV exposure (77%)
among interstate cases, compared to 72% among new
Victorian diagnoses. The majority of previous diagnoses
overseas were made in Asia (25%) and New Zealand
(24%). Heterosexual exposure accounted for 38% of
cases previously diagnosed overseas, compared to 18%
of new Victorian diagnoses. Twenty percent of individuals
diagnosed overseas were born in Asia and 16% in subSaharan Africa, compared to 5% and 9% respectively for
new Victorian diagnoses.
Around 10% of HIV infections reported in Victoria
have been previously diagnosed elsewhere. Interstate
migrants displayed similar characteristics to those
diagnosed locally, however international migrants
differed substantially. Changes in the proportion of cases
diagnosed outside Victoria may reflect trends in testing,
as well as modifications to the systems used to detect
previously diagnosed cases. There is currently no way to
record outward migration of people with HIV infection
from Victoria. Service planning needs to take account of
the differing characteristics of people moving to Victoria
with previously diagnosed HIV, compared to those already
resident at the time of their initial diagnosis.
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Ward J, McDonald A, Middleton M, Kaldor J
National Centre in HIV Epidemiology and Clinical Research,
University of New South Wales, Sydney Australia

THE IMPACT OF MIGRATION ON THE
BURDEN OF HIV INFECTION IN VICTORIA,
AUSTRALIA
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HOW IS THE ABORIGINAL AND TORRES
STRAIT ISLANDER POPULATION FAIRING
IN THE AUSTRALIAN HIV EPIDEMIC?-AN
ANALYSIS OF DATA FROM 1993-2007
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UNEXPECTEDLY HIGH HIV PREVALENCE
AMONG THAI SEX WORKERS IN A
RESPONDENT-DRIVEN SAMPLING SURVEY
Manopaiboon C1, Whitehead SJ1, Subhachaturas W2,
Tanpradech S1, Siangphoe U1, Johnston L3; Thepamnuay
S1, Anand A4; Sumanapun S5; Fox K1,4
1
Thailand MOPH – U.S. CDC Collaboration, Nonthaburi,
Thailand; 2Bangkok Metropolitan Administration,
Bangkok, Thailand; 3Tulane University School of Public
Health and Tropical Medicine, New Orleans, USA; 4Centers
for Disease Control and Prevention, Atlanta, USA; 5Chiang
Rai Provincial Health Office, Chiang Rai, Thailand.
Commercial sex has been a major driver of the HIV
epidemic in Thailand. Recent evidence suggests that the
highly successful HIV prevention programs of the past
decade may now be eroding. The structure of sex work
has changed substantially, with fewer brothel-based sex
workers (SW) and more non-venue-based SW who are
excluded from the annual sentinel surveillance system. We
conducted a respondent-driven sampling (RDS) survey of
HIV prevalence and risk behaviors among female SW in
Bangkok and Chiang Rai.
Initial participants were selected by staff, then recruited
peers according to RDS methods. Consenting participants
completed a demographic and behavioral questionnaire
by handheld computer and provided oral fluid specimens
for HIV antibody testing (Oral Fluid Vironostika™ HIV-1
Microelisa, BioMeriux, Durham, NC) and urine specimens
for Chlamydia trachomatis and Neisseria gonorrhoeae by
polymerase chain reaction (Amplicor, Roche Molecular
Systems, Branchburg, NJ). Data were analyzed using
RDS Analysis Tool (RDSAT) software which adjusts for the
network properties of respondents. RDSAT-weighted data
were exported to SAS for multivariate analysis.
A total of 707 women were recruited in Bangkok and
366 in Chiang Rai. A total of 73% of Bangkok participants
were non-venue-based compared to 24% in Chiang Rai.
The RDSAT-adjusted rate of condom use with last client
was higher in Bangkok (93%; 95% confidence interval (CI):
90%-95%) than Chiang Rai (69%; 95% CI: 61%-76%); HIV
prevalence was also higher in Bangkok (20%; 95% CI 16%25%) than in Chiang Rai (10%; 95% CI 6%-13%). In a logistic
regression model for Bangkok participants, HIV infection
was associated with age>25 (adjusted odds ratio (AOR)
4.5; 95% CI: 1.3-16.5), price<700 baht (~USD23) (AOR
3.3; 95% CI: 1.4-8.0), and concurrent sexually transmitted
infection (AOR 4.5; 95% CI: 1.5-13.0); older age and lower
price were highly correlated with street-based SW. No
examined factors were statistically significantly associated
with HIV infection in Chiang Rai.
HIV prevalences in this survey were significantly higher
than 2007 sentinel surveillance findings among SW
(Bangkok, 2.5%; Chiang Rai, 2.6%). Our findings suggest
that important high risk groups, especially street-based
SW in Bangkok, are in urgent need of prevention efforts
and should be included in routine surveillance.
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THE MOLECULAR CHARACTERIZATION OF
THE HIV-1 EPIDEMIC IN FIJI
Ryan CE1,2, Kama M3, Darcy A3, Aleksic E1, Mirza T4,
Chaudhary A5, Rogers G6, Crowe SM1,2
1
Burnet Institute, Melbourne, Australia; 2Dept of Medicine,
Monash University, Melbourne, Australia; 3Fiji Centre
for Communicable Disease Control, Suva, Fiji; 4Suva STI
Clini, Suva, Fiji; 5Lautoka STI Clnic, Lautoka, Fiji; 6Griffith
University, Brisbane, Australia
The HIV epidemic in Fiji remains largely uncharacterized.
By the end of 2006, UNAIDS estimates that there were
219 reported infections, a figure which is thought to be
a gross under-representation. The majority of infections
occur among the 20-39 year age group and are reported
to result from heterosexual contact. There is currently no
published data concerning the HIV subtype in the Pacific
Islands, with the exception of Papua New Guinea, which
has been shown to have a predominantly subtype C
driven epidemic.
In 2008, consenting HIV-1 positive individuals are being
recruited through the hub doctors in Fiji and asked to
complete a basic demographic and behavioural survey.
Following this, 50µl of venous blood is spotted onto
Whatman FTA Elute filter paper and stored at room
temperature for 1-6 months before transport to the Burnet
Institute. DNA is extracted using a low cost extraction
procedure before undergoing a nested PCR designed
to amplify the HIV-1 envelope region. Additionally,
the reverse transcriptase and protease regions will be
amplified using an in-house, low-cost genotyping assay
to gain information on circulating drug resistance. All
resulting sequences undergo phylogenetic analysis with
published reference sequences to assign a subtype, and
to assess their relatedness to each other, and to other
epidemics in the region.
To date, 9 samples have been processed, with 8 yielding
a PCR product and good envelope sequence. Of the 8
samples, 4 (50%) are subtype C, 3 (37.5%) are subtype B,
and 1 (12.5%) subtype A. An additional 20 samples have
been collected in Fiji and are awaiting transport to the
Burnet Institute. This data, along with the genotype and
demographic data will be presented.
This survey offers the first molecular information
concerning the apparent diverse HIV epidemic in Fiji and
provides valuable data regarding the movement and
transmission of HIV-1 in the Pacific Islands. Continued
surveillance of HIV subtypes throughout the world is
recommended in order to gain a deeper understanding
about the diversity of HIV and the impact this has on
vaccine development and antiretroviral therapy.
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This year, the Australian Antiretroviral Guidelines sessions
will be held on the Thursday 18 and Friday 19 afternoons of
the ASHM 08 program. These sessions include evidencebased presentations from international and local experts
on the latest research and developments in HIV treatment
and provide the opportunity for discussion.
Dr Roy Gulick is a member of the US Department of
Health and Human Services (DHSS) Panel on Antiretroviral
Guidelines for Adults and Adolescents and will represent
DHHS at these sessions. The DHSS Guidelines for the
Use of Antiretroviral Agents HIV-1 Infected Adults and
Adolescents have been endorsed by Australia and
form the basis on which the Australian commentary
is developed. The Australian commentary to the latest
Guidelines for the Use of Antiretroviral Agents in HIV-1
Infected Adults and Adolescents is available at: http://
www.ashm.org.au/aust-guidelines/.

Gulick R, MD, MPH
Weill-Cornell Medical College
New York
Recent developments lead to improved management of
antiretroviral therapy for treatment-experienced patients.
Newer approved drugs with novel resistance profiles
(the NNRTI etravirine, the protease inhibitors darunavir
and tipranavir) or new mechanisms of action (the
CCR5 antagonist maraviroc and the integrase inhibitor
raltegravir) offer significant virologic activity even in
patients with extensive treatment experience and drug
resistance. Recognizing these developments, current
treatment guidelines state that the goal of antiretroviral
therapy for ALL patients is suppression of HIV RNA to <50
copies/ml and that the optimal way to do that is to design
a regimen with 2 (or preferably 3) fully active drugs.
Etravirine, a new NNRTI, demonstrated activity against
many viral strains with resistance to efavirenz and
nevirapine and was safe and well-tolerated when used
with an optimized antiretroviral regimen containing
darunavir in the phase III DUET studies of treatmentexperienced patients. Subanalyses revealed that the
virologic activity of etravirine was impacted only by
the presence of 3 or more NNRTI-associated mutations
(excluding K103N). Additional investigational NNRTIs with
activity against drug-resistant virus are in development.
The newer HIV protease inhibitors darunavir and tipranavir
demonstrated activity against PI-resistant viral strains in
the POWER and RESIST phase III studies, respectively, and
are not necessarily cross-resistant to one another. Safety
and tolerability considerations, particularly hepatic, favor
darunavir over tipranavir. Additionally, because of drugdrug interactions, tipranavir cannot be co-administered
with etravirine.
Drugs with new mechanisms of action demonstrate
virologic activity, even against multi-drug resistant strains.
Maraviroc, the first approved CCR5 antagonist, blocks HIV
entry by R5 virus and demonstrated significant virologic
activity and was well-tolerated in treatment-experienced
patients with R5 virus (determined with a tropism assay)
in the phase III MOTIVATE studies. An investigational CCR5
antagonist, vicriviroc, currently is under evaluation in phase
III trials. Additional investigational chemokine receptor
inhibitors also are in development. Raltegravir, the first
approved HIV integrase inhibitor, inhibits strand transfer of
viral DNA to host cell DNA and demonstrated significant
virologic activity and was well-tolerated in treatmentexperienced patients in the phase III BENCHMRK studies.
Phase III studies of an investigational integrase inhibitor,
elvitegravir, recently opened. Additional new agents with
novel mechanisms of action also are in development,
including CD4 attachment inhibitors and maturation
inhibitors.
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Australian Antiretroviral Guidelines: Consensus Conference

The Annual Consensus Conference is this year
incorporated into the clinical stream of the main
ASHM 08 Conference program. Previously, the Annual
Consensus Conference has been held on the Saturday
afternoon immediately following the close of the ASHM
Conference. Feedback from previous years has suggested
that attendance and participation would be maximised
if the Australian Antiretroviral Guideline sessions were
moved into the ASHM program.

NEWER AGENTS FOR TREATMENTEXPERIENCED PATIENTS

thursday 18 september 2008:1.30pm – 3.00pm

Australian Antiretroviral Guidelines:
Consensus Conference
1.30pm – 3.00pm
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1. Tim Read, sexual health physician at Melbourne Sexual
Health Centre and Victorian infectious Diseases Service
(Royal Melbourne Hospital).
Managing suspected early virologic failure.
A patient with cerebral toxoplasmosis had a viral load
decrease of only 0.6 log, four weeks after commencing
tenofovir, emtricitabine and nevirapine. Seeing this
result at week six, should we have immediately switched
treatment OR continued this treatment until seeing
results of a genotypic resistance assay?
2. Catriona Ooi, Director of Sexual Health, Hunter New
England Area Health
Juggling antiretroviral therapy and cardiovascular risk.
Should a smoker with impaired glucose tolerance, high
triglycerides and impaired renal function continue to be
treated with abacavir, lamivudine and efavirenz?

thursday 18 september 2008:1.30pm – 3.00pm

Australian Antiretroviral Guidelines: Consensus Conference

case presentations
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iNCREASING THE CONTRIBUTION OF
SOCIAL RESEARCH TO HIV PREVENTION:
DEVELOPING AND TESTING A THEORYDRIVEN INTERVENTION TO REDUCE
UNPREMEDITATED RISK-TAKING IN MSM

The present study illustrates that theory-based
translational social research holds substantial promise
for the strengthening of behavioural prevention of HIV,
in particular when conducted in close collaboration
between researchers and prevention experts. More
specifically this study shows that non-premeditated,
contextual processes that underly risk-taking in MSM
can effectively be adressed in interventions based
on innovative theorizing and using state-of-the-art
intervention delivery.

Social Research – Desire

Social Research – Desire
1.30pm – 3.00pm

De Wit, JBF1,2, Adam, PCG1,3
1
National Centre in HIV Social Research, University of New
South Wales, Sydney, NSW, Australia; 2Department of Social
Psychology, Utrecht University, Utrecht, The Netherlands;
3
Institute for Prevention and Social Research, Utrecht, The
Netherlands
For more than a decade studies conclude that sexual
risk-taking among MSM is increasing or remains high.
But what are effective approaches to HIV-prevention in
this era of HAART? This paper addresses this question
by drawing on a program of social research concerned
with the translation of theory-based understanding of
individual and social processes underlying risky practises
into effective HIV-prevention. A range of explanations has
been offerred for increasing trends in risk behavior, STI
rates and HIV notifications in MSM worldwide, collectively
emphasizing reduced motivation. However, as expected
from recent social theorising of behaviour, studies we
conducted in 5400 French and Dutch MSM showed
that risk-taking with casual partners, mostly occurs in
highly motivated men and is mainly unpremeditated.
As unpremeditated risk-taking is largely unaddressed
in current HIV-prevention, in collaboration with a major
French NGO a novel theory-driven online intervention
was developed and tested.

17-20 september 2008 @ Perth Convention Centre, Western Australia 				

thursday 18 september 2008:1.30pm – 3.00pm

In an RCT 331 MSM who engaged in sex with casual
partners and experienced difficulties in practising
safer sex were randomly assigned to either a reference
group not receiving any prevention advice, or one of
two intervention groups receiving advice to promote
their vigilance and control over situations related to
unpremeditated risk-taking (e.g., when strongly aroused).
Intervention format was either an e-card or a 3 min.
interactive e-animation. The e-animation had a strong
impact at immediate post-test and 6 months follow-up,
while the e-card was generally not effective. In particular,
the e-animation increased men’s intention to exert
vigilance and control to prevent unpremeditated risktaking at post-test (p<.05), increased effective vigilance
and control behaviors at follow-up (p=.001), and reduced
willingness to engage in risk-taking at post-test (p<.01)
and follow-up (p=.000). Most importantly, 6 months after
the intervention the e-animation had reduced UAIC by
23% (adj.OR=.770, p=.001).
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SEX PIGS: A ROUGH GUIDE TO DIRTY SEX

GAY MEN WHO ENGAGE IN GROUP SEX ARE
AT INCREASED RISK OF HIV INFECTION AND
ONWARD TRANSMISSION: DATA FROM THE
THREE OR MORE STUDY

Triffitt, K A
Positive Life NSW, Sydney, Australia
Australian research has identified gay men who practice
adventurous sex as a priority group for HIV/STI prevention.
Sexually confident HIV positive gay men are highly
represented in this subculture. Specifically, the challenge
was to develop a prevention campaign that adapted
to participant’s sexual limits and included the way new
understandings of risk, safety and health are incorporated
in HIV positive gay men’s sexual lives.
Drawing on a review of SEX PIGS: DARK AND DIRTY SEX
AND MANAGING YOUR HEALTH produced by Positive Life
NSW, this paper will examine campaign development
and implementation, and incorporate the ways sexually
adventurous gay men ‘care for self’ and their partners.
By producing a more sophisticated understanding
on prevention, adventurous sex is positioned as a
‘productive’ concept. It highlights values and models of
behaviour, and harm minimisation applied to condom
and drug use. While condom use with casual partners of
unknown HIV status is a key message, the campaign also
acknowledges gay men continue to redefine the limits of
risk and safety.

thursday 18 september 2008:1.30pm – 3.00pm

HIV/STI prevention is not only a behavioural intervention,
but is also a cultural practice, which engages and
reproduces community ethics and values. This work
creates opportunities for sexually adventurous gay men
to speak through their culture and helps to define the
sexual and subjective spaces they share.
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Prestage G1,2, Hudson J3, Bradley J1, Corrigan N4, Down I4,
Grulich A1, McInnes D5
1
National Centre in HIV Epidemiology & Clinical Research,
UNSW; 2Australian Research Centre in Sex Health and
Society, La Trobe University; 3Faculty of Medicine,
University of Sydney; 4AIDS Council of NSW; 5School of
Communications, University of Western Sydney.
Background: Group sex has been associated with risk
behaviour and HIV seroconversion among gay men. We
examined risk factors for risk behaviour in a communitybased study of homosexually active men who participated
in group sex activity in Australia.
Methods: The Three or More Study (TOMS) was an
anonymous self-complete survey of men who had
engaged in group sex with other men within the previous
five years. Detailed information about sexual, drug-using
and other behaviour during their most recent group sex
encounter was collected. Men who reported group sex in
the previous six months were included in these analyses.
Results: In broader surveys of Australian gay men, about
one quarter had engaged in unprotected anal intercourse
(UAI) with non regular partners in the previous six months,
whereas among the 746 TOMS participants, 29.4%
reported UAI with non regular partners at their most recent
group sex encounter, and 22.4% reported UAI with any
partners they did not know to be the same HIV serostatus
as themselves. After controlling for age, education, and
location, not having a clear intention to use condoms,
being HIV-positive or HIV status unknown, having more
men at the group sex encounter, and engaging in group
sex at least monthly were independently associated with
UAI.
Conclusion: Gay men who engage in group sex, and
particularly those who do so regularly and with more
partners, are much more likely to engage in risk behaviour
in general than are other gay men, and this risk behaviour
often occurs in the context of group sex encounters.
Group sex among gay men should be a high priority in
HIV-prevention efforts in this population.
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Background: Sex on premises venues (SOPV) are a primary
site for health promotion interventions. Understanding
the sexual practice of SOPV patrons requires an
understanding of the ways in which the physical and
social environments shape, constrain or co-vary with this
practice.
Methods: Detailed interviews with SOPV patrons capture
in rich narrative detail the exact nature, duration and
sequencing of the sexual interactions that occurred
during the men’s most recent visit to an SOPV. The data
allow us to describe trajectories of engagement with
sexual possibilities during visit to an SOPV.
Results: 219 men completed telephone interviews
within 48 hours of their visit. Interviews detailed the
pattern of visits to SOPVs using time sequences that
plotted their venue trajectory. Each sexual episode
was further detailed in terms of partner characteristics,
sexual practices and sequencing. 82% of men were
HIV-negative. 68% of the men described themselves as
single and 27% had a regular male partner. Most visits
lasted between one and four hours. The most clearly
sex-related sites (cruising areas, cubicles and wet areas)
account for 70% of men’s time. 74% of men’s time does
not involve a sexual interaction. Sexual encounters lasted
an average of 26 minutes. Over half of the encounters
took place in cubicles. Cubicles accounted for 83.9% of
encounters involving anal intercourse, both protected
and unprotected. The partner’s age was more likely to be
undetermined in cruising areas than in other sites such as
cubicles. Partners’ ages were assessed as somewhat older
in cruising areas and wet areas compared to cubicles.
Partner’s HIV status was unrelated to site.
Conclusions: Detailed examination of trajectories of sexual
practice in SOPVs provides useful contextual direction
for effective targeting and delivery of health promotion
interventions. Understanding SOPVs as a complex and
dynamic social space will enhance outreach efficacy.

Adam PCG1,2, De Wit JBF1,3
1
National Centre in HIV Social Research, University of
New South Wales, Sydney, NSW, Australia; 2Institute for
Prevention and Social Research, Utrecht, The Netherlands;
3
Department of Social Psychology, Utrecht University,
Utrecht, The Netherlands

Social Research – Desire

Grierson J1, Smith A1, Von Doussa H1
1
La Trobe University, Australian Research Centre in Sex,
Health and Society, Melbourne, Australia

SEXUAL DESIRES, SEXUAL CONTROL AND
SEXUAL RISK-TAKING IN MEN WHO HAVE
SEX WITH MEN

Sex is about more than preventing risk and a body of
research shows that some sexual desires, reflected in
the notion of sexual sensation seeking, are associated
with risky practises. However, research also suggests that
individuals can be effective self-regulators who do not
indiscriminately enact what is considered a personal sexual
disposition. Based in emergent theorising concerning the
self-regulation of health behaviors, the aim of this study is
to go beyond the notion of sexual sensation seeking as
risk factor, and assess the extent to which any influence
of sexual sensation seeking on sexual risk-taking among
MSM is moderated by differences in men’s perceived
sexual control. Sexual control reflects individuals’ agency
in sexual contexts that can potentially be promoted to
support men in having both gratifying and safe sex lives.
An online survey in The Netherlands recruited 1,613
MSM; 1,299 men who had sex with casual partners were
included in this study. Potential sexual risk-taking in the
preceding 12 months was indexed by number of causal
partners (1-9 vs. ≥10), unprotected anal intercourse with
casual partners (UAI-C; no vs. yes), and self-reported
sexually transmitted infections (no vs. yes).
Sexual risk-taking with casual partners was highly
prevalent in this online sample of MSM; 48.5% had had 10
or more causal sex partners, 39.8% had engaged in UAI-C,
and 19.2% reported having had a STD. Multivariate logistic
regression analyses showed that sexual sensation seeking
was significantly related to more risk-taking according to
each outcome variables, while all effects of sexual self
control were significantly protective. As expected, sexual
self control moderated the effects of sexual sensation
seeking on behavioral indicators.
This study is the first to show that, although MSM who
are higher in sexual sensation seeking are more likely to
engage in sexual risk-taking, some men can effectively
self-regulate this sexual disposition. While men high in
sexual self control may spontaneously control their sexual
desires, men low in sexual self control may benefit from
a new generation of prevention methods that, inspired
by a self-regulation approach, promote planning ahead
of time.
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WALKING AFTER MIDNIGHT: TRAJECTORIES
OF SEX ON PREMISES VISITS
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Medicine, risk factor, pleasure 
enhancer or safe sex aid?
The use of Viagra and other 
sexuopharmaceuticals by gay men
Holt M1, Bernard D1 and Race K2
1
National Centre in HIV Social Research, The University of
New South Wales; 2The University of Sydney
This paper aims to i) analyse the representations of Viagra
and other drugs designed to treat erectile dysfunction
(‘sexuopharmaceuticals’) in the HIV research literature and
the accounts of gay men, and ii) identify the implications
of sexuopharmaceutical use for HIV prevention and harm
reduction among gay men.
31 gay men were interviewed in Sydney about
contemporary gay life for the Qualitative Interviews
Concerning Key Issues and Experiences (QUICKIE) project.
A discursive analysis of accounts of sexuopharmaceutical
use is presented here. The HIV research/public health
literature is also drawn upon to illustrate how Viagra is
considered a risk factor for HIV transmission.
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Although
not
all
participants
had
used
sexuopharmaceuticals, their accounts suggested
that Viagra and similar drugs are seen as aids to safe
sex by some gay men; drugs that can offset erectile
difficulties when using condoms, particularly in
the context of alcohol or other drug use. Negative
accounts of sexuopharmaceutical use were rare among
participants. We suggest that the following contribute
to a perception among gay men that Viagra and similar
drugs are benevolent and pose few risks: i) the status of
sexuopharmaceuticals as beneficial medicines and sexual
enhancers, ii) gendered expectations that men should be
able to perform sexually on demand, and iii) the trend
that encourages biomedical or pharmaceutical fixes to
behavioural problems.
Negative outcomes associated with sexuopharmaceutical
use may be overlooked by gay men, suggesting a need
for harm reduction information. The idea that problems
with condom use and safe sex can be solved through
pharmaceutical intervention requires ongoing and critical
attention.
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Paul R. Gorry.
Centre for Virology, Macfarlane Burnet Institute for
Medical Research and Public Health, Melbourne, Victoria,
Australia.
CCR5-restricted
(R5)
HIV-1
variants
cause
immunodeficiency in the majority of HIV-1+ subjects
who progress to AIDS, but the pathogenic mechanisms
of R5 HIV-1 are poorly understood. The CD4-bound
JRFL crystal structure of gp120 containing the V3 loop
and the b12-bound gp120 crystal structure were used
as templates to generate 3D models of 17 R5 gp120
proteins isolated patients with chronic/pre-AIDS (PAR5 Envs) HIV-1 infection or AIDS (A-R5 Envs). Structural
features were correlated to Env functional/genetic data
including fusogenicity, CD4 binding, CD4-dependence,
antibody binding and amino acid variations. A more
open conformation of the CD4 binding site associated
with movement of the V5 variable loop was present in
the majority of A-R5 Envs and correlated with reduced
CD4-dependence, increased CD4 binding and enhanced
fusogenicity. In addition, the V3 loop of A-R5 Envs was
more likely to exist in a conformation that brings the
tip of the V3 loop closer to the co-receptor binding site,
a conformation associated with enhanced binding of
the anti-co-receptor binding site antibody 17b, altered
reliance of CCR5 N-terminal and ECL residues for fusion
and entry, as well as greater binding of CD4. These
models suggest structural heterogeneity in R5 Envs may
affect CD4 and CCR5 interactions and contribute to HIV1 pathogenesis in subjects who continue to harbour R5
viral variants to late stages of infection.

Simon Mallal1, Tomer Hertz2, Mina John1, Silvana
Guadieri1, Ian James1, Elizabeth Phillips1, David Nolan1
and Nebojsa Josic2.
1Institute for Immunology and Infectious Diseases
Royal Perth Hospital and Murdoch University, Perth,
Australia, 2Microsoft Research, One Microsoft Way,
Redmond, WA 98052, USA

HIV Immunology

Heterogeneity in primary R5 HIV-1
gp120 structures affecting CD4 and 
CCR5 interactions and exposure of 
neutralising antibody epitopes.

HOW MIGHT UNDERSTANDING OF THE COEVOLUTION OF HLA AND VIRUSES INFORM
CONTEMPORARY CLINICAL ISSUES

Class I MHC molecules are under diversifying selection
but share the preference for binding to conserved areas
of human proteins, and most target human viruses with
similar efficiency. However flaviviruses, such as Hepatitis
C, are unusual in that non-conserved areas may be
preferentially targeted. MHC binding can be considered
as ‘nature’s estimator of sequence conservation/
functionality’ and MHC targetting acts a fundamental
force shaping the adaptation of pathogens and different
viruses have taken different strategies to escape these
selective pressures.
Some individuals exposed to Hepatitis C clear the virus
during acute infection while others become chronically
infected and there is also intra-patent variability in the
response to therapy. This is likely to be determined by
both variability in host alleles and the degree to which the
infecting virus has adapted to those responses. However,
to predict likely clinical outcomes it is also essential
to first understand which responses are effective and
constraining the virus from those host responses which
are being elicited by the virus and are non-effective or
even harmful to the host.
The failure of the STEP trial of the Merck developed
Ad5-based HIV vaccine, which demonstrated that HIV
acquisition was unexpectedly enhanced in vaccinated
individuals despite evidence of immunogenicity has
created new challenges in HIV vaccine research. We
have found evidence of characteristic HLA allele-specific
adaptations that induce T cell responses that are not
just ineffective or neutral but actively enhancing to
viral infection and harmful to immune control. These
responses may appear strong by standard measures but
they represent the consequence rather than the cause
of adaptation and as such, serve the interests of the virus
rather than the host. These findings support the concept
that the more generally ‘immunogenic’ a vaccine is to
this highly adaptable pathogen, the greater harm the
vaccine may do unless the enhancing viral elements
are pre-emptively identified and excluded from the
immunogen.
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ROLE OF INNATE IMMUNITY IN HIV
INFECTION

REASSESSING VACCINE RESPONSES

Seema N Desai Ph.D.1, Jeffrey Martinson B.A.1,
Carlos Montoya M.D.2,and Alan L. Landay Ph.D.1
1
Department of Immunology/Microbiology, Rush
University Medical Center, Chicago, IL; 2Universidad de
Antioquia, Medellín, Colombia
Innate immunity plays an instrumental role in
activation and priming of adaptive immune response
in HIV infection. HIV infection significantly impacts the
frequency of innate cells mainly natural killer (NK) cells,
plasmacytoid (p) and myeloid (m) dendritic cells (DCs).
Highly active antiretroviral therapy (HAART) restores
the frequency though functional impairment persists
especially in pDC, the principle interferon-α producing
cell. pDCs are activated via endosomal toll like receptors
(TLR) 7 and 9. Our studies indicate that despite reduced
numbers, pDCs remain responsive to TLR mediated
activation and to AT-2 inactivated HIV-1 virus that
induces IFN-α to a higher degree in healthy individuals
compared to HIV infected. In vitro studies to examine
the effects of activated innate immune responses in
HIV infection, indicated that exogenous IFN-α induced
program death Ligand-1 (PD-L1) on AT-2 HIV-1 activated
monocytes and T cells which downmodulated T cell
responses. Activation of pDC via TLR7 and 9 and AT2 HIV also resulted in up-regulation of the enzyme,
indoleamine 2-3 dioxygenase (IDO), which degrades the
essential amino acid, tryptophan, leading to decreased
proliferation of antigen specific T cells. Blocking pDC
activation using chloroquine, a 4-aminoquinoline
drug that inhibits endosomal fusion and acidification
completely abrogated TLR7, 7/8 and 9 mediated IFNα production and downstream metabolic signaling
molecules IRF-7 and IRAK-4. Chloroquine impaired IDO
and its activity. Chloroquine also downmodulated PDL1 expression on pDCs and CD38 on T cells. Thus IFN- α
that exhibits antiviral effects in the acute phase of HIV
infection has a paradoxical role in the chronic phase that
is associated with downmodulation of T cell responses
via PDL1-PD-1 interaction or IDO synthesis. Chloroquine
reverses the damage by blocking pDC activation in the
endosome and downstream molecules in the IFNα synthesis pathway suggesting its merit in adjuvant
therapy with HAART.
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Kelleher AD, NCHECR, UNSW and Centre For Immunology
St Vincent’s Hospital Darlinghurst, NSW
The recent early completion of the phase IIb proof of
concept vaccine trial, STEP, because of lack of efficacy, has
resulted in a reappraisal of what is required for an effective
HIV vaccine. In particular these results have raised
questions about the currently accepted assays used to
measure immunogenicity of T cell vaccines: IFN-γ ELIspot
and ICC. Further these results have raised questions as
to whether a T cell based vaccine can prevent or control
HIV infection. The increased rate of infection in those with
higher rates of pre-existing Adenovirus immunity also
highlights the need to more fully understand immune
responses to the backbone of recombinant vectors as a
part of vaccine development. The generation of strong
mucosal immunity, generally accepted as a desirable
component of a vaccine for HIV, may be problematical in
the case of HIV vaccines. Increasing the pool of activated
HIV specific CD4+ T cells in the mucosa may facilitate
amplification of the initially transmitted quasispeces,
encouraging rather than blocking productive infection.
A brief review of the STEP trial results will be presented
as will a review of our current understanding of the
determinants of T cell immunity and how these impact
on future vaccine design and development.
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Changes in circulating CCR5+ T-cells 
and antigen-specific CD4+ T-cells 
during monotherapy with a small 
molecule CCR5 antagonist SCH532706,
compared with combination 
antiretroviral therapy (cART)

p=0.01). Declines in M.TB-, CMV-, HSV-, and Gag-specific
CD4+ T-cells occurred during receipt of SCH532706/r and
cART. MAI-specific CD4+ T-cells declined significantly on
cART vs. SCH532706/r (p=0.037).
CD4+ T-cell increases were modest on SCH532706/
r and cART. However, CD8+CCR5+ T cells increased
substantially during receipt of the CCR5-antagonist, but
not cART, suggesting alterations in trafficking due to
CCR5 blockade. Declines in CD4+ T-cells responsive to
CMV, HSV and HIV Gag were equivalent during use of
SCH523706/r and subsequent cART.

Pett SL1,2, Zaunders J3, Bailey M3, Murray J1,4, Cooper DA1,2,
MacRae K2, Emery S1, Kelleher A1,2,3
1
National Centre in HIV Epidemiology and Clinical Research,
University of NSW, Darlinghurst, Sydney, Australia; 2HIV,
Immunology and Infectious Diseases Clinical Services
Unit, St. Vincent’s Hospital, Sydney, Australia; 3Centre for
Immunology, St. Vincent’s Hospital, Sydney, Australia;
4
School of Mathematics and Statistics, University of NSW,
Sydney, Australia.
We previously found that HIV- and CMV-specific CD4+ Tcells were CCR5+.
Therefore we investigated whether levels of these cells
were altered in HIV-infected subjects given SCH532706 (a
CCR5-antagonist) with low-dose ritonavir (/r).

Ian Thompson Memorial Session – Clinical Anti Retroviral Therapy

Ian Thompson Memorial Session
– Clinical Anti Retroviral Therapy
3.30pm – 5.00pm

Subjects received SCH532706/r for 10 days (phase 1),
followed by a 15-day “washout” (phase 2); cART was
initiated on day 25. CCR5+ T-cell subsets and CD4+ T-cells
specific for Mycobacteria tuberculosis and avium (M.TB
and MAI), cytomegalovirus (CMV), Herpes simplex (HSV)
and HIV Gag were measured at days 1, 3, 10 (phase 1);
20, 25 (phase 2) and 28, 35 on cART (phase 3); changes
were analysed using the Mann-Whitney test. Changes in
CCR5+ T-cell subsets were assessed by area-under-thecurve comparisons.
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Ten males, with median 242 CD4+ (range 93-551) and
783 CD8+ (range 353-1115) T-cells/µL and 4.5 log10
copies/mL viral load (range 3.8-5.7) were enrolled. At
baseline, a median 20% of CD4+ and 50% of CD8+ T-cells
were CCR5+. Antigen-specific CD4+ T-cells for M.TB, MAI,
CMV, HSV and HIV Gag were 0.45%, 5.7%, 5.0%, 2.3% and
1.75%, respectively. Median viral load declines for phase 1
and 3 (SCH532706/r vs. cART) were –1.5 and –1.75 log10
copies/mL, respectively (p=0.7).
Median changes in CD4+ T-cells for phases 1, 2, 3 were
+16, -26, +28 cells/µL respectively (1 vs. 3: p=0.7); CD8+
T-cell changes were +91, -142, -71, respectively (1 vs.
3: p=0.02). Relative to baseline cell counts, changes in
CCR5+CD4+ T cells for phases 1, 2, 3 were +22%, -24%
and +24%, respectively (1 vs. 2: p=0.002; 2 vs. 3: p=0.01).
In contrast, changes for CCR5+CD8+ T-cells were +33%,
-13% and -10%, respectively (significant for phases 1 vs. 3;
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EFAVIRENZ (EFV) PLASMA
CONCENTRATIONS IN PATIENTS STOPPING
THERAPY AFTER AT LEAST ONE MONTH DUE
TO NEUROPSYCHIATRIC DISTURBANCES: AN
INITIO SUBSTUDY

ESPRIT (Evaluation of Subcutaneous 
Proleukin® in a Randomised 
International Trial): FActors 
associated with ongoing cycling with 
recombinant interleukin-2 (rIl-2)

Read TRH1,2, Mallon P3, Mijch A4, Goodall R5,
Hudson F5, Wand H6, Carey D6, Emery S6, on behalf of the
INITIO Coordinating Committee
1
Melbourne Sexual Health Centre, Victoria, Australia;
2
Victorian Infectious Diseases Service, Victoria, Australia;
3
Mater Misericordiae, University Hospital Dublin, Ireland;
4
Monash University, Melbourne, Australia; 5Clinical Trials
Unit, Medical Research Council, London, UK; 6NCHECR/
UNSW, Sydney, NSW, Australia

Seneviratne N1, Lin E1, Wentworth D2,
Courtney-Rodgers D1, Carey C1, Pett SL1, Kearney L1,
French M3, Finlayson R4, Cooper DA1, Emery S1 for the
ESPRIT Research Group.
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney, Australia,
2
Department of Biostatistics, University of Minnesota,
Minneapolis, USA; 3Dept Clinical Immunology, Royal Perth
Hospital, Perth, WA, Australia; 4Taylor Square Private Clinic,
Sydney, NSW, Australia.

Neuropsychiatric symptoms, including dreams, dizziness,
insomnia, somnolence and mood changes can limit EFV
use. Symptoms usually resolve within several weeks,
but can persist in some patients necessitating EFV
cessation. Central nervous system disturbances have
been associated with elevated EFV concentrations. We
examined EFV plasma concentrations in a retrospective
nested case control study of HIV+ adults participating
in INITIO, a large, international trial of initial antiretroviral
therapy.
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Cases (n=35) were participants who ceased EFV after >4
weeks therapy due to neuropsychiatric disturbances.
Controls (n=75), matched for gender, country and time
since randomisation; continued EFV for >6 months.
Validated HPLC methods quantitated EFV concentrations
in plasma collected (at or prior to EFV cessation for cases)
and stored at -70oC. Cases and controls were compared
using non-parametric methods.
11 participants (6 cases; 5 controls) had undetectable EFV
levels and were excluded from analysis. EFV concentrations
were >500 µg/L in all 99 participants and >1000 µg/L in
94, indicating acceptable adherence. Baseline age, height,
weight, body mass index, HIV stage, serum creatinine,
ALT, CD4 count or HIV RNA did not differ. Concomitant
protease inhibitor therapy use was not different (p=0.61).
Cases were more likely to be smokers (62% versus 27%;
p=0.0011). Median EFV concentrations were not different
in cases compared to controls (2259 [IQR 1768-2825]
µg/L vs (2085 [IQR 1684-3336] µg/L respectively; p=0.77).
EFV concentrations were >3000 µg/L in 17% of cases and
27% of controls (p=0.30), and >4000 µg/L in 7% and 16%
respectively (p=0.24).
In a large randomised trial, EFV plasma concentrations
did not predict drug cessation due to neuropsychiatric
disturbances after at least one month of therapy. We
cannot exclude that differences in adherence and time
post dose of sample collection may account for our
findings. It is possible the high prevalence of smokers
amongst cases may represent individuals with preexisting psychiatric disturbances.
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ESPRIT is an ongoing phase III clinical trial evaluating the
clinical impact of intermittent SC rIL-2 plus antiretroviral
therapy (ART) vs. ART alone in HIV-1-infected individuals
with CD4+ T-cells ≥300 cells/µL. After year 1 rIL-2
induction further rIL-2 dosing cycles should be given to
achieve/sustain the CD4+ T-cell target (baseline x2 or
≥1000 cells/µL when baseline was 300-499 or ≥500 cells/
µL respectively). The aim of the 2007 cycling initiative was
to encourage all rIL-2 patients not at CD4+ target and
without medical contraindication to receive further rIL-2.
The aim was to describe baseline and on-study predictors
of ongoing rIL-2-cycling.
The reasons for non-cycling in eligible patients were
summarised. Multivariate analyses were performed to
determine the relationship between baseline and onstudy predictors of receipt of ≥ 1 rIL-2 dosing cycle in
2007. Predictors considered were age, gender, ethnicity,
geographical location of enrollment, baseline/nadir CD4+
T-cell count, prior ADI, previous rIL-2 cycles received and
recent CD4+ T-cell count.
In 2007, 1107 patients were eligible to cycle. Median age
was 40 years, 83.3% male, 76.8%, 10.8%, 8.0% were of
white, black, Asian ethnicity respectively, 44.1%, 27.5%,
15.3%, 8.8% and 4.4% were enrolled in Europe/N.Africa,
N.America, S.America, Asia and Australia respectively.
Median baseline, nadir and recent CD4+ T-cell counts (in
2006) were 460, 184 and 568 cells/µL respectively; 26.1%
had had a prior ADI.
Only 19.6% (n=217) received ≥1 rIL-2 dosing cycle in
2007. The main reasons given for non-cycling were
“patient wish” (62.8%), “other” (17%), “previous rIL2-related
toxicity” (11.7%) and CD4+ “high enough” (11.5%). Patients
cycling in 2007 were more likely to have higher CD4+
counts in 2006 and had received a greater number of
previous cycles (p<.001 for each). Geographical location
of enrolment was also a determinant of cycling, with
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to change to a protease-inhibitor-based regimen (48% vs.
16%; p<0.001).

The 2007 rIL-2 cycling initiative was not very successful. It
is disappointing that patients with potentially the most to
gain from further IL-2 cycling – those with lowest recent
CD4+ counts and little previous IL-2 experience – were
the least likely to re-cycle. It is unclear why re-cycling rates
differed across geographical regions.

We found that among a cohort of HIV patients across
Asia, nearly half remained on a failing regimen one year
after treatment failure. Deferred modification of regimen
following treatment failure in many Asian countries may
have implications for accumulation of drug resistance
and response to second-line treatment. There is an urgent
need to scale up access to second-line regimens and viral
load monitoring in this region.

Deferred modification of 
antiretroviral regimen following 
treatment failure in Asia: results 
from The TREAT Asia HIV Observational 
Database (TAHOD)
Zhou J1, Li PC2, Kumarasamy N3, Boyd M1, Pujari S4, on
behalf of The TREAT Asia HIV Observational Database
1
National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney,
Australia; 2Queen Elizabeth Hospital, Hong Kong, China;
3
YRG Centre for AIDS Research and Education, Chennai,
India; 4Institute of Infectious Diseases, Pune, India

McLellan DGJ - see page 230
Byakwaga H - see page 224
Bloch M - see page 223
Chibo D - see page 225

Effective new combination antiretroviral regimens
(cART) in patients who experience treatment failure
are not readily available in many Asian countries.. - We
analysed the rates of treatment failure and antiretroviral
modification following failure in patients from TAHOD.

Ian Thompson Memorial Session – Clinical Anti Retroviral Therapy

the highest and lowest rates in Asia (37.1%) and Europe/
N.Africa (12.9%) respectively.

Treatment failure was defined according to WHO
guidelines. Time to treatment modification following
cART failure was assessed by person-time method.
Types of modification were summarised. Countries were
categorised into high- and low-income by World Bank
criteria.
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Among 2446 patients (71% male) who initiated cART 447
developed treatment failure (242 immunological failure,
112 virological failure and 93 clinical failure) over 5697
person-years (7.8 per 100 person-years, 95% confidence
interval CI 7.2-8.6). A total of 253 patients (76% male)
changed at least one drug after treatment failure (51.6
per 100 person-years, 95% CI 45.6~58.4). There was no
difference between patients from high- and low-income
countries (unadjusted hazard-ratio HR 1.03; p=0.829).
Compared to patients with virological failure, patients
with either immunological or clinical failure were less
likely to modify treatment (unadjusted HR 0.55; p<0.001
and 0.50; p<0.001, respectively). When modifying
treatment, 24 (10% of 253) patients added one or more
drug, 92 (36%) changed one and 137 (54%) two or more
drugs. Compared to patients from low-income countries,
patients from high-income countries were more likely to
change two or more drugs (67% vs. 49%; p=0.009) and
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Epidemiology – Morbidity and
Mortality
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A faster decrease in CD4+ T cell 
counts after HIV infection for older 
individuals contributes to levels of 
immunosuppression at HIV diagnosis
Murray JM1,2, Kelleher AD2
1
School of Mathematics and Statistics, University of New
South Wales, Sydney, NSW, Australia; 2National Centre in
HIV Epidemiology and Clinical Research, University of
New South Wales, Sydney, NSW, Australia.
It has been observed that older individuals at HIV
diagnosis are more likely to present with lower CD4+ T cell
counts, suggesting a longer time between infection and
diagnosis with older age. We investigated whether this
same correlation between age and CD4+ T cell numbers
at diagnosis was also true in Australia. Additionally we
assessed whether some of the loss in CD4+ T cell counts
at diagnosis for older individuals could be attributed
to faster immunosuppression. CD4+ T cell counts at
HIV diagnosis (7,244 men and 1,045 women), and at
primary HIV infection (1,206 men) were determined
from the HIV Public Access Dataset. CD4+ T cell counts
for 25 HIV-uninfected individuals were obtained from the
Sydney AIDS Project, and CD4+ T cell counts for 259 men
followed from primary HIV infection were obtained from
the AIEDRP CORE01 Study.
CD4+ T cell counts for 25 HIV-uninfected men aged
from 23 to 65 exhibited a non-significant increase with
age. However median CD4+ T cell numbers per mm3
of blood for men at HIV diagnosis decreased from 500
for 15 to 24 year olds to 210 for those over 60, while for
women these decreased from 534 to 175. At primary HIV
infection men over 60 years of age had median CD4+ T
cell counts of 352 per mm3 significantly lower than each
age group younger than 45 where the medians ranged
from 540 to 510 (p<0.05 Tukey Test). Two years after
primary HIV infection CD4+ T cell counts for treatmentnaïve men were significantly negatively correlated with
age (p=0.01).
Although CD4+ T cell counts increase with age in
uninfected individuals, levels at HIV diagnosis are
significantly lower for older individuals with many
presenting with AIDS level immunosuppression. Some of
this will be due to longer times until diagnosis for older
individuals, however a significant component is related
to greater suppression at primary infection and while
untreated for older HIV-infected individuals.
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Predictors of long-term changes in 
mean CD4 cell counts amongst HIV
infected patients from the Asia-Pacific 
Region during active combination 
antiretroviral therapy
Egger S1, Petoumenos K2, Kamarulzaman A3, Hoy J4,
Sungkanuparph S5, Chuah J6, Falster K2,7, Zhou J2, Law MG2,
on behalf of the Asia Pacific HIV Observational Database
(APHOD)
1
The Cancer Council NSW, Woolloomooloo, NSW
Australia; 2National Centre in HIV Epidemiology and
Clinical Research, University of NSW, Sydney, Australia;
3
Department of Medicine, University of Malaya, Lembah
Pantai, Kuala Lumpur, Malaysia; 4The Alfred Hospital,
Monash University, Melbourne, Australia; 5Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand; 6Gold
Coast Sexual Health Clinic, Queensland, Australia; 7School
of Public Health and Community Medicine, University of
NSW, Sydney, Australia
The primary objective of this study is to investigate
the predictors of long-term changes in mean CD4 cell
counts among HIV positive patients, up to 6 years after
the commencement of combination antiretroviral
treatment (cART) in the Asia-Pacific HIV Observational
Database (APHOD), a collaboration of the Australian HIV
Observational Database (AHOD) and the TREAT Asia HIV
Observational Database (TAHOD).
Patients in APHOD who first commenced cART after
January 1 1997, and who had a baseline CD4 cell count
and viral load measure, and at least one follow-up
measure between 6 and 24 months were included. CD4
cell counts were determined at every 6-month period
following the commencement of cART for up to 6 years.
Linear random effects models were used to examine the
change in and predictors of mean CD4 cell counts for
each of the cohorts over a 6-year study period.
1638 patients fulfilled the inclusion criteria with a
median follow up time of 58 months. At baseline TAHOD
patients were slightly younger (37.6 vs 40.1 years), more
likely to have prior AIDS (44% vs 13%) and substantially
lower CD4 cell counts (176 vs 386 cells/µL) than AHOD
patients. Lower post-cART mean CD4 cell counts were
found to be associated with increasing age (-14 cells/µL
per 10-year increase in age 95%CI [-21, -7], p<0.001), precART hepatitis C coinfection (-41 cells/µL 95%CI[-79,-2],
p=0.038), prior AIDS (-23 cells/µL 95%CI[-42, -2], p=0.019),
prior viral load 100,000 copies/ml (-40 cells/µL 95%CI[-56,
-25], p<0.001), and the Asia-Pacific region (27 cells/µL
95%CI[-46,-8], p=0.005). Higher absolute post-cART mean
CD4 cell counts were associated with lower post-cART
viral load levels and higher baseline CD4 cell counts.
Higher increments in post-cART mean CD4 cell counts
was found to be associated with lower baseline CD4 cell
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Middleton MG1, Jauncey M1, McDonald AM1, Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney,
Australia
Objective: To describe demographic, behavioural and
clinical risk factors for AIDS in the HAART era in Australia.
Methods: AIDS cases diagnosed in three area health
services in New South Wales in the years 2003 – 2005,
including deaths in 2001 – 2005, and notified to the
National AIDS Registry were eligible for inclusion in the
study. A questionnaire asking for clinical, behavioural and
demographic information was forwarded to people with
AIDS (PWA) via the notifying doctor.
Results: Of the 131 PWA who were alive at the time of the
survey, 36 (27.5%) responded. Twenty-five respondents
(73.5%) were MSM and 22.2% spoke a language other
than English at home. There was a high correlation
between the demographic and risk factor information
provided by patients and clinicians. Thirty-six percent of
respondents were diagnosed with HIV ≤ 90 days prior
to AIDS (late diagnosis), 38.9% had received suboptimal
HAART, and another 19.4% had not received HAART prior
to their AIDS diagnosis. Of those with a late HIV diagnosis,
85% did not consider themselves at risk of HIV infection
at the time of their diagnosis, 53% reported they had
never had a previous negative test, and 31% reported
delaying their HIV-test. The main reasons people did not
consider themselves at risk of HIV infection were that they
had never had a sexually transmissible infection (60%),
had always had safe sex (50%), had not had many sexual
partners (50%), or thought their sexual partners were HIV
negative (50%). Sixteen PWA (44.4%) were treated with
HAART prior to their AIDS diagnosis. Of these, 5 (31.3%)
did not commence treatment soon enough, 5 (31.3%)
had difficulty complying with treatment and 4 (25%) had
a structured treatment interruption. Of the 7 PWA not
treated prior to their AIDS diagnosis, 3 (42.9%) declined
treatment and 3 (42.9%) were not offered treatment.
Conclusions: Most PWA with a late HIV diagnosis were
not tested for HIV because they considered their sexual
behaviour to be low risk. The majority of people who
received HAART prior to their AIDS diagnosis received
suboptimal treatment.
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Patients with continuously or intermittently sustained
virological response experience ongoing CD4 cell
increases for several years after commencing cART, with
higher increases among patients with lower baseline CD4
cell counts. This increase was demonstrated in both the
AHOD and TAHOD cohorts, despite the slightly lower,
albeit statistically significant, overall absolute CD4 cell
response in TAHOD over the six years.

WHO GETS AIDS IN THE HAART ERA?
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counts. Rates of mean CD4+ growth rates plateaued at 6
years of cART with sustained viral suppression.
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HIGH MORTALITY ASSOCIATED WITH HIV
INFECTION AMONG ILLICIT DRUG USERS IN
THE HAART ERA

CANCER AND HIV IN AUSTRALIA: A
COMPARISON ACROSS EARLY AND LATE
HAART PERIODS

Grebely J1, Raffa JD2, Lai C3, Krajden M4, Dore GJ1,
Shannon K3, Kerr T3,5 and Tyndall MW3,5
1
National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW, Australia; 2Department of
Statistics and Actuarial Science, University of Waterloo,
Waterloo, Canada; 3BC Centre for Excellence in HIV/AIDS;
4
British Columbia Centre for Disease Control; 5Department
of Medicine, University of British Columbia, Vancouver,
Canada.

Van Leeuwen MT1, Vajdic CM2, Middleton MG1, McDonald
AM1, Law M1, Kaldor J1, Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney, NSW,
Australia; 2 University of New South Wales Cancer Research
Centre, Prince of Wales Clinical School, University of New
South Wales, Sydney, Australia.

Introduction: The impressive decrease in HIV-associated
morbidity and mortality related to the introduction of
highly active antiretroviral therapy (HAART) has been
less dramatic in marginalized populations. This study was
designed to measure mortality rates among a cohort of
illicit drug users in Vancouver.
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Methods: CHASE is a cohort study of inner city residents
recruited from Vancouver, Canada between January
2003 and June 2004. Participants were then followed
retrospectively and prospectively through health-related
database linkages. HIV and HCV status were determined
through linkage with provincial virology databases.
Mortality data were derived from the British Columbia
Vital Statistics registry (2003-2006). Causes of death were
categorized according to ICD-10 chapter headings. Rates
of all cause, drug-related, HIV-related and other causerelated mortality were measured. Factors associated with
all cause and HIV-related mortality were also assessed
using Cox proportional hazards models.
Results: Of 2913 participants, 305 and 1366 were infected
with HIV and HCV, respectively. Among 178 deaths, the
major causes were due to infection (23.0%), external
causes of morbidity and mortality (18.5%), neoplasms
(12.4%), respiratory system (11.8%), other ill-defined or
unspecified causes (11.2%) and circulatory system (10.7%).
Deaths were HIV-related in 34 (19.1%), drug-related in 30
(16.9%), liver-related in 12 (6.7%) and other cause-related
in 102 (57.3%). All cause, HIV-related and drug-related
mortality rates were 198.2, 37.9 and 33.4 cases/10,000
p-yrs. All cause mortality remained stable over the study
period, with observed rates of 239.0, 179.5, 198.4 and
202.5 cases/10,000 p-yrs from 2003 to 2006, respectively.
Overall, Cox proportional hazards analyses stratifying on
age demonstrated that injection drug use in the previous
6 months (adjusted hazard ratio (AHR) 1.42; 1.03-1.94,
p=0.030) and HIV infection (AHR 3.14; 2.11-4.66, p<0.001)
were associated with all cause mortality. HIV-related
mortality was independently associated with unknown
HIV status (AHR 5.43; 1.53-19.30, p=0.009).
Conclusions: In this large retrospective-prospective
analysis in the HAART era, mortality rates in illicit drug
users were consistently high. Although injection drug use
and HIV infection were strongly associated with all cause
mortality, there were a range of other causes that could be
prevented through targeted public health interventions.
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The epidemiology of cancer in people with HIV infection
since the introduction of highly active antiretroviral
therapy (HAART) remains unclear. Using data from
national, population-based registries, this study examined
changes in cancer incidence among people with HIV
infection in Australia post-HAART.
Probabilistic data linkage between the National HIV
Registry, the National AIDS Registry and the National
Cancer Statistics Clearing House (NCSCH), was used to
ascertain incident cancer diagnoses in adults (16-80
years) with HIV infection in Australia from 1982-2004.
Person-years of follow-up were accrued from the date
of seroconversion or HIV diagnosis, or from 01 Jan 1982,
until the date of cancer diagnosis, death, or 31 December
2004. The observed number of cancer diagnoses was
compared with that expected in the Australian general
population through the calculation of five-year age-, sex-,
state- and calendar-year-specific standardised incidence
ratios (SIRs). SIRs were examined pre- and post-HAART,
and across ‘early’ (1996 – 1999) and ‘late’ (2000 – 2004)
HAART periods.
In total, 2 762 cancers (2 168 AIDS-defining, 594 non-AIDSdefining) were identified on the NCSCH in 20 232 people.
Overall, risk for Kaposi sarcoma (KS, SIR 5 379, 95%CI 4
793 – 6 036) and non-Hodgkin lymphoma (NHL, SIR
15.3, 95%CI 13.6 – 17.2) remained elevated post-HAART,
though declined significantly across the early and late
HAART periods (Ptrend <0.001). Risk for Hodgkin disease
(HD) peaked during the early HAART period (SIR 17.3,
95%CI 10.3 – 27.2) but declined significantly thereafter
(SIR 7.4, 95%CI 3.7 – 13.2; Ptrend<0.023). Risk remained
significantly elevated for anal cancer in males (SIR 34.4,
95%CI 22.7 – 50.1), and for leukaemia (SIR 2.0, 95%CI 1.1 –
3.4), and was non-significantly elevated for cancers of the
lip, oral cavity and lung. All cases of liver cancer occurred
post-HAART (SIR 3.5, 95% CI1.7 – 6.2).
People with HIV infection remain at risk for several cancers
post-HAART including the AIDS-defining cancers NHL
and KS, as well as leukaemia, liver, and anal cancer. Risk
for NHL and KS continued to decline in the late HAART
period. While the increase in risk for HD post-HAART has
been previously observed, the recent decline in risk has
not been elsewhere reported.
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UPDATE of the Australian Long-term 
non-progressor (LTNP) cohort
Gelgor L1, Anderson B2, Baker D3, Finlayson R4, McFarlane
R3, McMurchie M3, Kelleher A1, Kaldor J1 on behalf of the
Long Term Non-progressor study group
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney NSW,
Australia; 2St Leonards, Sydney NSW, Australia; 3East
Sydney Doctors, Darlinghurst, Sydney NSW, Australia;
4
Taylor Square Private Clinic, Darlinghurst, Sydney NSW,
Australia.
The Australian LTNP cohort was established in 1994 to
investigate viral, genetic and immunological factors that
may influence disease progression. Individuals were
eligible for the study provided they had documented HIV
infection and remained asymptomatic for at least 8 years
with a CD4+ count above 500/μl. This cohort has been
followed clinically on an annual basis, with specimen
storage for specialised analyses and regular recording of
CD4+ counts, viral load, clinical disease and therapeutic
intervention. Updated analysis of the cohort was
undertaken to determine what proportion of the cohort
sustained non-progression and to compare the viral load
and CD4+ T cells over time with those within the cohort
who had progressed
Of 111 people recruited into the cohort 30 are lost to
follow up, 3 died, 9 developed AIDS, 35 commenced
antiretroviral treatment, 34 (31%) remain untreated.
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The median duration of infection of the 34 subjects that
remain untreated is 21 years (Range 8-24 years) with
those in the treatment group being infected for 22 years
(Range 12-24 years). Median time to treatment is 13 years
(Range 9-21 years). Those who remain untreated had
lower median viral load of 2300 copies/ml at study entry
with the most recent median viral load measuring 2700
copies/ml, compared to 9600 copies/ml in the treated
group at study entry with the median HIV-1 RNA 32,200
copies/ml prior to the start of therapy . The median CD4+
T cell counts are within normal range for both the treated
(550 cells/µL) just prior to treatment start and the most
recent measured in the untreated (620 cells/µL) group.
Survival analysis using the Log rank test for comparison
indicated that a higher CD4+ T cell count (p<0.002) and
lower HIV-1 RNA (p<0.003) at study entry were significant
predictors of sustained nonprogression.
A substantial proportion of this cohort, remain untreated
20 years after diagnosis and exhibit ongoing viral load
control with normal CD4+ T cell counts. The mechanisms
underlying this phenomenon of control of HIV infection
remains elusive. Continued studies of long-term nonprogressioncontributetounderstandingthepathogenesis
of HIV-1 infection and for the development of improved
treatment strategies such as vaccine development.
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DIFFERENT COMMUNITIES, DIFFERENT
NEEDS: SHAPING HIV/AIDS MESSAGES FOR
SIX NEW SOUTH WALES CULTURALLY AND
LINGUISTICALLY DIVERSE COMMUNITIES

Working with CALD Communities/
Working with Media
3.30pm – 5.00pm
SAFE SEX NO REGRETS- SEXUAL HEALTH IN
MAINSTREAM MEDIA IN WA
Crawford G1, Brown G2, Nicholson C2, Langdon T1.
1
Western Australian AIDS Council, Perth, WA, Australia
2
WA Centre for Health Promotion Research, School of
Public Health, Curtin University of Technology, Perth, WA,
Australia
Social marketing focusing on STIs and HIV has been absent
from WA televisions since the 1990’s, following a shift away
from broad based marketing strategies. Following the
success of the Safe Sex No Regrets mass media campaign
in NSW, the campaign was implemented in WA, for 10
weeks between December 2007 and February 2008
incorporating television, print and night venue initiatives.
Objectives were primarily to increase awareness of safe
sexual practice, and increase positive attitudes towards
safe sex, and also increase knowledge of early testing,
detection and treatment. The campaign, with party
and nightclub focused imagery targeted sexually active
heterosexuals under 30 and men who had sex with men
under 45. Evaluation sought to determine whether the
campaign has achieved its objectives and to test the
efficacy of the approaches.
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Two hundred pre and post campaign questionnaires were
administered via telephone to a random cross section
of the target group. A further 50 venue based intercept
surveys were administered in night venues frequented
by the target group. The survey examined campaign
recall, attitudes, beliefs and risk behaviour toward safe sex,
condom use, STIs and testing.
Baseline data indicated low levels of STI testing and
condom use, but indicated high rates of awareness and
attitude shifts amongst the target group concerning
sexual health issues and protective behaviours. The
evaluation methodology highlighted challenges in
achieving enough telephone survey participants who
identified having ‘casual partners’. However a venue based
sample in nightclubs was achieved with surprising ease.
Television and other media strategies have a role in HIV/
STI prevention to raise awareness and reinforce condom
use and testing messages. However behaviour change
requires sustained social marketing as only one part of an
integrated approach to prevention. Also the high success
in achieving a venue-based sample may be useful for
other campaign evaluations.
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Shaw MJ1, Sabri W2, McMahon T2, Edwards B3,
McGowan L4
1
HIV & Related Programs Health Promotion Team
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New South Wales, Australia; 3HIV & Related Programs Unit,
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Programs Health Promotion Team (Liverpool), Sydney
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New South Wales has a significant overseas born
population with almost one third of people born outside
of Australia. As part of increasing patterns of international
mobility, temporary and permanent residents of NSW
travel to their country of birth to visit friends and family
or conduct business. To ensure that culturally and
linguistically diverse (CALD) communities understand
how HIV/AIDS is transmitted and prevented, as well as the
particular risks associated with overseas travel, the NSW
CALD HIV Interagency established a Travel and Mobility
Working Group to identify health promotion initiatives
which might address the HIV/AIDS risk posed by overseas
travel among CALD communities.
The Working Group is made up of HIV/AIDS health
promotion stakeholders from Sydney South West Area
Health Service (SSWAHS), South East Sydney Illawarra
Area Health Service (SESIAHS) and the Multicultural HIV/
AIDS and Hepatitis C Service (MHAHS).
The Multicultural HIV/AIDS and Hepatitis C Service, in
conjunction with the Travel and Mobility Working Group,
commissioned an assessment of the HIV/AIDS information
needs of six CALD communities: Chinese (Mandarin
speaking); Vietnamese; Thai; Cambodian; Indonesian;
and African communities. These communities have been
identified by NSW Health as being a high priority among
CALD communities in NSW. The key findings from the
needs assessment will be used to inform community
education campaigns with each community, including
resource development.
This paper will discuss these key findings including:
• Current sources of health information
• Gender issues relating to HIV/AIDS messages
• Understanding and perceptions of HIV/AIDS within an
Australian and overseas context
• Level of interest in information about HIV/AIDS
• Preferred communication mechanism for each
community
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This paper explores how HIV is constituted as a matter of
public concern in Australia, where – unlike much of the
rest of the world – there is a continuing low incidence
of heterosexual transmission. In this context, it is timely
to explore how the media contributes to the ongoing
mobilisation of public interest in HIV, and how HIV is
constituted as a public concern in relation to the past,
present and future of heterosexual audiences.
This paper identifies three prevailing approaches to
generating public concern in HIV news stories published
in The Sydney Morning Herald between 2000 and 2005
as well as in academic media analysis and HIV education
and advocacy. The study focused on this period because
sufficient research had already been conducted on
Australian HIV media coverage in the previous two
decades of the HIV epidemic.
Each of the three themes identified pivots on the question
of how to generate or regenerate a sense of urgency
around HIV as a topical and relevant issue for Australian
audiences. Firstly, reflections on fear revisit the early years
of the epidemic, distinguishing different generations
of Australians as either marked or unmarked by the
1987 Grim Reaper campaign. Secondly, narratives of
complacency focus on an apparently widespread lack of
concern or naïvety about HIV in the broadest population
today. Lastly, projections in risk forecast a multiplication
of HIV risk environments, incorporating new trends
such as medical tourism or criminal cases of relationship
‘betrayal’.

Sabri W.
Multicultural HIV/AIDS & Hepatitis C Service
Australia is culturally diverse and HIV infection rates reflect
this. Some 21% of national HIV notifications annually are
among people born in non-English speaking regions of
the world. The pattern of HIV infection among culturally
and linguistically diverse (CALD) communities in Australia
largely reflects prevalence rates in countries-of-origin.
The Multicultural HIV/AIDS and Hepatitis C Service
(MHAHS) implemented a one-year project with the
Vietnamese community to empower and increase
their awareness and knowledge using a community
development framework around crucial, yet sensitive,
issues of HIV testing and prevention in partnership with
Vietnamese community organisations.

Working with CALD Communities/Working with Media

Newman CE1, Persson A1
1
National Centre in HIV Social Research, The University of
New South Wales Sydney NSW Australia

RADIO DRAMAS, HIV/AIDS & THE
VIETNAMESE COMMUNITY IN SYDNEY

This paper describes a key strategy of the project - the use
of “Radio Dramas” designed to raise HIV/AIDS awareness
amongst the Vietnamese community in NSW. It details the
evaluation process and findings in relation to the reach of
HIV/AIDS messages among the target communities.
The paper will also examine how this approach to
community development demonstrates that community
engagement, empowerment and partnership can result
in capacity building and increase social capital around
HIV/AIDS issues amongst CALD communities.

thursday 18 september 2008: 3.30pm – 5.00pm

THE MAKING OF HIV AS A PUBLIC CONCERN:
THREE THEMES IN THE CONTEMPORARY
AUSTRALIAN NEWS MEDIA COVERAGE OF
HIV

Together these three themes represent a shared moment
in the history of public discourses on HIV, constructing
Australian publics as passive, vulnerable, unaware and
potentially uncaring. And yet they do little to engage the
mainstream as more than merely spectators of public
concern about HIV. This has significance for the future of
HIV prevention in Australia, specifically in responding to
changing dynamics in the global and local epidemics.
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REFLECTIONS ON IMPROVING HEALTH
OUTCOMES
Eisenberg M, Katsaros E
Multicultural HIV/AIDS and Hepatitis C Service, Sydney,
NSW, Australia
People from culturally and linguistically diverse (CALD)
backgrounds make up approximately one fifth of HIV
notifications in NSW and are now recognised as a priority
population by the NSW HIV/AIDS Strategy.
The Multicultural HIV/AIDS and Hepatitis C Service
(MHAHS) is a state-wide service providing client support,
community development, and advocacy for and with
people from CALD backgrounds affected by HIV and
hepatitis C. It currently employs 100 bilingual/bicultural
workers, known as co-workers, in working with people
from almost 30 language backgrounds.
This paper uses two complex HIV/AIDS cases to examine
some factors which contribute to positive and less
positive outcomes for the client, in particular the values
and level of commitment of the workforce, both within
and outside the MHAHS. It suggests that the practice
of social inclusion is perhaps not quite what the rhetoric
of diversity promises and argues that professional
supervision for all workers is a crucial tool in improving
health outcomes for all clients.

ACCULTURATION, SEXUAL BEHAVIOUR, RISK
AND KNOWLEDGE IN VIETNAMESE MEN
LIVING IN METROPOLITAN SYDNEY
O’Connor CC1,3, Wen LM2, Shaw M1, Quine S3
1
Sexual Health Service, Division of Community Health,
SSWAHS, Camperdown, Sydney; 2Health Promotion Unit,
Division of Population Health, SSWAHS, Camperdown,
Sydney; 3School of Public Health, University of Sydney
Objectives: To describe the relationship between
acculturation, sexual risk and Sexually Transmissible
Diseases (STDs) and Blood Borne Viruses (BBVs) knowledge
among Vietnamese men living in inner Sydney and to
compare this prevalence with national data.
Method: Telephone interviews were completed with
a random sample of 499 Vietnamese men, selected
from the electronic phone book using a list of common
Vietnamese surnames.
Results: Of the 761 eligible men contacted, data were
obtained from 499 men giving a response rate of 66 %.
There was an association between lower acculturation
scores and having more than ten lifetime sexual partners,
more than 50 lifetime sexual partners, never using a
condom, ever or recently had commercial sex, ever
had an STD, were hepatitis B carriers or had ever been
imprisoned.

thursday 18 september 2008: 3.30pm – 5.00pm

Conclusion: There is an association between acculturation
and many aspects of sexual behaviour
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The average age of seroconversions is increasing; people
with HIV are living longer, more men in their 40s and 50s
are becoming HIV positive. This 90 minute session brings
together a range of researchers, and service delivery
and health promotion professionals to explore some
of the specific issues related to developing appropriate
responses for older men in terms of HIV prevention and
health promotion activities.
The session will include an examination of available data
both nationally and internationally that highlight issues
in relation to risk behaviour and factors impacting on
seroconversions amongst this target group. Additionally
the session will explore aspects of sex cultures and the
framing of prevention messages, specific interventions
targeted to older HIV positive men, as well as exploring
the Implications for an ageing GLBT community, including
workforce development needs in the medical and aged
care sectors.
Chairs: Stevie Clayton ACON &
Health
Panellists
Garrett Prestage
NCHECR
John Imrie
NCHSR
Dermot Ryan
ACON
Russell Westacott
ACON
Rob Lake
Positive Life NSW

Geoff Honnor NSW

Imrie J1,2, Elam G2, Macdonald N3, Hickson FC4, Power RM5,
McGarrigle CA6, Fenton KA6,7, Gilbart V6, Ward H3, Evans BG6
on behalf of the INSIGHT Collaborative Research Team
1
National Centre in HIV Social Research, The University
of New South Wales Sydney, NSW, Australia; 2Centre for
Sexual Health and HIV Research, Royal Free and University
College Medical School, London, UK; 3Department of
Infectious Disease Epidemiology, Imperial College Faculty
of Medicine, London, UK; 4Sigma Research, University of
Portsmouth, London, UK; 5Centre for Harm Reduction,
Burnet Institute, Melbourne, VIC, Australia; 6Department
of HIV and STIs, Health Protection Agency – Centre for
Infections, London, UK; 7National Center for HIV, Viral
Hepatitis, STD, and TB Prevention, Coordinating Center
for Infectious Diseases, Centers for Disease Control and
Prevention, Atlanta GA, USA
Gay men in their mid-life have survived the worst years
of the HIV epidemic, so why are they now acquiring HIV?
In England, men who have sex with men (MSM) age 35
to 44 years accounted for over a third (34% 787/2301) of
all new diagnoses of HIV in 2006. InSIGHT (Investigation
into seroconversions in gay men that HIV test) explored
why gay men continue to acquire new HIV infections.
This paper reports on one aspect of the qualitative stage
of the study - our investigation of the context of HIV
seroconversion among older gay men seeking repeat HIV
tests at sexual health clinics in England and the factors
contributing to unprotected anal intercourse (UAI).
In-depth interviews exploring the context of UAI were
conducted among 26 recent HIV seroconverters (cases)
and 22 controls purposively selected from the quantitative
arm – the InSIGHT case-control study.
We found that older men are more likely to be exposed
to major relationship and lifestyle changes, bereavement
and loss. These factors impact on their sexual lifestyles
and decisions to engage in higher risk sexual behaviour.
In addition, among older men, the improved prognosis
of HIV infection compared to other age related chronic
health conditions reduces perceptions of the seriousness
of HIV infection.
A range of psychosocial reasons led some men to engage
in high risk UAI, despite high levels of risk awareness.
The study findings indicate specific factors contributing
to seroconversion in older men and a relationship
between sexual and emotional needs, risk perceptions
and behaviour. More work is required to understand the
sexual needs and expectations of older men in order to
inform specific health promotion measures aimed at
reducing the risk of HIV infection in this group.
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Prevention and Treatment Issues For Older Gay Men - Sponsored by NSW Health and ACON

ACON & NSW Health Present:

Prevention And Treatment Issues For Older Gay Men.
A sponsored ASHM conference session on differences in
risk, behaviour and health promotion need in men over
40

RISK, REALITIES AND HIV
SEROCONVERSIONS IN OLDER GAY
MEN: QUALITATIVE RESULTS FROM AN
INVESTIGATION OF SEROCONVERSIONS
IN GAY MEN WHO HIV TEST IN ENGLAND
(InSIGHT STUDY)

thursday 18 september 2008: 3.30pm – 5.00pm

Prevention and Treatment Issues For
Older Gay Men - Sponsored by NSW
Health and ACON
3.30pm – 5.00pm
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TREATMENT ISSUES AND RESPONSES
Lake, R.
Chief Executive Officer, Positive Life NSW
What kinds of peer support, policy and resource
interventions are provided to, and valued by, older gay
men living with HIV? Do newly positive older gay men
have different issues and needs?
What services provide to people, and what is valued by
them may be quite different. Positive Life and other HIV
service providers, have developed services following
evidence both of need and demand from this group.
Responses to our targeted peer support and resources
have been strong, but in identifying and providing for
a wide range of needs, this may be a starting point, not
the end. Services have often framed interventions for
people living longer with Hiv, often older gay men, as
rehabilitation. Peer support, social opportunities, and re
engagement are key requests. One of the lessons for us
is to recognise diverse needs, seek as much evidence as
possible about those needs, and refine services to meet
them.
For newly diagnosed older gay men, whether in their
forties or sixties, the question is the difference their age
has on the impact of a diagnosis. Does a positive diagnosis
heighten existing concerns about ageing, relationships,
income and the future? Or does the response parallel the
lack of pessimism often ascribed to younger gay men
who seroconvert today?
The common point for these groups is ageing. What is
different for gay men ageing, and how big an impact
does their Hiv status have? Is their general state of health,
particularly a poorer state of health over a longer period
of time, likely to have a more significant impact and direct
their health, housing, income and community service
and support needs? Are there are other significant events,
such as relationship end or partner change, retirement,
Hiv progression, onset of other critical or chronic health
conditions? This presentation will include feedback from
our interventions, evaluations and will highlight research
needs.
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ASHM Plenary – Policy,‘Australia’s response to HIV in Asia and the Pacific: new partnerships and collaborations’.

ASHM Plenary – Policy, ‘Australia’s
response to HIV in Asia and the Pacific:
new partnerships and collaborations’.
5.00pm – 6.30pm
New policies for clinical and 
operations research in resource 
limited settings
Professor David A. Cooper
Director, National Centre in HIV Epidemiology and
Clinical Research, University of New South Wales, Sydney,
Australia.
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The delivery of existing HIV interventions to resource
limited settings has increased dramatically in recent
years. Although the funding for these initiatives is still
insufficient, the need for new clinical and operations
research in these settings is essential to developing
sustainable interventions and approaches into the future.
The incorporation of research studies into HIV programs
is necessary not only to determine the effectiveness
of specific interventions in these settings but also to
respond to unique challenges that arise in resource
limited settings and to examine outcomes that may be
specific to particular regions. Examples of this may include
determining the cause of early mortality in patients
starting antiretroviral therapy in resource limited settings
or the influence that HIV treatment may have in areas with
high rates of other infectious diseases like tuberculosis or
malaria. Collaborations in the Asia-Pacific region have been
established not only in order to provide counseling and
clinical care but also to support HIV training and research
in the region. The HIV-NAT collaboration, between the
Netherlands, Australia and Thailand, and the Cambodia
Treatment Access Program have successfully enhanced
the HIV research capacity and training in the region.
Additionally, the Sydney Declaration of 2007 highlighted
the need for and increased awareness of the requirement
for a firm commitment to sustained research funding in
order to address HIV in resource limited settings.
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CHARACTERISATION OF TNF BLOCK
HAPLOTYPES AND GENOTYPES THAT
PREDICT AN INDIVIDUAL’S RISK OF
STAVUDINE-ASSOCIATED SENSORY
NEUROPATHY.

Response & Predictions in ART
5.00pm – 6.30pm
Evaluation of the relationship 
between HLA-B*5701 status and HIV
reverse transcriptase codon 245
variation in South Australian HIVinfected individuals
Warner MS1, James HM2, Higgins GD1and Ratcliff RM1
1
Infectious Diseases Laboratories, Institute of Medical and
Veterinary Science (IMVS), Adelaide, SA Australia; 2Division
of Human Immunology, IMVS, Frome Rd, Adelaide, South
Australia
Abacavir hypersensitivity occurs in four to eight percent
of patients and is strongly associated (greater than 100fold increase) with the human leukocyte antigen (HLA)–
B*5701 allele. HLA class I loci can shape viral evolution by
selecting for HIV viral variants which evade the specific
cytotoxic T lymphocytes produced. Investigators in
Canada recently demonstrated a strong association
between possessing the HLA-B*5701 allele and variations
at codon 245 of HIV reverse transcriptase (RT).

thursday 18 september 2008: 5.00pm – 6.30pm

Between June 2004 and January 2007, 40 of 409 (9.8%)
HIV positive patients screened possessed the HLA B*5701
allele. Of patients screened for HLA*B5701, 290 (70.9%)
had HIV sequence testing performed, and of these, 29
(10%) were positive for HLA-B*5701. Of these 29 patients, all
but one had codon substitutions at position 245. Overall,
139 (53.1%) of 262 HLA-B*5701-negative and 28 (96.6%)
of 29 HLA-B*5701–positive isolates had a polymorphism
at position 245. The sensitivity and specificity of codon
245 substitutions for predicting HLA B*5701 were 97%
and 47% respectively. The positive predictive value (PPV)
of a codon 245 substitution was 18% and the negative
predictive value (NPV) was 99.2%.
The presence of wild type sequence at RT codon 245
was highly correlated with the absence of the HLAB*5701 allele. These results are similar to those found by
Chui et al (2007) although we found significantly more
codon 245 variants in virus from HLA-B*5701–negative
individuals than in their study (53.1% versus 24.5%),
resulting in a lower specificity of codon 245 variation in
predicting HLA-B*5701 positivity (47% vs 75%). PPV (18%
vs 20%) and NPV (99.2% vs 96%) were similar. Given the
high negative predictive value for detection of wild type
codon 245 and the possession of the HLA-B*5701 gene,
RT sequencing could be used as a simple screening tool
to identify patients who could safely be treated with
abacavir.
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Chew C SN1, Cherry CL2,3,4,Affandi J1 , Valente F5, Imran D6,
Kamarulzaman A7, Tan HY7 and Price P1
1
Pathology and Laboratory Medicine, University of
Western Australia, Perth, WA, Australia; 2Burnet Institute,
Melbourne, VIC, Australia; 3Alfred Hospital, Melbourne,
VIC, Australia; 4Monash University, Melbourne, VIC,
Australia; 5University of Denis Diderot, Paris, France;
6
Cipto Mangunkusumo Hospital, University of Indonesia,
Indonesia; 7Infectious Disease Unit, University of Malaya
Medical Centre, Malaysia
Sensory Neuropathy (SN) is common in HIV patients
and is promoted by exposure to the anti-retroviral drug,
stavudine (“d4T-SN”). Stavudine remains in first-line HIV
treatment in resource-limited settings as it is effective,
inexpensive and does not cause anaemia. We are
addressing genetic determinants of d4T-SN risk.
Alleles of genes in the TNF haplotype block may
modulate d4T-SN risk. We associated TNFA-1031*2
carriage with d4T-SN in both Australian and Indonesian
HIV patients exposed to d4T. As linkage disequilibrium
within the TNF block hampers identification of single
nucleotide polymorphisms (SNP) responsible for disease
associations, we are undertaking additional genotyping
in control donors and d4T-exposed HIV patients from
various ethnic populations. We use the PHASE algorithm
to define haplotypes based on 37 SNP spanning 6 genes
around TNFA.
We find 15 conserved haplotypes account for >94% of
healthy Caucasians (n=398). Sixteen haplotypes also
account for >97% of South East Asian donors (n=247) this includes 8 haplotypes found in Caucasians. Although
TNFA-1031*2 is associated with d4T-SN in both Indonesian
and Australian patients, the underlying haplotypes
appear different in each population. Haplotype FV10
can be tagged by IKBL+446*2. FV10 occurs at similar
frequencies (11-12%) in Caucasian and South East Asian
controls and hence is a candidate risk haplotype. FV10
accounts for 52.9% of Australian patients exposed to d4T
carrying TNFA-1031*2 and may associate with d4T-SN
in these patients (31% vs 16%, p=0.27), but this requires
confirmation.
To date five TNF block SNP have been genotyped in
d4T-exposed Indonesian patients. Surprisingly, linkage
disequilibrium was observed between TNF-1031*2
and IKBL+446*2 in d4T-exposed patients without SN
(p=0.0009), but not in d4T-SN patients (p=0.76). Carriage
of TNF-1031*2 and homozygosity for IKBL+446*1 was
associated with an 8-fold increased risk of d4T-SN in
Indonesians (p=0.004). This makes it unlikely that FV10
will associate with risk in Indonesians.
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naturalLy Ocurring POlymorphisms 
in HIV-1 INTEGRASE: RELATIONSHIP TO
HIV suBTYPE, INTEGRASE INHIBITOR
RESISTANCE AND IMMUNE SELECTION
Tschochner M1, Chopra A1, Maiden T1, Ahmad I1, Fordham
A1, Mallal S1, John M1
1
Centre for Clinical Immunology and Biomedical Statistics,
Royal Perth Hospital and Murdoch University, Perth,
Western Australia
Integrase inhibitors have emerged as an important new
class of antiretroviral agents. A number of resistance
associated mutations have been described based on
pre-clinical testing. In order to determine whether viral
subtype or HLA-specific immune selection may contribute
to baseline integrase inhibitor resistance, we examined
the prevalence of naturally occurring polymorphisms in
the integrase sequences of 202 HIV-1 infected patients
in the Western Australian HIV Cohort, all of whom were
naïve to integrase inhibitors. We further examined these
changes in relation to HIV subtype, co-variation patterns
and established associations with HLA alleles.

Response & Predictions in ART

Taken together, these findings suggest that TNFA-1031*2
may play a role in the pathogenesis of d4T-SN, rather than
being a marker for a risk haplotype. This work is continuing
with additional genotyping and haplotype analyses,
including DNA from cohorts of additional ethnicities.

The subtype distribution in the cohort revealed 74.8%
were subtype B, 4% C, 4.5% CRF01, 0.5% CRF02, 0.5%
CRF06 and 15.8% inter-subtype recombinants. Residues
E92, T97, F121, and Y143 were absolutely conserved,
however at other sites the prevalence of resistanceassociated mutations was as follows: E138K (1.2%), G140S
(2.3%), V151I (2.9%), M154I (2.4%), N155S (0.6%), E157Q
(3.6%), G163R (3.0%), Y226D (0.6%), D232N (0.6%). Several
residues (51, 61, 74, 125, 147, 148, 153, 183 and 230) had
some degree of polymorphism but none that were drug
resistance-associated changes. No sequences contained
the resistance associated T125K. However, an alternative
polymorphism T125A occurred in 35.5% of sequences
and was dominated by non-B subtype sequences (3% of
sequences with T125 were non-B subtypes versus 62.3%
with A125). Notably, this polymorphism corresponds to
HLA-B*5701/-B*5703 and -B*5801 driven escape within
the known SW10 epitope.
In a population-based cohort, most integrase residues
previously associated with integrase inhibitor resistance
are highly conserved across and within HIV‑1 subtypes,
in keeping with being sites of significant functional,
catalytic or structural importance. T125A appears to be
subtype-specific as well as a result of immune selection
in individuals expressing HLA-B*57/5801. Otherwise, the
low prevalence of natural polymorphism is consistent
with the lack of overlap between evident immune and
drug targets in the integrase gene.
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Integrase sequences obtained by bulk sequencing and
4-digit HLA class I genotypes determined by sequence
based typing were examined at a codon-specific level.
The subtypes of all samples were assigned on the basis of
the genome wide sequences using the NCBI genotyping
tool.
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PATIENT CHARACTERISTICS AND
PREDICTORS OF TIME TO COMMENCE
ANTIRETROVIRAL TREATMENT IN A
PROSPECTIVE COHORT IDENTIFIED AT
PRIMARY HIV INFECTION (PHI). (THE
PHAEDRA COLLABORATIVE COHORT)
Grey P1, Srasuebkul P1,Finlayson R2, Workman C3, McFarlane
R4, Bloch M5,Medland N6, Roth N7, Anderson J8, Hoy J9,
Read T10,Petoumenos K1, Kelleher A1.
1
National Centre in HIV Epidemiology and Clinical
Research, Sydney, Australia; 2Taylor Square Private Clinic,
Sydney, Australia; 3Aids Research Initiative, Sydney,
Australia; 4 407 Drs, Sydney, Australia; 5 Holdsworth House
Medical Practice, Sydney, Australia; 6 The Centre Clinic,
Melbourne, Australia; 7 Prahran Market Clinic, Melbourne,
Australia. 8Carlton Clinic, Melbourne, Australia; 9 The Alfred
Hospital, Melbourne, Australia;10 Melbourne Sexual Health
Clinic, Melbourne, Australia.
Primary Infection (PHI) presents an opportunity to study
HIV disease throughout its infection period. The PHAEDRA
cohort was established to determine immunological,
virological and therapeutic factors related to disease
progression. There are a number of theoretical reasons,
which support early antiretroviral treatment (ART). To
find out what factors influenced the time to initiation of
treatment in this cohort, a range of baseline factors were
assessed.
From September 2002 to June 2007 data was collected
on consenting subjects identified with either acute or
early infection or with known dates of seroconversion.
Acute and Early infection was defined by standard
serological criteria. Demographic data plus Western Blot
ELISA, Viral load, CD4, PHI symptoms and ART history
were collected.
Of the 341 patients who consented, at the time of analysis,
79 were never treated (NTX) and 262 commenced
therapy (103 through clinical trials (CTX), 159 off clinical
trials (TX). Median age overall was 36 years. In the NTX
group 35% were acutely infected compared with 67% in
the TX and 62% of CTX. In the NTX group 67%had PHI
symptoms against 85% of TX group and 87% of CTX
patients. Median CD4 and RNA at baseline was 637.5cells/
mm3, 4.6 log10 for NTX respectively, 510cells/mm3, 5.9
log10 for CTX and for TX 495cells/mm3, 5.6 log10. The
median time to commence treatment in CTX group was
1.5 weeks compared to 6 weeks in TX group. Therefore
despite similar clinical baseline characteristics therapy
was commenced earlier in CTX patients. In multivariate
Cox-regression analyses, predictors of time to commence
treatment were: Acute status (p = <0.001), the presence
of PHI symptoms (p =0.037), clinical trial status (p =
<0.001) and lower CD4 at baseline (p=0.028) with higher
RNA (p = 0.010).
Having a higher viral load and lower CD4 with PHI
symptoms at baseline, predicted the uptake of
antiretroviral treatment at seroconversion. These
determinants were no different between commencing
therapy, on or off a trial but the time to start treatment
was much less in those in the CTX group.
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Kerr SJ1,5, Avihingsanon A1, Putcharoen O2, Chetchotisakd
P3, Duncombe, C1,5, Teeratakulpisarn S4, Phanuphak N4,
Ruxrungtham K1,2, Cooper DA,5 Phanuphak P1,4.
1
HIV Netherlands Australia Thailand Research
Collaboration, Bangkok, Thailand; 2Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand; 3Faculty of
Medicine, Khon Kaen University, Khon Kaen, Thailand;
4
Thai Red Cross AIDS Research Centre, Bangkok, Thailand;
5
National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW. Australia
Excellent adherence to HAART will maintain viral
suppression and offset resistance. We compared two selfreporting tools that can be used for rapid assessment of
adherenceinaclinicalconsultation,andassessedpredictors
that might allow early identification of non-adherent
patients. Tool one was a visual analogue scale (VAS),
tool two, the 3 question CASE adherence questionnaire
(CASE). Poor adherence was defined as < 95% on VAS and
≤ 11 out of a possible 16 on CASE. 224 patients (Male
63%, age 38 (interquartile range [IQR] 33 – 44) years) from
3 sites in Thailand and duration of HAART treatment 51
(IQR 26 – 82) months completed the questionnaires and
had plasma HIV-RNA (viral load) assessments. Daily pill
burden was 4 (IQR 2 – 6) pills; 49 (22%) patients were on
their first regimen. 24 (11%) patients had poor adherence
on VAS; 17 patients had poor adherence on CASE. Six
patients had poor adherence on both tools. 24 patients
had plasma viral load detectable at > 50 copies/mL. The
odds ratio (OR) for poor adherence and detectable viral
load with VAS was 4.4 (95% confidence interval [CI] 1.6
– 12.2) and for CASE was 5.7 (95%CI 1.9 – 17.3), and for
patients who scored with poor adherence on both tools
was 19.8 (95%CI 3.4 – 114.9). Time to complete VAS was
15 (IQR 7 – 28) seconds and 45 (IQR 30 – 60) seconds
for CASE. Gender, education, marital status, income, pill
burden, transmission group, alcohol use, concurrent
treatment with drugs for opportunistic infections or TB,
duration of HAART or whether the patient paid for drugs
themselves were not associated with poor self-reported
adherence with either tool. Most questions about affect
and self-esteem were also not associated with poor
self-reported adherence, but patients indicating at least
fairly often, felt ‘unable to cope with all the things they
had to do’, had lower adherence scores. For patients who
said they missed at least one dose of medication in the
previous month, fear of arousing suspicion was cited as an
important factor. Both adherence tools could be rapidly
conducted in a clinical setting and poor scores predicted
detectable viral load.

Herrmann S1, McKinnon E1, John M1,2, Nolan D1,2, OP
Martinez 1,2,3, Phillips E1,2 , Mallal S 1,2
1
Centre for Clinical Immunology & Biomedical Statistics,
Royal Perth Hospital & Murdoch University; 2Department
of Clinical Immunology & Immunogenetics & PathWest
Laboratory Medicine, Royal Perth Hospital; 3School of
Pathology and Laboratory Medicine, University of Western
Australia.
HIV Cohort research in Royal Perth Hospital (RPH) between
the years 2002-2005 found that adherence to ART
predicted viral suppression and CD4 T-cell recovery and
diminishing adherence was associated with indicators
of perceived stress, depression and the impact of side
effects, particularly fatigue and skin itching. Whether
these variables were associated with a particular regimen
or dosing schedule was not studied.

Adherence to Antiretroviral Therapy

ASSESSING ADHERENCE IN THAI PATIENTS
TAKING HAART

Side effects, dosing schedules,
pill burden and perceived stress:
Interaction and influence on 
medication adherence

Patients attending the Immunology Outpatient Clinic
at RPH over a 3 month period in 2008 completed a
questionnaire on ART (N=156), concomitant medications,
pill burden, dosing schedule, side effects and perceived
stress. Doctors verified the regimen and assigned a
medication score indicating ART adherence.
The majority of regimens included a nucleoside backbone
of abacavir/lamivudine (50%), tenofovir/emtricitabine
(23%) tenofovir/lamivudine (8%) or zidovudine/
lamivudine (7%) combined with either a ritonavir-boosted
PI (35%; atazanavir 22%), efavirenz (28%) or nevirapine
(25%). 108 vs 48 patients were on OD vs BD regimens
respectively. Adherence improved since 2005 with 75%
vs 55% of patients surveyed reporting 100% adherence
over the previous month. Neither dosing schedule nor
pill burden was associated with poorer adherence. Nonadherent patients reported more coping difficulties
(p=0.02) than adherent, and the number of side effects
experienced correlated with higher total perceived stress
score (p=0.004). 130 patients experienced at least one
side effect, 36% taking medication for relief. Compared
with five years ago reported diarrhoea was reduced (34%
vs 51% of patients), but reported fatigue (59%) muscle
pain (36%), headache (36%), nausea (32%) and skin itch
(39%) were comparable. Although boosted PI regimens
were associated with more frequent side effects than
NNRTI regimens, including headache (54%), diarrhoea
(54%) and fever (atazanavir: 41%), they did not strongly
correlate with reduced adherence (p=0.3).
In our cohort adherence has improved in the last two
years: simpler dosing schedules and the decreased
frequency of certain side effects such as diarrhoea
may have contributed. In those patients with a higher
frequency of reported symptoms and perceived stress,
reduced adherence may be associated with health related
quality of life (HRQL) issues not measured in this study.
Further research is needed to understand the interaction
between HRQL and medication adherence.
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Improved treatment adherence 
associated with treatment 
simplification

ADHERENCE TO ANTI-RETROVIRAL THERAPY
AMONG PATIENTS IN BANGALORE, INDIA

Baker D1, Vale R1, Doong N2, Bloch M3, Hudson J2,
McMurchie M1, McFarlane R1
1
407 Doctors, Darlinghurst, NSW, Australia; 28 Burwood
Rd, Burwood, NSW, Australia, 3Holdsworth House Medical
Practice, Darlinghurst, NSW, Australia
Objective: The OneDa study is a randomised, multicentre, open-label study in well-controlled treatmentexperienced HIV-infected patients to assess adherence
to a once-daily regimen of antiretroviral therapy versus
continuation of current anti-retroviral regimen delivered
at least twice daily over a 48 week period.
Method: Adherence with therapy was measured using
electronic monitoring (MEMS cap), patient self-report
(MASRI questionnaire), therapeutic drug monitoring
(TDM) and doctor assessment. Prior to randomisation all
patients had a one month baseline observation period
during which their adherence with their current twicedaily combination therapy was evaluated. Patients
were then randomised to continuing current therapy or
switching to once-daily treatment with any approved
once-daily regimen. At week 24 patients were switched
to once-daily therapy.
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Results: 96 patients with fully suppressed virus were
randomised. 94 were males, with an average age of 43
and average length of HIV infection of 10 years. Adherence
(medication prescribed / medication taken) in the baseline
month, as measured by MEMS cap, was 84.4%. 24 weeks
adherence (MEMS caps) was significantly higher in the
once-daily arm at 95.0% versus the continuation arm at
85.6% (p value 0.019). No virological failure (VL > 400
copies/mL) was reported in either arm.
Conclusions: Treatment simplification to once daily
treatment appears to be an effective and safe approach
to improving adherence to antiviral therapy.
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Cauldbeck MB1, O’Connor C2, Saunders JA3, O’Connor
MB4, Rao B5, Mallesh GV5, Praveenkumar KN5, Mamtha D5,
McGolderick C6, Laing RBS6, KS Satish5.
1
The School of Medicine, University of Aberdeen,
Aberdeen, Scotland; 2GU/STD Clinics, Mid-Western
Regional Hospital, Limerick, Ireland; 3Department of
Mathematics and Statistics, University of Limerick,
Ireland. 4Department of Medicine, South Infirmary Victoria University Hospital, Cork Ireland; 5Department of
Respiratory and HIV Medicine, Rajajinagar and Wockhardt
Hospital and Heart Institute, Bangalore, India; 6Infection
Unit, Aberdeen Royal Infirmary, Aberdeen, Scotland.
HIV has an estimated prevalence of 0.9% in India (5.2
million). Anti-retroviral drugs are the treatments of choice
and non-adherence is an important factor in treatment
failure and development of resistance, as well as being
a powerful predictor of survival. This study proposes to
assess adherence to ART in HIV+ patients in Bangalore,
India a country where 10% of those who need get
therapy.
A cross-sectional anonymous questionnaire survey of
60 HIV+ patients was carried out on patients attending
HIV outpatient services in Bangalore, India. Consent was
obtained and translation was carried out when required.
Data was analysed using SPSS.
A response rate of 53/60 (88%) was achieved. The mean
patient age was 39.85 yrs, with 50% aged 30-40 and
73.6% of participants were male. Mean family size =4.8
(1-13). 21% lived <50kms & 21% >400kms from clinic.
60% were fully adherent to their medications. Adherence
was statistically significantly linked to regular followup attendance (70.5%, p=0.002). No other results were
statistically significant but trends were found. Better
adherence were seen in older patients(>40=50%,
<40=15%), males, those from larger families, those who
had AIDS (AIDS=72%, Well= 50%), those taking fewer
tablets (<5 =76%, 5-9=41%) and without food restrictions
(Without=70%, With= 48%). Commonest side-effects
causing non-compliance were metabolic reasons (66%)
and GIT symptoms (50%). No differences were seen for
education level, family income, distance travelled to clinic,
time since diagnosis, or time on ART.
In conclusion regular attendance for follow up was
statistically significant for adherence. Positive trends were
seen in those in larger families, older, those who had
AIDS, simple regimes, and without side-effects. Education
income, distance travelled and length of time diagnosed
or treated had no effect.
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AIDS Dementia Complex (ADC) and 
mental illness: The role of the NSW
Mental health Act in managing 
compliance with Highly Active Anti 
Retroviral Therapy (HAART)
Ibrahim D1
1
AIDS Dementia and HIV Psychiatry Service (ADAHPS),
Sydney, NSW, Australia
ADC is a well recognised syndrome that is generally
associated with advanced HIV disease and is prevalent in
some 10% of the HIV infected population. It is commonly
characterised as a ‘frontal-subcortical’ dementia and
is typified by impairments in cognitive and motor
functioning, and may be associated with emotional/
personality disturbances.
The level of impairment seen in ADC can compromise
an individual’s ability to maintain their capacity for
independent living and their capacity for rational decision
making. Further compounding this problem is the higher
incidence of mental illness amongst HIV sufferers and,
therefore, those with ADC, which can further impinge
upon competent decision making and the ability of
individuals to act in the interests of their own health and
welfare.
A significant health and welfare issue in this population is
medication adherence. Studies show a strong correlation
between good HAART compliance and neurological
improvement in cognitively impaired individuals.
Cognitively compromised individuals with a concomitant
mental illness are at further risk, in that poor compliance
with their non-HAART medications can often lead to a
relapse of psychotic symptoms.
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In recent times, clients of our service with ADC who have
been placed on Community Treatment Orders (CTOs), for
the treatment and management of psychotic symptoms
related to their mental health issues, have also had HAART
medications placed on the treatment order. This indicates
that cognitive health and mental health are seen as
closely linked, and that the management of mental health
issues (in this particular client group) cannot be made in
isolation from the management of cognitive issues.
To date, the effectiveness of CTOs in compelling individuals
with ADC and mental health issues to take HAART has yet
to be evaluated. This paper will present a case study, and
will canvass the views of a number of health & welfare
practitioners working in the HIV field regarding CTOs &
HAART. Certain questions will be explored, for instance:
What would happen if an individual took objection and
challenged the order? Could an individual be hospitalised
under the Mental Health Act for not complying with
HAART treatment in the order? Could CTOs be applied
to those with cognitive impairment, but without a
concomitant mental illness?
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AUTOIMMUNE HAEMOLYTIC ANAEMIA:
AN UNUSUAL PRESENTATION OF HIV
SEROCONVERSION
Sherry NL1, Korman TM1,2
1
Department of Infectious Diseases, Monash Medical
Centre, Melbourne, VIC, Australia; 2Department of
Medicine, Monash University, Melbourne, VIC, Australia
Autoimmune haemolytic anaemia (AIHA) is uncommon
is HIV, although positive direct antiglobulin tests (DAT)
occur quite frequently. Previous reports describe this
condition mainly occurring in advanced AIDS. We
describe a case of AIHA as a novel presentation of HIV
seroconversion. A 54 year-old man presented with
fever, rash and sore throat, followed by dyspnoea and
haemoglobinuria one week later. AIHA was diagnosed,
characterised by positive DAT with C3b specificity and
negative cold agglutinins. The patient’s haemoglobin fell
to 62g/L, and improved with high-dose corticosteroids
and intravenous immunoglobulin. Anti-HIV ELISA was
positive, and a positive Western blot evolved consistent
with HIV seroconversion. Baseline CD4 count was 92
cells/µL with a HIV viral load of 75,000 copies/mL, and
antiretroviral therapy was subsequently commenced.
We review previous published reports, specifically stage
of HIV, haematological parameters (characteristics of DAT,
reticulocyte count), management and outcome data.

Peel T1, McLean C2,3, Cameron P1,3, Hoy J1,3, Wright E1,3,4
1
Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC,
Australia; 2Department of Anatomical Pathology, Alfred
Hospital, Melbourne, VIC, Australia; 3Faculty of Medicine,
Nursing and Health Science, Monash University, VIC,
Australia; 4Burnet Institute, Alfred Medical Research and
Education Precinct, Melbourne, VIC, Australia
We present the case of a 36 year old HIV positive man with
the management dilemma of a prolonged Cryptococcal
Immune Restoration Disease (IRD) managed with highly
active anti-retroviral therapy (HAART) and corticosteroid
therapy.
The patient initially presented in September 2006 with
cryptococcal meningitis, occurring on a background of HIV
diagnosed in 1997. The patient had ceased HAART several
years previously but had restarted abacavir, lamivudine
and boosted atazanavir one week prior to presentation
wherein his CD4+ cell count was 11.0/uL and plasma HIV
load was 55, 000 copies/ml. Cryptococcus neoformans
was cultured from the CSF and serum and cerebrospinal
(CSF) cryptococcal antigen titres were 1:4096 and 1:256,
respectively. Initial treatment comprised two weeks
of amphotericin B deoxycholate (0.7mg/kg/day) and
5-fluorocytosine (2g QID) followed by oral fluconazole
400mg daily.
The patient’s course was complicated by multiple
presentations with headache, fever, seizures, raised
intracranial pressure and obtundation coinciding with
attempts to reduce the corticosteroid dose. Serial Magnetic
Resonance Imaging of brain demonstrated progressive
leptomeningeal enhancement. A brain biopsy showed
encapsulated yeast cells; morphologically consistent
with Cryptococcus however, cultures from tissue and
CSF failed to isolate the organism. In February 2008,
the patient presented with cervical lymphadenitis and
airway compromise. Lymph node biopsy demonstrated
abundant yeast cells, consistent with Cryptococcus, but
no organisms were cultured. Of concern, the patient has
had significant complications secondary to prolonged
corticosteroid therapy including mood disturbance,
weight gain, osteoporosis and vertebral crush fractures.
Adjunctive non-steroidal anti-inflammatory agents did
not have clinical benefit.
The patient has remained on HAART throughout with
virological suppression, but poor restoration of CD4+
cell counts. Fluconazole therapy has been maintained
throughout. Serum and CSF Cryptococcal antigen titres
have decreased to 1:512 and 1:4, respectively.
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STEROID DEPENDENT CRYPTOCOCCAL
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POSITIVE PATIENT
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The management of Cryptococcal IRD comprises
HAART and antifungal therapy. In the setting of severe
or refractory Cryptococcal IRD corticosteroids may be
beneficial. In the case described corticosteroids have
been poorly tolerated however their dose reduction has
precipitated life-threatening events. Future management
may require substitution of corticosteroids with other
immunosuppressive therapy.

A CASE OF TENOFOVIR-ASSOCIATED RENAL
TUBULAR ACIDOSIS WITH NEUROLOGICAL
IMPAIRMENT
Barber B, Denholm J, Fuller A, Hoy J
Department of Infectious Diseases, Alfred Hospital,
Melbourne, Victoria, Australia.
A 47 year old HIV positive man was admitted to hospital
in August 2007 with two days of diplopia, expressive
dysphasia and right sided paraesthesia, on a background
of several months of lethargy and weight loss. His HIV
had been stable since 2002 on tenofovir, emtricitabine
and delavirdine, with a recent CD4 cell count of 200 cells/
µl and HIV viral load of 450 copies/ml.
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On admission, MRI of brain revealed multifocal hyperdense
lesions of uncertain aetiology. CSF revealed an elevated
protein, undetectable HIV viral load, and no lymphocytes
or other abnormalities. CSF PCR for HSV, VZV, JC virus, CMV,
EBV and toxoplasma was negative, as was serum syphilis
serology. Pathological examination of a brain biopsy was
consistent with an active chronic meningoencephalitic
process. He was commenced on empirical antibiotics,
although the diagnosis remained uncertain.
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Four days after admission his conscious state deteriorated
and he developed complete left gaze paresis,
corresponding with progression of the MRI findings.
His deterioration corresponded with the development
of a profound non-anion gap metabolic acidosis (Na+
142, Cl- 118, HCO3 4), in addition to hypokalemia,
hypophosphatemia, proteinuria (0.41g/L), decreased
creatinine clearance (50mL/min) and urinary biochemistry
consistent with proximal renal tubular acidosis (RTA). A
diagnosis of Fanconi’s syndrome was made and the
patient was admitted to ICU and commenced on a
bicarbonate infusion in addition to aggressive fluid
and electrolyte replacement. Tenofovir and other
antiretrovirals were ceased. The patient responded to
correction of his acidosis and was discharged one month
later with significant improvement of his neurological
symptoms and MRI findings.
Prior to discharge he was commenced on etravirine,
darunavir, abacavir, lamivudine and ritonavir. Six months
post discharge the patient remains on 30g of sodium
bicarbonate and 6.5g of potassium citrate daily. His renal
function remains impaired with a creatinine clearance of
56 mL/min.
Proximal RTA is a well recognised adverse effect of
tenofovir and adefovir. We describe a case of severe
Fanconi’s syndrome resulting in irreversible metabolic
acidosis and renal impairment. In addition this case raises
the possibility of neurotoxicity as a result of tenofovirassociated acidosis.
17-20 september 2008 @ Perth Convention Centre, Western Australia

Community acquired methicillin resistant Staphylococcus
aureus (CA-MRSA) infections are increasing in frequency
in Australia and overseas. Most of these infections are
confined to the skin, but more serious deep-seated
infections can occur. Risk groups identified have included
some indigenous communities, injecting drug users
and sporting teams. CA-MRSA has also been described
overseas in association with HIV infection and in men who
have sex with men (MSM). Sexual transmission of a highly
resistant CA-MRSA isolate has recently been reported
amongst MSM in North America. To our knowledge no
studies have examined the relationship between MSM,
HIV and CA-MRSA infections in Australia.
We describe the case of a 46 year old gay man with a
life threatening CA-MRSA infection in the setting of HIV
infection with a low CD4 cell count (60/microlitre).
The infection originated from multiple skin abscesses.
Subsequent bacteraemia was complicated by the
development of a large prostatic abscess and metastatic
pulmonary foci. The isolate was resistant to methicillin,
ciprofloxacin and erythromycin but it remained susceptible
to trimethoprim-sulfamethoxazole, rifampicin, fusidic
acid and vancomycin; it tested positive for the virulence
factor Panton-Valentine leukocidin. Further molecular
characterisation is in progress.
Successful management required surgical drainage of
the prostatic abscess followed by prolonged intravenous
then oral anti-staphylococcal therapy, totalling 37 days.
His course was complicated by prolonged fever and
antibiotic allergies.
Antiretroviral therapy, which had been previously
discontinued, was restarted, with attention to interactions
with oral anti-staphylococcal therapy.
To our knowledge, this is the first case of disseminated CAMRSA infection reported in association with HIV infection
in Australia. A high prevalence of CAMRSA among HIV
positive patients in Australia or the sexual transmission
of MRSA locally would have significant implications for
individual health and for the empirical management
of staphylococcal infections. A study of CA-MRSA to
delineate the incidence and transmission among HIV
positive patients and MSM in Australia is needed.

Chang CC1, McLean C2, Vujovic O1, Jenney AWJ1, Short M3,
Lyon S4, Storey E3, Lewin SR1,5
1
Infectious Diseases Unit; 2Anatomical Pathology
Department; 3Neurology Department; 4Radiology
Department, The Alfred Hospital; 5Department of
Medicine, Monash University, Commercial Road, Prahran,
Victoria 3004, Australia.
A 41 year-old woman was transferred from a peripheral
hospital to our institution with 2 days of fevers, headache,
neck pain and progressive flaccid quadriparesis. She had a
background of HIV infection diagnosed 15 years ago, with
the most recent CD4 T-cell count (and nadir) of 155 cells/
µl (7%) and HIV RNA of 6000 copies/ml three weeks prior
to admission. She had no history of AIDS-defining illness.
Two weeks prior to her presentation, her antiretroviral
regime was changed from lamivudine, nevirapine and
abacavir to lamivudine, raltegravir and ritonavir-boostedatazanavir for immunological and virological failure.
At presentation, she had a flaccid quadriparesis and was
febrile and drowsy with demonstrable neck stiffness
and an occasional vesicular lesion over her trunk. CT
brain was normal and lumbar puncture revealed bright
yellow cerebrospinal fluid (CSF) with an opening pressure
of 15cmH20. CSF analysis revealed xanthochromia,
extremely elevated protein of 39.0g/L (normal range
[NR] 0.15-0.4g/L), glucose of 2 mmol/L (NR 2.5-4.5mmol/
L), 1400 red cells, 40 polymorphs and 2 lymphocytes
suggestive of necrotising myelitis. CD4 T-cell count at
presentation was 83 (9%).
A clinical diagnosis of VZV-associated necrotising
meningomyelitis was made. Empirical intravenous
dexamethasone 10mg 6-hourly, acyclovir 500mg 8hourly, ceftriaxone 2g 12-hourly and benzylpenicillin
1.8g 4-hourly were immediately administered. MRI brain
and spine revealed meningeal enhancement around
the circle of Willis and brainstem, contiguous with
marked oedema and expansion of her cervical cord with
abnormal T2 signal. “Sugar-coating” of her entire spinal
cord was noted. Progressive bulbar palsy and respiratory
failure ensued and she died 60 hours post arrival to our
institution.
Varicella zoster virus (VZV) was detected by PCR in her CSF
and skin vesicle. Post-mortem examination confirmed
extensive infarction and haemorrhagic necrosis of
the entire spinal cord due to necrotising vasculitis in
association with a lymphocytic meningitis.
This is the first case report of VZV-associated fulminant
haemorrhagic meningomyelitis with necrotising
vasculitis occurring in a moderately immunosuppressed
HIV-infected patient in the HAART era. We believe this is
potentially related to VZV immune restoration disease.
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1 Victorian Infectious Diseases Service, The Royal
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Victoria Australia.

FATAL ACUTE VARICELLA-ZOSTER VIRUS
HAEMORRHAGIC MENINGOMYELITIS WITH
NECROTISING VASCULITIS IN AN HIVINFECTED PATIENT
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THREE’S A CROWD: THE RELATIONSHIP
BETWEEN CA-MRSA, HIV AND
MSM
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The role of T-cells in HIV immunity:
lessons from China and West Africa
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PUBLIC HEALTH AND SOCIAL SCIENCE IN
CLINICAL RESEARCH: THE INTEREST OF A
MULTIDISCIPLINARY APPROACH
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Bruno Spire1, Catherine Leport2, François Raffi3, Geneviève
Chêne4 and Jean-François Delfraissy5
1
INSERM U912/ORS-PACA, Marseille, France; 2Faculté
Xavier Bichat, Paris, France; 3Hôtel-Dieu, Nantes, France
4
INSERM U 897, Bordeaux, France; 5French Agency of
research on HIV and viral hepatitis (ANRS), Paris, France
This presentation aims to summarise almost 10 years of
results obtained through interactions between social
scientists and clinical researchers in France since the
advent of highly active antiretroviral therapy (HAART).
Such collaborations have been set up in the context
of cohort studies or clinical trials which included
collection of both clinical and socio-behavioural data.
This co-operation conveys several key messages about
adherence, quality of life and sexual behaviours. One
major result is the demonstration that adherence to
HAART is not predictable before treatment initiation.
Moreover, adherence is a behaviour which changes over
time. However, the impact of non-adherence on longterm immuno-virological outcomes is crucial during the
treatment induction phase and justifies interventions
at treatment initiation. Interestingly, one randomised
clinical trial also showed the positive impact of an
educational and counselling type intervention which
took into account the cognitive, emotional, social and
behavioural aspects of patients’ daily lives on virological
outcomes. Cohort studies have given us the opportunity
to highlight a specific role of depression, independently
of non-adherence, on HIV clinical progression. Among
other important results, it is important to underline the
role of patient’s perception of HAART-related toxicity:
the perception of subjective side-effects is detrimental
to adherence, risky sexual behaviours, patient-provider
relationships and quality of life. Another randomized trial
also showed that patients’ quality of life, estimated by the
number of self-reported side effects, was better with LPV/
r monotherapy when compared with a triple regimen of
LPV/r+AZT/3TC. Among future perspectives involving
collaboration between clinicians and social scientists,
other socio-behavioural issues should be addressed such
as the level of forgiveness associated with adherence to
a specific drug combination. The comparison of several
HAART regimens should be evaluated for joint outcomes
which could combine for example immuno-virological
and quality of life outcomes. Answering these research
questions through a multidisciplinary approach is critical
for the comprehensive care of PLWHA.
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Sarah Rowland-Jones, Nuffield Department of Medicine,
Oxford University, John Radcliffe Hospital, Oxford OX3
9DU, UK
The role of T-cell immunity in controlling HIV infection
and shaping HIV evolution in the infected individual
has been controversial. The example of HIV-2 infection
in West Africa provides a potentially valuable (if underappreciated) model of human co-existence with a
pathogenic retrovirus, in that the majority of HIV-2infected people have a normal lifespan with no signs of
immune deficiency whilst those who develop disease do
so in a manner identical to AIDS caused by HIV-1. Recent
studies in the Gambia and Guinea-Bissau have shed light
on the relative contributions of host and virus in longterm non-progression in HIV-2 infection.
Whilst initial studies in Perth, WA, suggested that T-cells
play a major role in determining how HIV evolves under
selection pressure in an infected person, more recent
analysis proposed that founder effect is an important
factor that may have confounded the initial studies. We
have evaluated the role of HLA-mediated selection in a
Chinese village where infection with a single or closelyrelated virus strain(s) occurred during a plasma donor
scheme. This study, where founder effect is not a relevant
factor, suggests that HLA-mediated selection is indeed
the major cause of viral mutation in this cohort.
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Introduction: Led by UNAIDS, “Know your epidemic,
know your response” has become a rallying cry for an
intensified focus on HIV prevention, spurred by the
sobering realization that for every two people enrolled
in antiretroviral treatment programs, five more become
newly infected. The quest to better understand epidemics
reflects growing recognition that there is no single global
HIV epidemic, but rather a multitude of diverse epidemics.
The era of “standard” global prevention guidance is over.
However, there is a globally useful distinction between
concentrated and generalized epidemics, which are
fundamentally different – not because of arbitrary
prevalence thresholds, but regarding who gets infected
and how.
Methods: Understanding who gets infected and how
has led to the development of research methods to
understand incident HIV infection - the figurative last
1,000 infections in a given context. Methods include
cohort studies, BED and other assays, modeling of
incident infection and epidemiological syntheses.
Results: Analysis of the last 1,000 infections illustrates
the limited extent to which HIV programming is
matched to epidemic contexts. For too long, the global
HIV prevention community has pursued generalized
responses in concentrated epidemics, concentrated
approaches in generalized epidemics, or hedged their
bets and done a bit of everything everywhere. Many
national AIDS strategies are unfocused, developed in the
face of glaring data and analytic gaps and mismatched to
epidemic context. Moreover, too few strategies are based
on proven approaches.
Conclusions: The challenge is clear. For too long, AIDS
activists, academics and national and international
institutions have given insufficient emphasis to aligning
prevention priorities with epidemic transmission
dynamics, compromising effective prevention with
unfocused or mismatched responses. The global AIDS
community in its entirety has been slow to implement
genuinely proven approaches at adequate scale. With
the knowledge of HIV transmission dynamics and proven
prevention approaches we already have, far more should
have been – and can still be - done to curb HIV globally.

Pietro Vernazza
St. Gallen, Switzerland
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David Wilson
Lead Health Specialist, the World Bank and Adjunct
Professor,
Centre for International Health, Curtin University of
Technology

BIOLOGICAL FACTORS OF SEXUAL
TRANSMISSION OF HIV

In general, transmission of HIV is rather an unusual event
during a sexual encounter between two HIV-serodifferent
partners than the rule. In newly diagnosed cases with HIVinfection only approximately 20% of the actual steady
sexual partners are found to be HIV-positive despite a
longer period of unprotected sexual exposure to the
infected partner. However, some case reports document
frequent transmission of HIV from one infected individuals
to a majority of his sexual partners. Several factors may
explain this observed heterogeneity in transmission risk.
The contributing factors could be divided into those
which modify susceptibity in the non-infected partner
and others influencing infectiousness in the positive
partner. Inborn and acquired (specific) immunity will
affect susceptibility as well as any disruption of the
mucosal surface in the setting of sexually transmitted
diseases (STDs) or other inflammatory genital conditions.
The most potent factor influencing infectiousness of the
HIV-positive partner is the concentration of HIV-Viral load
in the blood. However, additional factors – mainly STDs –
are the second important factor influencing transmission
risk to the non-infected partner. The biologic mechanism
explaining the epidemiologic evidence of increased
transmission under STDs might include (among others)
an increase in the number of infected cells and free virus
in the genital secretions.
The presentation will summarizeour knowledge on
the numerous biological factors contributing to the
heterogeneity of HIV transmission.
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Peter Meese memorial Session – Clinical
– Associated Conditions Complications
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PROFILE OF HIV ASSOCIATED TUBERCULOSIS
IN THE SETTING OF FREE ANTI-RETROVIRAL
THERAPY AT A TUBERCULOSIS HOSPITAL IN
INDIA
Agarwal U1, Kumar A1, Behera D1
1
Antiretrviral therapy Centre, Department of Medicine,
LRS Institute of TB and Respiratory Diseases, New Delhi,
India
Human immunodeficiency virus (HIV) associated
tuberculosis (TB) poses a serious threat to public health.
With the rollout of the national program, free of cost
antiretroviral therapy is available to the Indian population
since 2004. It still remains to be seen, how TB in HIV
patients changes in terms of presentation, outcome,
relapse and diagnostic modalities.
This study was undertaken with the aim to assess the
presentation and outcome in patients concurrently
treated for TB and HIV.
Retrospective review of medical records of 251 adult and
adolescent HIV positive patients, registered between
January 2006 and June 2007 was performed. Patients
were said to be concurrently diagnosed with HIV and
active tuberculosis if the two diseases were diagnosed
within one month of each other.
73 (29.1%) of the 251 HIV infected patients, were
diagnosed with concurrent active tuberculosis. Weight
loss of more than ten percent and fever were the
commonest presenting symptoms. Eighty seven per cent
of the HIV-TB patients presented with CD4 counts less
than 200 cells/µl. The mean CD4 count at presentation
was 108.2 cells/µl.
38.4% patients had purely pulmonary tuberculosis, 39.7%
had purely extra-pulmonary tuberculosis and 21.9%
had both. Sputum positivity for acid fast bacilli (AFB) in
those with pulmonary disease was 34.1 %. Four sputum
negative patients of disseminated TB, revealed AFB on fine
needle aspirate of lymph nodes. Immune reconstitution
inflammatory syndrome (IRIS) was seen in 20.5% patients.
The mean interval between initiation of ART and IRIS was
found to be 17.7 days (median 15, range 7- 44).
Sixty seven per cent patients had a favorable outcome to
tuberculosis treatment (cure and treatment completed),
there were four defaulters and two treatment failures.
There was only one patient of proven multi drug resistant
(MDR) tuberculosis in this data. Case fatality of 17.8% was
observed.
We concluded, nearly 30% of HIV infected patients
accessing medical care had concurrent active tuberculosis.
Despite profound immunosuppression at presentation,
treatment of both the conditions together lead to an
improved outcome. Efficient HIV-TB collaboration should
be an integral component of comprehensive HIV care.
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GENERAL PRACTITIONER DESCRIPTIONS
OF CHALLENGES IN THE MANAGEMENT OF
DEPRESSION IN GAY MEN AND MEN WITH
HIV
Newman CE,1 Kippax SC,1 Mao L,1 Rogers GD,2 Saltman D,3
Kidd MR4
1
National Centre in HIV Social Research, The
University of New South Wales Sydney NSW
Australia; 2School of Medicine, Griffith University,
Gold Coast, QLD Australia; 3Institute of Postgraduate
Medicine, Brighton and Sussex Medical School
Brighton, United Kingdom; 4Discipline of General
Practice, Faculty of Medicine, The University of Sydney
Balmain NSW Australia
In contrast to the substantial literature on the management
of depression in the general population in primary
care settings, little is known about the management of
depression affecting HIV-positive men and men who
identify as gay (hereafter ‘gay men’) attending general
practice clinics, particularly in the Australian context.
This paper will explore qualitative descriptions of how
depression in gay men and men with HIV is managed
by general practitioners (GPs) who are accredited to
prescribe antiretroviral medications in three Australian
settings.
The Primary Health Care Project on HIV and Depression is
a three year multi-method study funded by the General
Practice Clinical Research Program of the National Health
and Medical Research Council (2006-2009). The research
team represents a unique collaboration between social
researchers, general practice researchers, GPs and
community partners. The study employs both qualitative
and quantitative methods to answer a range of research
questions including the prevalence and nature of
depression among gay men (both with and without HIV)
and heterosexually-identified men attending general
practice clinics, factors associated with depression in
these three groups, and the clinical and self-management
of depression by GPs and patients themselves, especially
those living with HIV.
As part of the qualitative component, interviews were
conducted with 16 GPs representing three geographical
settings and 7 practices: Sydney (4 practices), Adelaide
(1) and a rural-coastal town in New South Wales (2).
Participants included 14 male GPs and two female GPs,
and the number of years each had been working in
HIV medicine ranged from two to 24. Semi-structured
face-to-face interviews of around one hour in length
explored the diagnosis, treatment and management of
depression, aspects of depression related to HIV, gender
and sexuality, and reflections on practice. This paper will
present the results of a thematic analysis that identifies
strengths (eg. providing supportive counselling, making
use of specialist support programs) and challenges (eg.
patients’ experiences of sexual dysfunction, expanding
GP responsibilities) encountered by GPs in managing
depression in this population. In doing so, this paper
provides a unique and timely insight into the primary care
management of depression by antiretroviral prescribers
working in general practice settings in different parts of
Australia.
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information and supporting source documentation; in all
63 cases, one or more reviewers felt there was inadequate
information and documentation provided to make an
informed decision about cause of death. Unknown
cases included 16 persons who were reported as having
been found dead, and another 15 who were reported as
suddenly dying with limited details to help identify the
underlying etiology.
The underlying cause of death was non-AIDS-defining
diseases for most deaths (72%), and reflects the changing
epidemiology of HIV in the HAART era. Accurate
classification of cause of death requires provision of
complete information and documentation, and is critically
important for clinical studies.

The aim was to describe processes for death reporting
and to review specified attributions of mortality in large
international HIV trials according to a uniform set of
standards for assigning immediate, contributing and
underlying causes, for large international HIV trials.
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The three international trials were conducted during
1997-2008, with 11,593 enrollees from multiple sites in
36 countries. The trials were ESPRIT, SILCAAT and SMART.
Three Clinical Endpoint Review Committee members
independently reviewed each death report and
supporting source documentation to assign underlying
cause of death (defined as disease or injury initiating
the train of events leading directly to death, or accident
or violence producing the fatal injury), and all decisions
were adjudicated until agreement was achieved.
Of 453 deaths reported through January 14, 2008, the
underlying causes of death were: 47 (10%) AIDS-defining
illnesses; 93 (21%) non-AIDS malignancies; 39 (9%) liver
diseases (excluding malignancy); 40 (9%) cardiac diseases;
36 (8%) non-AIDS-defining infections; 22 (5%) suicides; 23
(5%) other trauma-related events or accidents; 20 (4%)
drug overdoses or acute intoxications; 52 (11%) other
identified causes; and 74 (18%) cases with “unknown”
underlying cause.
For 63 unknown cases, ERC reviewers were specifically
asked on the death review form about adequacy of
17-20 september 2008 @ Perth Convention Centre, Western Australia 				
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RE-INITIATION OF ANTIRETROVIRAL
THERAPY (ART) IN THE CD4 CELL-GUIDED
CART INTERRUPTION GROUP IN THE SMART
STUDY LOWERS RISK OF OPPORTUNISTIC
DISEASE OR DEATH
Hoy JF1,2, Drummond FM2, Emery S2, Cooper DAC2 and the
SMART Study Group
1
Infectious Diseases Unit, Alfred Hospital and Department
of Medicine Monash University, Melbourne, VIC, Australia.
2
National Centre in HIV Epidemiology and Clinical
Research, University of NSW, Sydney, NSW, Australia

counts for DC patients post-January 2006. These findings
reinforce the recommendation not to interrupt cART
using the CD4 cell-guided strategy evaluated in SMART.
Oral Posters:
Rotty J - see page
Furner V - see page

The SMART Study established that CD4-guided
intermittent cART was inferior to continuous cART for
major clinical outcomes. On January 11, 2006, based on
the recommendation of the DSMB, ART-experienced
patients (95.6% of all Drug Conservation (DC) patients)
in the intermittent cART arm were encouraged to restart
cART. Follow-up continued to study closure in July 2007
to assess whether risk associated with intermittent cART
could be reversed.
5472 patients with CD4 > 350 cells/µl were randomized
to intermittent CD4 cell-guided cART (stop ART>350
and start<250 cells/mm3) (DC, n=2720) or continuous
cART (Viral Suppression [VS] n=2752). Hazard ratios (HR)
for major clinical outcomes were estimated using Cox
Proportional Hazards models for 2 time periods: from
randomisation to January 11, 2006 (pre-January 2006),
and from January 11, 2006 to July 11, 2007 (post-January
2006).
Pre-January 2006, DC patients spent 34% of follow-up
time on cART compared to 94% for VS patients. PostJanuary 2006, DC patients spent 71% of time on cART
compared to 91% for the VS group. Percentage of followup time spent with CD4<350 cells/µl decreased from
31% pre-January 2006 to 23% post-January 2006 for DC,
and 8% and 7%, respectively for VS. Pre-January 2006,
rates for opportunistic disease (OD) or death, death, and
a composite outcome of serious cardiovascular disease
(CVD), renal and hepatic events were significantly greater
for DC compared to VS. Post-January 2006, rates for all
3 outcomes declined for DC, whilst rates for VS patients
remained stable. HR (DC/VS) improved for DC patients
once they restarted cART, but remained significantly
greater for OD or death post January 2006 (1.37 fold),
while risk of death and composite outcome were no
longer significant.
Following the recommendation to reinitiate ART for
patients in the DC group, the risk of OD or death was
significantly reduced from 2.52 to1.37 fold. However, less
than full reversal of risk for DC compared to VS patients
for OD or death was noted. This may be attributed in part,
to some patients not initiating cART, and lower CD4 cell
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Huang R1, Torzillo PJ1
1
Nganampa Health Council, SA, Australia
Nganampa Health Council (NHC) has managed a data
collection and surveillance system for monitoring STIs on
the remote Anangu Pitjantjatjara Yankunytjatjara (APY)
Lands for over twelve years as an important component
of their comprehensive STI Control and HIV Prevention
Program. This customised system provides a method of
monitoring important indicators of clinical care such as
participation rate in annual screening, treatment rates
and time to treatment of various STIs, contact tracing, and
in recent years population mobility.
Each year in the month prior to the annual populationwide screen a consistent population update is
undertaken. The population update process is pivotal to
obtaining comparable cross-sectional prevalence rates
over thirteen consecutive years of annual populationwide screening for chlamydia, gonorrhoea and syphilis
undertaken by NHC. The trends in these STIs over the
thirteen year period of screening are discussed. Marked
reductions in all three STIs has occurred but there was a
rise in gonorrhoea over the period 2004-2007.
An appropriate monitoring and evaluation system
managed within the health service has allowed informed
and timely choices to be made about many aspects of this
STI control program. It has guided choices and provided
information such as appropriate age groups to test during
annual population-wide screening, risk factors associated
with STIs, and uptake of HIV testing. It has provided an
early alert to the rise in gonorrhoea prevalence 20042007 which has allowed further research into the cause.
NHC has now commenced using a patient information
recall system (PIRS) live in all their remote clinics. The
application of this system as an adjunct to the current
data monitoring systems is briefly discussed.

A, Slater
Hunter New England Population Health Services, Capacity
Building Service Team, Hunter New England Area Health
Services, Tamworth, NSW, Australia
Background: Aboriginal people are up to 10 times more
likely to contract Hepatis C when compared to the broader
population (Bloodborne viral and sexually transmitted
infections in Aboriginal and Torres Strait Islander People:
Surveillance Report 2007). However, treatment statistics
across the Hunter New England Area Health service
suggest that Aboriginal people are less likely to access
specialist Hepatitis C (Hep C) treatment services when
compared to the broader population.
Aim: This project aimed: to identify barriers which
prevent Aboriginal people from accessing specialist Hep
C services; and to promote opportunities to increase
Aboriginal people and community groups knowledge of
the Hep C virus, routes of transmission, testing, treatment,
care and available support services.
Method: Working within a cultural context and
understanding community dynamics, project staff visited
9 towns and communities across North-West NSW over
a two month period. The project staff convened Hep
C discussion groups across a wide representation of
local community groups, service providers and priority
population group’s e.g. Aboriginal people in correctional
facilities. These groups were facilitated by an Aboriginal
person known to the local community and aimed to
encourage group discussion around access to specialist
Hep C services and to deliver advice and information
sessions to participants.
Results: Discussion groups identified a poor understanding
of: available specialist Hep C services; and the Hep C
virus, routes of transmission, testing, treatment, care
and available support services. Where appropriate, local
community members were opportunistically referred
to specialist Hep C services and other local treatment
options during the course of the discussion groups.
Conclusion: Discussion groups convened at a community
level were an ideal vehicle for providing information to
community groups, service providers and at risk client
groups. Working within a cultural context, with an
understanding of community dynamics and being known
to the local community is important when encouraging
the uptake of specialist Hep C services within Aboriginal
communities. If we are likely to address the growing
incidence of Hep C within Aboriginal communities future
projects of this type are required.
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A CULTURAL WORLD AIDS DAY IN THE
ABORIGINAL COMMUNITY

BERRIMA WOMEN’S PROJECT

David Webb
Aboriginal Sexual Health Worker, Sydney West Area Health
Service, NSW Australia
The Sydney West Area Health Service (SWAHS) World
AIDS Day (WAD) event is held at the Holy Family Church
Emerton, a suburb of Mt Druitt in NSW. This area has a
large Aboriginal community, and the Church traditionally
has important links with this community and its’ culture.
The Holy Family Church has been holding World AIDS
Day events for the last 10 to 15 years. The Church garden
area has become a significant place where the ashes of
Aboriginal People who have passed way with AIDS are
scattered through out the garden.
SWAHS has been privileged to host a World AIDS Day
event at the Holy Family Church for the past 3 years as
a part of its’ wider AIDS awareness programs that have
been running in the area for the past 16 years. The aims
of this event, which are in line with the NSW HIV/AIDS,
STI and Hepatitis C Strategies: Implementation Plan for
Aboriginal People 2006-2009, are to:
• increase Aboriginal community engagement in HIV/
AIDS issues;
• increase community awareness and knowledge of HIV;
• find ways of reducing the risk of transmission amongst
Aboriginal people; and
• For all these to be done in the context of continually
supporting and affirming the culture and heritage of
Aboriginal people.
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The presentation will focus on the partnerships which
supported this program and will outline the following
strategies:
• a WAD painting representing the families communities
of those have passed away from AIDS;
• the “Healing Tree”/”Tree Ochering” to highlight the
impact of HIV/AIDS on both the indigenous and wider
community in the Mt Druitt area;
• Women’s business activities; and
• A focus on Aboriginal culture by featuring a traditional
Welcome to Country in language, and then translated in
English and a Smoking Ceremony by a local Aboriginal
Elder.
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Smith M , Tyne M.
HIV & AIDS Related Programs (HARP) Health Promotion,
Western Zone, Sydney South West Area Health Service
(SSWAHS) Sydney NSW Australia;
HIV prevalence among people entering the Australian
prison system in the year 2004 rose primarily within New
South Wales (NSW) and South Australia (SA). This rise was
particularly among women. The numbers of HIV+ women
entering the prison systems are almost 40% higher than
that of men.
Among new HIV diagnoses in 2002 – 2006, the most
frequent reported route of transmission in the nonindigenous population was male homosexual contact
(65%) heterosexual contact (20%) and injecting drug use
(3%). In the Aboriginal and Torres Strait Islander population,
HIV infection was attributed to male homosexual contact
(37%) in heterosexual contact (34%) and injecting drug
use (18%).
The Berrima Women’s Project provides Aboriginal inmates
of the Berrima Women’s Correctional Centre in NSW with
HIV and sexual health education in a traditional form,
as identified in the National Aboriginal and Torres Strait
Islander Sexual Health and Blood Borne Virus Strategy
2005-2008 (Section 3) and the National HIV/AIDS Strategy
Revitalising Australia’s Response 2005-2008 (Section 6).
The Project comprises 18 sessions on sexual health and
relationship topics. Each session includes interactive
games on HIV, sexually transmitted infections and health
topics followed by informal discussions with questions
and answers. The women contribute to the project
using traditional learning skills such as painting, craft and
poetry/song to develop sexual health resources for use in
other Aboriginal communities.
The project aims to increase to the women’s capacity
to make informed decisions about their sexual health;
increase the number undertaking regular health check
ups and develop knowledge of health/community
service networks beyond the corrective centre.
This presentation will discuss partnership building with
the Department of Corrective Services and Justice Health;
the development of interactive relationships between
the HARP health promotion service and the women; and
among the women themselves.
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THE PROCESS OF MANAGING AN HIV +VE
INDIGENOUS WOMAN WITH A CHAOTIC
LIFESTYLE IN A RURAL SETTING

Gilles MT1, Ferguson C1, Smith P1, Edel M1
1
Western Australian Country Health Service, WA Australia

Authors: Armstrong, K2, Cain A1, Douglas, C2
1
Department of Clinical Immunology & Immunogenetics,
Royal Perth Hospital, WA; 2 WACHS Goldfields- Population
Health, WA

Staff from the unit providing this rural care will be asked
to record the duration and type of every interaction with
their HIV clients for one month. This will include text
messages, phone calls, home visits, and appointments.
Using this diary and the staff salary an economic value will
be produced for each client. In addition staff will undergo
semi structured interviews relating to the emotional
impact this work has on their lives.
The analysis and final report will incorporate both
financial and emotional costs. There is no question in the
team’s mind that this level of care is worth it. Ironically
the services success which has prevented the predicted
HIV holocaust has reduced its visibility and money that
used to be available for this service is drying up. This
paper examines the issue of “willingness to pay” in this
emotionally charged and important area of health
delivery.

Indigenous women with HIV face a number of unique
social and medical issues. This presentation describes the
medical, social and legal steps that needed to be taken
to adequately manage an HIV positive woman originally
from a remote Aboriginal community but now living in
Kalgoorlie, and to manage the public health risk that she
posed. Supported by the Department of Immunology
at Royal Perth Hospital and the Case Management Unit
in Perth, staff from the Goldfields Public Health Unit
have been actively involved with this patient since her
diagnosis in April 2006.
Her history of repeated head injuries, epilepsy and alcohol
related brain damage have led to cognitive deficits which
have made education and treatment issues difficult.
She has been unable to maintain confidentiality of her
diagnosis, and due to her risk taking behaviour she has
faced stigmatisation and discrimination by her family,
community and service providers. Her lifestyle was
becoming increasingly chaotic as she had no fixed abode
and regularly sought company and shelter wherever she
could find it. This was frequently associated with groups
of people who were drinking large amounts of alcohol.
Often she would disappear for days at a time and the
Public Health team would only discover her whereabouts
after she presented to the local hospital emergency
department having had a convulsion.
Good teamwork has been required between the
local Public Health Unit and other medical and health
practitioners in order to maintain her health and
compliance with medication, and thus the health of the
wider community.
Along the way it has been necessary to commence
directly observed therapy seven days a week, invoke
the Public Health Act and apply for guardianship and
administration orders through the Offices of the Public
Trustee and Public Advocate.
The presentation includes a timeline that outlines the
events described above and highlights some of the
challenges and successes which have allowed her viral
load to remain undetectable, and the public health risk
to be minimised.
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It has been acknowledged that poor medical outcomes
in Aboriginal people can be attributed to inequity in the
delivery of services to this population. In a recent paper
reviewing the outcomes of health care to a group of
socially and geographically disadvantaged women with
HIV infection. It was demonstrated that if adequately
resourced and culturally appropriate care is supplied
similar outcomes to those in non-Aboriginal metropolitan
based HIV positive people can be achieved. The estimated
cost per woman for this rural support plus the coordinated
multidisciplinary care was $57,545 per pregnancy. But
this took no account of the true investment in this cohort.
This study seeks to determine how much this level of care
really cost?

Indigenous Health

WILLNESS TO PAY: WHAT IS THE TRUE COST
OF PROVIDING EQUITABLE HEALTH CARE  IN
A DISADVANTAGED COMMUNITY?
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Risk reduction patterns of 
Unprotected anal intercourse:
relative risk FOR HIV Acquisition in the 
Health In Men (HIM) Study
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RATES OF HIV SEROCONVERSION IN
PATIENTS WHO HAVE PREVIOUSLY USED
NPEP: DATA LINKAGE OF THE VICTORIAN
NPEP SERVICE DATABASE WITH THE
VICTORIAN HIV SURVEILLANCE REGISTRY
Pierce AB1, Stoové MA2, Yohannes K2, Guy R3, Watson K1,
Armishaw J1, Price B1, Hoy JF1,4, Wright EJ1,4
1
Victorian NPEP Service, Infectious Diseases Unit, The
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Epidemiology and Population Health Research, The
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Centre in HIV Epidemiology and Clinical Research, The
University of New South Wales, Sydney, NSW, Australia; 4
Department of Medicine, Monash University, Melbourne,
Vic, Australia
The Victorian NPEP Service (VNPEPS) is a state-wide service
co-ordinated at The Alfred Hospital. Although patients
are encouraged to return for HIV diagnostic testing three
months following NPEP, return rates are poor, there is no
long term follow-up and subsequent HIV diagnoses in
those who have ever presented for NPEP are unknown.
The HIM study reported an association between NPEP
use and subsequent HIV seroconversion. We matched
the VNPEPS database with the Victorian HIV Surveillance
Registry to determine the numbers and rates of HIV
seroconversion among NPEP users in Victoria. Patients
in the VNPEPS (N=1595) database between Jan 2001 and
Feb 2008 were linked with all entries in the Victorian HIV
surveillance registry up to May 2008 using alpha-numeric
identifier codes.
Sixty-one VNPEPS patients were identified as HIV positive,
giving an incidence rate of 1.54 per 100 PY (95%CI=1.191.87) in those presenting for NPEP. Sixteen were HIV
positive at baseline, thus giving an HIV incidence rate of
1.14 (95% CI =0.84-1.51) per 100 PY in those HIV negative
at first NPEP presentation. All HIV diagnoses occurred in
males with a mean age of 33.7 years. Two diagnoses were
potential NPEP failures occurring within 3 months of NPEP
prescription. A further eight HIV diagnoses occurred more
than 3 months post NPEP with no intermediate negative
HIV test recorded. The majority of HIV positive results
(84%) occurred in those who presented for NPEP on
only one occasion with a further 12% occurring among
patients presenting twice for NPEP.
The incidence of HIV infection in HIV negative men who
present to the VNPEPS is similar to the overall rate of
seroconversion reported in the HIM study, and lower than
the rate reported in men who had received NPEP in this
study. Surprisingly, most HIV infections were diagnosed in
men who had only one presentation for NPEP. Although
Australian incidence data is limited, these findings
suggest that HIV incidence among VNPEP presenters
is comparable to estimates reported among gay male
populations. Further evaluation including examining risk
behaviour both before and after NPEP in this population
is required.
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Jin F1, Crawford J2, Prestage GP1, Zablotska I2, Imrie JC2,
Kaldor JM1, Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research; 2National Centre in HIV Social Research,
University of New South Wales, Australia
A range of so-called risk reduction behaviours (RRBs)
in which homosexual men practice unprotected anal
intercourse (UAI) has been described. There are no
published longitudinal data on the risk of HIV infection of
these behaviours.
Between 2001 and 2004, 1,427 men were enrolled.
They were followed up with 6 monthly behavioural
interviews and annual HIV testing. Four possible RRBs
were investigated, namely serosorting, negotiated safety,
strategic positioning, and withdrawal during receptive
UAI (UAI-R). These RRBs were defined behaviourally.
RRBs were common in this cohort. In most (88%) follow
up periods with UAI reported, UAI occurred in the context
of at least one RRB involved. Compared with those
who reported no UAI, the risk of HIV infection was not
raised in negotiated safety (HR=1.67, 95% CI 0.59-4.76)
and strategic positioning (HR=1.54, 95% CI 0.45-5.26).
Serosorting outside negotiated safety was associated
with an intermediate rate of HIV infection. Withdrawal
was associated with a higher hazard ratio (5.00, 95% CI
1.94-12.92), but this was largely because it was commonly
practiced with HIV positive partners. With such partners,
withdrawal was associated with a substantially lower
risk than was UAI-R with ejaculation. Men who reported
serosorting were much less likely to report UAI-R with
withdrawal (OR=0.52, 95% CI 0.43-0.63) or strategic
positioning (OR=0.44, 95% CI 0.36-0.54). Overall, men
who reported any one of these RRBs were more likely
to seroconvert to HIV than men who reported no UAI
(HR=3.01, 95% CI 1.31-6.92), but they were much less
likely to become infected than men who reported UAI
without any of these RRBs (HR=0.29, 95% CI 0.14-0.54).
All RRBs were associated with an incidence of HIV
infection that was intermediate between that in those
who reported no UAI and higher risk activities suggesting
that these behaviours did indeed reduce risk. In the
presence of serosorting (including negotiated safety)
strategic positioning and withdrawal were very unlikely,
which suggests that men felt that practicing one RRB
provided adequate protection. Researchers and policy
makers need to address the reality that UAI in the context
of RRB is common among gay men and help inform the
choices around these behaviours.
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In Australia, HIV prevalence among homosexual men is
low in men aged under 30 years and increases with age.
This gives rise to the possibility that increasing partner
age may be an important risk factor for HIV infection,
particularly in younger men. We aimed to determine
partners’ age as a risk factor for HIV seroconversion in a
community-base cohort of HIV negative homosexual
men in Sydney.
Participants were men from the HIM study recruited
between 2001 and 2004, followed to June 2007.
Participants responded to “how many of your male sex
partners were much older than themselves in the last
6 months” at baseline (none, a few, about half, most).
In addition, those who were in a regular relationship
reported the age of that partner at each interview.
A total of 1427 men were recruited. At baseline, about
20% of men reported that half or more of their partners
were much older. Having more partners who were
much older was associated with an increased risk of
HIV seroconversion (p trend=0.002), and this remained
significant after adjustment for number of episodes of
sero-non-concordant unprotected anal intercourse (UAI),
age, and number of casual partners (Hazard ratio for
those who reported more than half partners were older
compared to those who reported none older of 2.50, 95%
CI 1.13-5.53, p trend=0.019). Stratified analysis showed
that this trend was significant in participants aged both
under and above the median age of HIV infection (37
years). In those who were in a regular relationship, men
who reported their partner’s age was within 5 years of
their own were at lowest risk of HIV infection, compared
with those who reported an older partner, but this was
not significant. Interestingly, similar although weaker
and non-significant patterns of increased risk were seen
for men who reported that more partners were much
younger.

Wilson DP, Hoare A, Regan DG, Law MG
National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney,
NSW, Australia
Newly infected people enter the stage of primary HIV
infection (PHI). In this stage viral loads are higher than at any
other time during the course of infection. Consequently,
people in PHI have the greatest infectiousness per sexual
encounter. Newly-infected people are also generally
unaware of their new serostatus and potential to cause
secondary HIV transmissions. In this study we address
the research questions: (i) what proportion of new HIV
infections in Australia is transmitted from people who are
(a) undiagnosed, (b) in PHI, (c) on antiretroviral therapy?
(ii) what is the expected epidemiological impact of (a)
increasing rates of early treatment, and (b) increasing HIV
testing rates?
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Jin F1, Prestage GP1, Mao L2, Imrie JC2, Kippax SC2, Kaldor
JM1, Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW; 2National Centre in HIV Social Research,
UNSW

Importance of promoting HIV
testing for preventing secondary 
transmissions: modelling the 
Australian HIV epidemic among men 
who have sex with men

We used a mathematical model to simulate HIV
transmission in men who have sex with men (MSM) in
Australia. We calibrated the model using established
biological and clinical data and a wide range of Australian
MSM epidemiological and behavioural data sources.
We estimate that ~19% of all new HIV infections are
transmitted from the ~3% of MSM who are in PHI; ~31% of
new HIV infections are estimated to be transmitted from
the ~9% of MSM with undiagnosed HIV. We estimate that
the average number of transmissions from HIV-infected
MSM through the duration of PHI is ~0.14-0.28. The
epidemiological impact of increasing treatment in PHI
would be modest due to insufficient detection of newlyinfected individuals. In contrast, increases in HIV testing
could have substantial epidemiological consequences.
The benefit of testing will also increase over time.
Promoting increases in the coverage and frequency of
testing for HIV could be a highly-effective public health
intervention and could increase the effectiveness of
any strategy based on treating PHI. Treating PHI requires
further evaluation of its long-term effects on HIV-infected
individuals.

Men who reported older partners were at increased risk
of HIV infection and this was independent of UAI with
sero-non-concordant partners.
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Sexual partners’ age as a risk factor 
for HIV seroconversion in the Health 
in Men (HIM) Study
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THE PARADOXICAL EFFECTS OF USING
ANTIRETROVIRAL-BASED MICROBICIDES TO
CONTROL HIV EPIDEMICS

HIV RISK BEHAVIOR AMONG HIV-INFECTED
MEN WHO HAVE SEX WITH MEN IN
BANGKOK, THAILAND

Wilson DP1, Coplan PM2, Wainberg MA3, Blower SM4
1
National Centre in HIV Epidemiology and Clinical
Research, Faculty of Medicine, The University of New South
Wales; 2Center for Clinical Epidemiology and Biostatistics,
University of Pennsylvania School of Medicine; 3McGill
University AIDS Centre, Jewish General Hospital; 4Semel
Institute for Neuroscience and Human Behavior and
UCLA AIDS Institute, David Geffen School of Medicine at
UCLA
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Vaginal microbicides, designed to prevent HIV infection
in women, are one of the most promising biomedical
interventions. Clinical trials of second-generation
microbicides have begun; if shown to be effective
they could be licensed within 5-10 years. Since these
microbicides contain antiretrovirals (ARVs) they could be
highly effective. However there is concern that, if used by
HIV-positive women, ARV resistance may evolve.
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We develop and analyse a novel mathematical model of
a phase III clinical trial of ARV-based microbicides used by
women at high risk of HIV infection. We also develop a
dynamic transmission heterosexual model to investigate
the potential population-level effects of microbicides
that contain ARVs that are highly absorbent. The models
are parameterized using epidemiological, clinical and
behavioural data to predict the consequences of widescale usage of high-risk microbicides in a heterosexual
population.
We find that adherence could have both beneficial and
detrimental effects on trial outcomes. Most importantly
we show that planned trial designs could mask resistance
risks and therefore enable high-risk microbicides to pass
clinical testing. Surprisingly, we show that reducing a
participant’s risk of resistance during a trial could lead to
unexpectedly high rates of resistance afterwards when
microbicides are used in public health interventions.
We also find that, paradoxically, although microbicides
will be used by women to protect themselves against
infection they could provide greater benefit to men.
More infections in men, than women, will be prevented
if there is a high probability that ARVs are systemically
absorbed, microbicides are less than ~50% effective, and/
or adherence is less than ~60%.
Men will always benefit more than women in terms of
infections prevented per resistant case; but this advantage
decreases as the relative fitness of drug-resistant strains
increases. Interventions that use ARV-based microbicides
could have surprising consequences.
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BACKGROUND: HIV prevalence among men who have
sex with men (MSM) in Bangkok, Thailand increased from
17% to 28% between 2003 and 2005. However, limited
data on sexual risk behaviors are available to guide HIV
prevention efforts for MSM.
METHODS: HIV-infected MSM attending an STI clinic in
Bangkok were interviewed about sexual risk behaviors
and evaluated for sexually transmitted infections (STI),
as part of routine services. Patients were examined for
genital ulcers and had serologic testing for syphilis and
urethral PCR testing for chlamydia and gonorrhea. Steady
partners were defined as regular sexual partners for >2
months; STI was defined as a positive laboratory test or
clinician-confirmed genital ulcer. Electronic clinic record
data were analyzed using SAS.
RESULTS: During October 2005-October 2007, 154 HIVinfected MSM were included. Median age was 28 years
(range, 17-65 years). Sexual intercourse in the last 3
months was reported by 131 (85%) men. Of these, 79
(60%), 69 (53%), and 19 (15%) reported sex with steady
male partners, casual male partners, and female partners,
respectively. Condoms use during last sex was reported
by 60% with steady male partners, by 75% with casual
male partners and by 63% with female partners. Among
those with steady male partners, 39% had disclosed their
HIV status, 38% reported their partner had been HIV
tested and 60% reported the partner tested HIV-negative.
Among those with discordant steady partners, condoms
use at last sex was reported by 64%. STIs were found in
41% of men (10%, chlamydial infection; 13 %, gonorrhea;
20% reactive syphilis serology; and 10%, genital ulcer).
Unprotected last sex was more likely among MSM with
steady male partners than other partner types (OR=2.65,
95% CI=1.2-5.6). Age, education, time since HIV diagnosis,
antiretroviral therapy, CD4 count, and current STI were
not significantly associated with unprotected sex.
CONCLUSION: Sexual risk behaviors and STIs were
common among this group of HIV-infected MSM in
Bangkok. High HIV discordance and low disclosure rates
with steady partners highlight the need for effective HIV
prevention strategies for MSM. Increasing condom use
should be a focus of HIV prevention efforts among HIVinfected MSM.
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In 2008 Secretariat of the Pacific Community (SPC) and
Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM) commissioned the Australasian Society for HIV
Medicine and the National Centre in HIV Social Research
in partnership with SPC to undertake an evaluation of
existing HIV testing and counselling services in the 11
Pacific Countries supported by the GFATM: Cook Islands,
Federated States of Micronesia, Fiji, Kiribati, Niue, Palau,
Samoa, Solomon Islands, Tonga, Tuvalu and Vanuatu.
This evaluation is in line with A guide to evaluating HIV
testing and counselling services in the Pacific Island
Countries and Territories (PICTS) using minimum
standards devised by the Albion Street Centre Sydney for
SPC and GFATM in 2007.
The minimum standards for voluntary counselling and
testing services aim to develop more consistent, better
quality and effective HIV test counselling services, both at
country level and across the region.
The response from sites participating in the evaluation
has been largely positive and many have been interested
in determining minimum levels of service provision and
areas for improvement. Services with identified gaps will
be supported with follow-up technical expertise, training
and resource provision.
It has been found that in applying minimum standards
there needs to be a flexible approach, particularly
where VCCT services are located within more general
health services as opposed to stand alone VCCT/HIV
and STI services. Also, important differences in the pre
registration training of health professionals across the
Pacific may mean that counselling skills training and
ongoing supervision and support requires solutions that
are country specific. Policy and protocol development
were also identified as gaps within service provision.

Kelly, A.
National Centre in HIV Social Research, UNSW
There is nothing new in the desire to test people and
determine their HIV status. However, attempts to scale up
access to ART, and consequent recent shifts in HIV testing
policy from opt-in to opt-out, has seen a resurgence in
debates around HIV testing practices. This has been
especially true in resource poor settings. It is argued that
testing is the gateway to treatment, yet, with a minority
of HIV-positive people who already know their status
receiving treatment, increasing testing as evident in PNG
does not guarantee access to ART.
When we examine available surveillance data of vertical
transmission, it is evident that in PNG the prevention of
mother to child transmission program (PMTCT) has not
been successful. In a desperate attempt to stem the
numbers of children acquiring HIV the government has
endorsed PICT as a means to address this issue. However,
this policy shift has occurred without an examination
of the PMTCT programs and how those already testing
positive can be better supported to return for the delivery
of their child, to maintain strict feeding regimes and to
maintain ongoing connections with health care workers
at the PMTCT clinics. In addition, we have not examined
from the health care providers perspectives why they
have been unable to successfully care for such women
and babies. It is important that as we continue to critique
the policy we monitor the practice, especially in relation
to counseling, consent and confidentiality. Health care
professionals already yield a great deal of power; we must
be certain that we do not deny those who seek their care
any less. As suggested by the PICT guidelines there must
be a guarantee of an enabling environment; at present,
this is not the case for women in PNG. Until we can
improve the social and health outcomes for women, their
children and families already testing positive with opt-in
it is not ethical or in the interests of maternal and child
health to shift direction in HIV testing. While policies and
practices continue to unfavorably prejudice and police
women’s bodies then we are not ready to move beyond
critiquing test practices.

This paper will discuss the findings of the evaluation of
HIV testing and counselling services against the Minimum
Standards and the implications of applying Minimum
Standards to under resourced health services in low
prevalence settings in the Pacific.
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Providing HIV Services to Prisoners in 
Thailand: Peer Outreach, Voluntary 
Counseling and Testing (VCT), and 
Linkages to Care
Poolsawat M,1 Ngamtrairai N,2 Suwannaraksa P,3 Prajongkit
C,4 Lertpiriyasuwat C,5 Chiawcharn P,3 Manopaiboon C,1
Visavakum P,1 Fox K1,6
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Thailand; 5Ministry of Public Health, Nonthaburi, Thailand;
6
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High HIV prevalence has been reported among prisoners
in Thailand, yet HIV prevention programs and care
referral systems are limited within Thailand’s prisons. We
established an HIV peer education program, condom
access, and counseling and testing (CT) services in Prison
A (900 male inmates). One year later, we conducted a
cross-sectional survey to evaluate the intervention and to
assess needs at Prison B (4000 male inmates).
A simple random sample of male inmates was selected
in each prison. Consenting participants completed selfadministered questionnaires using handheld computers.
We conducted multivariate analysis of factors associated
with anal sex and condom use.
At the two prisons, 746 male inmates (median age 24)
were surveyed. Drug offenses were the most common
reason for incarceration (49%), yet only 4% had ever
injected drugs. Potential HIV risk behaviors in prison
included sharing tattoo equipment (64%), penile
modification (27%), anal sex (14%), and injecting drugs
(1%). Independent factors associated with having anal
sex in prison were years incarcerated (adjusted odds
ratio [ORa] 1.3, 95% confidence interval [CI] 1.1-1.4),
being unmarried (ORa 2.4, 95% CI 1.2-4.9), receiving a
tattoo in prison (ORa 2.2, 95% CI 1.1-4.7), and undergoing
penile modification in prison (ORa 2.4, 95% CI 1.6-3.8).
Among inmates reporting anal sex, all at Prison A and
20% at Prison B believed condoms were easy to access
in prison; perceived easy access to condoms was the
only independent factor associated with condom use
(ORa 11.0, 95% CI 3.4-35.6). Most inmates at Prison A had
been exposed to peer education (82%) and reported
they trusted the confidentiality of prison CT services
(70%). Of 171 inmates who accessed CT, 13 (8%) tested
HIV-positive; all 13 were enrolled in HIV care and 3 have
begun antiretroviral treatment.
Tattooing, penile modification, and anal sex were common
behaviors in this population. Easy access to condoms was
strongly associated with condom use. Peer education
and prison CT services were well-received and linked HIVinfected inmates to care. These services should be key
components of prison HIV interventions in Thailand.
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PROPOSED APPRAISAL OF HIV TESTING
STRATEGIES EMPLOYING SIMPLE/RAPID
TESTS
Elizabeth M. Dax and Susan J. Best
National Serology Reference Laboratory, Australia
The use of HIV testing strategies employing so-called
simple/rapid tests is gaining momentum internationally.
The objective is to test larger numbers of people, so that
those who need antiretroviral treatment can be treated
as soon as possible. Increasingly, HIV testing is being
conducted in non-laboratory settings, by personnel not
trained in laboratories. The success of testing programs
involving simple/raid tests is typically measured by the
numbers of people being tested, notified of their HIV
status, or treated with anti-retroviral drugs. However,
such measures can be misleading if used in isolation. The
effectiveness of new testing strategies will depend on
whether the quality of testing can be maintained when
the throughput of testing is increased. Proper assessments
of new strategies have often not been made.
The World Health Organization (WHO) is in the process of
generating a number of revised testing strategies. These
strategies, which have become quite complex, should
not be adopted until and unless their integrity can be
appropriately substantiated.
When seeking to substantiate new strategies, the
following should be taken into account:
• Many individual tests have been subject to laboratory
evaluations, and shown to operate appropriately and
to accurately define true positive and true negative
samples;
• However, evaluations of tests when used individually
do not necessarily allow us to assess their performance
when used in combination. A major reason for this is
that tests may use similar antigens. As a result, tests
proposed for use in combination may share either
common false reactivity or common false negative
results;
• An initial mathematical assessment of a strategy
involving a combination of tests can be performed if the
tests have been individually evaluated, using the basic
formulae for predictive values of testing to estimate the
probability that a result obtained from such a strategy
is a true result. A model for this assessment has been
established;
• However, mathematical assessment of any new strategy
must be supplemented by scientific assessment,
considering the mechanisms of each of the tests that
are proposed to be combined;
• After mathematical and scientific assessment, the
proposed new strategy must also be subject to a
thorough practical validation in the laboratory e.g. in
a validation of six HIV simple/rapid tests and enzyme
immunoassays that was conducted in the same
samples, four of 43 falsely reactive samples showed
reactivity in at least two of the tests.
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The increasing emphasis on the use of simple/rapid
tests for HIV makes it very important to remember these
principles. This is because many simple/rapid tests
employ similar antigens, and sometimes two available
tests are actually the same product, differently packaged.

USE OF DRY BLOOD SPOTS (DBS) TO AID
HUMAN IMMUNODEFICIENCY VIRUS
(HIV) DIAGNOSIS IN CHILDREN IN THE
ABSENCE OF LOCAL NUCLEIC ACID TESTING
LABORATORY CAPACITY
Allison WE1, Cunningham P2, Hawkins C2, Kiromat M3,
Vince J3, Kaldor J1.
1
The National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW, Australia; 2NSW State Reference
Laboratory for HIV, St Vincent’s Hospital, Sydney, NSW,
Australia; 3Department of Paediatrics, Port Moresby
General Hospital, Port Moresby, Papua New Guinea.
Mortality rates of HIV infected children in Africa have
been shown to approach 50% within the first two years
of life. Early diagnosis is therefore important in order to
ensure early access to care, treatment and support. The
gold standard for diagnosis of HIV in children under 18
months old is nucleic acid detection via the polymerase
chain reaction (PCR). In less resourced settings, including
Papua New Guinea (PNG), nucleic acid testing often not
available.
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In the context of a prospective study looking at predicators
of HIV infection at Port Moresby General Hospital (PMGH)
dry blood spot samples were collected from children
on Whatmans Protein Saver #903 cotton based paper.
These DBS were transported to the laboratory in Sydney
in individual dessicated airtight pouches. Blood was
extracted from the filter paper and HIV-1 DNA amplified
by PCR (Roche Amplicor HIV-1 test version 1.5, CA USA).
Of 122 samples analyzed 107 were found to be negative,
17 reactive and 1 indeterminate.
Laboratory capacity for nucleic acid testing in PNG is
under development but in the interim, transport of DBS
to the NSW State Reference Laboratory can be a feasible
alternative for diagnosis of HIV infection in children under
18 months old. The advantages of DBS include use of heel
or finger prick to obtain blood (venesection in infants can
be difficult) and ease of transport (less of a biohazard, no
temperature requirement). With established systems in
place for sending and receiving samples and reporting of
results there is the potential for the NSW State Reference
Laboratory to also offer this diagnostic service to other
institutions in the region who as yet do not have the local
diagnostic capabilities.
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The Annual Consensus Conference is this year
incorporated into the clinical stream of the main
ASHM 08 Conference program. Previously, the Annual
Consensus Conference has been held on the Saturday
afternoon immediately following the close of the
ASHM Conference. Feedback from previous years has
suggested that attendance and participation would
be maximised if the Australian Antiretroviral Guideline
sessions were moved into the ASHM program.
This year, the Australian Antiretroviral Guidelines sessions
will be held on the Thursday 18 and Friday 19 afternoons of
the ASHM 08 program. These sessions include evidencebased presentations from international and local experts
on the latest research and developments in HIV treatment
and provide the opportunity for discussion.
Dr Roy Gulick is a member of the US Department of
Health and Human Services (DHSS) Panel on Antiretroviral
Guidelines for Adults and Adolescents and will represent
DHHS at these sessions. The DHSS Guidelines for the
Use of Antiretroviral Agents HIV-1 Infected Adults and
Adolescents have been endorsed by Australia and
form the basis on which the Australian commentary
is developed. The Australian commentary to the latest
Guidelines for the Use of Antiretroviral Agents in HIV-1
Infected Adults and Adolescents is available at: http://
www.ashm.org.au/aust-guidelines/.
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Australian Antiretroviral Guidelines: Consensus Conference

EFFICACY AND SAFETY OF PREFERRED ART:  
EMERGING DATA

Australian Antiretroviral Guidelines:
Consensus Conference
1.30pm – 3.00pm
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Roy M. Gulick, MD, MPH
Weill-Cornell Medical College, New York
Current treatment guidelines recommend specific
antiretroviral drugs as preferred components of initial
regimens based on their comparative efficacy, safety,
tolerability, convenience, and other factors. Current
preferred components are: abacavir/lamivudine and
tenofovir/emtricitabine (nucleoside analogues); efavirenz
(NNRTI); and atazanavir/ritonavir, fosamprenavir/ritonavir,
and lopinavir/ritonavir (protease inhibitors). Emerging
data further define the efficacy and safety of these
preferred ART components.
ACTG 5202 recently demonstrated that abacavir/
lamivudine was virologically inferior to tenofovir/
emtricitabine and also associated with a shorter time to
severe toxicity in patients with pre-treatment baseline HIV
RNA levels >100,000 copies/ml. Abacavir hypersensitivity
reaction is avoided with the use of baseline HLAB5701
screening. Unexpectedly, abacavir was shown to be
associated with an increased risk of cardiovascular
events in both the D-A-D cohort and the SMART study,
although the mechanism is unknown. Both abacavir and
tenofovir have favorable lipid profiles compared with
older nucleoside analogues. Tenofovir uncommonly is
associated with renal toxicity in clinical trials and cohort
studies.
Efavirenz remains the preferred NNRTI. A subanalysis of
ACTG 5095 demonstrated consistent activity of efavirenzbased regimens across pre-treatment HIV RNA levels and
CD4 cell counts. An extension of the 903 study recently
demonstrated 7-year durability of efavirenz-based
regimens. ACTG 5142 demonstrated efavirenz-based
regimens were virologically superior to lopinavir/ritonavirbased regimens, although CD4 responses were less good
and drug resistance at virologic failure occurred more
commonly. Newer agents such as maraviroc, raltegravir,
and the NNRTI rilpivirine, demonstrate comparable
virologic responses to efavirenz. A surprising finding
from A5142 was that lipoatrophy was described more
frequently with efavirenz than lopinavir/ritonavir. Longterm central nervous system side effects with efavirenz
occur uncommonly.
The preferred protease inhibitors, each boosted with
ritonavir, are atazanavir, fosamprenavir, and lopinavir and
head-to-head studies (CASTLE and KLEAN) demonstrate
their comparable efficacy. More recently, head-to-head
studies demonstrate the comparable efficacy to lopinavir/
ritonavir of darunavir (ARTEMIS) and saquinavir (GEMINI).
Atazanavir/ritonavir is given once-daily and studies
suggest the activity of once-daily ritonavir-boosted
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The risk of reactivation of latent tuberculosis infection is
significantly increased in the setting of HIV co-infection.
Interventions to reduce the risk of reactivation of latent
tuberculosis have been well established. Clinicians need
to be able to diagnose latent tuberculosis to be able to
offer these interventions to their patients. The tuberculin
skin test (based on a delayed type skin hypersensitivity
reaction to tuberculin) has been the most commonly
used test to diagnose latent tuberculosis infection.
However, it has limitations that include specificity,
sensitivity and practical aspects.  New diagnostic tests
for latent tuberculosis infection based on the detection
of interferon gamma that is produced in the presence
of Mycobacterium tuberculosis antigens have been
developed and are now recommended as an alternative
to the tuberculin skin test in the latest iteration of the US
DHHS antiretroviral treatment guidelines. These tests
may be more specific for tuberculosis than the tuberculin
skin test, but the role of these assays in the HIV setting has
not been completely defined. This joint presentation will
highlight the current data that relate to the use of each
test to diagnose latent tuberculosis infection in people
with HIV infection.

Australian Antiretroviral Guidelines: Consensus Conference

Testing for latent TB in HIV patients 
– the new or the old?
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fosamprenavir and lopinavir. Atazanavir uncommonly
is associated with renal stones. Comparative studies
demonstrate differences in the lipid profiles of ritonavirboosted protease inhibitors; a recent meta-analysis
suggested ritonavir-boosted fosamprenavir and lopinavir
were associated with the greatest lipid increases
compared to atazanavir, darunavir, or saquinavir.
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Social Research – Sexual Risk in Space and Time
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HIV/AIDS and Australian Gay Life: A
Generational Overview

Social Research – Sexual Risk
in Space and Time
1.30pm – 3.00pm

Dr Robert Reynolds
National Centre in HIV Social Research

I MET HIM AT THE CANDY STORE:
COMMUNITY ATTITUDES TO SEX ON
PREMISES VENUES AND THEIR PATRONS
Smith A1, Grierson J1, Von Doussa H1
1
La Trobe University, Australian Research Centre in Sex,
Health and Society, Melbourne, Australia
Background: In developing health promotion
interventions for sex on premises venues (SOPVs) it
is critical to understand the place they have in the
communities that access them.
Methods: An anonymous, self-complete questionnaire
was administered to men attending the Midsumma gay
community carnival in 2007. The survey consisted of 21
items assessing participant characteristics and knowledge
and attitudes relating to SOPVs and their patrons.
Results: A total of 287 surveys were returned. Mean age
was 39 years. 50% were in a regular relationship. 51%
had had an HIV test in the previous 12 months and 8%
of the sample was HIV positive. 8% had had an STI in
the previous 12 months. 46% had met a sexual partner
at an SOPV in the 12 months prior to survey. Generally
attitudes indicate little community disapproval of venues
and their patrons. Respondents tended to disagree with
statements that characterise patrons of SOPVs negatively.
There was fairly comprehensive rejection of the premise
that closing venues would reduce HIV/STI infections or
reduce the amount of sex gay men had. When asked to
rate how they might feel telling their gay friends that they
had met a new boyfriend at a number of different places,
men were significantly less comfortable reporting SOPVs
than other settings (including online sites). Generally
SOPV users were more strongly supportive of SOPVs and
demonstrated a more nuanced conceptualisation of
patrons.

We are fast approaching the 30th anniversary of the
emergence of HIV/AIDS in Australia, or, more specifically,
30 years since the first notification of AIDS in Australia
(November 1982). Traditionally, a generation spans 30
years; thus we can now speak historically of a generation
of HIV/AIDS.
This appellation, however, does not adequately do justice
to the ebb and flow of HIV/AIDS over 30 years and its
impact on Australian gay life, including the impact of the
AIDS epidemic on changing formations of gay identity.
HIV social researcher Jeffrey Grierson noticed in the late
1990s three distinct cohorts of gay men: pre-AIDS; PeriAIDS; and Post-AIDS.
I think Grierson’s formulation has stood the test of time,
and in this presentation I want to revisit these three
cohorts. During 2004-7, I conducted a series of in-depth
short life history interviews with a group of men ranging
in age from the mid-50s to the mid-20s. These interviews
were written up in a monograph which traced three
decades of gay life in Sydney. While HIV/AIDS was not
a central pre-occupation of the book, it nevertheless
shadowed the participants’ narratives of self-identity. In
this presentation, through a close reading of some of
these narratives, I hope to show how the AIDS epidemic
has effected the formation of gay identities, and how this
has changed over time.

Conclusions: Understanding what the peers of SOPV
patrons believe about the venues and their customers can
help us to tailor messages that can: address stigmatisation
of users if this is evident; target specific populations
in ‘insider’ language; mobilise patron expectations of
venue standards; suggest approaches that embed SOPV
practice in broader social and sexual practices; or avoid
reinforcing typologies that distance patrons from the
target message.
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Background: Little attention has been paid to the issue of
age in relation to HIV risk behaviour in Australia in recent
years. Since 1996, the average age of new HIV infections
has been increasing and since 2001 HIV prevalence has
declined among younger men, particularly in Sydney.
Methods: The Gay Community Periodic Surveys (GCPS)
are repeated, cross-sectional surveys conducted
using anonymous, self-complete questionnaires with
recruitment at gay community venues, clinics and large
gay community events. Men were asked to report HIV
testing and sexual behaviour. We included 2007 data
from Sydney, Melbourne and Brisbane.
Results: Among men aged over thirty, there was little
difference in terms of behaviours between those aged
in their thirties, those aged in their forties, or above. The
main differences were between those aged under and
above thirty. Men aged over thirty were more likely to
report being in non-monogamous relationships than
their younger counterparts (p<0.001), though these
relationships were of longer duration and the men
were more likely to know their own or their partners’
HIV serostatus (p<0.001). Men aged over thirty reported
sex with a greater number of casual male partners in
the previous six months (p<0.001). Approximately one
quarter of the sample reported engaging in any UAIC in
the previous six months but there was little age difference
in the likelihood to report UAIC. Men aged over thirty
were more likely to engage in group sex.
Conclusion: While age is a consideration in the assessment
of risk of HIV transmission among gay men, this risk is
dependent upon the context in which it occurs: Agemixing may be important in understanding HIV risk
among young gay men. Men aged over thirty appear to
be more sexually active in general and are more likely to
engage in more adventurous sex play such as group sex.

Lee J, Rawstorne P, Worth H
National Centre in HIV Social Research
Issues: In Timor-Leste, various socio-cultural factors such
as political instability and associated violence, mobile
populations and low condom use have all contributed to
the increased HIV vulnerability amongst MSM.
Description: There are no designated venues where MSM
congregate or socialise in Dili, the capital, or indeed the
districts. Whilst a well established social network between
men who identify as being homosexual or MSM (as they
term themselves) does exist in Dili, the sexual networks
between MSM and their sexual partners (or clients as they
are referred to) remain relatively unknown.
The MSM clients are an even more ‘hidden’ group and
represent a highly dynamic population. It is difficult
to quantify the exact number of clients, as each MSM
may have from 2-20 clients. These clients identify as
heterosexual and often have girlfriends or wives. For
the most part, the client appears to hold power in their
relationships with MSM, only performing anal intercourse
in the insertive position, and get rewarded by MSM for
sexual services. Usually these rewards take the form of a
monetary payment or goods such as mobile phone cards.
This information was elicited during a mapping exercise
as part of a larger behavioural surveillance survey.

Social Research – Sexual Risk in Space and Time

Garrett Prestage,1 Susan Kippax,2 Fengyi Jin,1 Andrew
Frankland,2 John Imrie,2 Andrew Grulich,1 and Iryna
Zablotska2
1
National Centre in HIV Epidemiology & Clinical Research,
UNSW; 2National Centre in HIV Social Research, UNSW.

SEX BETWEEN MEN IN TIMOR-LESTE: WHAT
DOES IT MEAN?

Lessons learned: Little is known about the clients of MSM,
yet they represent a potential link for HIV transmission from
a more-at-risk group (MSM) to the general population. In
addition, this is a group that is not well serviced by health
promotion, largely as the practices of this group are
clandestine and are yet to be documented.
Next steps: Utilising the findings of this research, health
promotions can be designed and tailored to meet the
specific needs of this hidden population. In addition, a
greater understanding of the social and sexual dynamics
of MSM and their clients will inform policies and
programmes addressing HIV in Timor-Leste.
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‘1 msg then sex’: Temporality,
spatiality, safety and risk in gay and 
bisexual men’s accounts of online 
sex-seeking
Holt, M1
1
National Centre in HIV Social Research, The University of
New South Wales, Sydney, New South Wales, Australia.
Online sex-seeking by gay and bisexual men has often
been characterised as a cause for concern. The use
of gay chat sites that facilitate the advertising of and
search for sex partners is seen as a highly efficient way
for men to find each other. Speed or efficiency, together
with the abundance of potential partners and relative
anonymity have been seen as factors that could drive
unsafe sexual activity or HIV transmission (although direct
links between internet use and unsafe practice are rarely
demonstrated). What are often missing in discussions of
men’s online sex-seeking are the accounts of gay and
bisexual men themselves. How do men characterise their
online practice and the ways in which they search for and
meet partners? Do these accounts trouble narratives of
risk and online practice?
The e-male survey of Australian gay, bisexual and samesex-attracted men provided an opportunity to consider
these issues. While the majority of participants received a
quantitative survey, 491 men (10% of eligible participants)
were directed to a small set of open-ended questions,
including an item about men’s most recent experience
of online sex-seeking. Analysis of this item indicates that
men employ a variety of temporal and spatial strategies
when looking for partners online, and that accounts of
safety, care and deliberation are more common than
those of risk or abandon. While many men’s accounts
spoke to the speed and efficiency of online sex-seeking
(e.g. ‘1 msg then sex’), many others referred to the space
of the internet as territory where they could get to know
partners before meeting them offline. Intervals of days or
weeks between first online contact and meeting face-toface were not uncommon.
Participants’ accounts also indicated, as expected, that
most men continue to seek and practice safe sex with
their online partners. Quickly arranged encounters
did not always feature anal sex, and men pointed out
that in these situations HIV disclosure was unlikely or
unnecessary. Most accounts of anal sex emphasised the
use of condoms; unprotected anal intercourse was rare
and usually negotiated. These accounts suggest that the
majority of men’s sexual encounters initiated online are
safe, pleasurable and feature planning or deliberation.
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EDUCATION SESSIONS SUPPORT
ADHERENCE AND IMPROVE CLINICAL
OUTCOME, HEDURU CLINIC PORT MORESBY,
PNG.

Conclusion Nurse delivered culturally appropriate
education sessions are associated with reduced loss to
follow-up amongst HIV patients at Heduru. The inclusion
of volunteer patient educators has a marked impact on
sessions, encouraging open discussion and reassurance
concerning outcome of ART.

International: PNG

International: PNG
1.30pm – 3.00pm

Sawiya, G.; Ragagalo, O.; Nauna. T.; Nano, G; Tau,G.
Heduru Clinic, Port Moresby General Hospital, Port
Moresby, PNG.
Background. Adherence to antiretroviral therapy (>95%)
predicts HIV outcome. Individual understandings of HIV/
treatments, practical supports to adherence are factors
predicting adherence in PLWHA. From 2004 (start of ART
at Heduru) culturally appropriate group HIV education
sessions on antiretroviral therapy, factors supporting
adherence and problem solving for individuals on
treatment have been delivered weekly.
Aim: To describe the development, delivery and evolution
of education sessions at Heduru and to examine the
influence of attendance at education sessions on
outcome.
Results: All patients are invited to attend at least one
of weekly presentations on: HIV/AIDS, how ART work,
taking ART; when, how and what to expect, side effects
management, ARV resistance prevention, adherence
(how and why) and health maintenance (nutrition, safe
sex, safe water, safe parenthood, influence of religion),
follow-up and review protocols.
The program has evolved including encouragement
of patient treatment partners to attend (late 2004),
incorporation in practical National Prescribers Training
Programs (2005), inclusion of expert patient trainers
(2006), development of flip charts and modification for
beginning staff members (2007).
Education Session Attendance

HAART (n) Participants(n)

Non
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New registrations(n)

participants(n)

2005

238

199

141

58

2006

330

269

320

10

2007

489

387

233

154

Of 231 individuals attending first assessment/registration
January to June 2007, 205 (88%) attended a group
education session; of 177 individuals commencing ART 94
(53%) attended education sessions. The attendees did not
differ from non-attendees by gender, age, marital status
or baseline WHO clinical stage or performance grade.
Although 11% have died in each group the proportion
lost to follow-up at one year was 12 (13%) amongst the
attendees compared to 22 (26%) in those not attending
education session.
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HIV/AIDS awareness and ACCESS TO
ANTERETROVIRAL THERAPY (ART) MAKES
A DIFFERENCE IN PEOPLE’S LIVES IN
SOUTHERN HIGHLANDS, PNG
Rondopali, Sr Rose John, Gaudentia Sr. HIV/AIDS Office,
Diocese of Mendi, SHP, PNG.
Introduction: Southern Highlands Province (SHP) is
situated in the interior of mainland PNG. It is divided into
eight districts where remoteness, lack of infrastructure
and disparate languages as well as cultural differences
make response to the increasing burden of HIV/AIDS a
substantial challenge.
Aim: To describe the development of the Mendi
Catholic HIV/AIDS diocesan network. This aims to ensure
PLWHA live positively, supported without stigma and
discrimination to access treatment and care within local
communities in a context of respect and love.
Methods: A regional approach based on a network of
parishes will be demonstrated. Activities involved will
be detailed; establishment of parish HIV Committees,
community awareness programme, implementation
of a system of PLWHA follow-up and family education
and supports within local parishes and ART clinic
establishment.
Results: SHP Catholic HIV/AIDS programme has been
based in remote areas where Government services do
not reach. During 2006, 2007 and to February 2008 the
Mendi clinical service has provided voluntary counseling
and testing to 1806 individuals 173 (9.6%) diagnosed
with HIV infection. ART has become available and fortysix individuals are receiving treatment and eight-seven
cotrimoxazole prophylaxis and general care. Antenatal
Provider Initiated HIV Counseling and Testing (PICT)
has been provided to more than 2000 women and
PMTCT have been provided where required (6 women).
Availability of ART and care has resulted in individuals
attending for diagnosis and treatment and the associated
obvious health benefits (return to families and work,
ability to tend gardens to sustain themselves and their
families, acceptance into the community activities
including school and church).
Conclusions: A decentralized model of HIV/AIDS care
and follow-up is being established within the network
of Catholic parishes in Southern Highlands. The lessons
learnt from our training, awareness, networking and
clinical/follow-up activities within the responsible
parishes is the basis for further human rights based
service development.
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LIFE COACHING – MISSION NOT IMPOSSIBLE
Martinez Cipri
Positive Services Department Western Australian AIDS
Council
Since the uptake of Highly Active Antiretroviral Therapy
(HAART) in the mid nineties, the health prospects of
People Living with HIV (PLWHA) in Australia has become,
and continues to be, increasingly positive. Whilst this has
improved their health status and survival overall, some
have not necessarily enjoyed an improvement in their
quality of life, particularly those who were diagnosed
prior to the availability of HAART.
Many of this group of people have found it difficult to
move forward and therefore remain on disability support
pensions, feeling isolated and lacking motivation. They
are unable to see anything positive in their future and
continue to have a perception of their illness that is not
matched with their clinical results. In other words, their HIV
is under control on paper, and yet some PLWHAs continue
to live with a perception that they don’t have a future.
In response to this issue, in 2007 the Western Australian
AIDS Council (WAAC) introduced the Life Coaching
project. The aim of the project is to assist PLWHA to
improve their quality of life through carefully identifying
their values, beliefs and goals with the aim of achieving
their personal vision. Since the introduction of the Life
Coaching project, 14 WAAC staff have been trained or
are in the process of being trained as Life Coaches, with 6
staff currently having clients.

HIV POSTIVE SPEAKERS BUREAUX 
– A MODEL FOR SUSTAINABILITY AND
RELEVANCE IN 2008 AND BEYOND
Niggl MR
People Living with HIV/AIDS Victoria Inc, Melbourne, VIC,
Australia
The People Living with HIV/AIDS Victoria (PLWHA
Victoria) HIV Positive Speakers Bureau is recognised for its
management, training and expertise in delivering talks
about the realities of living with HIV in the 21st century
contributing to reducing HIV stigma and discrimination
in the wider community. The Bureau has developed
a highly successful and sustainable model that strives
for excellence and consistently delivers talks to more
than 3500 Victorians per year. The visibility of Victorian
HIV Positive speakers adheres to the UNAIDS Greater
Involvement of People Living with HIV/AIDS (GIPA)
Principle and The Ottawa Charter of Health Promotion.
In other Australian States, Speakers Bureaux have had
limited success. This paper will illustrate how Victoria
developed a sustainable model that is still relevant in
2008. Management methods of funding, recruitment,
induction, training, administration will be illustrated. Key
factors of retention and support for speakers from diverse
backgrounds will be outlined.
A hallmark of Victoria’s success is the speaker’s
professionalism and with that professionalism comes a
recognition that we need to move to sophisticated social
marketing to attract different audiences and remain
relevant. An overview of the Victorian Bureau’s innovative
new campaign will emphasise it’s future sustainability
and credibility.
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Since the project started, 21 PLWHAs (16 males and 5
females) expressed an interest in engaging with the life
coaching process. Two thirds (14 people) were assessed
as being suitable for coaching (9 identifying as gay, 4 as
heterosexual and 1 as bisexual) and were allocated to
coaches. Since the project began 4 people have ceased
coaching for various reasons. Of the ten currently being
coached, their commencement ranged from October
2006 to January 2008.
This presentation will provide an overview of what Life
Coaching is, how the model works and what it has to
offer PLWHA. The expected and unexpected benefits
for PLWHA and staff, including how it complements
other strategies such as therapeutic counselling will be
discussed.
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TREATMENT QUESTIONS? ANSWERS BY
INTERNET AND SMS IN INDONESIA

THE TREATAWARE INFOLINE A NATIONAL
HIV TREATMENT HEALTH PROMOTION
SERVICE FOR PEOPLE LIVING WITH HIV

Green C1
1
Spiritia Foundation, Jakarta
Antiretroviral therapy (ART) has been provided free-ofcharge to people living with HIV (PLHIV) in Indonesia who
meet the WHO criteria since late 2004. There are now some
6,000 people on ART, provided through some 200 AIDS
referral hospitals. Thus each hospital has on average 30
patients on ART, but the number is much lower in many.
Although each hospital has at least one doctor trained to
manage ART, many of these have very little experience,
and little time to spend educating themselves. For similar
reasons, doctors can rarely spend more than ten minutes
with any patient.
As a result, PLHIV frequently have unanswered questions
about their therapy. The Spiritia Foundation (the national
peer support for PLHIV) has responded to this challenge
in two ways. First, by training members of peer support
groups as treatment educators. But five days training
cannot provide answers to all these questions, and the
group educators often feel reluctant to train their peers,
fearful of difficult questions.
To address this, Spiritia offers two Q&A services. The first
allows anonymous submission of treatment questions
to our web site, where they are usually answered within
36 hours. This is supplemented by a mobile phone SMS
service, where we attempt to answer more swiftly, usually
within one hour.
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While Internet access is still not universal, Internet cafes
are widely available and relatively cheap, so many
PLHIV can use this service, while also browsing the
Spiritia site for information. But mobile phone service is
almost ubiquitous in Indonesia, and SMS messages are
relatively cheap, offering an alternative for the internetchallenged.

DeMaere K1, Whittaker B1
1
National Association of People Living with HIV/AIDS
(NAPWA), Sydney, NSW, Australia
Increased scientific knowledge and the continuing
development of better antiretroviral treatments have
significantly changed the outlook for many Australians
living with HIV today. The goal of maximizing health
and wellbeing of people with HIV over the long-term is
assisted by a strong doctor/patient partnership in health
planning. To support this partnership, people with
HIV need reliable and accessible treatment and health
information sources to inform health decision making.
In mid 2008 the National Association of People Living with
HIV/AIDS (NAPWA) launched a suite of health promotion
initiatives under the banner of Treataware. This paper will
focus on the Treataware infoline project, a communitybased service which provides a central place for people
with HIV to obtain information about treatments, health
planning and health issues. The Treataware infoline is also
designed as a useful referral point for doctors and other
health professionals.
The Treataware infoline offers a free, confidential,
national telephone information service to HIV positive
people. Callers are able to discuss treatment, care,
health and research issues with trained HIV treatment
educators.
This paper will present the preliminary results of the
Treataware infoline; provide an overview of promotional
activities for the service; describe training, monitoring and
evaluation arrangements; and highlight future directions
for this community-based initiative.

We now answer an average of more than two questions
every day on the web site, plus as many as 4-5 via SMS.
If the SMS question is complex, we offer to call back to
discuss the matter in more detail.
The main challenge is that there is no equivalent service
for the ‘worried well’, so some 30% of the questions are of
the ‘am I infected?’ type.
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Triffitt, K A , Flanagan,G, Santana H
Positive Life NSW, Sydney, Australia
Research has identified people living longer with HIV as
a priority group in terms of future needs for both clinical
services and care. The psychosocial impacts of living longer
with HIV are only now starting to become clearer through
research, clinical outcomes and community consultation.
Those living longer with HIV are a diverse group. While
many have put their lives on hold, others have made
significant career choices. Both of these situations are not
static and can change, sometimes rapidly, in a variety of
ways. Daily living for many people with HIV also includes
interactions between ageing, long-term psychosocial
and clinical experience of treatments, and the long-term
impact of the virus itself.
Responding to the needs of people living longer with
HIV, Positive Life NSW has developed work in the areas
of social marketing, peer support, systemic advocacy
and health education. These different areas all combine
to enhance skills, reorient services and create supportive
environments. This paper will report on policy work,
focus and group discussions, individual interviews
and community forums. By incorporating and sharing
personal strategies for change and enhancing quality
of life, this work promotes the development of capacity
at both policy and community level to negotiate the
challenges of living longer with HIV.
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The pattern of HIV infection among culturally and
linguistically diverse (CALD) communities in Australia
largely reflects prevalence rates in countries-of-origin. In
2002-2006, people born overseas accounted for about
31% of new HIV diagnosis in Australia. Of these people
born in Sub-Saharan Africa accounted for up to 18%.
In 2007, the Multicultural HIV/AIDS and Hepatitis C Service
(MHAHS) implemented a one year project targeted at the
African communities to build their capacity in relation to
HIV/AIDS issues including safe sex practices and living
with HIV/AIDS.
The paper mainly discusses the use of theatre and dance
as a creative intervention, designed to raise HIV/AIDS
awareness and knowledge. It details the process and
steps undertaken to involve the African community
members in the script writing and the performance of
the “African Dance and Theatre Drama”.
The paper also describes the community development
frame work adoted to mobilise community members
in the development and the implementation of a major
community event around such a sensitive issue.

GETTING ON WITH IT AGAIN - responding 
to the needs of people living longer 
with HIV
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DANCE, THEATRE DRAMA, HIV/AIDS & THE
AFRICAN COMMUNITIES IN SYDNEY
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ELEVATED LEVELS OF INTERLEUKIN-6
AND D-DIMER ARE ASSOCIATED WITH AN
INCREASED RISK OF DEATH IN PATIENTS
WITH HIV
Drummond FM1, Hoy J1, 2, Emery S1, Cooper DA1 and the
SMART Study Group
1
National Centre in HIV Epidemiology and Clinical
Research, University of NSW, Sydney, NSW, Australia;
2
Infectious Diseases Unit, Alfred Hospital and Department
of Medicine Monash University, Melbourne, VIC, Australia
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In SMART, CD4-guided intermittent antiretroviral
therapy (ART) as compared to continuous ART resulted
in an increased risk of cardiovascular disease (CVD) and
of all-cause mortality, the latter primarily due to nonAIDS causes. To explore reasons for these increased
risks, we evaluated four inflammatory (high sensitivityC reactive protein [hsCRP], interleukin-6 [IL6], amyloid
A and amyloid P) and two coagulation (D-dimer and
prothrombin fragment 1+2 [F1.2]) markers that have high
laboratory and biological reproducibility and that have
been associated with mortality and CVD in the general
population.
Patients with CD4+ count >350 cells/mm3 were
randomised to viral suppression (VS, continuous ART
n=2752) or to drug conservation (DC, CD4-guided
intermittent ART, n=2720). To assess the short-term effect
of intermittent ART on the biomarkers, stored plasma
samples at baseline and Month 1 after randomisation
for a random set of DC (N=249) and VS (N=250) patients
were analysed. In addition, a nested case control study
was carried out in which two controls were matched (age,
gender, country, date of randomisation) to each death
(N=85) and case of CVD (N=136). Adjusted odds ratios
(OR) for the 4th versus the 1st quartile for each biomarker
at baseline were estimated using logistic regression.
IL6 and D-dimer levels increased by 30% and 16%,
respectively, one month after randomisation in the DC
group and changed little in the VS group (5% and 0%)
(p<0.0001 for treatment difference in each biomarker).
For DC patients, increases in IL6 and D-dimer after one
month were related in a graded manner to the increases
in HIV RNA at month 1 (p<0.0001 for each biomarker).
IL6 and D-dimer determined at baseline were strongly
related to mortality with ORs greater than 12 for those
in the 4th versus 1st quartile. Associations with CVD were
more modest and were significant for IL6 and amyloid P.
Associations of baseline levels of the biomarkers with allcause mortality and with CVD were similar for DC and VS
patients.
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ART interruption results in significant increases in IL6 and
D-dimer. Elevated levels of D-dimer and IL6 identify a
sub-group of HIV-infected patients at high risk of death in
both treatment groups. Increases in IL6 and D-dimer may
explain, in part, the increased risk of mortality and CVD in
the DC group.

CARDIOVASCULAR DISEASE (CVD) RISK IN
THE STEAL STUDY COHORT
Bloch M1, Hoy J2, Woolley I3, Hounsfield V4, Humphries A5,
Amin J5 on behalf of the STEAL investigators
1
Holdsworth House Medical Practice Darlinghurst NSW
Australia; 2The Alfred Hospital Melbourne VIC Australia;
3
Monash Medical Centre Clayton VIC Australia; 4Royal
North Shore Hospital St Leonards NSW Australia; 5NCHECR
UNSW Darlinghurst NSW Australia.
Combination antiretroviral therapy (cART) has increased
survival in HIV patients and shifted attention to broader
health issues including cardiovascular disease (CVD) risk.
HIV itself, as well as cART toxicity may increase CVD risk.
In the STEAL study, 360 participants were randomised 1:1
to receive fixed-dose abacavir-lamivudine or tenofoviremtricitabine. On entry, all participants had HIV-1
infection, were on stable cART with plasma RNA <50
copies/ml for at least 3 months. Our aim was to assess
baseline CVD risk in the STEAL study and compare it to
other Australian cohorts.
All subjects enrolled in the STEAL study were assessed
for individual CVD risk factors including age, gender,
smoking status, fasting total and HDL cholesterol, blood
pressure (at baseline or up to 3 months prior), personal
history of diabetes, hypertension and CVD. Framingham
10-year risk was calculated for those participants with all
required data (n=272).
The STEAL cohort were 98% male, aged 45±9 years, had
a mean systolic BP of 125±14mmHg, and diastolic of
BP 78±10mmHg, total cholesterol 5.3±1.2mmol/L, and
HDL cholesterol 1.3±0.4mmol/L. 96% had no history of
diabetes, and 35% were current smokers. The average 10
year CVD risk was 8±6%, with 68% in the low risk category
(<10%); 28% in the moderate risk category (10-20%);
and 3% in the high risk category (>20%). These results
compare favourably with other published HIV cohort data
but are lower than in Australian population based studies
(approximately 12-14% CVD risk). It has been previously
noted by the D:A:D Study Group, that the Framingham
equation underestimates observed CVD risk in an HIV
population.
At the commencement of the STEAL study the cohort
was representative of an Australian HIV cohort with a 10
year CVD risk slightly lower then that reported in a nonHIV Australian cohort.

17-20 september 2008 @ Perth Convention Centre, Western Australia

Carey DL1, Baker D2, Petoumenos K1, Chuah J3, Rogers
G4, Watson J5, Cooper DA1,6, Emery S1, and Carr A6, for
the FLASH Investigators
1. NCHECR/UNSW, Sydney, NSW, Australia
2. 407 Doctors, Sydney, NSW, Australia
3. Gold Coast Sexual Health Clinic, Miami, QLD, Australia
4. Griffith University, Gold Coast, QLD, Australia
5. National Association of People living with HIV/AIDS,
Sydney, NSW, Australia
6. St Vincent’s Hospital, Sydney, NSW, Australia

Delaying PLA treatment by 24 weeks did not impact
change in FSTV or tissue depth in injection planes. FSTV
and soft tissue thickness were higher at week 48 than at
week 24 in early PLA recipients suggesting that the PLA
treatment effect was durable. PLA was safe and welltolerated over 48 weeks.

Clinical – Toxicity

POLY-L-LACTIC ACID FOR HIV-1 FACIAL
LIPOATROPHY: 48-WEEK FOLLOW-UP

Oral Posters:
Knox D - see page
Mackie K- see page
Hooker D - see page
Russell D - see page

Poly-L-lactic acid (PLA) injections modestly increase
objectively assessed facial thickness but not facial volume.
We report the impact of a 24-week delay in PLA injections
on efficacy, safety and quality of life. Longer term efficacy,
safety and durability were also evaluated.
HIV+, lipoatrophic adults were randomised to 4 openlabel PLA treatments administered every two weeks
from week 0 (immediate group, n=50) or after week 24
(deferred group, n=50). Endpoints included facial soft
tissue volume (FSTV) assessed by volumetric computed
tomography, facial lipoatrophy severity, quality-of-life,
and safety. Analyses were by intention-to-treat.
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PLA treatment adherence was 98%. At 48 weeks, mean
change in FSTV was 14 (95% confidence interval [CI] –1 to
29) cm3 in the immediate group and 18 (95% CI 5 to 30)
cm3 in the deferred group (between-group difference, –
34[95% CI –22, 16] cm3; p=0.71). These represent changes
of 4% and 5% respectively (between-group difference,
–1%; p= 0.66). There was no significant between-group
difference for changes in tissue depth in injection planes
(base of nasal septum p=0.44; and maxilla p=0.22). Viral
load, CD4+ cell count, antiretroviral adherence, patient
and physician-assessed facial lipoatrophy severity, and
Multidimensional Body-Self Relations QuestionnaireAppearance Scales (MBSRQ-AS) scores did not differ
significantly. The Short Form (SF)-36 Health Surveyassessed mental health score was significantly higher in
the immediate group than the deferred group (5.2 and –
3.7 respectively; p=0.027). Soft tissue thickness in injection
planes increased modestly between weeks 24 and 48 in
early PLA recipients. At week 48, mean change in FSTV
was 14 (95% CI –1 to 29) cm3 (p=0.06) in immediate
group participants and increases in tissue thickness were
observed in both injection planes (p<0.0001). Median
duration of treatment-related adverse events was 2
(interquartile range: 1-3) days.
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IMPACT OF A NON-OCCUPATIONAL POSTEXPOSURE PROPHYLAXIS PROGRAM FOR
HIV IN WESTERN AUSTRALIA
Laing SC1, Dykstra CA2, Marshall LJ3, McCloskey JC2,
Langdon P4, Brown G5 and Mak DB1

that they receive appropriate referrals from the phone
line and available data indicates that the proportion of
patients receiving NPEP who met the recommended
guidelines has increased from 50% (n = 34) during the
period May 2002 - April 2003 to 96.7% (n = 30) during the
period May 2006 - April 2007.
Initial concerns that a campaign might encourage
inappropriate and over use of NPEP have not been
realized.

Communicable Disease Control Directorate, Department
of Health WA, Perth, WA, Australia, 2Sexual Health Service,
Royal Perth Hospital, Perth WA, Australia, 3Infectious
Diseases Department, Fremantle Hospital, Fremantle,
WA, Australia, 4WA AIDS Council, Perth, WA, Australia, 5WA
Centre for Health Promotion Research, Curtin University
of Technology, Perth, WA, Australia.
1

Since late 2001, the Department of Health (DOH) has
monitored provision of non-occupational post-exposure
prophylaxis (NPEP) for HIV in WA. Up to 31 December
2007, 214 cases received NPEP.
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Gay Community Periodic Surveys (2002 and 2004)
showed that the Perth community awareness of NPEP
availability was low.
In May 2005, the DOH and the WA AIDS Council
commenced a targeted campaign to raise awareness of
NPEP availability and to increase the level of appropriate
treatment. The campaign is aimed at health care providers
and people at high risk of HIV infection - men who have sex
with men, people in sero-discordant relationships, people
living with HIV/AIDS, people who inject drugs and people
who have been sexually assaulted or had unsafe sex with
a person known to have HIV, or to be strongly suspected
of being HIV-positive. Strategies have included resource
development and distribution (pamphlets, fact sheets,
posters, press advertisements in gay press and banner
advertisements on Gaydar), establishment of a 1300
phone line to triage cases, and provision of information
for health care providers.
Since the campaign commenced, awareness of NPEP has
increased. In 2006, a significantly higher percentage of
Perth Gay Community Periodic Survey respondents was
aware that NPEP was readily available compared to the
two previous surveys (18.5% [2002], 26% [2004], 48.2%
[2006], χ2 test for trend, p<.001 for both).
The average number of cases receiving NPEP per year
increased by 16.6% since the campaign commenced (34.3
cases per year, May 2002 - April 2005; 40 cases per year,
May 2005 - April 2007). Evidence from clinicians indicates
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NON-OCCUPATIONAL POST EXPOSURE
PROPHYLAXIS AGAINST HIV (NPEP)
AND SUBSEQUENT HIV INFECTION IN
HOMOSEXUAL MEN: FINAL DATA FROM THE
HIM COHORT

Kaye MB1,2, Chibo D1 & Birch CJ1,2.
1
HIV Characterisation Laboratory, Victorian Infectious
Diseases Reference Laboratory, Melbourne, VIC, Australia.
2
Microbiology Department, Monash University,
Melbourne, VIC, Australia.

Poynten IM1; Jin FY1; Prestage G1; Mao L2; Kippax S2; Kaldor
J1; Grulich AE1
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, Australia; 2National Centre in
HIV Social Research, UNSW, Sydney, Australia

A total of 376 patients (369 males, 7 females) infected with
HIV-1 subtype B between 1996 and 2006 were investigated
based on conclusive serological evidence that they had
become infected within the preceding 12 months. All
patient information was de-linked prior to undertaking
the analysis. Phylogenetic analysis was performed on
1035-nucleotide (nt) HIV-1 pol sequences initially using
distance-based methods. Monophyletic clusters were
confirmed using Bayesian methods. Virological links
were regarded as likely based on bootstrap values of
greater than 90%, intra-cluster average genetic distances
of less than 0.03nt substitutions per site and posterior
probabilities of 1.0.
Phylogenetic analysis identified 54 transmission clusters
involving 226 (60%) newly infected patients. Although 41
clusters included linkages between only 2 to 4 individuals,
13 clusters involved 5 or more individuals and accounted
for 113 (30%) PHIs. The largest cluster included related
viral sequences from 22 individuals infected over a period
spanning 8 years. Other clusters linked 14, 12 (n=2) and 8
(n=2) individuals with a maximum period of transmission
within clusters spanning 9 years. Within these large
clusters groupings of 3 or more individuals who had been
infected within a period of 12 months were frequently
observed.
This study demonstrated the existence of several large
clusters of patients infected with related viral strains
many of which were transmitted within restricted time
frames. This suggests transmission of HIV to multiple
recipients contributes to the number of new infections in
Melbourne and that onward transmission of HIV during
early stages of infection is a factor in the continuing
epidemic. Phylogenetic surveillance of HIV transmission
within the local population provides the opportunity to
identify sources of multiple transmissions and carry out
targeted education programs aimed at reducing the
number of new infections.

Non-occupational post exposure prophylaxis (NPEP)
as a means of HIV prevention has yet to be established
globally. In Australia, guidelines recommending the use
of NPEP were first released in New South Wales in 1998.
NPEP is now available in most states.
In a community-based cohort of HIV negative homosexual
men, the Health in Men (HIM) study, we aimed to
determine the awareness of availability of NPEP; the
frequency and predictors of use of NPEP at baseline and
during the study and the incidence of HIV seroconversion
in NPEP users. Annually, men were asked questions about
NPEP, tested for HIV and detailed quantitative data on
unprotected anal intercourse (UAI) were collected. NPEP
awareness, use and predictors of use at baseline were
analysed using logistic regression. Cox regression models
examined incident NPEP use, HIV seroconversion and
time trends in NPEP use.
1,427 participants were enrolled. Final HIM interviews were
completed in July 2007. At baseline, 78.5% of participants
were aware of NPEP and 6.3% reported previous use of
NPEP. By the fifth annual interview, 97.4% of participants
had heard of NPEP.
During follow up, NPEP use increased significantly from
1.7/100PY in 2002 to 9.9/100PY in 2006 (p < 0.001).
Previous use of NPEP at baseline was associated with UAI
in the past 6 months with casual partners (p < 0.001),
and UAI with partners of unknown or positive HIV status
(p < 0.001). UAI was a strong predictor of use of NPEP
during the study. Use approached 25/100 PY in men who
reported receptive UAI with casual partners if ejaculation
occurred and exceeded it if the partner was known to be
HIV positive. By the end of 2006, 49 HIV seroconversions
were identified (HIV incidence 0.80 per 100 PY (95% CI
0.60-1.060)). Men who received NPEP had a significantly
higher rate of HIV seroconversion during the study
period.
NPEP use is increasing. Awareness of NPEP among
HIM participants was almost universal. Use seemed
appropriate, with many men reporting highest risk
behaviours also reporting NPEP use. In this setting, men
who received NPEP were at higher risk of subsequent HIV
infection.
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Primary HIV infection (PHI) and its association with elevated
viral load is thought to be a critical period for onward
transmission of the virus, particularly if the individuals
concerned are unaware of their HIV-positive status. To
determine whether such transmission contributes to the
rates of infection observed in Melbourne, phylogenetics
was utilised to investigate virological links amongst newly
HIV-infected patients.

Network Sex

EXTENSIVE TRANSMISSION LINKS
AMONGST NEWLY HIV-INFECTED PATIENTS
CONTRIBUTE SIGNIFICANTLY TO THE
INCIDENCE OF HIV-1 INFECTION IN
MELBOURNE.
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Network Sex

‘SEX IN OTHER CITIES’ – RESPONDING TO
INCREASES IN OVERSEAS ACQUIRED HIV
DIAGNOSES IN WA

NORTH QUEENSLAND TRAVELLERS
PROJECT: HETEROSEXUAL HIV CLUSTER

Langdon PA
Western Australian AIDS Council Inc, West Perth, WA,
Australia.
Over the past three years, there has been a dramatic
increase in the number of new HIV diagnoses amongst
WA men acquiring HIV overseas. New diagnoses
amongst heterosexual men increased by 212%, (50 in
2005-2007 compared with 16 in 2002-2004) and by 42%
amongst homosexual men (20 in 2005-2007 compared
with 14 in 2002-2004). In the same period, the number
of heterosexual and homosexual men acquiring HIV in
Australia remained stable.
Western Australia is currently experiencing an
unprecedented resources boom with commensurate
labour demands, including for temporary 457 visa
holders. The resource industry labour market is structured
around fly in fly out workers, which impacts on personal
relationships and the capacity for service delivery within
community settings. Overseas travel for work and leisure
in nearby high prevalence countries is higher amongst
Western Australians compared with other Australians.
These factors combined with poor population health
infrastructure, in rural and remote WA and high endemic
rates of STIs in some regions means there is potential
downstream vulnerability for local populations,
particularly women and Aboriginal people.
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The WA AIDS Council (WAAC) has planned an integrated
community response to this issue with the aims of
minimising the number of people acquiring HIV overseas
and preventing onward HIV transmission in Australia. The
strategies are aimed at a population level rather than an
individual level, including advocacy for specific policy
development. Tailored research and surveillance is also in
the pipeline which will inform future service delivery.
WAAC is building partnerships with governments,
resource companies and occupational medicine
companies with the aim of providing information, training
and development for professionals. Targeted social
marketing is aimed at work and leisure travellers using
in-flight magazines, mining publications, travel industry
publications and community newspapers. A new website
www.sexinothercities.com.au has been developed and
has applicability for travellers from Australian states and
territories.
Targeting people acquiring HIV outside Australia is
complex. Vulnerable men do not necessarily belong
to any specific community or groups and are not easily
accessible. New strategies and different partners are
required to respond to this growing phenomenon.
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Harper RE1, Russell D2,3, O’Mullan C3
1
Family Planning Queensland, Cairns, QLD, Australia;
2
The University of Melbourne, Melbourne, VIC, Australia; 3
Cairns Sexual Health Service, Cairns, QLD, Australia
Heterosexual men travelling to Papua New Guinea for
employment purposes have been identified as a small,
but significant population at risk of HIV transmission. They
are also under-represented in service statistics, and less
likely to identify themselves as at risk.
In 2007 5/26 of all new HIV diagnoses in Cairns were
acquired by heterosexual males reporting sexual contact
in Papua New Guinea, an increase from 1/16 cases
acquired by this group in high prevalence countries in
2006.
This spike follows similar national trends, with the
Northern Territory and Western Australia also recording
significant increases in diagnoses acquired in high
prevalence countries. The Far Northern cluster, however,
has described a unique demographic. The males are all
heterosexual, aged between 47-66, and based in Cairns
and/or PNG locations. Three out of the 6 males also had
a female partner living in Cairns – these women have all
tested negative for HIV infection.
In response to this cluster, Queensland Health has
funded Family Planning Queensland to implement
a social marketing campaign advocating safer sex
practices amongst those travelling between Cairns and
neighbouring high prevalence countries, with a particular
focus on Papua New Guinea. The campaign will measure
awareness of risk of STI and HIV transmission among the
target group, awareness of preventive strategies and
testing options, and the uptake of testing and treatment
services in the Cairns district among the target group.
This target group poses significant difficulties in health
promotion. Uptake of information provided through
brochures, convenience advertising and in-flight
magazines depends on the target group reading and
remembering this information. Men in this target group
may not be interested in reading these resources.
Increased knowledge, awareness of risk and even
increased intention to use condoms may not be
sufficient to influence behaviour change. Cultural and
environmental factors (e.g., being unable to easily acquire
suitable condoms at the destination, engaging in sexual
activity spontaneously or while intoxicated, engaging in
surreptitious sexual activity to conceal the fact from his
regular partner) may mitigate against men in the target
group from adopting preventive measures, despite
increases in knowledge.
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A Kamarulzaman
University of Malaya. Kuala Lumpur.
In many parts of Asia, HIV epidemics have been largely
driven by injection drug use, and transmission among
sex workers and their clients. HIV rates of greater than
20% among injecting drug users have been recorded in
many countries, including Indonesia, Malaysia, Myanmar,
Thailand, and Vietnam. In response to the escalating
epidemics, several countries in the region have embarked
on harm reduction efforts but in many instances these
responses have come somewhat too little and too late.
Despite recent global initiatives that have increased the
number of people receiving antiretroviral therapy in the
region by almost threefold, injecting drug users remain
disproportionately less likely to have access to these
medications. Some of the major obstacles to access to
antiretrovirals for injecting drug users include legal policies
surrounding drug use, inadequate health infrastructure,
cost, and pervasive stigma and discrimination, which
hinder drug users from coming forward for treatment.
In some countries, where access to antiretrovirals in the
community has increased, continued criminalisation of
drug users has led to periods of treatment interruption for
HIV-positive IDUs when they are imprisoned. This raises
the risk for development of antiretroviral resistance.
In Asia, an inadequate health infrastructure and lack of
healthcare workers with the relevant skills and training
to provide treatment are major obstacles to access to
antiretrovirals, particularly for injecting drug users. The
complexity of managing HIV infected drug users, who
often present with multiple medical problems, makes it
crucial that health professionals are adequately trained.
High rates of co-infection with hepatitis C and tuberculosis
increase the risk for antiretroviral-associated toxicities as
well as complex drug-drug interactions.
Integrated treatment for substance abuse, general medical
care, HIV and psychiatric treatment and psychosocial
support in non-traditional health care settings such as
hospitals and clinics is a model of care that should be
examined and extensively developed in the region. Finally,
scaling up antiretroviral and opiate substitution treatment
must be accompanied by a commitment to improve
social support services, in order to help integrate people
back into society, with their families, and into job training
and placements. Building the capacity of health care
professionals alone will not be adequate. Peer support,
peer-based treatment education, patient advocacy,
case management and social services are other crucial
services that must be developed for a comprehensive
and successful management of HIV infected drug users.

Dr Vannda Kab
Korsang
In Cambodia, illicit drug use has increased dramatically in
the past eight years. The injecting drug use level appears
to be small but increasing. Amphetamine (yama) appears
to be the most widely used illicit drug (with regard to HIV
transmission).
Concern about illicit drug use is increasing in the country
because there is a possible link between such illicit drug
use (yama, glue) with increased sexual risk/transmission
of HIV and other sexually transmitted infections (STIs),
and yama use has been found among the above highly
vulnerable groups.We have observed that among the
vulnerable population there also has been an increase
in heroin injecting, while the yama users have switched
from smoking yama to smoking heroin and then injecting
heroin.

International: Harm Reduction in Asia

Harm Reduction in Asia – A Clinician’s 
Perspective

RISK LIFESYLES OF DRUG USERS IN PHNOM
PENH, CAMBODIA

The injection related infections have been considerably
high among the injecting drug users (IDUs) because the
injection equipment has been reused up to 5 or more
times a day. The sharing of the used syringes and other
injection equipment with the lack of HIV transmission
education, the lack of sterile injection equipment and the
zero knowledge of how to clean injection equipment with
bleach play very crucial part in the HIV/AIDs epidemic in
the community.
Moreover, the zero knowledge of vein care or overdose
prevention plus the basic lack of over all health care and
nutrition, this has lead to many preventable deaths.
Korsang is a small grass roots program located in Phnom
Penh, Cambodia. It is fairly new program, beginning in
September 2004. The main component of the Korsang
team is to engage in intensive, risk reduction based IDU
and drug user outreach and education through peer
related connection. Korsang is targeting Cambodians
who are engaged in injection drug use and yama use
who are currently un-served and at serious risk of HIV and
other health-related hazards that accompany drug use
and high-risk sexual behavior. Korsang staff visits areas
where street based injection drug use is a serious issue
and sex worker areas where yama and unprotected sex
go hand in hand.
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International: Harm Reduction in Asia
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THIS IS THE REAL WORLD - NOT AS WE
KNOW IT

Professor Nick Crofts
Senior Research Fellow, Nossal Institute for Global Health

Speed T.

HIV among and from injecting drug users is still driving
the AIDS epidemic in much of Asia, as it has since HIV
first appeared in the region. Substantial progress has
been made in developing supportive environments for
effective harm reduction responses in many countries in
the region, and in implementing such responses – and
Australia has been a major contributor to this progress.
However, harm reduction programs in Asia are still far
outweighed by the sheer scale of numbers of the HIV
epidemics, and are reaching only small proportions of
those at risk and affected. As well, policy environments
remain ambiguous at best and openly hostile at worst.
This session will examine the situation and challenges
in HIV among and from IDUs in Asia, and the needs and
opportunities for heightened Australian involvement and
support.

Australian Injecting and Illicit Drug Users League Inc.
(AIVL) Canberra, ACT, Australia In the context of large
and growing HIV and hepatitis C epidemics, not to forget
the impact of coinfection, amongst people who inject
drugs across the Asia region, AIVL is extending itself to
tackle what is without a doubt one of the organisation’s
greatest yet most rewarding challenges - our foray into
international development work.
Were we ready for the steep learning curve this work
presented? Were we ready for the easily established
rapport, the warmth from our peers in the region,
enthusiastic to work alongside us? How is it to work
in an environment where to be a drug user can mean
death by firing squad, where government ‘war on drugs’
propaganda is not rhetoric?
Whilst not wishing to be too voyeuristic nor perhaps even
alarmist by way of this presentation, we seek to share our
experiences and learnings eg what could ‘dry injecting’
possibly mean and how do you work with this concept
without shuddering? This presentation will share the
extreme hardships some of our peers face, the context of
their drug use and drug treatment, and the nature of their
drug use, what this means to health and humanity.
This presentation will conclude with an exploration of
some of the key issues and barriers that will need to be
addressed if an effective response to HIV and hepatitis
C prevention and treatment among people who inject
drugs across Asia is to be developed effectively and in line
with need and their growing proud voices.
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International: Harm Reduction in Asia

HARM REDUCTION IN ASIA – AUSTRALIA’S
ROLE
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DEVELOPMENT OF A NEW HEALTH-RELATED
QUALITY OF LIFE QUESTIONNAIRE SPECIFIC
TO HIV/AIDS: AN INTERNATIONAL AND
CROSS CULTURAL INITIATIVE  
Duracinsky M1, Herrmann S2, Acquadro C3, Berzins B4,
Lecoeur S5, Hyland N6, Fournier I7, E. McKinnon2, Nolan
D2,8, Mallal S2,8, Chassany O3.
1
Service de Médecine Interne et de Maladies Infectieuses,
Hôpital Universitaire de Bicêtre, Paris, France; 2Centre for
Clinical Immunology & Biomedical Statistics, Royal Perth
Hospital & Murdoch University, Perth Western Australia;
3
Département de la Recherche Clinique, Hôpital SaintLouis, Paris, France; 4Division of Infectious Diseases,
Northwestern University, Chicago, USA; 5Programs for HIV
Prevention and Treatment (PHPT), Chiang Mai, Thailand;
6
Sexual Health Services Royal Perth Hospital, Perth
Western Australia; 7Institut Pasteur du Cambodge, Phnom
Penh, Cambodia; 8PathWest Laboratory Medicine WA

domains such as daily activities, stigma, and relations with
family and/or friends. Cognitive debriefing was carried out
at each centre on 5 participants not part of the original
interview group, using a 70 item questionnaire that had
been developed—this was subsequently reduced to 60
items after harmonization.
At the next stage the questionnaire will be administered
to 100 participants at each centre. In WA the results will be
correlated with appropriate clinical information from the
WA HIV Cohort database. It is anticipated that following
psychometric validation and translation into the target
languages this questionnaire will be a contemporaneous
tool to use with WA patients and migrants from high
prevalence countries. Globally, the new HRQL instrument
will be used by those who seek to measure the impact of
HIV and treatment on PLWHA accurately.

Social Research – Lives Worth Living

Social Research – Lives Worth Living
3.30pm – 5.00pm

Health-Related Quality of Life (HRQL) questionnaires (Q’s)
specific to HIV/AIDS were developed before the advent
of antiretroviral therapy (ART) and/or before current coformulations which have, purportedly, a lower toxicity
profile. Arguably, these Q’s have diminished sensitivity to
measure the current impact of HIV disease and treatment
on People Living With HIV/AIDS (PLWHA). Relevant
domains important for PLWHA such as sleep, perception
of treatment and impact of current common side effects,
including lipodystrophy are missing and the assessment
of psycho-social impact could be improved.

friday 19 september 2008: 3.30pm –5.00pm

The objective is to develop a new Patient-Reported
Outcomes (PRO) questionnaire to measure the HRQL
of PLWHA in different countries and cultures, using an
item bank developed from semi-directive interviews
which explored the multidimensionality of PLWHA’s
HRQL with participants. To capture cultural differences in
perceptions, interviews were held in: Senegal, Brazil, USA,
Australia, Thailand, China, Cambodia, India and France
and recorded, transcribed and translated into English and
French.
Globally 148 (47% female) individuals consented to the
interviews from which the domains representing PRO’s
were identified. Using participants’ verbatim, 300 items
were generated in French and English and organized
into a 24-domain item bank. An endpoint model was
designed to explain the relationship between PRO’s,
health status, symptoms, side effects and the different
domains of HRQL. Cultural differences were identified in
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ASSESSING THE NEEDS OF YOUNGER HIV
POSITIVE MEN
Bavinton B1, Gray J1
1
ACON, Sydney, NSW, Australia
The rate of seroconversion amongst gay men aged 29
years and under in NSW has remained fairly stable for a
number of years at 80 to 90 each year. At any given time
there are approximately seven to eight hundred men in
this category. However, NSW does not have any services
specifically targeting this age group. Although there is
anecdotal evidence suggesting that the needs of this
group may be different from those of older positive gay
men, there is very little research focusing on younger
positive men.
In 2007-08, ACON conducted a needs assessment with
this target group, which sought to determine whether
there are unique needs faced by this group, and if so, how
these might be addressed.
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A high level of involvement by the target population
was an integral component of the needs assessment.
Volunteers helped to determine areas for further
discussion and facilitated a series of five discussion
nights with other young positive men. The discussion
nights each focused on a different topic – including sex,
relationships, mental health/emotional wellbeing/drugs
and alcohol, disclosure, and health/treatments. These
sessions were complemented by an online survey which
added quantitative data to the rich qualitative information
produced by the discussion nights. The young men
assisted in the analysis of the data.
The needs assessment determined that younger positive
men have specific needs that can be met through a
range of programmatic responses. The most significant
needs that were identified concerned stigma and
discrimination, peer support, social identification, nonconcordant sex and relationships, and service usage.
Addressing these issues requires a multifaceted approach
that works with younger HIV positive men to improve
skills, reduce social isolation, build a culture of service
usage, and support these young men around sex and
relationships. Additionally, a separate focus must be on
reducing the levels of HIV stigma and discrimination
amongst HIV negative men.
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BEING HIV POSITIVE IN AOTEAROA /NEW
ZEALAND: A TWO STUDY COMPARISON
2001-2007
Grierson J1, Thorpe R1, Pitts M1, Hughes T2, Saxton P2, Smith
J3, Smythe E2, Thomas M4
1
La Trobe University, Australian Research Centre in Sex,
Health and Society, Melbourne, Australia; 2 New Zealand
AIDS Foundation, Auckland, New Zealand; 3 Eventimento
NZ Ltd, Auckland, New Zealand; 4Auckland City Hospital,
Infectious Disease Department, Auckland, New Zealand
Background: Understanding the lived experience of HIV is
critical for the provision of treatment and support services
in ways that appropriately reflect the contexts and needs
of PLWHA.
Methods: HIV Futures New Zealand is an anonymous,
cross-sectional survey of people living with HV/AIDS. The
survey covers the domains of HIV testing and counselling;
health status and management; antiretroviral therapy;
service use; well being and mental health; social support
and community engagement; relationships and sex;
recreational drug use; accommodation; employment;
finances; and discrimination. First conducted in 2001
(N=226) it was replicated in 2007 (N=261). Participant
demographics were generally representative of the
known HIV positive population in terms of gender age
and ethnicity.
Results: All results reported are 2001 then 2007. Ratings of
health status and well being were similar across the two
surveys. A greater proportion had been diagnosed with
an AIDS defining illness in the two years prior to survey
(5%, 14%). Similar proportions had ever used antiretroviral
treatments (78%, 79%), while current use was higher
(64%, 73%). Service use was lower across all services at
HIV organisations in the most recent survey. For example,
treatments advice (55%, 34%); treatments information
(26%, 15%); and counselling (48%, 31%). More participants
owned or were purchasing their own home (37%, 46%).
Fewer were in public rental accommodation (18%, 13%).
More reported being in paid employment (53%, 62%).
Median weekly personal income has increased ($330,
$486), and this is greater than the change in consumer
price index. Fewer reported experiencing discrimination
in relation to accommodation, at health services and in
relation to obtaining insurance.
Conclusions: A general improvement in the health
and well being of New Zealand PLWHA can be seen
from these comparisons. Critical economic and social
disadvantage still remains when compared with the New
Zealand population.
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Where accessible, effective, simplified treatments
transformed HIV infection into a chronic condition. The
changing needs of HIV-positive people have prompted
health-care systems worldwide to improve and adjust
services. We consider current access to care among HIVpositive people.
Data collected in 2006 from a community-based cohort
of HIV-positive gay men (Positive Health) in Sydney
(N=270) were used. Participants were asked about their
health/clinical and community-based service needs and,
subsequently, about difficulty in accessing services. We
report the prevalence of specific needs, barriers, and
predisposing factors associated with them.
Participants most commonly used a GP (64%), hospital
clinic/outpatient services (39%) and sexual health clinics
(14%) for HIV management. All participants needed at least
one HIV-related health service (mostly multiple services)
- doctors experienced in HIV management, dentists,
antiretroviral prescribers and hospital pharmacies. Most
were able to use available services without problems.
However, problems appeared in relation to obtaining
doctor appointments and opening hours for hospital
pharmacies. Cost emerged as a substantial barrier to
dental care (91% of those in need) and psychological
counselling. Need for one or more community–based
services was reported by 46% of the men. The most
difficult to access were income and peer support, public
housing (supported accommodation); usually due to
poor services and staff attitudes. Income level was a
single predisposing factor associated with limited access
to services.
Conclusion: In Australia, health service needs outweigh
those for social support. Complex medical and social
support services remain essential to HIV-positive people.
Worldwide, positive changes in health and life expectancy
have translated into HIV-infected people with highly
specific health care needs. This results in growing stress
on health and social services, some of which are currently
not meeting the needs of HIV-positive people. The ability
of society to provide an adequate standard of care
depends on the adaptability of services to the changing
needs of HIV-positive people.

Dean Murphy,1 Jeanne Ellard, 1 kylie valentine,2, Jahan
Tyson1
1
National Centre in HIV Social Research, University of New
South Wales; 2Social Policy Research Centre, University of
New South Wales
Phylogenetic analysis is the calculation of genetic
distance between viral strains. This analysis can determine
the degree of relatedness between two samples of HIV,
and has been used forensically to prosecute people for
transmission of HIV.

Social Research – Lives Worth Living

Zablotska I.B.1, Imrie J.1, Prestage G.2, Frankland A.1, Grulich
A.2, Sue Kippax2
1
National Centre in HIV Social Research, University of New
South Wales, Sydney, NSW, Australia; 2National Centre in
HIV Epidemiology and Clinical Research, University of
New South Wales, Sydney, NSW, Australia.

VIRAL FAMILIES: ANALYSING KINSHIP
DISCOURSE IN HIV TRANSMISSION

The Viral Families project is a pilot qualitative study
investigating two social and political dimensions of
this technology: the potential for new forms of social
connection and belonging; and the potential for new
forms of biological identity. Its theoretical innovation is
the use of science and technology studies to explore the
intra-action of clinical technologies and human actions.
In this presentation we identify discourses of kinship in
the narratives of gay men engaging in deliberate HIV
transmission or acquisition, and in media coverage of HIV
transmission.
We undertook a content analysis of HIV-related articles
published in print-based media from 2007 and 2008. We
also analysed the public areas of selected gay chat sites
with a focus on ‘barebacking’ (intentional unprotected
sex ) for use of familial and genealogical tropes, especially
in relation to HIV infection, as well as ‘bug-chasing’ and
‘gift-giving’ (intentional HIV transmission) discourses.
Our preliminary analysis of chat sites and recent Australian
media has documented intentional HIV transmission, but
there is little evidence that people are seeking to become
transmit or acquire HIV from a particular source in order
to create kinship connections. There is also evidence of
bug-chasing and gift-giving but there is an absence of
any notion of viral specificity i.e. connectedness based on
similar virus or origin of infection.
Nonetheless, kinship and reproductive terms like ‘daddy’,
‘boy’, ‘breed’ and ‘seed’ are found in print media and
websites, indicating the importance of genealogical
constructions in the different social arenas of mainstream
media and gay sexual culture. The circulation of these
genealogical constructions between clinical, social and
criminal discourses is important to the co-constitution of
scientific and social knowledges of HIV.
The next phase of the study will involve interviews with
HIV-positive gay men to explore their understandings of
the implications of this technology.
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CURRENT CARE AND SUPPORT NEEDS OF
HIV-POSITIVE GAY MEN: WHAT FACTORS
LIMIT ACCESS TO AVAILABLE SERVICES?
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National Needs Assessment of sex
workers who live with HIV 2008
Fawkes J
The one year community based needs assessment
project sought to identify the needs of HIV positive sex
workers in Australia through qualitative interviews and
utilising community development approaches. This
paper will outline the key recommendations from the
final report (http://www.scarletalliance.org.au/library/
hiv-needsassessment08/) as well as the process that was
critical to the projects strong outcomes.
Established as a peer-based project, in line with Scarlet
Alliance’s principles and GIPA (Greater Involvement of
People Living with HIV/AIDS), the project was designed to
empower the participants, members of the HIV positive
sex worker community, to run the project. The project
involved capacity development for community members
and community building activities including encouraging
HIV positive sex workers to share their stories in “proVision”
the Scarlet Alliance magazine.
All approaches were underpinned by a strong sense of
need to protect participants rights and ensure the project
followed recognised ethical approaches. Productive ways
of working with participants individual privacy needs
were developed to increase participation. Additionally, the
project had continual reference back to the participants,
via the project officer, Kane Matthews, and engaged with
participants about the nature of their contributions and
their “comfort” with the way the needs assessment was
carried out and reported.
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The process ensured that the written report reflects what
the contributors offered. This was done in a way which
valued peer based networks and provided evidence that
these networks can be productive and generate sound
knowledge about what the issues and needs are for those
within the network.
The project also included a survey of health care services.
The responses demonstrate a need for increased training
of health care workers; the need to address discrimination
and stigmatising approaches; and improved access to up
to date information on the legal rights of sex workers
living with HIV.
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Pietro Vernazza
St. Gallen, Switzerland
During the past few years, HIV-physicians as well as
community members have started to question the need
for barrier protection methods in HIV discordant couples if
the infected partner was on HAART and some physicians
have openly talked to patients about the limited risk in
such situations. In late 2007, several individual physicians
have given public statements regarding the low risk of
transmission.
Based on an evaluation of a Swiss HIV expert group the
Swiss commission on AIDS has informed Swiss physicians
in January 2008 that the commission considered it
adequate to inform their patients about the limited risk
of transmission under HAART. This step was considered
necessary to harmonize the information that individual
physicians have given to their patients. Particularly, it
was considered important, to inform physicians and the
community about the potential of interfering risk factors
which were not considered by most physicians in the
past.
Since no randomized controlled trials exist to calculate
transmission risks in discordant couples and will be
very unlikely to be available in the near future, the Swiss
expert’s evaluation of transmission risk was based on
three methods of approximation: i) estimation based on
the lack of documented individual cases in Switzerland
and Europe, ii) extrapolation of a mathematical model for
transmission risk based on free viral load in semen, and iii)
support of these estimates by biological studies.
In summary, all available estimates indicated that
transmission risk in discordant couples is in a very low
range. A comparison of the most conservative risk estimate
with other risks in daily life as well as the risk of condomprotected sex in the absence of treatment support the
notion that the residual risk associated with sex in the
presence of a fully suppressive HAART is negligible.
The presentation will focus on the background and
development of the Swiss commission’s statement and
will discuss the most important arguments that were
raised against the Swiss statement.

Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM
National Centre in HIV Epidemiology and Clinical
Research, The University of New South Wales, Sydney,
NSW, Australia

Swiss Statement

BACKGROUND AND RATIONALE
- NORMALISING SEX IN STABLE
SERODISCORDANT RELATIONSHIPS

RELATION BETWEEN HIV VIRAL LOAD AND
INFECTIOUSNESS

Abstract
A consensus statement released on behalf of the Swiss
Federal Commission for HIV/AIDS suggests that people
receiving effective antiretroviral therapy—ie, those with
undetectable plasma HIV RNA (<40 copies per mL)—are
sexually non-infectious. We analysed the implications of
this statement at a population level.
We used a simple mathematical model, based on
the empirical data used by the Swiss, to estimate the
cumulative risk of HIV transmission from effectively
treated HIV-infected patients (HIV RNA <10 copies per
mL) over a prolonged period. We investigated the risk of
unprotected sexual transmission per act and cumulatively
over many exposures, within couples initially discordant
for HIV status.
Assuming that each couple had 100 sexual encounters
per year, the cumulative probability of transmission to the
serodiscordant partner each year is 0·0022 (uncertainty
bounds 0·0008–0·0058) for female-to-male transmission,
0·0043 (0·0016–0·0115) for male-to-female transmission,
and 0·043 (0·0159–0·1097) for male-to-male transmission.
In a population of 10 000 serodiscordant partnerships,
over 10 years the expected number of seroconversions
would be 215 (80–564) for female-to-male transmission,
425 (159–1096) for male-to-female transmission, and
3524 (1477–6871) for male-to-male transmission,
corresponding to an increase in incidence of four times
compared with incidence under current rates of condom
use.
Our analyses suggest that the risk of HIV transmission in
heterosexual partnerships in the presence of effective
treatment is low but non-zero and that the transmission
risk in male homosexual partnerships is high over repeated
exposures. If the claim of non-infectiousness in effectively
treated patients was widely accepted, and condom use
subsequently declined, then there is the potential for
substantial increases in HIV incidence.
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Chris Burrell
SA Pathology/IMVS and University of Adelaide
Hepatitis B virus infects approx. 30 % of the world’s
population at some point in their lives, and the ~350
million individuals who remain persistently infected have
a 20-30% probability of dying from hepatitis B. The natural
course of infection involves a number of distinct decision
points in the balance between virus and host defence. (1)
the acute infection may be symptomatic or subclinical (2)
acute infection may be cleared, or may persist indefinitely
(3) during persistent infection, patients may progress
through four distinct and sequential phases, each
with different virological, immunological and disease
parameters (4) concurrently, variable progression of liver
disease through to cirrhosis and liver cancer occurs in a
proportion of patients.
Many risk factors or predictors for this progression in
individual patients have been defined in recent years,
and indications for antiviral therapy to assist clearance
are becoming better defined. However, the basic
immunological and virological drivers of this complex
progression are still poorly understood.
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This session will cover the latest research on bio
infections from biomedical through to clinical research.
Presentations will be delivered by experts in their field.

Natural History of Hepatitis B
Infection
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Goller JL1, Guy R1, Lim M12 Gold J1, Leslie, D3, BK Tee4, Roth
N5, Fairley C6, Higgins N7, Hellard ME12
1
Centre for Epidemiology and Population Health Research,
Burnet Institute, Melbourne, VIC, Australia; 2Department
of Epidemiology and Preventive Medicine, Monash
University, Melbourne, VIC, Australia; 3Victorian Infectious
Diseases Reference Laboratory, North Melbourne, VIC,
Australia, 4The Centre Clinic, St Kilda, VIC, Australia, 5
Prahran Market Clinic, Prahran, VIC, Australia, 6Melbourne
Sexual Health Centre, Carlton, VIC, Australia; 7 Department
of Human Services, VIC, Australia
In Victoria, since early 2000, there has been a steady
increase in diagnoses of HIV and sexually transmissible
infections among men who have sex with men (MSM).
These findings arise from passive surveillance which
is highly dependant on the extent of testing. In April
2006, three sentinel surveillance networks for HIV, syphilis
and chlamydia commenced operation at five Victorian
medical practices with a substantial MSM clientele. The
system aimed to provide testing rates, prevalence and
risk behavioural information to assist in interpretation
of passive surveillance trends. Demographic and
risk behaviour information were collected through a
questionnaire from all MSM undergoing routine testing
and linked with laboratory results. This paper compares
results from April-December 2006 and January-June
2007. Overall 5126 HIV, 5193 syphilis, and 3046 chlamydia
questionnaires were received in 15 months. In all three
networks, three quarters (74-77%) of MSM reported casual
anal sex partners in the last six months and about one
third (33-36%) reported inconsistent condom use with
these partners. These behaviours remained consistent
in both time periods. The proportion of MSM diagnosed
with infectious syphilis increased significantly from 1.6%
of 2858 MSM tested in 2006 (95% CI: 1.2-2.1) to 2.7% of
2295 MSM tested in 2007 (95% CI: 2.0-3.4; p<0.01). The
relative risk of an infectious syphilis diagnosis was 6.5
(95% CI: 3.1-13.7) in HIV positive MSM compared to HIV
negative MSM. HIV and chlamydia prevalence remained
steady over both time periods: HIV - 1.9% in 2006 and
2.0% in 2007; chlamydia - 5.8% in 2006 and 5.4% in 2007.
Further demographical and behavioural information will
be presented and discussed in the context of Victorian
passive surveillance trends. The increasing infectious
syphilis prevalence among those tested highlights the
need for initiatives aimed at reducing syphilis transmission
with a particular focus on reducing transmission in HIV
positive men.

Higgins N1, Fairley C2, ReadT2 3, Csutoros D1, Wallis S2,
McBryde E3 1
1
Department of Human Services, Melbourne, VIC;
2
Melbourne Sexual Health Centre, Carlton, VIC, 3Royal
Melbourne Hospital, Parkville, VIC,

Clinical Epidemiology

HIV, syphilis and chlamydia in 
MSM in Victoria: risk behaviour 
and prevalence at clinic SEntinel 
surveillance sites

RISE IN SYPHILIS NOTIFICATIONS IN
VICTORIA − A CASE SERIES STUDY

Annual notifications of infectious syphilis in Victoria have
risen more than 40-fold from 9 cases in 2000 to 423
cases in 2007, with men who have sex with men (MSM)
continuing to comprise a majority of the cases (85% in
2005-2007).
A case series study was conducted to examine and better
understand the cause(s) of the syphilis increase in Victoria.
Cases notified to the Department of Human Services
between 1 January and 31 March 2008, aged 18 years or
older with evidence of infectious syphilis and a Victorian
postcode of residence were eligible for inclusion. A
telephone administered questionnaire was used to collect
data relating to demographic, social/sexual behaviour,
testing history and health seeking behaviour.
Of the 103 infectious syphilis cases, 48 males consented
to participate (response rate of 47%); 88% were in MSM
and 25% reported co-infection with HIV. Thirty-four cases
reported casual sexual partners in the preceding month,
potentially exposing more than 67 persons. Of the cases
reporting casual sexual partners, nearly all reported
unprotected oral sex and 66% reported unprotected
anal sex. Ten of the 48 cases (21%) reported no anal sex
at all. The most frequent site for meeting sexual partners
was in a bar/club or over the internet (35% and 31%
respectively). Thirty-nine cases (81%) were symptomatic
with an average time to diagnosis of 32 days (median =
20 days, range: 7 to 119 days). Cases reported hours of
operation, time and cost as the largest barrier to health
care (29%, 23% and 21% respectively).
The results suggests that syphilis cases are not diagnosed
in a timely way and public health interventions to improve
health seeking behaviours should be considered.
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SEROPREVALENCE AND INCIDENCE OF
HSV-1 AND HSV-2 IN AN HIV SEROPOSITIVE
COHORT
Authors: Srirajalingam M1, Aitken S1, Taylor J2, Dwyer DE2,
Chuah J1
1
Gold Coast Sexual Health Clinic, Miami. Gold Coast,
Australia; 2Westmead Millennium Institute, Sydney
University and Westmead Hospital, Westmead, Australia.
Background
Genital herpes is associated with increased rates of
acquisition and transmission of Human Immunodeficiency
virus (HIV).

The Relative Risk of seroconversion to HSV-2-Pos status in
HSV-1-Pos vs. HSV-1-Neg subjects was 0.76 (95% CI 0.193.07); the Risk Ratio based on incidence rates with personyears of follow-up was 1.01 (95% CI 0.97-1.03).
Conclusions
There was a high prevalence of HSV infection and
evidence of ongoing HSV-2 acquisition in this group of
HIV seropositive subjects. As HIV and HSV have synergistic
effect on each others transmission, measures to control
HSV infection may be important.

Objective:
Determine the prevalence and incidence of Herpes
Simplex virus type 1 and 2 (HSV-1,-2) infections in an HIV
positive cohort.
Methods
Baseline HSV type-specific IgG serology was carried out
on 256 HIV positive patients attending a Sexual Health
Clinic. Follow-up testing was available for 106 subjects
between 1997-2003.
Results
Prevalence study: Of the 256 subjects (232 males, mean
age 39 y, range 19-71y and 24 females, mean age 32 y,
range 18-47 y) 56% (56% of men and 58% of females)
were HSV-2 seropositive and 83% (84% of men and 71%
of females) were HSV-1 seropositive.
Longitudinal study: 106 subjects (96 males, 10 females)
had testing performed on more than one occasion.
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Seven (70%) females were HSV-1 seropositive and 3 (30%)
were HSV-2 seropositive. There were no seroconversions
in this group.
Among the males baseline seropositivity for HSV-2 and
HSV-1 were 20.8% (n=20) and 67.8% (n=65) respectively.
Among the 76 HSV-2-Neg males at baseline there were
11 HSV-2 seroconversions (52.71/103 P-Y). Among the
31 HSV-1-Neg males there were 3 HSV-1 seroconversions
(30.9/103 P-Y).
Among the 65 HSV-2-Neg/HSV-1-Pos males there
were 9 HSV-2 seroconversions (52.79/103 P-Y). Among
the 11 HSV-2-Neg/HSV-1-Neg males, there were 2
HSV-2 seroconversions (52.38/103 P-Y). There were 3
seroconversions among the 31 HSV-1-Neg subjects
(30.9/103 P-Y).
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The WA AIDS Council (WAAC) has been operating sexual
health clinics in the two sex on premises venues (SOPVs)
in Perth for 14 years. This very effective model provides
opportunistic, free, anonymous HIV and STI testing to atrisk men. Over half of the clientele attend specifically for
testing with the rest being sauna patrons at the time of
the clinic. The clinics operate for 4 hours per week.
Following a syphilis outbreak among gay men in 2006,
WAAC undertook a community based response (social
marketing and editorial in print and web-based media,
poster, pamphlets and verbal information to sexual, social
and community groups and cyber-based outreach etc)
with one of the aims to increase syphilis testing.
We examined the attendance and STI testing data of
the two SOPV clinics, comparing the 18 months prior to
the response with the 18 months of the response. Clinic
attendance has increased by over 21% (from 263 to 320
men) with the majority of men citing the increase in
syphilis infections as the reason for attendance. In Clinic A
there was a marked increase (29%) of men attending the
SOPV clinic specifically for testing. In Clinic B there was a
marked increase (41%) of SOPV patrons seeking testing.
There has been a 36% increase in syphilis tests and nearly
30% increase in HIV tests, with a significant increase in the
yield of positive syphilis test results per test completed.
(0.88% in the eighteen months prior to the intervention
to 3.88% after the intervention started). In the same time
frame, the HIV yield increased from 0 to 1.33%. There
has also been a significant increase in the number of
Chlamydia and gonorrhoea diagnoses.
An integrated community based response has shown
that at-risk men will respond to a call to be tested and
that accessible sexual health services are a vital plank in
achieving a sustained response to an outbreak. It has
also shown the value of undertaking comprehensive STI
screening when the opportunity arises.

Moyer J1
1Fairfield House, Infectious Diseases Unit, The Alfred
Hospital, Prahran, VIC, Australia
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Bradstreet B, Yam SH, Langdon PA
Western Australian AIDS Council Inc, West Perth, WA,
Australia.

THE ROLE OF THE NURSE IN SYPHILIS
(AND OTHER STI) RISK ASSESSMENT IN
A SUBACUTE INPATIENT SETTING AT THE
ALFRED HOSPITAL, MELBOURNE, VICTORIA

Fairfield House (FFH) is a sub-acute inpatient ward at
The Alfred Hospital with fifteen beds dedicated for
HIV patients. Syphilis notifications have progressively
increased in Victoria, predominantly in men who have
sex with men (MSM), with a significant proportion of
these notifications occurring in HIV patients. This paper
will examine the nurse’s role in the process by which
these patients are tested for syphilis and other sexually
transmitted infections (STIs) during admission at Fairfield
House.
Syphilis testing on HIV+ inpatients at FFH is currently
performed either based on presenting symptoms or by
STI risk assessment. STI risk assessment may be done on
admission by the Infectious Diseases medical team but
may be initiated by nursing staff and then communicated
to the medical team. As there is no current protocol at FFH
for nurse initiated STI risk assessment, STI risk assessment
by nursing staff and consequent testing of inpatients at
FFH, particularly syphilis testing, may be inconsistent.
To examine the current variations in nurse-initiated STI
risk assessment with a particular emphasis on syphilis, a
medical record search using an audit tool will be applied
to all HIV inpatients admitted to FFH over a three month
period (October-December 2007). Preliminary data
indicate 31.6% (25/79) of inpatient visits during the study
timeframe were tested for syphilis.
The information from this study will highlight gaps in
nurse-initiated STI risk assessment at Fairfield House.
The results of this study will be used towards up-skilling
nursing staff if inadequate STI risk assessment is noted,
and to develop protocols for STI risk assessment and
testing with the FFH multidisciplinary team.
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McMillan K.E.1.
1
National Centre in HIV Social Research, University of New
South Wales, Sydney, Australia.

ZIMBABWE, ADOLESCENT SEXUAL HEALTH
AND THE POWER OF NARRATIVES
Power R1, 2Cowan F, Langhaug L2, 3Matudsi M
1
Centre for Harm Reduction, Burnet Institute, Melbourne,
Australia; 2University College London; 3University of
Zimbabwe (Funded by the NIH, USA)
The narrative data presented here derive from a
community-randomised trial of a complex adolescent
sexual health intervention in rural Zimbabwe. This
research comprised 30 communities, with a cohort of
6,600 students, followed up over a four-year period.
The main outcome measures were reductions in the
incidence of HIV-1, HSV2 and unintended pregnancy.
Alongside the quantitative data, qualitative data were
collected to better understand the contextual and cultural
issues associated with sexual behaviour and adolescent
lifestyles. We conducted a series of participatory
workshops with young people to explore these issues
further. By means of risk mapping, pair-wise ranking and
role play, we constructed narratives that depicted some
of the key risk situations and environments confronting
these young people. Risk environments and contexts
included: the family, school, church, the highway, bottleshop. These narratives (a selection of which will be played
during the presentation) were used to imagine more
positive futures. As a result community-level interventions
were developed to attain these goals and to improve the
sexual and reproductive health of rural Zimbabwean
adolescents.

The Pacific is a region that has not commanded a lot of
attention in HIV research to date. To a large extent, the
particularities of Pacific island nations are effaced in a
consignment to the category ‘Asia- Pacific’; a category
in which the ‘Pacific’ tends to appear as rim to an Asian
epicentre.
This paper reports on data gathered via 62 in-depth
interviews with 18-25 year olds in Tonga and Vanuatu,
during March and April 2008. The face to face interviews
enquired into young people’s personal experiences of,
and thoughts about, condom access and use.
While the results are largely consistent with international
data on young people and condom use (e.g. the
importance of peer networks, and a mismatch between
knowledge and practice), some of the data highlight issues
related to social and cultural factors that are common
to Pacific nations (e.g living in close communities with
strong traditions, and rapid social change), and other
results indicate marked differences between the Tongan
and Ni-Van participants, directing attention to specificities
of each location, (e.g the community of fakaleiti, and the
condom positivity of Ni-Van parents) and consequently
to particular opportunities for condom promotion in
both Tonga and Vanuatu.
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Walizopa LD1, Emori R 1, Nosi S 1, Akuani F 1, Kupul F 1, Kepa
B 1, Cangah B 1, Mek A1, Pirpir A 1, Keleba K1, Kelly A 2
1
Papua New Guinea Institute of Medical Research,
Operational Research Unit, Goroka, Papua New Guinea;
2
National Center for HIV Social Research, University of
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Antiretroviral therapies (ART) are highly concentrated and
those on treatment are advised to take them with food.
For most PLWHA in resource poor settings, the availability
of adequate food supply is not guaranteed. This can
cause not only challenges for the health and well being
of PLWHA on treatment, but also for adherence. To date
no research has been carried out in Papua New Guinea in
order to examine the relationship between ART and food
for PLWHA. This paper presents findings of data collected
in three) of six sites (Lae, Mingendi and Port Moresby from
a social impact study of ART in PNG.

Young people acquire knowledge and attitudes about
sex and HIV from a variety of sources. During this process,
young people are receptive to both accurate and
inaccurate information as well as judgmental and nonjudgmental beliefs.

A mixed-method approach was taken using survey and
in-depth interviews with PLWHA on ART. From three
provinces a total of 152 PLWHA (over the age of sixteen)
participated in the survey and 28 participated in the indepth interviews. Ethics approval was granted by the
PNG Medical Research Advisory Committee and UNSW.
Three quarters of the PLWHA from all three sites, reported
having an increased appetite since commencing
treatment. When asked if they had enough food to satisfy
their hunger; a total of 49 out of the 152 participants said
they did not; 36.8% were from Port Moresby while, less
than 1% were from Mingendi and Lae. Participants were
further asked if not having enough food was a barrier
to them not taking their medication. Of the 138 who
answered, 14.5 % (all of whom were from Port Moresby)
said yes, while in Lae and in Mingendi no participants
mentioned this. The qualitative data further validated this
finding. Fear of resistance, led many who were without
food, take them with water only or just a scone. Again,
this was only true for those from Port Moresby.
The availability of an adequate supply of food is an
important factor influencing PLWHA to adhere to
treatment in Port Moresby where food and basic
necessities constantly depends on money rather than
gardens.

Exploring how and where young people acquire
their knowledge and attitudes is important for
educators so that programs and campaigns are
appropriately developed. This paper explores the role
of comfort in young peoples´ knowledge acquisition
process towards sex and HIV in secondary schools
in Eastern Highlands Province, Papua New Guinea.
Focus group discussions (FGDs) were carried out among
Grade 12 students attending three secondary schools. A
guide was developed which involved 5 predetermined
categories, sex, HIV, discrimination, condoms, sex and HIV
education. A total number of 73 students participated.
Eight genders specific FGDs were carried out, 5 males,
3 females. Informed consent was provided by all
participants.
The level of comfort was the primary indicator of
students´ openness to talking or learning about sex and
HIV. Students felt most comfortable to share information,
which may or may not be accurate, their views and
experiences of sex and HIV with their peers. The extent
to which students felt comfortable was determined
by the gender of the person they spoke to, where
they were talking or listening, the age of the person
talking, the relationship of the person to them and their
beliefs in the other persons´ knowledge about sex.
An atmosphere of comfort is critical to engage students
in a meaningful and on-going way to talk and learn about
sex and HIV. Educators must take into account the ´space
of comfort´ in order to transfer accurate knowledge on
sex and HIV to young people and enable them to explore
their attitudes and behaviors.
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ADOLESCENCE SEXUAL Behaviour 
and Risks of ContRacting Sexually 
Transmitted Infections: a CrossSectional Analytical Study in Nepal
Regmi, K. 1, Regmi, S. 2 and Lamichhane G.3
1
School of Health & Social Care , University of the West of
England, Bristol, UK; 2Royal Berks NHS Hospital, Reading,
UK; 3HIV Prevention and Control Project, Kathmandu,
Nepal
It has been well documented about importance of sexual
behaviour and risk of contracting sexually transmitted
infections (STIs). Growing expansion of urbanisation and
in/out migration further create positive paradigm, which
facilitates sexual interactions between different hard
to reach/risk groups. Over past few decades, despite a
large gap in socio-cultural stigma, many young people
are engaged with pre/extra marital sexual relationships
and becoming inclined to STIs and HIV. This aim of this
research was to examine and analyse the patterns of
adolescences’ sexual behaviour and risks of contracting
STIs and HIV.
Five groups of young people comprised of both sexes,
15-24 age, were asked to describe their attitudes and
perceptions using in-depth interview (n=29) and group
consultations (n=55). To accommodate ‘sensitiveness’
in researching process, same sex researchers were
recruited and used. Respondents were also presented
statements and they indicated degree of agreement
or disagreement with each on Likert-type scale.
Discussion revealed that socio-cultural taboos, amongst
unmarried-adolescence, remain significantly high.
Majority of the respondents (75.32%) reported that
poor interaction between sexual health providers and
unmarried adolescence, fear of stigmatisation and limited
access, care and support found important barriers to
initiate discussion on all services related to STIs and HIV.
Study further demonstrates that, although pre/extra
marital practices have been discouraged, the level of
education/awareness and urbanisation have further
bring associated risks for contracting of STIs and HIV.
Study suggests that there was inseparable link between
unmarried young people and increasing risks of STIs and
HIV - due to change in sex and sexuality; and sexual norms
and independence. Most of the respondents (56.1%)
believed that early sexual experimentation with multiple
partners, alcohol consumption and erratic use of condoms
considered as‘high risk’behaviours contracting for STIs/HIV.
Implication for sexual health promotion, encompassing
the sexuality, life skills, and HIV/AIDS education adheres to
the socio-cultural context would bring positive changes
in safer sex practices amongst adolescence groups in
Nepal.
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Ward K1, Crooks L2, McAnulty J1
1
Communicable Disease Branch, NSW Health, Sydney,
NSW, Australia; 2 Australasian Society for HIV Medicine
Following a positive HIV test result, the diagnosing
clinician needs to provide support and information to the
patient and either direct clinical care or referral to relevant
services. We sought to identify the services that diagnose
HIV in NSW and in the case of general practitioners,
determine the level of experience in diagnosing HIV.
New South Wales doctors must notify demographic and
epidemiological information on all new HIV diagnoses.
We analysed the HIV surveillance data collected from
2000 to 2007 by the health provider making the first
diagnosis of HIV.
Preliminary results indicate that:
• 70% of HIV patients were diagnosed by a service in their
local area.
• 56% were diagnosed by a general practitioner (GP).
• 78% of all notifying GPs only notified one patient with
HIV over eight years. This accounted for 34% of all
patients diagnosed with HIV infections.
Most patients with HIV infections are diagnosed by GPs,
many of whom have not diagnosed HIV in the recent
past and therefore may not be familiar with recent
developments in diagnosis and management. GPs
require access to up to date resources to help manage
patients newly diagnosed with HIV.

Forrester JM, Boddy G, Kelly M on behalf of the Steering
Committee
Increasing patient numbers and finite resources threaten
the capacity of current models of HIV care across the
country. NAPWA and ASHM have identified this as a critical
issue and have commissioned an upcoming review. The
24% increase in the number of HIV cases seeking care in
Queensland since 2002, the complexity of HIV in relation
to non-HIV co-morbidities in the HIV population, the
ageing HIV population and without additional workforce
prompted a review of the capacity of the models of care
in Queensland.

Program Delivery

WHO IS DIAGNOSING HIV IN NSW?

Queensland HIV Models of Care 
Project 2008

The HIV Models of Care Project commenced on 25 March
2008 with the employment of the MOC Project Officer for
3 months. The aim of the project was to explore the current
model of care and service integration in Queensland. The
key focus was to examine the capacity of the models of
care given the increase in the HIV population over the last
6 years and the current HIV workforce. The Key objectives
of the project were:
1. Describe the current models operating in Queensland;
2. Map the gaps in the current clinical model operating in
Queensland;
3. Compare the current clinical model to models of care
in other Australian States;
4. Propose recommendations to Queensland Health to
improve the current clinical model
The project was limited to a clinical focus. Resources did
not permit thorough evaluation of current model from
PLWHA or social determinants of health perspective
although these are integral to models of care. The project
had a 14 person steering committee comprising of key
stakeholders. It was agreed to limit the focus of this
project to clinical aspects of care with three key areas of
clinical focus identified:
1. Traditional HIV clinical care;
2. Non-traditional HIV clinical care;
3. HIV workforce issues.
The project has been divided into 3 sections comprising
of a literature review, interviews with key stakeholders, the
writing of a report outlining the findings of the interviews,
the gaps in the model and the recommendations. 35
clinicians were interviewed across the state, 13 using a
tailored interview tool. These data will be presented at
the conference.
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THE WESTERN AUSTRALIAN RURAL
AND REMOTE HIV PROGRAM: A 10 YEAR
EXPERIENCE
Cain A1, Murray R2, Martinez OP1,3, French MAH1,3
1
Department of Clinical Immunology & Immunogenetics,
Royal Perth Hospital & PathWest Laboratory Medicine,
Perth, Western Australia; 2Department of Microbiology
& Infectious Diseases, Royal Perth Hospital & PathWest
Laboratory Medicine, Perth, Western Australia; 3School of
Pathology & Laboratory Medicine, University of Western
Australia, Nedlands, Western Australia
A Rural/Remote HIV Program was set up in Western
Australia in 1998 as a response to the increasing number of
HIV infected patients in country areas and the increasing
complexity of treatments and procedures used in the
management of HIV positive Patients. The Rural/Remote
Team is headed by a Consultant Clinical Immunologist,
assisted by other immunologists and an Infectious Disease
Physician and includes a Nurse Coordinator who runs the
program on a daily basis. The Team provides clinical and
nursing expertise and liaises closely with regional health
professionals including Population Community Health
Units, local GP’s and the Prison Service.
The programme also includes management of pregnant
women with HIV infection as part of a multidisciplinary
team of Doctors, Nurses and Social Workers.
There are only two S100 prescribers in regional Western
Australia. All HIV medications are prescribed at Royal
Perth Hospital and are sent to the regional Professionals.
The Rural/Remote Team conducts clinics and provides
formal education sessions for local health professionals.
In addition, telehealth facilities are utilised.
The program has registered a total of 236 regional HIV
patients since its establishment. The current enrolment
is 148 which includes 118 adults, 1 positive child and
26 uninfected children (24 of which are Aboriginal)
born to HIV positive mothers. Of the 118 adults, 78 are
male including 9 Aboriginal people and 40 are female
(including 20 Aboriginal people).
77 of the 118 adults are receiving Antiretroviral Therapy.
Of these, 64 (83%) have 100% adherence and 60 (78.5%)
have undetectable (<40 copies/ml) HIV RNA in plasma.
Of the 29 infected adult Aboriginal people (males and
females), 14 are receiving ART. Of these, 11 have 100%
adherence and undetectable HIV RNA in plasma.

COMPARISON OF CLINICAL HIV
PERFORMACE INDICATORS (POST-HAART)
BETWEEN  AHOD AND A REGIONAL SEXUAL
HEALTH CLINIC 1996-2007
Chuah J, Fankhauser W, Page M, Gold Coast Sexual Health
Clinic, 2019 Gold Coast Highway, Miami, Queensland,
4220; Dickson B., Ellem S., CaraData,
Parkwood,
Queensland 4214; Petoumenos K*; National Centre
for HIV Epidemiology & Clinical Research (NCHECR),
UNSW, Darlinghurst 2010, *on behalf of AHOD Steering
Committee and participating centres.
This study examined the patterns of a minimal set of
trend clinical performance indicators from a medium-size,
regional sexual health (SH) clinic, the Gold Coast Sexual
Health Clinic (GCSH) in comparison to a representative
“national” trend (AHOD - Australian HIV Observational
Database) during the same period (when available).
Between 01 January 1996 and 31 December 2007,
epidemiological and utility data were collected at the
GCSH, using the Sexual Health Information Program (SHIP
V7.7). The data were collated and expressed in graphs and
tables formats, in direct comparison to the Australian HIV
Observation Database (AHOD), representing the “national”
standard, covering the period of 01 January 1999 till 31
December 2007.
There has been an improvement trend in HIV performance
at GCSHC, compared to AHOD in recent years, with the
exception of crude death rate. New indicators suggested
substantial burden of CVD risks, Depression and Coinfections at GCSH, reflecting disparity in support services
& increased complexity of HIV management. This study
also re-iterated the potential roles of SHIP and SH
clinics in the surveillance and monitoring of provision
of ambulatory care in HIV management in Australia,
especially when regularly bench-marking against a
representative “national standard” like AHOD.
Oral Posters:
Saloner KL - see page 265
Lienert TM - see page 240

Our findings demonstrate that although Western
Australia is a large state and there is a lack of clinical HIV
expertise in Regional WA, it is possible to provide a high
level of care that is culturally appropriate to regional HIV
patients. The expertise of the Rural/Remote Team has
greatly enhanced the activities of local regional health
professionals to manage HIV infected patients.
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Immunopathogenesis of hepatic 
flare in HIV-Hepatitis B Virus 
(HBV) co-infected individuals 
following initiation of HBV-active 
antiretroviral therapy
Oliver B.G.1, Crane M2, Avihingsanon A.3, Visvanathan K.2,
Matthews G.4, Dore G.4, Price P.1,5 French M.1,5, Ruxrungtham
K.4, Lewin SR.2,6
1
School of Pathology and Laboratory Medicine, University
of Western Australia, Australia; 2Department of Medicine,
AMREP, Monash University, Melbourne, Australia; 3HIV
Netherlands Australia Thailand Research Collaboration
(HIV-NAT), Bangkok, Thailand; 4National Centre for
HIV Epidemiology and Clinical Research, University of
New South Wales, Australia; 5Clinical Immunology and
Immunogenetics, Royal Perth Hospital, Perth, Australia;
6
Infectious Diseases Unit, Alfred Hospital, Melbourne,
Australia

controls (p<0.05, ANOVA). The percentage of activated
NK cells significantly declined in both cases and controls.
IL-2,-6, -8, -10, TNF-α, IFN-α and -γ were not detectable in
the majority of case and control sera.
Rises in CXCL-10 (a chemokine induced by IFN-γ) and
sCD30 (an immune activation marker of the TNFR family)
correlate with HF following initiation of HBV-active ART in
HIV-HBV co-infected patients. Also implicated are markers
of IFN-γ induction (IL-18) and activity (CCL-2). These data
support our hypothesis that HF in this setting is the result
of HBV-related IRD in the liver.
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Following the initiation of HBV-active combination
antiretroviral therapy (ART) in HIV-HBV co-infected
individuals, hepatic flares (HF) are a significant clinical
problem. We hypothesised that HF in this setting is a form
of immune restoration disease (IRD).
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We conducted a case-control study of cases with HF
(n=8; defined as ALT > 5 X the upper limit of normal or
> 200 IU/L rise from baseline within the first 12 weeks
of treatment) and controls not having HF. Patients were
recruited as part of the Tenofovir in Co-infection (TICO)
study which is a prospective randomized (1:1:1) trial of
tenofovir (TDF) vs lamivudine (LMV) vs TDF/LMV within
an efavirenz based ART regimen (n=36). Quantification of
immune mediators (IL-18, -2, -6, -8, -10, soluble[s] CD26,
sCD30, CXCL-10, CCL-2, TNF-α, IFN-α and -γ in serum
was performed by ELISA, antigen capture bioassay or
cytometric bead array. The percentage of activated NK
cells (CD56brightTRAIL+) in PBMC samples was determined
by flow cytometry. In addition, immune mediator levels
were correlated with ALT, HBV VL, HIV VL and CD4 count
at each time point (Spearman’s test).
Cases had significantly higher HBV viral loads (p=0.011)
and ALT (p=0.008) than controls prior to initiation of ART.
Following ART, CXCL-10 levels significantly decreased
(p<0.05, Kruskal-Wallis) in controls but not in cases. In
cases, sCD30 levels increased and peaked at wk 8 (p<0.05,
ANOVA) while there was no significant change in controls.
Significant positive correlations were found between ALT
and CXCL-10, sCD30, CCL-2 and IL-18 at wk 8. There was a
significant increase in sCD26 over time in both cases and
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TENOFOVIR BASED HAART IS
ASSOCIATED WITH HIGH RATES OF
HBV DNA SUPPRESSION AND HBEAG
SEROCONVERSION IN THAI HIV-HBV
COINFECTED PATIENTS
Matthews GV1, Avihingsanon A2, Lewin SR 3,4, Sasadeusz J5,
Thio CL6, Bowden S7, Ayres A7, Locarnini SL 7; Ruxrungtham
K 2; Dore GJ 1
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney,
Australia; 2 HIV-NAT, Thai Red Cross AIDS Research Centre;
and Vaccine and Cellular Immunology Laboratory,
Faculty of Medicine. Chulongkorn University, Bangkok,
Thailand; 3 Department of Medicine, Monash University,
Melbourne, Australia; 4 Infectious Diseases Unit, Alfred
Hospital, Melbourne, Australia; 5 The Royal Melbourne
Hospital, Melbourne, Australia; 6 John Hopkins University,
Baltimore, MD, U.S.A; 7 Victorian Infectious Diseases
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Two randomised clinical trials of HBV-active HAART in
antiretroviral naive HIV-HBV coinfected subjects were
initiated in Thailand in 2004-2005. Randomisation was i)
zidovudine(AZT)/lamivudine(LAM)/efavirenz (EFV) or ii)
AZT/tenofovir (TDF)/EFV or iii) TDF/LAM/EFV in the TICO
study (n=36) and to i)AZT/emtricitabine (FTC)/EFV or
ii)TDF/FTC/EFV in HIV NAT 023 (n=18). Study follow-up
was to 48 weeks after which all subjects on LAM or FTC
HBV monotherapy added TDF.
This analysis aimed to determine >48 week HBV virological
and serological responses in HIV-HBV coinfected subjects
receiving TDF containing HAART.
47/54 HIVHBV coinfected subjects were followed for
a median of 27 months (range 14-40m) after HAART
initiation. Mean age was 38 years and 31/47 (66%) were
male. They were significantly immunosuppressed preHAART with a median CD4 count of 42 cells/mm3 and
45% were AIDS-defined. Median HBV DNA was 8.0 log10
IU/ml (IQR 7.5-8.7 log10 IU/ml) with 30/47 (64%) HBeAg
positive. All patients were on TDF-containing regimens:
19 in initial combination (TDF+LAM/FTC), 17 with late
combination after AZTTDF switch at 48 w, and 11 on
TDF monotherapy for HBV. Median duration of TDF was
25, 8 and 32 months respectively.
All patients had HIV RNA suppression < 50 c/ml and
median CD4 count was higher at 342 cells/mm3. 72% of
subjects had HBV DNA < 20 IU/ml with 94% HBV DNA
< 400 IU/ml. No subject had HBV DNA > 1000 IU/ml. No
significant differences were seen in proportion of patients
<20 IU/ml by type of TDF-regimen (p=0.236). HBeAg loss
occurred in 46% of HBeAg positive subjects with an antiHBe seroconversion rate of 33%. HBeAg loss was not
associated with age (p=0.08), CD4 nadir (p=0.71), change
in CD4 count (p=0.53), or baseline HBV DNA (p=0.48). The
cumulative rate of HBeAg loss was 13% at 3m, 30% at 6m,
40% at 12m, 50% at 18m and 67% at 24 months. HBsAg
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Lo G1, Herrmann S2, Cheng W3, Kontorinis N3, Phillips E 2,4,
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1
Royal Perth Hospital; 2Centre for Clinical Immunology
& Biomedical Statistics Royal Perth Hospital & Murdoch
University; 3Department of Gastroenterology Royal Perth
Hospital; 4PathWest Laboratory Medicine WA
Hepatocellular carcinoma (HCC) is a serious complication
of chronic viral hepatitis once cirrhosis has developed.
Screening for HCC allows for early detection in HCV or
HBV mono-infection and, if detected, possible treatment.
Since HIV co-infection is associated with faster progression
of liver disease in both HBV and HCV infection and nonAIDS cancers have recently been shown to be more
common and occur earlier in the setting of HIV, it is likely
that HIV co-infection increases not only the rapidity of
hepatocarcinogenesis but also the overall risk of HCC.
Screening for HCC by abdominal ultrasound and alfafeto protein (AFP) measurement is recommended at
6 to 12 month intervals for both HBV and HCV monoinfected patients. There are multiple treatment modalities
currently available for HCC including radio-frequency
ablation, percutaneous ethanol injection, trans-arterial
chemo-embolisation, resection and liver transplantation.
Treatment is a feasible option in those individuals with
hepatitis/HIV co-infection who are successfully treated
with HAART and otherwise healthy.
Fifty-one hepatitis/HIV co-infected patients attending the
Ambulatory HIV Service at Royal Perth Hospital (RPH) were
identified and their medical records reviewed to identify
uptake of HCC screening. Since 2000, 21 patients (41%)
were screened at least once by abdominal ultrasound,
5 more had ultrasound requested for other reasons
(e.g. renal failure). One patient was subsequently found
to have a HCC as an incidental finding. Nine of the 21
patients (42%) screened since 2000 have had a second
study performed and 8 more patients (31%) are awaiting
further follow-up. The mean interval between ultrasound
screening was 1.0 year (range 0.5-2.2). Thirty patients
(59%) have been screened for HCC with measurement of
serum AFP.
There has been poor uptake of initial and follow-up HCC
screening with abdominal ultrasound and AFP in hepatitis/
HIV co-infected patients at RPH and few patients have had
regular follow-up scans. Improved drug treatments have
resulted in decreased mortality from HIV in countries with
access to HAART but co-infection with hepatitis poses a
significant threat to those that might otherwise expect
a normal lifespan. Improved screening protocols for HCC
are warranted.
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Screening for hepatocellular 
carcinoma (HCC) in hepatitis/HIV coinfection using ultrasound imaging 
and alfa-feto protein levels
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loss occurred in 12%.
In conclusion TDF-containing HAART is highly successful
in achieving HIV and HBV-related virological suppression
in coinfected subjects initiating HAART in Thailand,
irrespective of regimen. Further work is needed to
understand the mechanism(s) of the high rates of HBeAg
loss and HBsAg seroconversion.
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GBV-C vs. HIV-1
SEVERAL GBV-C PROTEINS INHIBIT
DIFFERENT HIV REPLICATION STEPS

HIV AND HEPATITIS C CO-INFECTION: FROM
PATIENT TO EDUCATOR

Jung S, Fleckenstein B, Reil H
University Hospital, Department of Virology, Erlangen,
Germany
GBV-C, discovered during the search for new hepatitis
viruses displays itself by two extraordinary properties
confirmed by clinical studies as well as by in vitro
experiments: Although GBV-C is closely related to HCV
there is no relation between GBV-C viremia and hepatitis
or other diseases. Moreover, longterm GBV-C infection
correlates with a higher survival probability for GBV-C/HIV
patients.
By co-infection experiments on PBMC and T-cell lines we
demonstrate that GBV-C isolates differ in their ability to
impair replication of different HIV strains and clades. The
HIV inhibitory phenotype was corroborated by singleround of infection assays using reporter-HIV pseudo typed
with HIV specific or heterologous envelops mediating cell
entry by different mechanisms. Whereas GBV-C isolates,
predefined as HIV inhibitory isolates, suppress reporter-HIV
particles independent of the pseudo typed envelope and
in order that autonomous of the cell entry mechanism, the
majority of GBV-C HIV non-inhibitory isolates displayed no
effect on HIV and VSV pseudotype infection. Interestingly,
some GBV-C isolates have been identified which impair
exclusively the HIV gp120 mediated entry suggesting
that more than one GBV-C protein must be involved
in HIV suppression affecting different replication steps.
Therefore, each GBV-C protein was cloned and separately
expressed in T-cell lines and ongoing gene expression
was detected by FACS and immunofluorescence.
Infection assays with replication deficient reporter-HIV
pseudo typed with HIV, SIV, MLV and VSV envelopes were
performed to determine the inhibitory capacity of each
GBV-C protein and to differentiate between impairment
of the gp120/CD4 dependent HIV entry mechanism and
later HIV replication steps. Indeed, we identified three
GBV-C proteins with anti-viral properties: Whereas the
E2 protein blocks exclusively HIV-entry by the induction
of an unknown soluble factor, the non-structural GBVC proteins NS3/4A and NS5A impair HIV post-entry
replication steps.
Taken together our results arise that the existence of GBVC isolates with different HIV inhibitory phenotypes may
explain the controversial epidemiological data on the
influence of GBV-C infection for HIV progression in vivo.
Furthermore, the identification of three proteins derived
from an non-pathogenic virus reveals an interesting and
profitable source for the development of innovative,
antiretroviral drugs based on GBV-C derived peptides.
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Riley R1, Murphy G2
1
Immunology and Infectious Diseases Unit, John Hunter
Hospital, Newcastle, NSW, Australia; 2Hepatitis Service,
John Hunter Hospital, Newcastle, NSW, Australia
Social Workers at John Hunter Hospital worked with a
person co-infected with HIV and Hepatitis C through the
stages of assessment and treatment for Hepatitis C. After
a successful outcome to treatment the person was reengaged to reflect on and capture his experiences. His
experiences were developed into an educational format
to inform people in similar situations in the Newcastle
and Hunter area. The roles of each Social Worker and
the Non Government Organizations in enabling the
transformation from patient to educator will be noted.
The person has allowed his presentation to be included
within this presentation and it will highlight how he
prepared for and coped with treatment and it will
highlight the outcomes for him.
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Wood, Robin
Desmond Tutu HIV Centre, Department of Medicine,
University of Cape Town, South Africa
Tuberculosis control programs have failed to contain TB
incidence in those countries with high HIV-prevalence.
Sub-Saharan Africa is particularly heavily affected, with
80% of the global HIV/TB burden. In 2005 the World Heath
Organization declared HIV/TB to be“a regional emergency,
requiring urgent and extraordinary actions”. However, the
interactions between HIV and TB at a population level
have not been well understood and no new interventions
have been instituted within the region. The interactions
between HIV and TB are particularly intense in South
Africa townships where adult HIV prevalence is >20%,
TB incidence rates >1000/100,000 cases per annum and
annual risk of TB infection in children may exceed 4.0%
per annum.
Population TB/HIV prevalence studies in communities
with data on TB incidence and HIV status, allows
differential estimation of TB case finding proportions
for HIV-infected and uninfected individuals. Passive case
finding appears to be a less successful strategy for HIVinfected individuals. HIV-infection is also associated with
an increased prevalence of relatively asymptomatic but
sputum TB culture-positive individuals.
Observations of HIV-infected individuals from such
high TB transmission populations during increasing
immune compromise before initiation of ART, together
with changes in TB susceptibility during immune
reconstitution with ART have provided an opportunity to
gain new insights into the role of immune compromise
in the development of TB disease. ART decreases the
long-term susceptibility to TB but may also paradoxically
increase the severity and quantity of clinical presentations
of TB soon after treatment initiation. Increased survival
of HIV-infected individuals with advanced HIV-infection
with persistently increased susceptibility to TB may
diminish the potential benefits of earlier initiated ART as
a TB control measure. Molecular epidemiologic studies
of TB transmission within high density communities
identify both reactivation and rapid progression of recent
TB infection as important contributors to TB transmission
and specific TB strain association with HIV-infection.
Interventions to control TB transmission in high HIVprevalent settings include, environmental control,
improving DOTS program performance, active TB casefinding, isoniazid preventative treatment and antiretroviral
therapy. Available clinic and population-based data may
be combined to model the impact of individual and
combinations of intervention strategies.

French MA.
Department of Clinical Immunology, Royal Perth Hospital
and PathWest Laboratory Medicine, and School of
Pathology and Laboratory Medicine, University of Western
Australia
Co-infection with HIV and M. tuberculosis is common
in many resource-poor countries where antiretroviral
therapy (ART) programmes are currently established or
being introduced. As HIV and M. tuberculosis both infect
cells of the immune system, it is not surprising that coinfection with these pathogens has interacting and
complex effects on immune responses, especially during
immune reconstitution induced by ART.
It appears that ‘protective’ immune responses against
M. tuberculosis are restored by the use of ART as rates of
tuberculosis generally decline in HIV patients receiving
therapy. However, disease provoked by M. tuberculosis
infection can present during the first few months of
ART and might contribute to the higher mortality rates
observed during the first 6 months of ART in resourcepoor countries. Two patterns of disease are seen. Firstly,
10-20% of HIV patients who start ART after receiving
treatment for tuberculosis (TB) experience a ‘paradoxical
relapse’ of the TB. It is often characterised by unusual
or excessive inflammation and is therefore commonly
referred to as paradoxical TB immune reconstitution
inflammatory syndrome (TB-IRIS). Secondly, TB may
present de novo during the first few months of ART. This
is referred to as ART-associated TB and occurs about 20
times more frequently in patients from resource-poor
countries than in those from resource-rich countries.
Clinico-pathological and immunological studies suggest
that both TB-IRIS and ART-associated TB are types of
immune restoration disease (IRD). Tissue inflammation
often has the characteristics of a Th1 or possibly Th17
response and circulating interferon-γ+ T cell and/or
delayed-type hypersensitivity (DTH) skin test responses
to M. tuberculosis antigens are increased. ART-associated
TB is particularly associated with an early increase in
circulating T cells producing interferon-γ (IFN-γ after
exposure to RD1 antigens of M. tuberculosis whereas
paradoxical TB-IRIS is associated with a late increase
in circulating T cells producing IFN-γ after exposure to
PPD, which is preceded by increased DTH responses to
PPD. It therefore appears that although TB-IRIS and ARTassociated TB are both manifestations of IRD, there are
differences in the immunopathogenesis.
Increased understanding of the immunopathogenesis
of TB-IRIS and ART-associated TB will improve diagnostic
methods and management of patients with HIV and M.
tuberculosis co-infection.
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HIV AND TB CO-INFECTION

RESTORATION OF IMMUNE RESPONSES
TO M.tuberculosis IN PATIENTS WITH
HIV AND M.tuberculosis INFECTION IS A
DOUBLE-EDGED SWORD
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Conference Closing
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A Kamarulzaman. University of Malaya
In recent years, access to antiretroviral treatment has
expanded in every region of the world including East,
South and Southeast Asia with coverage expanding
more than 75% in some countries. Whilst this has led to
significant improvement in the morbidity and mortality
rates for people living with HIV, opportunistic infections
continue to be a significant issue in the management of
the HIV infected in the region.
Delayed presentation and diagnosis of HIV due to a myriad
of reasons mean that patients in the region continue
to present with a variety of opportunistic infections.
Despite advances and development in the science of
antiretroviral therapy, unfortunately the same cannot be
said for the diagnosis and management of opportunistic
infections. Diagnostic tools for the rapid detection of
common opportunistic infections such as tuberculosis
that are simple to use in the field and are inexpensive
continue to elude us. Access to microbiology laboratory,
radio-imaging and to less toxic, effective and inexpensive
medications for many serious opportunistic infections
can be poor outside of large cities in Asia and the Pacific.
This often results in inappropriate and delayed therapy
of these infections resulting in significant morbidity and
mortality.
Finally, with the emergence of MDR tuberculosis, many
healthcare centres in the region are ill-equipped to handle
the infection control needs to minimise the spread of this
infection to patients and healthcare workers alike.
Whilst the expansion of antiretroviral therapy has been
met with reasonable success, some attention needs to
be given to the ongoing need for better diagnostic tools
and treatment for common opportunistic infections
complicating HIV in patients living in the Asia and the
Pacific.
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Opportunistic Infections in Asia – The 
Unmet Needs
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Chan, M. L. 1, Petravic, J. 1, Ortiz, A. 2, Klatt, N. 2, Silvestri, G. 2,
Davenport, M. P. 1
1
Centre for Vascular Research, University of New South
Wales, Kensington, New South Wales, Australia; 2University
of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania, USA.
Human immunodeficiency virus (HIV) infection involves
the progressive decline of CD4+ T-lymphocytes, resulting
in severe immune deficiency. This in turn leads to
opportunistic infections and cancers characteristic of
AIDS, and eventually death. HIV is derived from simian
immunodeficiency virus (SIV) which infects primates. It
has been observed that natural hosts of SIV, such as sooty
mangabeys, are largely asymptomatic when infected. This
is sharply contrasted with non-natural hosts of SIV, such as
rhesus macaques, and untreated HIV-infected individuals,
who experience progressive CD4+ T-cell depletion and
go on to develop AIDS.
Currently, the lack of disease progression in natural
hosts of SIV is still not clearly understood. A better
understanding of why SIV is non-pathogenic in natural
hosts will therefore provide valuable insights into the
pathogenesis of AIDS in HIV-infected individuals and point
to new directions in treatment. Recent experimental data
show that CD4+ T-cells of SIV-infected sooty mangabeys
exhibit lower levels of the Ki67 activation marker than
those of rhesus macaques and HIV-infected individuals,
so that disease progression is apparently associated
with activation. However, few mathematical models
have been formulated to relate the levels of activation
to disease progression. In our study, we have developed
a model that demonstrates the relationship between
activation and disease outcome, and helps us understand
why SIV-infected sooty mangabeys are non-pathogenic
compared to SIV-challenged rhesus macaques and HIVinfected individuals.
We used a deterministic model of viral dynamics to
characterize the interactions between CD4+ T-cells and
the virus. Using this model, we can predict the changes
in the number of resting and activated CD4+ T-cells, the
number of infected cells and the number of virus particles
during acute and chronic phases of infection. Our
preliminary analysis reveals that a lower level of activation,
as seen in SIV-infected sooty mangabeys, results in
considerably less depletion of CD4+ T-cells, lower infection
levels and somewhat lower viral loads, as compared to
infected rhesus macaques and humans. Moreover, the
results agree with experimental data obtained from
our collaborators. Therefore, we conclude that the nonpathogenicity of SIV-infected sooty mangabeys may be
attributed to lower levels of activation of CD4+ T-cells.
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Progression of HUMAN
IMMUNODEFICIENCY VIRUS (HIV)
infection and activation of CD4+ Tlymphocytes

p106
Oral Poster friday 19 september 1635
– 1645

Apoptosis in HIV patients by LigationMediated Polymerase Chain Reaction
Hooker DJ1, Wesselingh SL1,2,3 and Cherry CL1,2,3
1
Macfarlane Burnet Institute for Medical Research and
Public Health, Melbourne Australia; 2Alfred Hospital,
Melbourne Australia; 3Monash University, Melbourne
Australia
Increased apoptosis in vivo has been associated with
serious, persistent antiretroviral drug toxicities, including
lipoatrophy. A biochemical hallmark of apoptosis,
internucleosomal DNA fragmentation, has been detected
in vivo by ligation-mediated polymerase chain reaction
(LM-PCR). Here we develop LM-PCR to measure apoptosis,
assess its reliability, validate it against two existing
apoptosis quantifiers and examine clinical associations
with LM-PCR results in well-characterized HIV patients.
Genomic DNA was column-purified from cells. For LM-PCR,
blunt-ended linkers were ligated to oligonucleosomal
apoptotic fragments. Removal of one linker strand
allowed amplification of the apoptotic population using
the other strand as PCR primer. We converted LM-PCR
into a comparative quantifier by digital image capture of
amplified fragmentation then division of trace quantities
of 600bp apoptotic amplicons into amplicons of the
single-copy CCR5 gene, generating the LM-PCR ‘value’.
In validation studies, apoptosis in staurosporine-exposed
Jurkat cells was measured over time in parallel by active
caspase-3/ELISA, terminal deoxynucleotidyl transferasemediated fluorescence at DNA strand breaks (TUNEL)/
FACS, and LM-PCR. We applied LM-PCR to PBMC samples
archived from a longitudinal study of HIV patients.
Dynamic range of the LM-PCR value is ≥17-fold (~200fold difference in apoptotic fragmentation). Inter-gel
reliability (reflecting electrophoresis, band detection and
photography) and intra-gel reliability (reflecting input DNA
mass, sample loading and trace quantity measurement)
are both excellent (intra-class correlation coefficients 0.97
and 0.95 respectively, standard errors of measurement
0.17 and 0.12 respectively). Validation experiments
reveal LM-PCR is as sensitive as caspase-3/ELISA and
more sensitive than TUNEL/FACS for distinguishing
low degrees of apoptosis (relevant spectrum in vivo).
In clinical samples, elevated PBMC LM-PCR results are
independently associated with both current treatment
exposures and clinical lipoatrophy.
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IMMUNODEFICIENCY VIRUS EXPLOITATION
OF DENDRITIC CELLS IN   THE EARLY STEPS
OF INFECTION
Junior Freddy KANKOU
University of Bangui (Central African Republic)
Bernard Frederic University of Bossangoa (Central African
Republic)
The unique capacity of dendritic cells (DCs) to capture
and process pathogens for presentation to the immune
system, combined with their capacity to express
costimulatory and adhesion molecules as well as
cytokines and chemokines, renders them powerful
antigen-presenting cells. However, immunodeficiency
viruses hijack DCs to facilitate virus dissemination while
subverting effective immune activation. Depending
on the activation level of the DC subset, human
immunodeficiency virus can use different receptors (CD4,
chemokine, and C-type lectin receptors) to bind to DCs.
These aspects likely impact whether a DC is productively
infected by or simply carries virus for transmission to more
permissive targets. DCs efficiently transmit virus to CD4+
T cells, driving virus growth as well as providing signals
to trigger virus expansion in virus-bearing CD4+ T cells.
There is accumulating evidence that viral determinants
(nef, tat) selectively modulate immature DC biology,
fostering DC–T cell interactions and virus replication
without up-regulating costimulatory molecules for
effective immune function. In addition, virus-loaded,
immature DCs activate CD4+ virus-specific T cells, and
mature DCs stimulate CD4+ and CD8+ T cells. Thus, even if
immature DCs entrap virus as it crosses the mucosae and
initiate a CD4+ T cell response, this is likely insufficient to
control infection. Appreciating how virus modulates DC
function and what determines whether virus is processed
for immune stimulation or transmitted between cells will
unveil the exact role of these cells in the onset of infection
and advance preventative microbicide and vaccine/
therapeutic approaches.
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LM-PCR has been modified, optimised, validated and
shown to be a reliable apoptosis quantifier able to
differentiate low degrees of apoptosis. In the validation
time course, the LM-PCR profile mirrored that of caspase3/ELISA (rather than that of TUNEL/FACS) reflecting the
known correlation between active caspase-3 levels
and induction of the endonuclease responsible for
internucleosomal cleavage. The development and
validation of LM-PCR to measure apoptosis provides a
new and versatile tool for monitoring and understanding
important antiretroviral drug side effects in HIV patients.
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Human leucocyte antigen (HLA) class-I restricted
Cytotoxic T Lymphocyte (CTL) responses play an
important role in the clearance of Hepatitis C virus (HCV)
infection. Although several HLA class I-restricted epitopes
within HCV have been described, the true extent of CTLdriven immune pressure on the virus is likely to be more
extensive than currently described. This is partly due to
the use of peptides derived from laboratory strains rather
than circulating viruses in cellular assays and the focus on
CTL epitopes restricted by common HLA alleles.
We previously described a population-based genetic
approach that identifies sites within the HCV genotype
(GT) 1 genome that represent in vivo targets of HLAdriven selection pressure. These sites, and flanking
sequence, were then further examined using web-based
programs (syfpheithi and BIMAS) to predict putative HLA
Class I-restricted epitopes. Sixty one predicted HLA Class
I-optimal peptides were identified. These HLA-specific
peptides along with their potential escape variants were
then tested using automated IFN-gamma ELISpot assays
on 50 HCV-infected Haemophilia patients with different
infection outcomes. Peptides were selected for each
individual based on their HLA Class I alleles. In addition,
we adjusted the H77 overlapping peptides (OLPs) to a
relevant consensus sequence based on our population
study of individuals with chronic GT1 infection.
CTL responses towards predicted HLA Class I epitopes were
detected as well as previously unknown escape mutations
that interfere with CTL recognition. Furthermore, in many
cases CTL responses against the adjusted OLPs induced a
CTL response but not the equivalent non-adjusted H77derived OLPs.
In conclusion, the ELISpot assays using H77-derived
OLPs underestimate the overall breath of the HLA
Class I-restricted immune response in HCV-infected
individuals. In order to capture the true extent of HLAspecific CTL responses we recommend that H77-derived
overlapping peptides should be adjusted for sequence
polymorphisms that are present in circulating viruses.
Furthermore, the population-based genetic approach
highlights sites within the viral genome that are under
HLA Class I-restricted selection pressure and can inform
HLA Class I-epitope predictions and identifies potential
escape mutations.
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MOLECULAR CLONING AND
CHARACTERISATION OF ENVELOPE FROM
HIV-1 PRE-SEROCONVERSION STRAINS
Reddy S M1, Center R J1, Suzuki K2, Gray L3, Gorry P R3,
Kelleher A4 &Purcell DFJ1
1
Department of Microbiology & Immunology, The
University of Melbourne, Melbourne, VIC, Australia;
2
Centre for Immunology, St. Vincent’s Hospital, Sydney,
NSW, Australia; 3Macfarlane Burnet Institute for Medical
Research and Public Health, Melbourne, VIC, Australia;
4
National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW, Australia.
Human trials have shown that HIV-1 vaccines eliciting
potent T-cell responses without stimulating broadly
neutralising antibodies (nAb) to HIV-1 envelope
protein (Env) failed to reduce HIV infections or disease
progression. Clearly, a better understanding of the nature
of the Env that supports HIV-1 transmission is required
to produce vaccines capable of raising broad nAb that
block HIV-1 at this earliest time. During the course of
infection extensive variations arise in Env driving escape
from humoral immune responses. Therefore, we sought
to examine Env sequences of transmitting strains derived
before seroconversion and ensuing selection of Env for
resistance to nAb. Transmission strain Env may expose
conserved domains sensitive to antibody neutralization
and hence studying HIV-1 Env from patients isolates
obtained before seroconversion may allow identification
of well-exposed neutralization-sensitive epitopes that
could inform vaccine design.
Whole blood was collected from patients at high risk for
HIV-1 infection and five pre-seroconversion (PSC) samples
were selected that were negative for HIV-1 antibody ELISA
and western blot, but positive for p24 antigen and HIV-1
RNA viral load assays. RNA was extracted from cell-free
virus and reverse transcribed into cDNA. A nested PCR
approach was used to amplify near full length envelope
genes. The PCR products were cloned and tested for
Env-mediated entry by pseudotyping a GFP reporter
virus and assaying infectivity in permissive cells. Of the
28 PSC clones tested, 10 (36%) were functional, and
these were fully sequenced. Within-sample variability
was very low, indicating limited genetic evolution or drift.
The number of potential N-linked glycosylation sites was
consistently lower in PSC clones in comparison with the
pNL4.3 and AD8 reference sequences. These clones will
be phenotypically characterized for their affinity for CD4,
co-receptors and known broadly neutralizing antibodies.
The clones will be further used for immunogenicity trials
in animals and the neutralization activity of the resulting
sera will be assessed.
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DO NATURAL KILLER CELLS COMPENSATE
FOR IMPAIRED
CD4+ T-CELL RESPONSES TO CMV IN HIV
PATIENTS RESPONDING TO ANTIRETROVIRAL
THERAPY?
Tan DBA1, Fernandez S1, French M1, 2, Price P1, 2
1
School of Pathology and Laboratory Medicine, University
of Western Australia, Perth, WA, Australia; 2Department of
Clinical Immunology and Immunogenetics, Royal Perth
Hospital, Perth, WA, Australia.
Although HIV patients beginning antiretroviral therapy
(ART) with extreme CD4+ T-cell depletion can achieve
a stable virological response, recovery of CD4+ T-cell
and natural killer (NK) cell numbers and function are
variable. We evaluated whether NK cell function might
compensate for deficiencies in T-cell responses to a
common viral pathogen, cytomegalovirus (CMV).
Male patients with nadir CD4+ T-cell counts <50 cells/μl
and undetectable plasma HIV RNA for >1 year on ART were
divided into low (CMV-lo, n=8) and high (CMV-hi, n=10)
responders based on CD4+ T-cell interferon-gamma (IFNγ)
responses to CMV. NK subsets and perforin expression
were quantitated cytometrically. NK IFNγ responses to
K562 cells were assessed by ELISpot. Cytokine receptor
mRNA was quantitated in unstimulated CD56+ cells.
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NK cell IFNγ responses and proportions of CD56+CD16+
cells were correlated in patients (p<0.001) and both were
lower than in controls (p=0.006 and p=0.007, respectively).
However, NK cell IFNγ responses correlated inversely with
the expression of IL-10R1 (p=0.002), IL-12Rβ1 (p=0.004)
and IL-12Rβ2 (p=0.024) mRNA. Expression of these
transcripts is reduced by exposure to the cytokines, so
low expression may reflect immune activation.
Proportions of CD56+CD16- NK cells correlated inversely
with current CD4+ T-cell counts and were weakly inversely
associated with CD4+ T-cell responses to CMV. Expression
of perforin in CD56+CD16- NK cells was higher in CMVlo patients than controls (p=0.046). Hence increased
proportions and cytolytic function of CD56+CD16- NK cells
may compensate for CD4+ T-cell dysfunction, but NK cell
IFNγ responses remain functionally deficient in patients
who began ART with extreme immunodeficiency.
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ASSESSMENT OF THYMUS-DERIVED NAÏVE
T-CELLS IN HIV PATIENTS WHO HAVE
EXPERIENCED IMMUNE RECONSTITUTION
Tanaskovic S, Fernandez S, Price P, French M A
Department of Clinical Immunology and Immunogenetics,
Royal Perth Hospital, and School of Pathology and
Laboratory Medicine, University of Western Australia,
Perth, Australia
The expression of CD31 by naive T-cells is known to
mark a CD4+ T-cell that has recently exited the thymus.
However CD31 has not been validated for use in other Tcell populations. Here we correlate expression of CD45RA
and CD31 on CD4+ T-cells, CD8+ T-cells, regulatory T-cells
(Tregs) and γδ T-cells with other indicators of thymus
function.
PBMC were cryopreserved from 27 previously
immunodeficient HIV patients with a stable response
to ART (nadir CD4+ T-cell count <50/μl, age 34-73 years)
and 23 healthy control donors (age 14-79 years). Flow
cytometry was used to identify cells co-expressing CD4,
CD8, FoxP3 (marking Treg) or γδ TCR, with CD45RA and
CD31. Naïve T-cells were enumerated in whole blood
using CD45RA and CD62L. TREC levels were quantitated
using real-time PCR in CD4+ and CD8+ T-cells purified
using magnetic beads.
The proportion of CD4+ T-cells co-expressing CD31 and
CD45RA correlated inversely with age in HIV patients
(p=0.026) and healthy controls (p<0.0001). In patients
and controls, co-expression of CD31 and CD45RA
correlated directly with CD4 TREC content (p=0.016 and
p=0.001, respectively), naive CD4+ T-cell counts (p=0.002
and p<0.0001, respectively) and thymus size (p=0.06, only
assessed in patients).
In controls, proportions of CD8+ T-cells co-expressing
CD45RA and CD31 correlated inversely with age (r=0.59, p=0.003) and directly with CD8 TREC content
(r=0.69, p=0.0003) and naive CD8+ T-cell numbers (r=0.47,
p=0.02). However, these relationships were not observed
in HIV patients. In controls, the proportion of γδ T-cells
co-expressing CD45RA and CD31 increased with age
(r=0.62, p=0.002). CD45RA+ CD31+ γδ T-cells were higher
in patients than controls (p=0.007) and did not correlate
with thymus volume.
These data validate CD31 as a marker of recent thymic
origin in CD4+ T-cell populations. Although CD31 may
mark CD8+ thymic emigrants in healthy controls, the
relationships were not evident in HIV patients. CD31
expression on γδ T-cells may not indicate a thymic origin of
these cells. The proportion of circulating CD45RA+ CD31+
γδ T-cells appears to increase when the immune system
is compromised, such as in older individuals and HIV
patients who have experienced immune reconstitution.
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Longitudinal plasma antibody titers 
in relation to IRD in HIV patients 
beginning ART in Kuala Lumpur
Yong YK1, Tan HY1, Tan DBA2, Kamarulzaman A1, Tan LH1,
French MA2,3, Price P2,3
1
University of Malaya Medical Centre, Kuala Lumpur,
Malaysia.
2
Pathology and Laboratory Medicine, University of
Western Australia, Australia.
3
Clinical Immunology & Immunogenetics, Royal Perth
Hospital, Australia.
A proportion of HIV patients beginning antiretroviral
therapy (ART) develop an immune restoration disease
(IRD). To investigate the underlying mechanisms,
longitudinal changes in plasma antibody titers were
investigated in relation to IRD in a cohort of HIV patients
beginning therapy with a range of opportunistic
infections.
Plasma were collected from 20 male (16 Chinese and
4 Malay) HIV patients beginning ART with <100 CD4 Tcells/µl at the University of Malaya Medical Centre, Kuala
Lumpur, on 5 occasions over the first year of therapy. 10
patients experienced IRD [2 with cytomegalovirus (CMV)
retinitis, 1 with Bell’s palsy, 2 with cryptococcal meningitis,
4 with tuberculosis lymphadenopathy (TB) and 1 with
varicella zoster virus (VZV)]. Plasma antibodies (IgG)
reactive with CMV, Cryptococci, PPD and VZV antigens
were assessed using standard ELISA methods.
All patients developed high levels of anti-CMV antibody
during 1 year on ART, regardless of IRD. Antibody reactive
to cryptococcal antigen peaked only at the time of
cryptococcal IRD. Anti-PPD titers were elevated at the
start of ART in two TB IRD patients and remained high or
increased further at the time of their IRD. However, the
other two TB IRD patients retained low to intermediate
titers throughout first year of ART. Anti-VZV titers were
detectable in the VZV IRD patient at the start of ART, with
a marginal increment during IRD. Bell’s palsy followed
high titers of antibody reactive with CMV and not VZV.
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Despite their immunodeficiency, most HIV-infected
patients display restored antigen-specific IgG antibody
responses during 12 months of ART. Antibody titers were
varied considerably between patients but were relatively
stable over time, suggesting inherent differences in
immune capacity. The high titers of anti-CMV IgG
developing in most patients regardless of IRD may reflect
the reactivation of CMV by chronic immune activation or
may reflect immune dysregulation associated with the
restoration of CD4 T-cell numbers and function.
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TRENDS OVER TIME IN THAI GAY MEN’S
ACCESS TO A SEXUAL HEALTH SERVICE IN
SYDNEY: AN ONGOING PARTNERSHIP
Dabbhadatta J1, Wang J2, Moreton R3, Prihaswan P4, Scott
S2, Suarez M5, Silveira M4, McGowan L4, Wong S2
1
HIV/AIDS and Related Programs Unit, South Eastern
Sydney and Illawara Area Health Service, NSW, Australia;
2
ACON, Sydney, NSW, Australia; 3Multicultural HIV/AIDS
and Hepatitis C Service, Sydney, NSW, Australia; 4HIV and
Related Programs Health Promotion Team, Sydney South
West Area Health Service, NSW, Australia; 5HIV and Related
Programs Health Promotion Team, Northern Sydney and
Central Coast Area Health Service, NSW, Australia
Thai gay men remain a priority group for HIV and sexually
transmissible infection (STI) prevention in Sydney. Research
indicates that poor access to sexual health check ups
may have contributed to undiagnosed HIV transmission
among people from culturally and linguistically diverse
(CALD) communities.
Working in collaboration with affected communities and
a range of services is essential in health promotion. A
media campaign, targeting both ethnic and gay press, to
increase HIV and STI testing rates among Thai gay men
has been implemented annually since 2006 through a
partnership of health services.
In 2008 the media campaign was reviewed to give a new
look and better connect with the target audience based
on the evaluation from previous years. A participation
strategy was also undertaken to involve Thai gay men in
the development of new campaign material. The project
continued to maintain strong partnerships between
services and Thai communities resulting in notable
support from the Thai press, publishing a series of articles
promoting access to HIV and STI screening for Thai gay
men.
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Evaluation of this new campaign is being conducted. This
will provide data prior, during and after the campaign
on Thai gay men’s access to a sexual health clinic. These
include attendance, proportion of new clients, HIV and
STI testings and diagnoses, number of asymptomatic
screens and trends over time.
This paper will describe the findings of the evaluation,
the process of working in an ongoing partnership, and
comment on the trends regarding access of Thai gay
men to sexual health screening.
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ASHM - Peter Meese Memorial Session 
- Clinical - Associated Conditions 
Complications
THE TB + HIV CONNECTION
Furner VL1, Moreton R2, Tawil V3, Christensen A4
1
Albion Street Centre, Sydney, NSW; 2Multicultural
HIV/AIDS and Hepatitis C Service, Sydney, NSW; 3AIDS/
Infectious Diseases Branch, NSW Department of Health,
4
Communicable Diseases Branch, NSW Department of
Health, NSW, Australia
Background: The NSW HIV/AIDS Strategy 2006-2009 has
identified people with HIV from CALD backgrounds as
a priority. In NSW, there are 350-420 HIV notifications
annually, with people from CALD backgrounds accounting
for 1 in 5 notifications. Further, 85% of people with TB
diagnosed in Australia are born overseas. However only
approximately 30% of those diagnosed with TB in NSW
have documented HIV tests. In November 2005, NSW
Health formed a NSW CALD Interagency committee to
enhance inclusion of CALD issues in the work of HIV and
related sectors.
Outcome: One of the key initiatives of the interagency
was the establishment of the NSW TB/HIV Working
Group in recognition of the nexus between TB and HIV
for people from priority CALD backgrounds. The working
group aimed to develop a strategic approach to support
partnerships and collaboration between the TB and HIV
sectors across NSW. The key initiative in 2007-2008 has
been the development of a state-wide “Roadshow”.
The purpose of the Roadshow was to bring together HIV,
sexual health and TB clinicians in each Area Health Service
to:
• promote the new NSW Health Policy Directives to
enable statewide standard practice of testing, diagnosis
and management of TB/HIV;
• formalise partnerships and strengthen clinical care
coordination between the TB, HIV and related sectors
at a local level.
The Roadshow outlined the principles of TB and HIV
testing, and management within the respective sectors.
It also highlighted key issues relating to migration,
settlement and refugee health within NSW.
The development, implementation and outcomes of the
“Roadshow” initiative will be discussed in detail including
the enhanced partnerships that have been generated
between the sectors, and also the lessons learnt in
developing and implementing the Roadshow at a state
and local service level. The model utilised may also be
relevant in addressing other health challenges in HIV care
and treatment in the future.
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SEXO LATINO. SEXO CALIENTE. SEXO
SEGURO. A SAFE SEX CAMPAIGN FOR
SPANISH SPEAKING GAY MEN
Prihaswan P1, Silveira M1, Suarez M2, Moreton R3,
Dabbhadatta J4, Wang J5, Wong S5, McGowan L1.
1
Sydney South West Area Health Service; 2Northern Sydney
and Central Coast Area Health Service; 3Multicultural
HIV and Hepatitis C Service; 4South Eastern Sydney and
Illawara Area Health Service; 5ACON

Rose JL, Williamson M.A and Allen. D
HIV and Sexual Health Service, Northern Sydney Central
Coast Health, Gosford, NSW, Australia.
A needs assessment was conducted of workers living in
the regional area of Central Coast NSW Australia in 2005
- 2006. 17% of sex workers reported that they either do
not have a regular sexual health checks or have never had
them. 43% of workers reported having infrequent sexual
health screening. Vaccination rates for hepatitis B were
low amongst survey respondents.
Recommendations were made to explore alternative
methods to increase the number of sex workers undertaking
regular sexual health screens. It was also recommended to
explore approaches to increase the number of sex workers
fully vaccinated against Hepatitis B.
The asymptomatic onsite brothel screening program was
developed and implemented by the Holden Street clinic
at Gosford NSW in November 2007.
An outreach screening and anaphylaxis policy was
developed. Letters were sent to all brothel managers
outlining the program and service provision.
This
included 7 Asian and 4 English speaking brothels to
which response was overwhelming. Screening was
offered to asymptomatic workers who were then
registered by the clinic, a sexual health history was
obtained, serology for Hepatitis A, B and C, syphilis, and
Human Immunodeficiency Virus; self collected vaginal
swabs, throat swabs for gonorrhoea, first void urine for
chlamydia. Follow up with results and vaccination was
offered 2 weeks post screening.
Post screening results have indicated that this program
gives workers an alternative choice to attending the
Sexual Health Clinic thus increasing uptake in screening
and education. Results show 50% of new sex workers
registered at the sexual health clinic in the past 5 months
occurred through the outreach program.
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The Culturally and Linguistically Diverse (CALD) Gay
Men’s Working Group is a partnership project targeting
high priority CALD populations to reduce HIV and STI
transmission. This presentation describes the processes
and outcomes of the development of a Spanish-speaking
Gay Men HIV and STI Campaign in metropolitan Sydney.
There is no available research about the sexual health
needs and behaviours of Spanish-speaking gay men
in Sydney. To inform the development of strategies a
series of focus groups and key informant interviews
were undertaken to explore understandings of HIV and
STI risk, current service access and testing practices, and
utilisation of gay and ethnic media.
Strategies have included a social marketing campaign
as well as a social support initiative. Campaign messages
were developed in close consultation with Spanishspeaking gay men. The social support component
provided an opportunity for Spanish-speaking gay men
to connect with each other and reduce social isolation for
those men who are not attached to the gay scene. It will
also allow for ongoing dialouge between this group and
service providers regarding their HIV and STI information
needs. Findings from these consultations and campaign
development processes will be presented.

P116
Brothel based asymptomatic 
screening of female sex workers in a 
regional setting.
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the diseases in specific terms of moderation of psychomorbidity. It modulates and reduces it by improving
function of immune system and positive attitude towards
the disease. Altered the immune system, may break the
vicious cycle of anxiety and depressed immune system
and cause psycho-physiological relaxation.

Clinical Medicine
P117
RELATIVE SIGNIFICANCE OF
PHYSIOTHERAPY IN THE TREATMENT
OF ACQUIRED IMMUNE DEFICIENCY
SYNDROME. A REVIEW OF LITERATURE
Amalnerkar, T.
Masterskill College of nursing & health sciences, Cheras
{Selangor}, Malaysia.
Objective: Acquired immune deficiency syndrome is
characterized by depressed and disturbed immune system
and in long term it leads to psychological symptoms
like stress, nervousness, anxiety, frustration and worries,
which in turns leads to a vicious cycle of Persistent pain
and agony. This review is an attempt to enlighten the
effectiveness of exercises and other physiotherapeutic
interventions for reduction in the stress and anxiety
thereby improvement in the psychological symptoms
which are commonly manifested in A.I.D.S and are used
clinically.
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Methods: A systematic review has been made by
MEDLINE, CINHAL, AMED, PUBMED, SCIENCE DIRECT,
SPORTS DISCUSS, PEDRO, BMJ, COCHRANE LIBRARY
and other OVID databases. “The awareness of inevitable
death leads to an irreparable damage to the psychology
which in turns leads to Psycho morbidity in terms of
stress, anxiety and depression. Hereby, speed of the
disease can be altered and moderated well with the
psychotherapeutic benefits of exercise. As regular active
exercises like jogging slow running, pace walking, weight
bearing, walking, resistance training, low impact aerobics,
bicycling, brisk walk, and muscular strengthening relatively
keeps the immune level steady, and decreases the speed
of deterioration. Improvements mostly are caused by
rhythmic, aerobic exercises, using of large muscle groups
of moderate and low intensity for example, jogging,
swimming, cycling, and walking. In addition, life style
modification and exercises gives feeling of psychological
well being, and “In addition a reason to live”.
Result: Exercise offers a low-cost alternative treatment
adjunct which is easy to adapt. Slight reductions in stress,
anxiety and change in the mood alleviate and reduce these
symptoms and thereby modulate the immune system.
Since ancient era exercises is being used successfully as
a therapeutic adjunct in a variety of psychiatric disorders.
Enormous strives have made for the treatment but very
little documentations has been done till now, however
this concept need’s more evidence based researches and
studies. In future we can develop specific physiotherapy
techniques and protocols and to the various stages of
the diseases which will be specific in terms of intensity
& duration.

P118
RESISTANCE TO ANTIRETROVIRAL DRUGS IN
HIV NAÏVE PATIENTS RECRUITED INTO THE
ALTAIR STUDY
Arriaga ME1, Puls RL1, Emery S1 for the Altair Study Group
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, NSW, Australia
The ALTAIR study is a Phase IIIb/IV, randomised, open
label study comparing three regimens of combination
antiretroviral therapy (ART) in treatment-naïve, HIVinfected subjects over a two-year period. The objective of
the study is to compare the safety, tolerability and efficacy
of these regimens based upon a fixed dose combination
of tenofovir and emtricitabine (Truvada®). The study is
being conducted at 36 sites in 15 countries across five
continents.
Evidence of harbouring ART-resistant HIV was an exclusion
criterion and where available, patients had a genotypic
resistance test by local service providers at screening. Two
sites sent samples to Sydney for testing. Point mutations
were analysed locally and patients were defined as “HIV
resistant” or “HIV non resistant” according to the current
International AIDS Society (IAS) guidelines.
Of 441 subjects screened, 24 were excluded because of
resistance. However, four were subsequently found not
resistant according to the IAS guidelines, leaving 20 (4.5%)
subjects with truly resistant HIV. Australia had the highest
mutation rate (13.6%), followed by Canada (6.2%), Europe
(4.3%), Latin America (3.4%) and Asia (2.9%). Resistance to
non-nucleoside reverse transcriptase inhibitors (NNRTI)
was the most frequent (45.0%), followed by nucleoside
reverse transcriptase inhibitors (NRTI) (31.0%) and protease
inhibitors (PI) (12.0%). Three patients were resistant to two
different classes of ART; two were resistant to NNRTI and
NRTI and one was resistant to NRTI and PI. When analysed
by region, Europe presented a different pattern with
the majority of mutations conferring resistance to NRTI
(75.0%) and then NNRTI (25.0%).
The prevalence of mutations associated with resistance
to ART in HIV-naïve subjects varied in different regions
with highest rates where ART is broadly available. Most
mutations conferred resistance to NNRTI and NRTI.
Although low in number, these results confirm the
importance of testing for ART resistance in patients
considering initiation of therapy, especially in countries
where ART is widely available.

Conclusion: No doubt, an inexpensive approach with
pain modulation approach is proved effective in treating

222 						

17-20 september 2008 @ Perth Convention Centre, Western Australia

TRIPLE CLASS HIV ANTIRETROVIRAL (ARV)
FAILURE IN AN AUSTRALIAN PRIMARY CARE
SETTING
Bloch M1, Farris M2 Tilden D3 Gowers, A1, Hughes, T1
1
Holdsworth House Medical Practice, Sydney, NSW,
Australia; 2Research Development Unit, Merck Sharp &
Dohme, Australia 3 Dominic Tilden, THEMA Consulting
Pty Ltd
The prevalence, predictors and outcomes of triple class
HIV ARV failure in primary care practice in Australia have
not been evaluated.
In a cross-sectional retrospective ethics-approved study
we reviewed records of all participants attending a
high caseload Sydney primary care practice who failed
triple class ARV virologically, immunologically or due to
intolerance in each class (NRTI, NNRTI, PI).
Triple class ARV failure prevalence was 5.1%, all were male
with a median age of 49. Median age at HIV diagnosis was
29, 96% of participants were diagnosed prior to 1997. 59%
initiated monotherapy and 10% dual therapy. At therapy
initiation, median CD4 T lymphocyte count was 303 cells/
µL, and 30%, 52% and 17% were CDC classification A, B
and C respectively.
From diagnosis to ARV initiation was 5.5 years (SD 4.11),
and time from initiation to triple class failure was 6.76
years (SD 3.17). Over 85% of participants ceased ARV due
to intolerance or virologic failure and 31% of participants
experienced triple class virologic failure. Intolerance was
experienced equally across NRTI, NNRTI and PI (32%,
36% and 34% respectively). Virologic failure was more
common with PIs than NRTI & NNRTI (33% vs 25% & 27%
respectively)
Resistance information was present for 57% of participants,
the prevalence of NRTI, NNRTI and PI resistance was 86%,
76% and 62% respectively. The following independent
mutations were prevalent in >35% of participants D67N,
L210W, M184V, M41L, T215Y, K103N, L90M, V82A.
For the 51 participants there were 30 unique regimens
in current ARV therapy. The median duration of current
therapy was 1.6 years. 78% of participants were currently
virologically controlled (VL<50).
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ASHM - Ian Thompson 
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P120
IDENTIFICATION OF THE GENETIC
MARKER HLA-B*5701 AND ABACAVIR
HYPERSENSITIVITY REACTION (HSR) IN HIV1 PATIENTS IN SYDNEY, AUSTRALIA AND
DEVELOPMENT OF MECHANISMS FOR RISK
REDUCTION
Bloch M, Quan D, Beileiter K and Franic T.
Holdsworth House Medical Practice, Sydney, NSW,
Australia
The HLA allele, HLA-B*5701, confers susceptibility to
abacavir HSR, a systemic allergic reaction which resolves
on abacavir cessation but can be life-threatening on
abacavir re-challenge. Although abacavir, and abacavir
containing compounds in conjunction with other NRTI
as treatment options are efficacious, the need to prevent
possible HSRs is clear. Hence we measured the prevalence
of HLA-B*5701 in a sample of HIV patients attending a
high HIV caseload Sydney primary care practice and used
this information to design methods of reducing the risk
of abacavir HSR.
Abacavir treatment naïve or previously clinically
diagnosed abacavir HSR HIV-1 patients were invited to
participate in an Ethics-approved cross-sectional study.
Patients who tolerated abacavir were excluded. 300
patients were enrolled, 90% were abacavir naïve, 23.3%
were antiretroviral naïve and 66.7% were on antiretroviral
therapy that excluded abacavir. All patients were male,
median age 43 yrs, of Caucasian (91%), Asian (5.3%),
Hispanic (1.7%), Mixed (1.3%), African and Aboriginal
(0.3%) ethnicities. The prevalence of HLA-B*5701 in the
abacavir naïve cohort was 8.5%. 10 percent (30/300) of
patients enrolled were previously diagnosed as having
an abacavir HSR. Interestingly, only 50% (15/30) were
positive for the HLA-B*5701 allele, all being Caucasian.
The median CD4+ count at the time of diagnosed HSR
was 580 cells/µL. 96.8% of patients consented to their
information being entered into a secure web-based
registry containing de-identified HLA-B*5701 status and
abacavir HSR details. The registry was created with graded
access for the treating physician and laboratory.
Successful implementation of a genetic screening
protocol revealed the prevalence and distribution of HLAB*5701 to be as described in previous studies, but the
clinical diagnosis of abacavir HSR may be a poor predictor
of HLA-B*5701 status. The acceptability of a secure web
based registry for retention and result access has potential
for wider application.

Thus triple class ARV failure in primary care represents 5% of
patients. The common characteristics of these patients is that
they had longstanding HIV and were initiated sub-optimally
however they are currently well controlled.
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P121
Towards evidence-based guidelines 
for anal cancer screening

P122
Oral Poster Thursday 18 September 
1635 – 1640

Botes L P 1, Hillman R 1
1
Sexually Transmitted Infections Research Centre,
University of Sydney, Sydney, NSW, Australia

Clinical ANti-retroviral therapy

Anal cancer is a condition with significant morbidity
and mortality. The early stages of anal cancer and precancer are typically asymptomatic and thus the majority
of patients are diagnosed with late-stage disease. As a
consequence, anal cancer generally has a poor prognosis,
with five-year survival rates between 20% - 70%.
Anal cancer is rare in the general Australian community,
with an incidence rate of approximately 1 case/100,000
per year. Such a relatively low rate may explain the
comparatively low levels of awareness amongst the
medical and general communities. However, rates
among MSM, particularly those with HIV infection, are
much higher – typically 30-50 cases/100,000.
The introduction of cervical cancer screening programs
is widely regarded as a major public health success, with
incident cases of cervical cancer decreasing from 40-50
cases/100 000 during the last 20 years to the current rate
of 8 cases/100 000. These programs are based on regular
cytological screening of ‘at-risk’ women for cervical
squamous intra-epithelial lesions. Women identified with
these lesions are then offered the opportunity for early
intervention, which prevents the development of cervical
cancer.
The aetiological, epidemiological and cytological
similarities between cervical and anal cancer have led
to increasing calls for the introduction of comparable
screening programs for anal cancer in high-risk
populations. To date, however, there are no Australian
data to support such a move
We therefore set out to determine whether anal
cytological screening was acceptable to HIV positive MSM
and investigate whether it would lead to a significant
increase in the detection of individuals with severe anal
dysplasia and anal cancer
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A prospective three-year study of 1000 HIV positive MSM
attending an HIV outpatient clinic has commenced
in Sydney. Epidemiological, behavioural, virological,
immunological, cytological and histological data from
the first 100 participants will be presented.
Anal cancer is now the third most common tumour
occurring in the HIV infected, and rates are rising. There is
increasing evidence that screening for anal cancer is now
technically possible, and probably desirable. These data
will help inform the development of evidence-based
Australian guidelines for the screening of HIV positive
MSM for anal dysplasia and cancer.
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HIV DISEASE PROGRESSION IN HIV-1
PATIENTS INITIATING COMBINATION
ANTIRETROVIRAL THERAPY WITH
ADVANCED DISEASE IN THE ASIA-PACIFIC
REGION: RESULTS FROM THE TREAT ASIA HIV
OBSERVATIONAL DATABASE (TAHOD)
Byakwaga H, 1Petoumenos K, 2Zhang F, 3Ananworanich
J on behalf of the TREAT Asia HIV Observational Database
(TAHOD).
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney, NSW,
Australia; 2Beijing Ditan Hospital, Beijing China; 3HIVNAT/The Thai Red Cross AIDS Research Centre, Bangkok,
Thailand
1

There is little data on HIV disease progression from
resource-limited settings in patients initiating combination
antiretroviral therapy (cART) with advanced HIV infection
To examine predictors of AIDS or death in patients
initiating cART with CD4 cell count ≤ 200 cells/µL in the
TREAT Asia HIV Observational Database (TAHOD).
Patients who commenced cART after 1 January 1997 in
TAHOD with a baseline CD4 cell count ≤200 cells/µL were
included. The main outcome measure was progression
to either an AIDS defining illness or death occurring
between 6 months and 2 years after initiation of cART.
Predictors of HIV disease progression were assessed using
survival analysis methods.
A total of 1253 patients included in these analyses
contributed 2056 person years of follow up, during which
113 patients were diagnosed with AIDS and 9 died. The
median CD4 count at start of cART was 63 (IQR 25-130)
cells/µL, the median absolute CD4 cell count six months
from start of cART was 175 (IQR, 106-268) and the mean
CD4 T-cell increase was 122 (SD, 105) cells/µL. The rate of
progression to the combined endpoint (AIDS or death)
was 5.9 per 100 person years. In univariate analyses gender
and CD4 count at month 6 were significantly associated
with HIV disease progression. CD4 count at month 6 was
the only independent predictor of disease progression
(HR 0.75, 95% CI 0.62-0.87, P<0.001).
In patients initiating cART with advanced disease (CD4
count ≤ 200 cells/µL), the CD4 count at month 6 but not
the baseline CD4 count is strongly associated with the risk
of HIV disease progression.
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HIV integrase inhibitors are a new class of antiretroviral
drugs that target a critical stage in the HIV replication
cycle by blocking the integration of viral DNA into the
host cell genome. Raltegravir, a strand-transfer inhibitor
of HIV-1 integrase, has been associated with complete
suppression of viral load when used with an optimised
background regimen in heavily pre-treated patients.
However, resistance to the drug has been described in a
small number of cases.
Here we describe a case of multidrug class resistant
HIV, including resistance to raltegravir. The patient was
diagnosed HIV positive in October 1993 with a CD4 cell
count of 66 (8%). He started on zidovudine monotherapy
in 1994 and over the next 8 years was treated with dual
therapy as well as various antiretroviral combination
regimens. Throughout this time, his CD4 cell count was
always less than 100 and HIV viral load greater than 80,000
copies/mL, suggesting poor adherence. In 2001 he
commenced treatment with enfuvirtide on an optimised
background but with only a transient response.
Raltegravir treatment was commenced in September
2007, resulting in a viral load reduction of approximately
3 log10 after 2 months but with a rebound thereafter. PCR
amplification and sequencing of the entire integrase
region in samples with viral loads of 3 log10 HIV copies
collected during March and April 2008 revealed a wild
type gene. Sequencing of the integrase region in a sample
collected in May with a viral load of 4 log10 HIV copies
identified an N155N/H mutation. Previous studies have
described this mutation as one of two possible genetic
pathways for development of resistance to raltegravir, the
other being Q148H. At this stage no secondary mutations
have been identified. The genetic barrier for resistance to
raltegravir is low. Adherence will be an important issue if
patients are to benefit optimally from its use.

Chong S, Ritchie B, Daly L, Shaw D.
Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide,
South Australia, Australia.

Clinical Medicine

Chibo D1, Roth N2, Birch C1.
1
Victorian Infectious Diseases Reference Laboratory,
Melbourne, Victoria, Australia; 2Prahran Market Clinic,
Melbourne, Victoria, Australia

P124
VACCINATION RATES IN HIV-INFECTED
PATIENTS ATTENDING HOSPITAL
INFECTIOUS DISEASES OUTPATIENT CLINICS.

Significant gaps exist between current immunisation
recommendations for HIV-infected patients and clinical
practice.
The aim of this study was firstly to determine the extent
of screening for viral hepatitis and secondly to evaluate
immunisation uptake of Influenza, Hepatitis A and B in
HIV-infected patients attending outpatient clinics.
A retrospective review of patient case notes, pharmacy
records and pathology results was performed. 291 HIVinfected patients visiting the outpatient department (≥1
visit) during the 12-month period of 2006 were identified
from our HIV database.
265 males (91.1%), mean age 46.1 years and 26 females
(8.9%), mean age 40.7 years, were analysed. Mean CD4
(cells/mm3) was 476.2 (95% CI: 444.6-507.8) with 196
(67.4%) having undetectable viral loads (<50 copies/mL).
Hepatitis C antibody was performed on 90.7% (264/291)
of patients with 15.9% (42/264) being antibody and PCR
positive.
From Hepatitis A testing, 28.9% (84/291) of patients were
non-immune and in 36.1% (105/291) serology status
was unknown. With Hepatitis B, 31.6% (92/291) patients
were identified as vaccine eligible but in 24.7% (72/291)
serology markers were incomplete or absent to fully
assess vaccine eligibility. 5.3% (14/262) of patients tested
for Hepatitis B surface antigen were co-infected.
There were no absolute contraindications to vaccination
in any patient. 24.4% (71/291) received Influenza vaccine;
36.9% (31/84) of eligible patients received ≥1 or more
doses of Hepatitis A vaccine, and 31.5% (29/92) of eligible
patients received ≥1 Hepatitis B vaccine dose. Immune
response to vaccination was not routinely performed.
Full serology markers for Hepatitis A and B were not
routinely requested in all HIV patients. Poor vaccine
uptake among high risk individuals was confirmed from
this study. Our findings highlight the real problems faced
with routine immunisation coverage in a busy ambulatory
HIV practice and emphasise the need for a dedicated and
proactive approach to identify, vaccinate and follow up
eligible patients. Having implemented a nurse initiated
“opt out” immunisation process for 2008, we plan to
review its impact next year.
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RESISTANCE TO THE HIV-1 INTEGRASE
INHIBITOR RALTEGRAVIR: A CASE STUDY
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P126
A RETROSPECTIVE ANALYSIS OF THE
ORAL HEALTH AND TREAMENT NEEDS IN
PATIENTS WITH HIV INFECTION

P125
A STUDY OF ALDESLEUKIN WITH AND
WITHOUT ANTIRETROVIRAL THERAPY
(STALWART): DESIGN AND BASELINE
CHARACTERISTICS
Carey C1, Kelly M2, Courtney-Rodgers D1, Wyman N3, on
behalf of the STALWART Protocol Team and the INSIGHT
network.
NCHECR, Sydney, NSW, Australia, 2AIDS Medical Unit,
Brisbane, Australia, 3Department of Biostatistics, University
of Minnesota, Minneapolis, USA.

Investigators: Freeman AD1, Logan RM1, Liberali SL1,2,
Coates EA2
1
School of Dentistry, The University of Adelaide, South
Australia;2 South Australian Dental Service, Adelaide
Dental Hospital, South Australia

1

STALWART is a clinical trial designed to evaluate
subcutaneous recombinant aldesleukin (rIL-2) as an
antiretroviral therapy (ART) sparing agent.
The primary objective of STALWART is to compare change
from baseline in CD4+ T-lymphocyte count after 32 weeks
in three groups of patients randomized to receive
1. 3 cycles of rIL-2 administered as monotherapy;
2. 3 cycles of rIL-2 with concomitant peri-cycle highly
active ART; or
3. neither ART nor rIL-2.
Patients with HIV-1 infection, CD4+ T lymphocyte count
≥ 300 cells/mm3 and who have not taken ART for at least
one year prior to randomization are to be enrolled.
This international, phase II, open label trial is randomizing
participants equally among the three groups. Protocol
implementation is overseen by a multinational team
and four International Coordinating Centers in Sydney,
London, Copenhagen and Washington DC.
Enrollment will stop on June 30, 2008. With at least 70
patients per treatment group, power exceeds 80% for
detecting pair-wise differences in CD4+ T lymphocytes
after 32 weeks of 80 to 100 cells/mm3.
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Through April 2008, 216 participants enrolled in the
STALWART study at 28 of the planned 35 sites. The mean
age is 38 years, 19% are female with a median entry CD4+
T-cell count of 414 cells/mL. 75% of participants are ART
naïve.

The introduction of highly-active anti-retroviral therapy
(HAART) has allowed HIV positive individuals to experience
a greater life expectancy but with the potential for an
increased risk of medical co-morbidities including non-HIV
related oral conditions. Little data is available describing
prevalence and severity of oral manifestations and little
evidence available for appropriate dental management
in a post-HAART cohort of patients.
The Special Needs Unit (SNU) at the Adelaide Dental
Hospital has provided comprehensive dental treatment
for patients with HIV since 1998. A retrospective case-note
analysis with emphasis on identifying the prevalence
of HIV-related oral lesions was performed, utilising
electronic and hand-written records. A total of 277 (264M:
13F) individuals were identified who had attended SNU
for dental care between 2001 and 2008.
The majority of patients presented with medical comorbidities. There were significant differences observed
in the prevalence of oral conditions between HAART and
non-HAART groups, and in comparison to a previous pilot
study performed in the late 1990s. HAART individuals
presented with more oral conditions, including
papillomatous lesions, xerostomia and candidiasis. Further
analysis of this sample, including the treatment needs of
these individuals is pending.
These findings provide information on the prevalence of
oral conditions and demonstrate the need to identify and
address oral health needs for people with HIV.

While a substantial phase II database exists on the effect
of rIL-2 on CD4+ T lymphocyte count with continuous
ART, data are more limited when rIL-2 is not used with ART
or with peri-cycle ART. STALWART will provide important
information on the potential use of rIL-2 as an ART-sparing
treatment in a diverse population.
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The Therapeutic Goods Administration (TGA) Act permits
access to unregistered medication for patients with
life threatening conditions via Special Access Schemes
(SAS). Post-registration an SAS changes status to an
Expanded Access Program (EAP) and EAPs may continue
until medications achieve listing on the Pharmaceutical
Benefits Scheme (PBS).
In setting up the ISENTRESS SAS a broad consultative
process was undertaken with internal and external
stakeholders.
This consultation process yielded specific decisions.
Australia would run the program as an SAS rather than a
global research protocol with the following criteria:
• similar inclusion/exclusion criteria and adverse event
reporting procedures to the research protocol
• no other patient data would be collected
• genotype results were removed as part of the inclusion
criteria as genotype testing was not available on the
Medicare Benefits Schedule
• a CD4 count restriction of < 200mm³/ml was required
for each patient enrolment
• any exemptions to the inclusion/exclusion criteria
would require approval by the Merck Sharp & Dohme
(MSD Australia) Medical Advisor
Australia became the first country outside of the United
States of America to commence an ISENTRESS® access
program on November 1, 2006.
The transition from SAS to EAP and then preparing for
PBS launch involves satisfying complex legal, regulatory
and logistical requirements, and being transparent in
communication with internal and external stakeholders.
This presentation discusses many of the challenges,
processes, protocols and successes experienced by
MSD Australia in initiating and managing the Australian
ISENTRESS® SAS/EAP.

P129
CHARACTERISATION OF PARTICIPANT
REACTION TO ABACAVIR IN THE STEAL
STUDY: A RANDOMISED, OPEN LABEL TRIAL
TO ASSESS THE SAFETY AND EFFICACY OF
SWITCHING TO FIXED-DOSE TENOFOVIREMTRICITABINE OR ABACAVIR-LAMIVUDINE.
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Gaur, D.¹, Strum, A.¹, Opitz, C.¹, Pasfield, C.¹, Aunedi, H.¹,
Dudek, L.¹, Arnold, G.¹
¹ Merck Sharp & Dohme (Australia) Pty Ltd.
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Davies SC1, Bloch M2, Haskelberg H3, Humphries A3 on
behalf of the STEAL investigators
1
Northern Sydney Sexual Health Service, Royal North
Shore Hospital, Sydney, NSW, Australia; 2Holdsworth House
Medical Practice, Darlinghurst, NSW, Australia. 3National
Centre in HIV Epidemiology and Clinical Research, UNSW,
Sydney, NSW, Australia
Abacavir causes a potentially severe hypersensitivity
reaction (HSR) in 5-8% of patients. The symptoms of
HSR can be non-specific, and in blinded trials HSR was
reported in 2-7% of participants not receiving abacavir.
The presence of the HLA-B*5701 allele is a strong predictor
for HSR and clinical diagnosis of the reaction has reduced
where screening has been implemented. In the STEAL
study 360 participants were randomised 1:1 to receive
either fixed-dose abacavir-lamivudine or tenofoviremtricitabine. All were screened for the HLA-B*5701
allele and excluded if positive (unless previously tolerant
to abacavir). We aimed to characterise clinical reports of
HSR against a case definition and perform epicutaneous
patch tests to determine whether these cases were true
immunological HSRs.
Two clinicians reviewed the reports of presumptive
abacavir HSR against a standardised case definition, and
classified them as true clinical HSR or not.The case definition
required at least two intensifying symptoms from a list of
5 categories (rash, fever, respiratory, gastrointestinal and
constitutional) within 6 weeks of commencing abacavir,
and resolving within 72 hours of ceasing abacavir. For
the skin patch test dilute concentrations of abacavir were
applied to the skin and reactions were assessed after 24h
and 48h. Erythema and vesicular rash limited to the patch
area characterised a positive result, with no response to
the control vehicle.
Of 441 participants screened for study eligibility, 28 (6.3%)
tested HLA-B*5701 positive and all except one (previously
tolerant to abacavir) were excluded from participation.
Four participants randomised to the abacavir-lamivudine
arm reported symptoms and ceased abacavir due to
presumptive HSR. Two of these met the case definition
for clinical HSR. Results from the skin patch test will be
presented.
Similar to previous reports, HLA-B*5701 screening resulted
in less frequent suspected abacavir HSRs. True clinical HSR
occurred in only two (1.1%) patients. True immunological
HSR results will be presented.
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KEY SUCCESSES, PROCESSES AND LESSONS
LEARNED:
THE ISENTRESS EXPANDED ACCESS
PROGRAM
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Coordination of international
clinical study – set up, ethics, and
local regulations
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Haskelberg H1, Puls RL1, Emery S1 for the Altair Study
Group
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, NSW, Australia
ALTAIR is a Phase IIIb/IV, international, open-label,
randomised, 96 week clinical trial designed to compare
the safety, tolerability and efficacy of three initial regimens
of combination antiretroviral therapy based upon a
fixed dose combination of tenofovir and emtricitabine
(Truvada®). This international study has randomised
329 treatment-naïve subjects at 36 sites in 15 countries.
This is an investigator-initiated study, sponsored and
coordinated by the NCHECR/UNSW.
To oversee and coordinate this trial, three structures were
put in place. Firstly, an Executive structure comprising the
Protocol Steering Committee (PSC) and the Data Safety
Monitoring Board (DSMB), secondly, the coordinating
centres in Sydney and Buenos Aires and thirdly, the site
base study teams. With this structure, time, distance and
language differences were overcome, primarily through
electronic means, including electronic case report
forms, a study website and teleconferencing/email
communication.
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As Truvada® is not licensed in Singapore, Thailand or
Malaysia, special importation permits were required. At
study completion, Truvada® will be available for an extra
year in these countries.
Twenty one sites (58.3%) submitted their own ethics
application, while the sponsor alone and in collaboration
with a locally contracted lawyer completed 13 (36.1%) and
two (5.5%) ethics approvals, respectively. Of the 17 sites
requiring national regulatory approval, two submissions
were made by the sites, 13 (76.5%) were made by the
sponsor and two (11.8%) were made by the sponsor with
legal collaboration. Ethics and regulatory submissions
took between 35 and 272 days to be approved, with a
median of 116.0 days. Following approval, sites took
between seven and 192 days to recruit their first patient,
with a median of 78.9 days. The main reasons for delay
include contractual and financial issues, access to few
naïve patients, importation permit and drug labelling
delays.
Thus far, the international nature of this trial has provided
many challenges, nevertheless full recruitment of the
Altair study was achieved within the expected timeline.
Overall, good design and careful management were
required for successful recruitment of the ALTAIR study.

228 						

Clinical Medicine
Clinical Audit: Virologic and 
Immunologic Response to 
Combination Antiretroviral 
Therapy in HIV Patients at a Sydney 
Sexual Health Clinic
Hsu DC1, Quin JW2
1
Department of Immunology, Concord Hospital,
Sydney South West Area Health Service, Sydney, NSW;
2
Department of Clinical Immunology and HIV medicine/
Sexual Health, Liverpool Health Services, Sydney South
West Area Health Service, Sydney, NSW
Bigge Park Centre (BPC) is a sexual health clinic located
in a socially disadvantaged area in South West Sydney.
This study served as a clinical audit, documenting
the patient demographics of BPC, identifying factors
associated with virologic, immunologic and discordant
responses, evaluating the centre’s ability in HIV control
and investigating changes in practice through time.
Data including age, gender, ethnicity, mode of
transmission, hepatitis co-infection, prior AIDS defining
illness, HIV-1 RNA and CD4 counts were collected from
medical records of patients on antiretroviral therapy for
treatment of HIV with at least 1 year follow up at the BPC
and analysed.
BPC manages HIV patients from diverse backgrounds.
Sequential monotherapy was significantly associated
with poor virologic and immunologic response. When
only treatment-naïve patients were analysed, Caucasian
race, high viral load at 1 month and triple-NRTI-regimen
were associated with lack of virologic control, whereas
lower baseline viral load and triple-NRTI-regimen were
associated with reduced CD4 count rise. Lower baseline
CD4 count and prior diagnosis of AIDS were associated
with poor immunologic response despite virologic
control. Virologic control and immunologic response
achieved were comparable to that documented in
medical literature. There was no significant change over
time in terms of timing of HAART initiation, attainment
of immunologic response or virologic control since the
late 1990s.
HIV control achieved at the BPC was comparable to that
reported in medical literature. Enhancement of strategies
to promote screening and improve adherence will likely
improve patient care.
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Imran D1, Irawati M1, Wahyuningsih R2, Jannis J1,Yamanie
N1
1
Department of Neurology, University of Indonesia, RSCM
Hospital, Jakarta, Indonesia; 2Department of Parasitology,
University of Indonesia, Jakarta, Indonesia
In Indonesia, mortality and clinical characteristics data of
cryptococcal meningitis in HIV patient was limited. The
objective of our study was to determine the mortality
and clinical characteristics of cryptococcal meningitis
in our hospital. Total of 209 lumbar puncture was done
from January 2005 to December 2007. Sixty patients
had cyptococcal meningitis, 52 diagnosed by positive
cerebrospinal fluid Indian ink stain and 8 had positive
serology. All of them HIV positive. 92% were males and
8% females. Age ranged 17-37 years old. CD4 ranged 1-90
sel/µl. The most common symptom was headache (65%),
admitted with unconsciousness 30%, neck stiffness 75%,
and focal brain lesion from CT Scan 13%. Amphotericin
B was given to 35 patients (59%) patients and among
them 66% survived. Twenty five patients did not received
Amphotericin B, of whom 21 (84%) died and 4 patients
(16%) survived. This was a first report of cryptococcal
meningitis in Indonesia.

P133
CORRELATES OF RENAL FUNCTION IN A
COHORT OF STABLE AND VIROLOGICALLY
SUPPRESSED HIV PATIENTS ON ART
SCREENED FOR THE STEAL STUDY.
Kelly M1, Davies SC2, Woolley I3, Amin J4, Jacoby S4,
Humphries A4 on behalf of the STEAL investigators
1
AIDS Medical Unit, Brisbane, QLD, Australia, 2Northern
Sydney Sexual Health Service, Royal North Shore Hospital,
Sydney, NSW, Australia; 3Infectious Diseases Department,
Monash Medical Centre, Clayton, VIC, Australia, 4National
Centre in HIV Epidemiology and Clinical Research, UNSW,
Sydney, NSW, Australia
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CRYPTOCOCCAL MENINGITIS IN  RSCM
HOSPITAL, JAKARTA

The STEAL study randomised HIV participants to receive
fixed-dose abacavir-lamivudine or tenofovir-emtricitabine.
Participants were screened for renal dysfunction by two
methods: glomerular filtration rate (eGFR) calculated
by MDRD equation and creatinine clearance (CCrCl)
calculated by Cockcroft-Gault equation. The MDRD
equation has not been validated in an HIV population but
is reported as more accurate than CCrCl. Our aim was to
examine the correlation between the two equations at
baseline in an HIV cohort and to determine correlates of
renal impairment.
eGFR and CCrCl were compared by pair-wise correlation.
Associations between those ineligible to participate
(n=17) because their eGFR was <70mL/min/1.73m2, and
biochemical parameters and family history were assessed
by logistic regression. Associations between both eGFR
and CCrCl and the above parameters, as well as HIV
infection related parameters were assessed by linear
regression. Parameters for associations were categorised
at their median.

While eGFR and CCrCl were highly correlated, we could
not evaluate these equations in terms of renal dysfunction
because very few participants had poor renal function.
Reduced eGFR and CCrCl were both associated with older
age and elevated urea, as expected. Our observations
regarding bilirubin and phosphate correlations with lower
eGFR prompt further analyses of STEAL data regarding
the use and duration of protease inhibitors and tenofovir
respectively.
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Measurements for eGFR and CCrCl were available on 438
of 441 screened patients. Despite some variation, there
was high statistical correlation between the two equations
(pair-wise correlation co-efficient=0.69, p<0.001). Only
three screened patients had eGFR <60mL/min/1.73m2,
one of which also had CCrCl <50mL/min. Elevated
bilirubin (p=0.03) and urea (p=0.04) were more common
in the 17 participants with eGFR <70mL/min/1.73m2.
Independent correlates of reduced eGFR were age ≥44
years (p=0.01), phosphate <1.01mmol/L (p=0.02) and
urea ≥5.3mmol/L (p<0.001). Independent correlates of
reduced CCrCl were age ≥44 years (p<0.001), BMI ≤25
(p<0.001), amylase ≥62U/L (p=0.012), urea ≥5.3mmol/L
(p=0.001). The following previously reported correlates
of renal impairment were not found to be significantly
associated in our cohort: HIV parameters, hypertension,
smoking, dyslipidaemia, diabetes and tenofovir use.
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INTERACTION BETWEEN INHALED
CORTICOSTEROIDS AND PROTEASE
INHIBITORS (PI) IN HIV-INFECTED
INDIVIDUALS - WHICH IS THE PREFERRED
INHALED CORTICOSTEROID?
Mackie K1, Vujovic O2, Topliss D3, Douglass J4, Duncan A1,
Forrester C1
1
Pharmacy Department, Alfred Hospital, Melbourne,
VIC, Australia; 2Infectious Diseases Unit, Alfred Hospital,
Melbourne, VIC, Australia; 3Department of Endocrinology,
Alfred Hospital, Melbourne, VIC, Australia; 4Department
of General Respiratory, Alfred Hospital, Melbourne, VIC,
Australia
Iatrogenic Cushing syndrome due to concurrent use
of inhaled fluticasone propionate and ritonavir is well
described in the literature and is not uncommon in
clinical practice. However, there are less, if any, reports of
the CYP3A4-mediated interaction between ritonavir and
other inhaled corticosteroids (budesonide, ciclesonide
and beclomethasone). The objective of this literature
review is to ascertain the inhaled corticosteroid causing
the least adrenal suppression when combined with
ritonavir boosted protease inhibitors (PIs) based on
available pharmacokinetic and comparison studies. A
search using electronic databases, Pubmed and Embase
was completed and included papers published prior to
1st March 2008.
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The finding of the review indicates that both inhaled
budesonide (Pulmicort®, Symbicort®) and ciclesonide
(Alvesco®) have less systemic corticosteroid effects than
fluticasone (Flixotide® , Seretide®) however the small levels
systemically active are also cleared via CYP3A4 pathways,
therefore the potential still exists for adrenal suppression
to occur if combining with ritonavir.

EFAVIRENZ AND POSITIVE URINARY DRUG
SCREEN FOR CANNABINOIDS
Mclellan DGJ1,2, Libertino SL1, Kerth JM1, Dyer JR1, Wilson
MA1, Clark BM1 and Edwards T2
1
Infectious Diseases Department, Fremantle Hospital,
FREMANTLE, WESTERN AUSTRALIA 6160; 2Western
Diagnostic Pathology, MYAREE, WESTERN AUSTRALIA
6154
We have observed two patients on long term efavirenz
therapy as part of an anti-retroviral regimen test positive
for urinary cannabinoids following routine employment
drug screening. In both cases use of cannabis was denied
but the positive results led to employment termination.
It is now recognised that a side chain of efavirenz can
interact with commercial drug assays resulting in a false
positive result. As drugs of abuse screening is now routine
in many employment sectors this interaction may have a
significant impact on employment choices and prospects
for those individuals receiving an efavirenz containing antiretroviral regimen. To explore this further, urine samples
from 15 individuals receiving efavirenz were assayed
by the cloned enzyme donor immunoassay (CEDIA,
Microgenics) for the presence of cannabinoids. A control
group of 20 individuals on non-efavirenz containing
regimens were also assayed. Confirmatory testing with gas
chromatography was performed on all positive samples.
Correlation between plasma efavirenz concentrations
and drug screen results was also determined. Our analysis
suggests that patients receiving Efavirenz should expect
a false positive urinary cannabinoid result when tested by
the CEDIA method. Additional confirmatory testing by
gas chromatography is required to clarify the result. This
information may be important in some individuals when
selecting anti-retroviral drugs.

Beclomethasone diproprionate (QVAR®) is not
metabolised by cytochrome P450 enzyme pathway.
Therefore, any beclomethasone absorbed systemically is
cleared regardless of ritonavir CYP3A4 inhibition. Further
research and clinical experience is required to determine
if beclomethasone should be considered the inhaled
corticosteroid of choice in HIV-infected individuals taking
ritonavir boosted PIs.
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Puls, RL1, Arriaga, ME1, Satchell C1, Dazo C1, Haskelberg H1,
Boesecke C1, Drummond F1, Srasuebkul, P1, Emery S1, for
the Altair Study Group.
1
National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW, Australia.

INCIDENCE AND CHARACTERISTICS OF
HIV-ASSOCIATED LYMPHOMA IN THE ERA
OF HAART AT FOUR MAJOR AUSTRALIAN
TREATMENT CENTRES
Rotty J1, Clezy K2, Hoy J1,3, van Leeuwen M2, Grulich AE2
1
Infectious Disease Unit, Alfred Hospital, Melbourne, VIC,
Australia,; 2National Centre in HIV Epidemiology and Clinical
Research, Darlinghurst, NSW, Australia; 3Department of
Medicine, Monash University, Melbourne, VIC, Australia
Since the introduction of highly active antiretroviral
therapy (HAART) a decrease in incidence of AIDS-defining
malignancies including non-Hodgkin’s lymphoma (NHL)
has been described. Whether the incidence of Hodgkin’s
lymphoma (HD) has decreased is unclear. In order to assess
incidence and characteristics of HIV-associated lymphoma
(HAL) in Australia we have collected longitudinal data
since 2003 from four major HIV-treatment centres.
During this five year period a total of 79 HALs were
observed. There was no apparent increase in HAL
diagnoses over time with an average of 13 new cases
per year (except 25 in 2005). The majority of HALs (n=64,
84%) was NHL with diffuse large B-cell lymphoma as
the predominant histological type (n= 38). Extra-nodal
involvement was common (n=64). The incidence for HD
was lower than for NHL with a total of 12 cases and no
increase over time.
For the majority of NHL-patients (76%) lymphoma was
the first AIDS-defining illness. The mean CD4-cell count
at HAL-diagnosis was relatively high with 258 cells/ul.
The mean nadir was 147 cells/ul. The majority of patients
(n=51) was ARV treatment-experienced and 42 patients
(53%) were on HAART at time of HAL-diagnosis. Of patients
on HAART 24 (57%) had achieved virological suppression
(< 500 copies/ml). There was no significant difference for
NHL and HD in viral load (VL) at HAL-diagnosis, CD4 nadir
and current CD4-cell count. The majority of patients (79%)
received HAART during chemotherapy. 42% achieved
complete response. 24% had a partial response. 21%
experienced progression of disease and 13% had stable
disease. Of 79 patients in this 5 year period 17 have died.
Due to the small number of cases we are limited to
making general observations only. However, this is
the first longitudinal cohort that will provide more
information about the natural history and incidence of
HAL in Australia.
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ALTAIR is a Phase IIIb/IV, international, randomised, open
label study comparing three regimens of combination
antiretroviral therapy (cART) in treatment-naïve, HIVinfected subjects at 36 sites in 15 countries on five
continents. Patients were randomised in a 1:1:1 ratio to
each cART regimen containing a fixed dose formulation
of tenofovir and emtricitabine (TDF/FTC), with either
efavirenz (EFV) or ritonavir boosted atazanavir (r/ATV)
or zidovudine (ZDV) plus abacavir (ABC). The primary
objective of this study is to compare safety and virological
efficacy, as measured by the time-weighted mean change
from baseline plasma HIV-RNA over 96 weeks.
Of 441 patients screened, 87 were ineligible, one died
before randomisation, eleven were outside the screening
period and 13 chose not to continue into the study. Of 329
randomised patients, two were incorrectly randomised.
Of those correctly randomised, 100 (30.6%) patients were
from Asia, 74 (22.6%) from Europe/Israel/Canada, 120
(36.7%) from Latin America and 33 (10.1%) from Australia.
Among ineligible patients, 20 (4.5%) were ineligible due to
genotypic resistance, 12 (2.7%) to HLA-B57*01 positivity,
20 (4.5%) to low creatinine clearance and 22 (5.0%) to
other laboratory parameters, including six (1.4%) with low
CD4 count and six (1.4%) with low plasma HIV viral load.
Patients were predominately male (76.6%), with category
A HIV infection (72.0%) and infected by homosexual
(52.0%) or heterosexual (45.9%) sex, respectively.
At randomisation, mean (SD) CD4+ T cell count was 229
+ 116 cells/µL and 11.3% of patients had >350 cells/
µL; mean (SD) plasma HIV viral load was 4.7 + 0.7 log10
copies/mL and 54.4% of patients had > 100,000 copies/
mL. Fasting glucose was 5.0 + 1.0 mmol/L, cholesterol
was 4.0 + 0.9, HDL was 0.9 + 0.3 and LDL was 2.5 + 0.8
mmol/L, triglycerides were 1.6 + 1.7 mmol/L. Baseline
Framingham cardiovascular disease risk was calculated for
304 patients and the mean score was 3.9 (3.5); 286 (94.1%)
were at < 10%, 16 (5.3%) were at between 10% and 20%
and 2 (0.6%) patients were at > 10% risk of cardiovascular
disease within ten years.
The study continues and the last patient will complete 96
weeks on therapy in February 2010.
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BASELINE DATA FROM THE ALTAIR STUDY:
A RANDOMISED, OPEN-LABEL, 96WEEK STUDY COMPARING THE SAFETY
AND EFFICACY OF THREE DIFFERENT
COMBINATION ANTIRETROVIRAL REGIMENS
AS INITIAL THERAPY FOR HIV INFECTION.
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HIV-TB CO-INFECTION: A SOUTH
AUSTRALIAN EXPERIENCE
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Sehu MM1, Stapledon R2, Shaw D3
1
Mater Misericordiae Health Services Brisbane, South
Brisbane, Queensland, Australia; 2South Australia
Tuberculosis Service, Adelaide, South Australia, Australia;
3
Royal Adelaide Hospital, Adelaide, South Australia,
Australia.

Transient Sick Sinus Syndrome 
related to Lopinavir-Ritonavir in a 
patient with AIDS
Santosh Chaubey1, Ashim Sinha1 ,Darren Russell2,3 , Henrik
Falhammar1, ,4
1
Department of Medicine, Cairns Base Hospital; 2 Cairns
Sexual Health Service; 3University of Melbourne;
4
Department of Molecular Medicine and Surgery,
Karolinska Institute
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A 42-year-old northern Thai man who recently migrated
to Australia developed transient sick sinus syndrome
soon after institution of treatment with Kaletra (liponavir/
ritonavir) and Kivexa (abacavir/lamivudine) is presented.
His most recent CD4 count was 390 cells/l, and he was
taking no other medications, nor any herbal medicines. He
presented with dizziness to the Emergency Department
after 3 doses of Kaletra (and 2 of Kivexa). There was no
history of any cardiac conditions and the only other
history of note is a positive VDRL test, and Herpes Zoster
6 months ago.
On admission he was bradycardic with pulse rate of 42/
minute. His ECG demonstrated sinus arrest with junctional
escape rhythm which later changed into atrial fibrillation
followed by sinus bradycardia. Three days after stopping
his medications he reverted to normal sinus rhythm. To
our knowledge only 4 similar cases have been described
in the literature, and 3 occurred in Japanese individuals.
All of these cases were associated with the introduction
of lopinavir/ritonavir. In contrast to our patient, however,
all of the previously described cases were on various
other medications apart from antiretrovirals, and the
mechanism of cardiac conduction defects with these
agents has not yet been elucidated.
Our case occurred in a man who is HLAB57-negative, and
it is proposed that lopinavir/ritonavir is the cause of this
mans sinus arrhythmia.
Even though the numbers of affected individuals are
small, 3 out of 4 individuals were of Asian origin which
raises the question about genetic propensity to this
particular manifestation of this particular combination of
antiretroviral (liponavir/ritonavir).

232 						

Tuberculosis (TB) is the most common opportunistic
infection in Human Immunodeficiency Virus (HIV) /
Acquired Immunodeficiency Syndrome (AIDS). The
accessibility of global travel, increasing migration as
well as displacement of communities due to conflict,
war and famine has led to increased human movement
throughout the world.
TB incidence had been falling in developed countries
until recently. However, with the rise of HIV infection,
TB has become a diagnostic and management issue for
clinicians worldwide. We present three recent cases of
HIV-TB co-infection which highlight practice points in this
setting.
The diagnosis of TB was made after the diagnosis of HIV
in all three of the cases. The possible place of acquisition
differed in all three patients. Two had typical radiological
findings consistent with TB. One was treated for TB prior to
HIV whilst the remaining had HIV treatment commenced
prior to TB treatment. All three had similar triple therapy
for HIV. Two had confirmed Mycobacterium tuberculosis
on culture with one showing partial resistance to
isoniazid. All three were commenced on standard
quadruple therapy; moxifloxacin and streptomycin was
added until microbiological confirmation for the third.
Intravenous therapy was needed in one patient due to
drug malabsroption. Treatment was halted temporarily in
two due to adverse drug reaction and for complications
arising from HIV/TB. Directly Observed Therapy was
utilized in two patients to ensure adherence to therapy.
The duration of therapy ranged from six months to two
years.
The HIV/AIDS pandemic is threatening to destabilize
control of TB, especially in areas of the world lacking
the resources to combat the burgeoning numbers of
HIV-TB co-infected individuals. Despite the relatively
low numbers of individuals co-infected with TB and HIV,
Australia is not immune to the effects of this growing
world trend The complexities associated with treatment
of HIV-TB co-infection should not prevent appropriate
and adequate treatment.
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Patient A presented in February 2007 requesting nonoccupational post-exposure prophylaxis (nPEP) for human
immunodeficiency virus (HIV). HIV testing confirmed
previously unknown established HIV-1 infection. A
negative HIV test was documented in October 2005. On
history he may have experienced seroconversion illness
during winter of 2006. Baseline HIV genotype testing
showed resistance to nucleoside reverse transcriptase
inhibitors (NRTIs), non-NRTIs and protease inhibitors. The
resistance associated reverse transcriptase mutations
detected were A98G, K103N, V108I and T215C. The major
and minor resistance associated protease mutations
detected were L10V, M46I, I54V, Q58E, A71V, L76V, V82F
and L90M. Subsequent contact tracing identified a
possible source patient (patient B) who was highly
treatment experienced with multi-drug resistant HIV
on antiretroviral therapy. Phylogenetic comparison of
the two patients’ HIV reverse transcriptase and protease
sequences confirmed a high (100%) probability of
transmission from patient B to patient A. Patient A was
counselled about the need for protected sex and relevant
disclosure of his serostatus. A third HIV-infected patient
(patient C) was identified in 2008 with a highly similar, if
not identical, antiretroviral resistance pattern to that of
patients A and B. Patient C had serology consistent with
recent HIV seroconversion. Patient A may be a more likely
source of HIV transmission to patient C, as the plasma viral
load of patient B has been nearly undetectable (but not
completely so) since starting a new antiretroviral regimen
in 2007.
We postulate that a multi-drug resistant strain of HIV-1
has been sequentially transmitted to two patients.

van Hal SJ¹, Deris Z¹,Chew CB¹, Wang B2, Shaw CO¹, Saksena
NK2, Dwyer DE¹.
¹Centre for Infectious Diseases and Micbrobiology (ICPMR)
Westmead Hospital, NSW, Australia; 2Centre for Virus
Research, Westmead Millennium Institute, Westmead,
NSW, Australia
In two Phase III trials (BENCHMARK-1 & 2), raltegravir (RAL),
an HIV-1 integrase inhibitor (INI), was documented to be
effective in treating patients with triple-class resistant
virus. RAL failure was associated with INI resistant virus
secondary to 3 distinct resistance pathways:
N155H; Q148H and Y143K each accompanied by
secondary resistance mutations.
RAL will be available in Australia in June 2008 for use
in treatment experienced patients. However, baseline
resistance remains largely unknown.
Methods: Following extraction of HIV RNA from the
patient’s plasma a one step RT-PCR (primers bpol2: 5’AGCTTTCCCGAAATATACATATGGT-3’ & Pol 1937
5’-AGAAGTAAACATAGTAACAGACTCAC-3’) followed by a
2nd round nested PCR was performed (primers: Pol-6: 5’ATGGTGTTTTACTAAACTTTTCCATG -3’ & Pol 1976:
5’-AATCATTCAAGCACAACCA-3’). Following purification,
the amplicons were sequenced (Applied Bioscience
Systems®).
Results: Of the 104 INI naïve isolates, 88% (n=91) were
clade B. The non-B
(n=13) isolates included 4 clade A; 4 clade C; 3 clade G
and one each of CRF02-AG and CRF01-AE. 51% (n=53) of
the isolates were from treatment experienced patients
with triple and double class resistant virus.
Compared to the IN clade B consensus sequence,
polymorphisms were observed in 43% (122/288) of all
amino acid positions. V30I; F100Y; L101I; T113V; K136Q;
V201I; T206S; T125A/V; and S283G were significantly
more likely to occur in non-B HIV clades. The presence
of V72I was significantly associated with RT and PI drug
resistant virus whilst L101I and A265V were significantly
associated with viruses from treatment naïve virus.
Previous antiretroviral therapy was significantly (p<0.01)
associated with greater genetic variability (mean 4.6%) on
distance matrix studies of integrase
(IN) gene (for clade B only) compared to ARV naïve isolates
(mean 3.8%).
No primary mutations were documented in any samples.
Secondary RAL associated mutations were observed in
9% (n=11) of samples, with G140S (n=2); L74I (n=5) and
I203M (n=4) detected.
Conclusion: Failure of previous antiretroviral therapy
selects for IN gene polymorphisms; some of which may
be secondary INI resistance mutations. No primary RAL
mutations were detected; secondary RAL mutations were
observed in 9% of HIV-1 isolates. It would be reasonable
that all patients have INI resistance genotyping prior to
the commencement of RAL
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Tong WWY1, McAllister J2, White PA3, Kelleher AD2,
Carr A2
1Department of Clinical Immunology, Royal Prince Alfred
Hospital, Sydney, NSW, Australia; 2HIV, Immunology
and Infectious Diseases Unit, St Vincent’s Hospital,
Sydney, NSW, Australia; 3School of Biotechnology and
Biomolecular Sciences, University of New South Wales,
Sydney, NSW, Australia.

P142
PREVALENCE OF INTEGRASE INHIBITOR
RESISTANCE MUTATIONS IN TREATMENT
NAÏVE AND TREATMENT EXPERIENCED HIV
INFECTED PATIENTS.
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P141
Sequential Transmission Of 3-Class 
Drug-Resistant HIV
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P143
BASELINE RESISTANCE TO ETRAVIRINE (TMC
125) IN ANTIRETROVIRAL EXPERIENCED AND
NAÏVE HIV INFECTED PATIENTS.

P144
THE ACCEPTABILITY OF A WEB-BASED
ELECTRONIC CASE REPORT FORM (eCRF)
FOR USE IN CLINICAL TRIALS.

Chew CB1, van Hal SJ1, Shaw CO1, Wang B2, Lau K2, Deris
Z3, Saksena NK2, Dwyer DE1
1
CentreforInfectiousDiseasesandMicrobiologyLaboratory
Services, ICPMR, Westmead Hospital, Westmead, NSW
2145, Australia; 2Retroviral Genetics Laboratory, Centre for
Virus Research, Westmead Millennium Institute, University
of Sydney, Westmead, NSW 2145, Australia; 3Department
of Medical Microbiology, Faculty of Medicine, University
of Science Malaysia, Kota Baru, Kelantan, Malaysia.

Vulcao JAV, Courtney-Vega K, Humphries A, Jacoby S,
Haskelberg H on behalf of the STEAL Study Group
National Centre in HIV Epidemiology and Clinical Research
(NCHECR), UNSW, Darlinghurst NSW, Australia.

The first generation of NNRTIs (nevirapine, efavirenz) can
rapidly select resistant HIV, with extensive cross-resistance
within the class. Significant NNRTIs resistance can be
mediated by a single mutation. Etravirine (TMC125), is
a second generation NNRTI that is active against HIV-1
resistant to the first generation NNRTI, including viruses
with the K103N RT mutations. TMC125 resistance may
occur with the accumulation of the NNRTI mutations;
V90L, L100I, V106I/A, Y181C/I/V, A98G, K101E/P, V179D/
F and G190A/S, with three or more of these mutations
required for full resistance.
Aim: To evaluate the potential role of etravirine in
antiretroviral experienced HIV infected patients who may
have K103N or other NNRTI mutations.
Methods
ARV resistance genotyping were performed on HIV-1
protease and RT regions from 730 HIV-1 infected patients:
74% (543/730) were ARV-experienced. Following RNA
extraction from plasma, RT (750 base pairs) and protease
(300bp) were amplified by nested PCR using gene-specific
primers, and sequenced. Interpretations of sequence for
primary and secondary RT and protease mutations were
directly adopted from the Stanford University HIV Drug
Resistance database.
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Results
Of the 543 ARV-experienced patients 22% (117/543) had
the K103N mutation. Etravirine associated mutations were
detected in 40% (47/117) of these patients. However, only
4 (0.9%) patients had ≥ 3 associated mutations (V106A,
V179D and G190A), 18 (15.4%) had 2 and 28 samples had
a single mutation.

The electronic Case Report Form (eCRF) is a web-based,
interactive data collection tool that has recently been
introduced into clinical trials conducted by NCHECR. The
aim of this paper is to examine the acceptability of this
new system by the site coordinator, and if the acceptability
has changed over 2 years.
The STEAL study was the first NCHECR trial to use eCRF. The
Inform eCRF was launched in 2006 at which time the first
acceptability survey was sent to all coordinators (n=34). In
2008 the same survey was sent again to all coordinators.
In 2008 20/29 (69%) responded, 13 of whom completed
the survey in 2006.
Overall, in 2008 there were significantly more coordinators
that prefer eCRF to paper CRF (from 53% in 2006 to 85% in
2008). For those coordinators (n=13) that completed both
surveys their preference for eCRF increased from 54% to
69% over the 2 years of the study. Overall preference for
the Inform product for future studies was 75% in 2008,
compared to 68% in 2006. Satisfaction with the eCRF
features, functionality, quality, reliability and ease of use
improved from approx 74% to 96% over the two years.
Overall comments included user-friendliness, faster
and cleaner data collection, quick query management
processing and better on environment.
Overwhelmingly study coordinators preferred entering
clinical trial data into internet-based eCRFs as compared
to paper-based forms. The poor overall response rate
of 69% may have skewed the results. Although this
was the first time NCHECR utilised an eCRF, there was
overwhelming positive support for it’s continued use.
For NCHECR the advantages include real-time access to
data, more efficient study monitoring and elimination of
storing paper-based CRF.

In ARV-naive patients (n=187), 10% had first generation
NNRTI resistant virus with K103N as the most prevalent
mutation (74%; 17 of 23). One patient (0.5%) had 3
associated mutations; 5 (3%) had 2 mutations and 13 (7%)
patients had a single associated mutation.
Conclusions
In ARV experienced and naive patients, etravirine efficacy
would be compromised in 0.9% (n=4) and 0.5% (n=1)
patients respectively. Care must be taken, with the use of
the first generation NNRTIs as the accumulation of 3 or
more mutations may limit TMC125 efficacy.
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HIV/AIDS PREVENTION IN PAKISTAN:
DYNAMICS OF CONDOM USE AMONG MEN
HAVING SEX WITH MEN
Akhtar MM, Punjab AIDS Control Programme, Lahore,
Pakistan.
HIV/AIDS is at an early stage in Pakistan and patterns of
risk behaviors facilitating rapid spread of infection are
widespread. Majority of clients buying sex commercially
do not use condom. Condom promotion among men
having sex with men was a major component in service
delivery package under World Bank funded Enhanced
HIV/AIDS Control Programme, implemented with men
having sex with men in Lahore, Pakistan. Out reach
workers visited the targeted population at Gurus’ houses
where clients were provided with information about HIV/
AIDS, motivated to have safe sex and offered condoms.
Selected information on condom use was collected from
500 clients. Majority of clients were unmarried and were
carrying condoms at the time of interview. Clients on
average had anal sex at least once a day. Condom use
rate was lower among married clients than unmarried.
Condom use rate declined with increase in age. Major
reasons for non-use of condom were decrease in sexual
gratification and non-affordability. In future, follow-up
visits to targeted clients would be increased and condoms
would be provided to non-affording clients.

P146
EMPOWERING WOMEN GROUP FOR HIV
PREVENTION
Aryal, K
Nepal Red Cross Society
Due to the little access to information Women in
communities are really out from different health facilities
and are found more vulnerable than males to HIV/AIDS
due to social and physiological reasons. So, Nepal Red
Cross Society (NRCS) started HIV prevention intervention
for women since 2002 aiming to reduce HIV transmission
rate by enhancing knowledge and skills among women
and to empower women through active participation
as a result they can take responsible decision regarding
Reproductive Health (RH), HIV/AIDS, STIs.

Community Program

Community Program

Women from low economical background marginalized
groups and excluded from the society, have no other
access of information regarding HIV and AIDS, who practice
relatively high risk behaviors are selected after orientation.
Selected women of aged 16-39 years are trained on
HIV/AIDS, RH, STIs and leadership skills and mobilized to
disseminate information in communities through peer to
peer sharing, organizing home visits, orientation sessions,
competition during different festivals and performance
of street drama. One of the major responsibilities of the
trained women groups is to organize a monthly meeting
aiming to enhance knowledge and skill regarding RH,
HIV/AIDS and STIs.These meetings are designed as the
input sessions so as to empower the women group
.They have to submit report containing activities carried
out, lesson learned, the impact of the programme and
feedback for the improvement. They collect address of
migrated people and send letter containing information
on HIV/AIDS.

Empowerment of women is essential to reduce the
risks of HIV/AIDS and STI. Similarly, activities have to be
designed focused on problems like, illiteracy and lack
of employment opportunities which are contributing
factors to weaken women status in the community and
should cover the women from high risk group.
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Although it has been not a long time, NRCS addressed
women group on its HIV prevention programme but
it has able to achieve successful result. The number of
women visiting health facilities for STIs treatment has
been increased; they are empowered to take a responsible
decision after project implementation in communities.
1460 women Peer Educators are developed. Increased
demand of condom indicates that service seeking
behavior among women has improved. They can talk
openly about HIV/AIDS, STI and RH.
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P147
PEER EDUCATORS CONFERENCE; TO
CONSOLIDATE LEARNING & EXPERIENCES
WORKING AS A PEER EDUCATOR
Aryal, K
Nepal Red Cross Society
With the motto “I serve” Junior/Youth Red Cross (J/
YRC) was established in 1965. Nepal Red Cross Society
through J/YRC from 1994 has been implementing HIV/
AIDS Prevention and Reproductive Health Program.
Annually 2297 Peer Educators (PEs) are developed. They
are instrumental to disseminate knowledge and skill
around HIV/AIDS amongst peer. Packing into account
the need to recognize their contribution to the program
Peer Conference was held with the objectives; to bring
the scattered PEs in one place in order to share their
experiences, lesson learned and obstacles of the program
period, to update their leadership skill and knowledge, to
develop independently problem solving skill.
Altogether 49 participants from different regions
i.e. terai, mid-hill, far and mid eastern and western
areas representing 13 districts of Nepal participated
in the conference. Gender balance was ensured in
the participation, the number of female participants
was equivalent so as to male. Participatory learning
methods like group discussions, question answers,
situation discussions, practical work, were applied. Media
presentation and models were used to make the sessions
more effective and educative. The participants made
presentation highlighting prominent issues around
Youth PEs. Altogether 33 abstracts were prepared by
the youths with the back up support of teacher sponsor.
Teacher Sponsors participated in the conference for the
encouragement of the PEs. To update knowledge of the
participants, input sessions were organized.
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The conference concluded with adopting Deceleration.
The deceleration reads:
Realizing HIV/AIDS
• a global and local concern
• has a large-scale social, economic and health impacts
• the young people are the most sufferers
Participants express commitments to; act actively to
raise awareness among youth and community at large,
support youth for positive behavioral changes ,engage in
the care and support to positive people and creating an
enabling environment to them, advocacy for increased
access to age-specific appropriate knowledge .
"This program has helped me in developing my skills,
now I am confident that I can express my self even in the
large gathering". Santi Tamang
Peer conference is essential to share experience, lesson
learned, obstacles of PEs, which automatically help to
reduce risk and burden of HIV/AIDS and STIs.
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EVALUATION OF A HEALTH PROMOTION
SHORT COURSE FOR THE HIV
COMMUNITY SECTOR
Brown G1, Donohoe, S2
1Western Australian Centre for Health Promotion
Research, Curtin University Perth, Australia
2Australian Federation of AIDS Organisations, Sydney,
Australia
The Australian Federation of AIDS Organisations and the
WA Centre for Health Promotion Research collaborated
in conducting a 3-day short course in Health Promotion
for those working within the HIV community sector. The
course was designed for people in the HIV community
sector with an emphasis on AIDS Councils, People Living
with HIV/AIDS Organisations, Sex Worker Organisations,
and other partner organisations.
After the trial of a two day condensed course with
Education Managers from the state AIDS Councils, a
broader 3 day course was developed to be conducted in
Melbourne, Sydney, Brisbane, Adelaide, Darwin and Perth.
Driven by the results of an online survey, the course took
a very hands-on and pragmatic approach.
The course aimed to develop or improve skills in health
promotion planning; community participation; achieving
the right strategy mix; and effective evaluation within
an HIV community response context. It was assumed
that there was a range of experience and skills in health
promotion amongst the participants of the workshop.
Over 100 participants have completed the course to
date.
A key aspect of the course was the understanding and
application of behaviour and social theories to planning
and evaluating strategies for the individual, group,
community and population level.
Impact evaluation of the course consisted of pre-course
online survey and post course survey with an emphasis
on self efficacy in applying key content areas, and then
a follow-up survey of participants two to three months
later to determine application of the knowledge, skills
and momentum created by the course.
Initial results show: increases in self efficacy regarding the
use of theory to support looking at a health issue and
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P149
Getting the Best HIV Care
The Checklist Guide: a unique
resource for people with HIV
Canavan P, Ogier A, Whittaker B
National Association of People Living With HIV/AIDS
(NAPWA), Sydney, NSW, Australia

Community Program

potential responses from different angles or perspectives
and guiding strategy development; more confidence in
applying evaluation approaches that are practice- and
theory-driven; and benefits from the opportunity to
participate in a planning and decision making process
with a real scenario with colleagues working in a similar
area. Full results of the follow up survey will be available at
the time of presentation.

HIV treatment and care have changed a lot over recent
years. The development of better treatments have meant
that more Australians with HIV can expect to live longer
and enjoy better health. Knowledge about HIV clinical
management has also increased, and today the focus is
on keeping people with HIV well over the long term.
Health and wellbeing requires careful planning, as HIV
and its treatment often complicates general health
management. The experience of living with HIV is different
for each HIV positive person. For people newly diagnosed
with HIV, adjusting to being HIV positive can be a stressful
time. Some people find that HIV has a serious impact on
their health and well being. Many other people enjoy
long periods of good health and live full and active lives.
Making decisions about health and HIV treatment
options can be challenging, but NAPWA believes that
people should be supported in taking an active role in
their health decision making. If people with HIV better
understand their own treatment and care choices
then they can actively participate in their healthcare
management with their doctors, and this can lead to
better health outcomes.
In May 2008 NAPWA launched Treataware – a national
health and treatment campaign for HIV positive
Australians. One arm of the campaign is a printed resource
called “Getting the best HIV care: a checklist guide for
people with HIV.”

An outline of the development process of this important
resource is presented, acknowledging the collaboration
with HIV positive contributors and a number of HIV
clinicians. A final discussion point will be next steps in
ongoing evaluation of this interactive resource for use by
patients with their doctors in the clinic setting.
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The guide gives people with HIV a checklist of issues
they can work through with their doctor when planning
their health and treatment. The booklet lists main tests
and health checks they should expect to receive as part
of comprehensive health care as well as support and
information services to access for living long-term with
HIV.

237

P151
POPULAR APPROACHES TO MANAGING
HEPATITIS C INFECTION AMONG
INDOCHINESE INJECTING DRUG USERS: “IT’S
ALL UP TO YOU”

Chola BM
OBJECTIVE(S):
• Increased access to reproductive health services
• Increased access to HIV/AIDS and STI diagnostic and
treatment services
• To empower community with life coping skills

Coupland H1, Day C2, Maher L1.
1
National Centre in HIV Epidemiology and Clinical
Research and the School of Public Health and Community
Medicine, University of New South Wales, Sydney, NSW,
Australia; 2 Drug Health Services, Faculty of Medicine,
University of Sydney, NSW, Australia

METHODOLOGY
The Peer Education strategy is employed where young
people aged between 13 and 18 are trained as Peer
Educators and reach out to fellow young people in
the community through one on one basis, group
discussions, drama performances, sports and drop-inshops that include barber shops, hair saloons, roadside
stalls, bars and markets. Through these activities, people
in the community have access to reproductive health
information, condoms, HIV/AIDS/STI diagnostic and
treatment services through the Community Health
Clinic and training in life coping skills that include critical
thinking, analytical skills, problem solving, negotiation
skills, assertiveness and decision making skills among
others.

Popular perceptions of the management of hepatitis
C (HCV) can provide important insights into decisionmaking about seeking HCV treatment. Little is known
about these approaches among culturally and
linguistically diverse groups. This ethnographic study
explores these approaches among Indochinese injecting
drug users (IDUs).

SUMMARY OF RESULTS
• Well informed community
• Increased number of young people seeking Voluntary
Counseling and Testing for HIV
• Reduced incidences of STIs and unplanned for
pregnancies
• Reduced stigma and discrimination of PLWHAs
• Improved access to ART

Popular approaches focussed on maintaining body
“strength” to “fight” HCV. This was achieved by “looking
after yourself” by eating a “healthy” diet, adequate
exercise and sleep and avoidance of drug and alcohol
use. For Vietnamese participants this also involved the
consumption of “cooling” foods or drinks, consisting of
fruits, vegetables or herbs, to restore humoral balance and
avoid becoming “weak”. The origins of these approaches
will be explored.

CONCLUSION
Integration of Community HIV/AIDS initiatives ensures
increased access to services, a continuum of services and
a sound base for program sustainability beyond donor
support.

These approaches could “maintain” or “stabilize” HCV
and prevent disease progression. However, while most
participants subscribed to these beliefs, applying them
in practice was described as difficult for IDUs and they
were rarely adopted. Awareness of potential outcomes
of HCV treatment, particularly that treatment could clear
the virus, was also limited. Participants expressed anxiety
about how “bad” their HCV had become and reported
being “scared” to undergo further monitoring, such as
liver function testing.
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INTEGRATED COMMUNITY HIV/AIDS
PREVENTION PROGRAM
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Ethnographic fieldwork and in-depth interviews were
conducted with Cambodian, Lao and Vietnamese IDUs
(n=72), to identify explanatory models of hepatitis C
(HCV) prevention and management and their influence
on health-seeking behaviours. Participants were recruited
using theoretical and snowball sampling based on peer
and street networks. A grounded theory approach was
used to identify emergent themes.

Data indicate the importance of promoting the need
for regular monitoring of liver function and disease
progression among this group, as well as potential HCV
treatment outcomes. Inclusion of information in posttest counselling and peer education activities, regarding
the role of diet, drug use and lifestyle in HCV disease
progression is also necessary to encourage testing and
treatment seeking.
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Green C1
1
Spiritia Foundation, Jakarta
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TB CO-INFECTION: WHY DO INDONESIAN
PLHIV STILL DIE?

ARE HOSPITALS BIOHAZARDS FOR PEOPLE
WITH HIV?
Lake, R,
Positive Life NSW
Preventable admissions and avoidable mortality are two
key features of the health systems advocacy agenda
proposed by Positive Life NSW for the period 20082010. A renewed Federal Government focus on health
prevention presents an opportunity to consider more
active prevention, screening and early intervention
approaches to prevent hospital admissions.
In addition to adverse events experienced generally by
hospital inpatients, patients with HIV face an increased
likelihood of privacy breaches, disclosure of HIV status
and in some cases, discrimination from other patients,
their visitors or allied health care staff when this occurs.
This presentation will detail some of these events using
case studies. There is growing awareness of screening
and other prevention strategies to consider the benefits,
particularly psycho social, to people with HIV of more
active and earlier health interventions to prevent hospital
admission or consider the use of innovative outpatient
options more frequently used with older people.
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TB is curable and preventable; yet TB remains the prime
cause of mortality for people living with HIV (PLHIV) in
the developing world. To respond to this in Indonesia,
the Spiritia Foundation (the national peer support for
PLHIV) has implemented a number of interventions:
informing PLHIV about TB-HIV co-infection; treatment
education; promoting infection control in peer group
and counselling settings; raising awareness of healthcare
workers; advocating for implementation of preventive
therapy; pressing for surveillance, including of MDRTB; encouraging integration of HIV and TB services; and
supporting efforts by partner organizations working in
related fields.
As a result, PLHIV are more aware of their vulnerability.
There have been advances in the healthcare sector,
particularly with an increasing number of primary
healthcare centres implementing one-stop shops that
provide TB and antiretroviral therapies.
Major challenges continue to exist, particularly in
encouraging doctors in the private sector to adhere to
the International Standards of TB Care, and raising the
level of suspicion about possible HIV co-infection in cases
of TB. Diagnosing TB among PLHIV is still delayed, with the
result that antiretroviral therapy is started late. In addition,
infection control in many hospitals and clinics is lacking.
In Papua, which is experiencing a generalized HIV
epidemic together with high rates of TB, the spitting
which accompanies the widespread habit chewing of
betel nut, even in hospitals, clearly raises the risk of active
TB, and a long-term campaign will be needed to address
this.
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P154
LIVING LONG TERM WITH HIV IN THE RAINBOW
REGION
Lienert TM1, Starkey RJ2, McKellar-Stewart NP3, Scott-Visser
B4,,Santana H5
123
ACON Northern Rivers, Lismore NSW, Australia; 4 SHAIDS
sexual health clinic, North Coast Area Health Service,
Lismore, NSW, Australia; 5 Positive Life NSW.
The Northern Rivers, including the Rainbow Region
of NSW, hosts a large number of people with HIV who
moved to the area from Sydney in the critical early days
of the epidemic, facing limited life expectancy. While their
goal was to experience a more relaxed quality of life, many
faced new problems inherent to rural communities such
as the need to travel long distances and a lack of transport,
limited access to specialised medical practitioners,
employment and housing, and limited social networks.
The advent of HAART brought unexpected challenges
to this group of people who, now ageing, had to swiftly
adapt to potentially long-term rural lifestyles.
In this paper we will explore the role that ACON’s Client
Services and HIV Health Maintenance staff, along with
the NCAHS HIV/AIDS Enhanced Primary Care (EPC) Coordinator, other partner agencies and local positive
people have played in addressing the complex needs of
people living long term with HIV in the region.

P155
ENHANCED PRIMARY CARE (EPC) AND
CARE CO-ORDINATION AS A CO-OPERATIVE
MODEL
Scott-Visser BR , Starkey R , Lienert T
SHAIDS, Lismore, NSW, Australia
ACON, Lismore, NSW, Australia
The terms empowerment and self determination can
become clichéd. Case management means many things
to many people. How can these values and perspectives
effectively be implemented to produce positive outcomes
for positive people, especially those with complex needs
living in a rural setting?
In this presentation, we discuss our unique roles, the theory
behind our work (differentiating case management and
care co-ordination), why we use these models and how
we have developed an effective partnership model.
The two presenters work in differing services in differing
roles, however they have developed a partnership
approach to initiate productive outcomes for positive
people, especially those with complex needs living in
rural Australia.
 SHAIDS, Lismore, NSW, Australia
	 ACON, Lismore, NSW, Australia
The terms empowerment and self determination can
become clichéd. Case management means many things
to many people. How can these values and perspectives
effectively be implemented to produce positive outcomes
for positive people, especially those with complex needs
living in a rural setting?
In this presentation, we discuss our unique roles, the theory
behind our work (differentiating case management and
care co-ordination), why we use these models and how
we have developed an effective partnership model.

poster abstracts

The two presenters work in differing services in differing
roles, however they have developed a partnership
approach to initiate productive outcomes for positive
people, especially those with complex needs living in
rural Australia.
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Murray KJ1
1
HIV Community Team, South Eastern Sydney Illawarra
Area Health Service (SESIAHS), Sydney Australia
SESIAHS covers a large geographical area including
Sydney’s Central Business District (CBD), East and Southern
suburbs, the Illawarra and South. Traditionally HIV funded
community health services have been concentrated in
the inner-east, with little or no service provision outside
this area. A new multidisciplinary Community Health
Team was established in November 2007 to provide
outreach services across SESIAHS.. The team comprises
nurses, social workers and a dietitian. Members of the
team have specialist experience in mental health, alcohol
and other drugs, HIV and primary care
People living with HIV/AIDS (PLWHA) may experience a
range of acute or chronic health problems and require
a number of different services to manage their needs.
Challenges for service providers can include issues with
medications, mental health, physical health, nutrition,
housing, finances and alcohol and other drugs. The
HIV Community Team provides advocacy and support
around these issues and works in partnership with other
health programs and agencies.
The service’s goals are to provide a strong consumerfocused model of care, strengthen partnerships with
other health services and agencies and avoid duplication
by providing services that compliment those of existing
service providers. A key focus is providing more equitable
and integrated service delivery across the SISIAHS.
Partnership arrangements to date include dietetic support
to Pt Kembla Sexual Health Clinic, care coordination
services through ACON, effective referral pathways
with mental health services and support to HIV/AOD
Integrated Service Model for Homeless People.

Perri, V
People Living With HIV/AIDS Victoria
Melbourne, Victoria, Australia
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ANY QUESTIONS...WHAT DOES MY PATIENT
REALLY WANT TO
KNOW?

As part of People Living With HIV/AIDS Victoria’s Health
Promotion work and through one of it’s courses/
workshops, participants are given the opportunity to
explore the many questions they can think of when
choosing a suitable General Practitioner with whom they
feel not only meets their medical needs but someone
they can talk to and trust without feeling embarrassed or
fearful when discussing intimate details.
In this conference workshop aimed at General Practitioners,
Nurses and other Health Professionals working with HIV
positive people, we will conduct this activity in order for
the participants to gain a sense of what their clients are
thinking and wanting out of their session.

P158
Power of positive digital story 
telling
Jeffrey Robertson
Straight Arrows Inc
Digital story project and its value in being used as an
educational tool in relation of infection, transmission and
prevention and also the power of personal stories to relay
their struggles around HIV medications and also living
well with HIV
This would be about a half hour presentation and the 20
minutes for questions and answers
Hopefully to point out relevant issues of people living
with HIV today
1 Living with HIV in 2008
2 Medication and how they improve people life
3 Travel and HIV among young people and their journeys
4 Personal perspective of HIV
Outcomes would hopefully give real life perspective to
people in the sector about progress made by people
who have overcome the issues in relation to HIV and how
this would give abeter insight into people living with HIV
not dying from aids
Attached is a pdf of the journeys into the unknown launch
and I would have permission to use some of these stories
in our presentation
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MULITDISCIPLINARY HIV COMMUNITY
HEALTH TEAM USES AN AREA-WIDE
APPROACH TO PROVIDE EFFECTIVE
REFERRAL AND CARE
COORDINATION SERVICES IN SOUTH
EASTERN SYDNEY ILLAWARRA AREA HEALTH
SERVICE
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PROVIDING ON-LINE SUPPORT FOR
TEACHERS IN DELIVERING SEXUALITY
EDUCATION IN WESTERN AUSTRALIA

ASHM - Oral Poster Session - Social 
Research, International, Community,
Indigenous

McKay E1 , Baker M1
1
Sexual Health and Blood-borne Virus Program,
Department of Health, Perth, WA,
Sexual health education is a subject that teachers are
frequently required to teach often without any prior
training. Some teachers view the subject as a priority
while others may feel uncomfortable or insufficiently
prepared to teach it.
A priority of the Department of Health’s (DOH) policy and
programming in public health is to work with the school
education sector to promote and support the conduct of
quality sexual health education. In addition to parents, the
DOH regards teachers and schools to be a fundamental
partner in providing sexual health education to student.
Since 2002, The DOH has funded the development and
implementation of set of resources for teachers called the
“Growing and Developing Healthy Relationships” (GDHR)
Curriculum Support Materials, and corresponding inperson professional development courses for teachers.
In 2005, an audit of the uptake of the GDHR materials
found that the materials are having a positive impact on
school sexual health education.
An impact evaluation is currently underway to examine
the influence on teacher and school nurse practise
from participation in the professional development and
training. The results will be available by mid-2008.
The DOH, in partnership with the Department of
Education and Training are moving towards providing
on-line support for teachers in order to increase their
access to up-to-date curriculum resources, training and
support.
The Project involves two components:
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1. Development of an interactive website based on
updated GDHR content. This will incorporate a range
of age-appropriate learning activities, links to resources,
statistics, background information, and an on-line
question box for teachers.

USER-CENTRED DESIGN IN A RESOURCE FOR
POSITIVE TRAVELLERS
Malhotra S1 and Reeders D1
1
PLWHA Victoria Inc, Melbourne, VIC, Australia
As a discipline, User-Centred Design (UCD) responds to
the challenge of finding intuitive conventions for interface
design to help users of online and print resources access
complex information according to their needs. PLWHA
Victoria adopted this approach during the development
of Up Up & Away – A Guide for Positive Travellers. Faced
with “apples vs. oranges” information about entry
restrictions against HIV-positive travellers, positing a thirtyday maximum visit allowed the generation of simple
categories: no restrictions, possible restrictions, known
restrictions, which are represented using an intuitive
traffic light metaphor. A dynamic, searchable companion
website makes full use of hypertext markup conventions
to highlight information updated after printing, and links
to source material and further reading.
The project offers a best-practice model for the
collaborative development of resources to communicate
complex information, which can be applied in other
contexts including clinical and pharmacy settings.
Supported by Roche Products over a period of six years,
the project grew from a collection of fact sheets into
print and now online resource formats. Contributing
organisations include NAPWA, ATPA, ACON, Positive Life
NSW and PLWHA Victoria, and a network of educators is
being established to maintain the companion website
(www.positivetravel.info) and reply to questions received
from visitors.
The presentation will introduce the UCD approach,
discuss its application to the positive travel project and
argue for its adoption in public health education.

2. Development of a corresponding on-line training
course. This course is designed to increase teachers’
confidence, comfort, knowledge and skills using online learning techniques such as asynchronous learning,
podcasts, video clips, discussion forums, interactive
games, and professional facilitation.
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Secondary  school nurses’ and their 
work providing school-based sexual 
and reproductive health programs in 
Victorian schools
Towers C
Secondary school nurses provide a broad range of school
nursing services in public, private and independent
schools in all Australian states and territories. However,
the role of Victorian Department of Human Service (DHS)
secondary school nurses (SSNs) in providing sexual and
reproductive health (SRH) education and services to
students is relatively unclear. Key focus areas developed
for SSNs by DHS required SSNs to play a key role in
reducing negative outcomes and risk taking behaviours
among students. Evidence is emerging that SSNs are
developing a key role in school-based SRH programs.
Therefore, evidence about SSNs work in sexual health is
required.
A cross-sectional survey of DHS secondary school nurses
(N=129) was conducted using self-completed anonymous
questionnaires. Seventy four SSNs responded, giving
a response rate of 57.4%. Over 90% of respondents
provided a diverse range of health promoting SRH
programs ranging from classroom programs, individual
and small group student consultations, and wider school
community programs.
Most respondents believed SRH was a major practice area
of SSNs. SSN readiness to provide sexual education and
student consultations regarding sexual health depended
on their qualifications, nursing experience, participation
in professional development, networks, and interest
in sexual health. Schools, policies, and the Secondary
School Nursing Program guidelines also affected their
ability to provide SRH education and care to students.
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Significantly, SSNs appear to have been overlooked as a
key stakeholder in school-based sexual education and
care of students. Sexual health is a DHS Victorian health
promotion priority area for 2007-2012 and SSNs need to
assert their right as a key SRH stakeholder, and participate
in key government groups developing strategies and
frameworks to guide sexual education and care of young
people.
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CLINICAL FEATURES ASSOCIATED WITH HIV
INFECTION IN CHILDREN AT PORT MORESBY
GENERAL HOSPITAL - INTERIM ANALYSIS
OF A PROSPECTIVE STUDY TO ASCERTAIN
PREDICTORS OF HIV INFECTION
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MOLECULAR EPIDEMIOLOGY OF
MYCOBACTERIUM TUBERCULOSIS IN
KIRIBATI
Aleksic E1, Cox H1, Ryan C1,4, Globan M3, Reiher B2, Toatu T2,
O’Connor J5, Crowe S1,4
1
Burnet Institute, Melbourne, Victoria 2Tunguru Hospital,
Tarawa, Kiribati 3Victorian Infectious Diseases Reference
Laboratory, Melbourne, Victoria 4Department of Medicine,
Monash University, Clayton, Victoria, 5Secretariat of the
Pacific Community, Noumea, New Caledonia
With an incidence of 348 cases/100,000 people, Kiribati
has the highest TB burden in the Western Pacific region.
Current data indicate there are 21 diagnosed cases/
month, a figure that has increased substantially over the
past 5 years, where incidence was 250 cases/100,000 in
2000. As HIV testing services are not well established
and data concerning prevalence are limited, the extent
of the effect HIV has on the incidence of TB is not fully
understood. A high proportion of the population are
highly mobile fisherman, among whom the prevalence
of STIs is high and condom use is low, thus providing a
perfect transmission environment for HIV.
We have designed a study to address the molecular and
epidemiologic factors associated with the recent increase
in cases in Kiribati. To date, we have enrolled 48 patients
with newly diagnosed TB. Epidemiological data are
gathered, sputum collected and both sent to Australia for
culture, DST and identification of MTb (IMVS, Adelaide).
DNA extracted from the MTb (VIDRL, Melbourne) is sent
to Burnet Institute for genotype analysis. Median time
from specimen collection to receipt in Australia is 29 days
(8-54).
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Using two genotyping techniques, MIRU-VNTR and
spoligotyping we have examined the relatedness of
strains from 30 patients, with an additional 18 in progress.
Molecular mapping has shown that >40% of strains
within our participants are of the Beijing genotype. There
is a high proportion of fishermen, administration workers
and students with a mean age of 34 (9-68). Approximately
half the participants are female (44%) and the median
number of people living per house is 8 (3–16). Nine (19%)
patients had a previous instance of TB in their family and
there were 6 (13%) individuals who reported prior TB.
Ten patients have been tested for HIV with; 8 (80%) of
respondents not knowing their result.

Allison WE1, Kiromat M2, Vince J2, Cunnigham P3,Kaldor J1.
The National Centre in HIV Epidemiology and Clinical
Research, Sydney, NSW, Australia; 2Department of
Paediatrics, Port Moresby General Hospital, Port Moresby,
Papua New Guinea, 3NSW State Reference Laboratory for
HIV, St Vincent’s Hospital, Sydney, NSW, Australia;
1

A number of clinical signs and symptoms are common
in both children infected with HIV and sick but HIV
uninfected children, particularly in resource-limited
settings. In settings where hospital prevalence of HIV
infection is high all admitted children may be tested
for HIV serostatus. In Papua New Guinea (PNG), where
prevalence estimates are much lower than Sub-Saharan
Africa, clinicians are faced with the challenge of which
children to select for testing based on clinical criteria.
We randomly recruited children who fitted the inclusion
criteria of all admitted children aged 0-16 years. Exclusion
criteria were children who were confirmed HIV serostatus
positive (HIV+) and ≥ 2 years old, children of any age on
antiretroviral treatment and refusal of informed consent
by the primary carer of the child. Recruited children were
tested for HIV infection by dry blood spot nucleic acid
testing and specific information was collected on clinical
history and physical examination.
Of the first 122 children recruited, 17 were found to be
HIV+ and 1 had an indeterminate result. History and
physical examination were analysed separately and
subjects with aspects of history or examination missing
from the data collected were excluded from the relevant
analysis. On history, chronic ear infection was found to
be significantly associated with HIV infection [p: 0.001, OR
(95% CI): 13.6 (3.1-59.9)]. On examination, oral thrush was
found to be significantly associated with HIV infection [p:
0.001, OR (95% CI): 9.2 (2.2-33.2)]
These early results are encouraging as to achievement
of the objective of the study which is to establish a firm
evidence base leading to guidelines in the use of clinical
criteria to select children for testing for suspected HIV
infection in PNG.

The finding of multiple strains of TB suggests that
there is a diverse TB epidemic occurring in Kiribati, with
overcrowding and mobility as contributors. The presence
of the Beijing genotype is of concern as this genotype is
often associated with multi-drug resistance. Currently,
patients with TB are not routinely tested for HIV, and those
that are do not necessarily return for their results.
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UNDERSTANDING THE EPIDEMIOLOGY
OF HEPATITIS C IN VICTORIA: REVIEW OF
CURRENT SURVEILLANCE MECHANISMS

Benjelloun S1, Akil A1, Bensghir R2, Wakrim L1, Oulad Lahcen
A2, Hassar M1, Ezzikouri S1, Himmich H2
1
Viral Hepatitis Laboratory, Institut Pasteur du Maroc,
Casablanca, Morocco; 2Service of Infectious Diseases, CHU
Ibn Rochd, Casablanca, Morocco

Goller JL1, Lim M12, Horyniak D1, Aitken C1, Stoove M1,
Samuel King J3; Brown J4, Fairley C5, Higgins N6, Hellard
ME12

Chronic HBV infection has been found in 2.2%, including
71.4% of heterosexuals. Two genotypes were found (D2
and B). HCV infection has been found in 9.4% of HIV-positive
persons overall; 13.3% of injection drug users, 3.3% of men
who have sex with men and 56.7% of heterosexuals. Most
of anti-HCV positive patients were positive for viral RNA
(67%) and 4 genotypes were detected (1a, 1b, 2c and 3a)
with predominance of genotype 1. The characteristics of
HIV infected persons differ according to the co-infecting
hepatitis virus, their epidemiologic patterns may change
over time, and surveillance systems are needed to monitor
their infection patterns in order to ensure that prevention
measures are targeted appropriately.

Centre for Epidemiology and Population Health Research,
Burnet Institute, Melbourne, VIC, Australia; 2Department
of Epidemiology and Preventive Medicine, Monash
University, Melbourne, VIC, Australia; 3 Access Health, St
Kilda, VIC, Australia, 4 Healthworks, Footscray, VIC, Australia,
5
Melbourne Sexual Health Centre, Carlton, VIC, Australia; 6
Department of Human Services, VIC, Australia
1

In Australia, an estimated 200,000 people are living
with hepatitis C virus (HCV), 13,000-20,000 individuals
are diagnosed annually with HCV; injecting drug use
(IDU) is the main route of transmission. Around three
quarters of infected individuals progress to chronic
HCV with long term sequelae for a minority of these
including liver failure and hepatocellular carcinoma.
The current Victorian Hepatitis C Strategy identifies
epidemiological surveillance as a core component of
the response to the epidemic. The Strategy recommends
enhanced notification systems that integrate prevalence,
incidence and disease outcome data in conjunction with
behavioural data, which focuses on transmission risk in key
populations. Up until a few years ago three HCV-related
surveillance systems existed in Victoria; (i) passive HCV
surveillance, (ii) annual surveillance of HCV and injecting
risk behaviour through the National NSP survey and (iii)
the annual Illicit Drug Reporting System (IDRS) which also
examines injecting behaviour. These systems provide
useful data but have several limitations, including being
unable to measure HCV incidence. In recent years, three
new data collection approaches have provided more
comprehensive and integrated HCV surveillance data in
Victoria; (i) targeted enhanced surveillance (established
2002), involving follow up of diagnoses with clinical or
laboratory indicators to identify incident HCV infections
and describe associated demographic and risk factors, (ii)
a sentinel network of nine primary health care clinics (GPs,
prisons, sexual health clinics) (established 2005) to monitor
HCV testing rates, prevalence and incidence among
people routinely tested for HCV, and (iii) a communitybased longitudinal cohort study of IDUs conducted
between 2001-2003 and 2005-2007 to provide detailed
information about injecting risk behaviour, injecting
networks, HCV subtypes and estimates of HCV incidence
and prevalence. We will describe epidemiological results,
running costs and strengths and weaknesses of these
initiatives. Recommendations will be made for future
Victorian HCV surveillance and research initiatives.
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In HIV-infected persons, an estimated 2–4 million have
chronic HBV co-infection and 4–5 million have HCV
co-infection. HBV, HCV and HIV share common routes
of transmission, but they differ in their prevalence by
geographic region and the efficiency by which certain
types of exposures transmit them. The aims of the present
study were to determine the prevalence of HBV and HCV
infection among 309 Moroccan HIV infected patients.
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Hepatitis B and C prevalence among 
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HIV in the Tropics: An analysis of 
new HIV infections in Far North 
Queensland December 2006 – March 
2008
Ms Carla Gorton1, Ms Joanne Leamy1, Dr Darren Russell1.
1
Cairns Sexual Health Service, Cairns, QLD.
In March 2008 a small scale study of all new HIV infections
managed at Cairns Sexual Health Service (The Dolls
House) was conducted. A total of 35 clients were newly
diagnosed as HIV positive at the Dolls House between
December 1, 2006 and March 31, 2008. Of these 33
(94%) were male and 2 (6%) were female. The mean age
of males was 38.8yrs and the mean age of females was
33.5yrs. 2 (6%) of the clients were Aboriginal and Torres
Strait Islanders.
24 (68%) of the clients had same sex partners, 9 (26%)
had opposite sex partners, 1 (3%) had partners of both
sexes and in one case (3%) partners were unknown. 9
(26%) clients had a regular partner who was HIV positive,
10 (28%) had a regular partner who was HIV negative, 7
(20%) were unsure of the status of their regular partner
and 9 (26%) had no regular partner.
6 (18%) of the clients had contracted HIV via heterosexual
sex in a high prevalence country (5 in PNG and 1 in
Malaysia). These clients were all male and their mean age
was 58yrs.
9 (26%) clients were co-infected with an STI at the time of
their HIV diagnosis, 18 (51%) tested negative for an STI at
the time of diagnosis and 8 (23%) declined STI testing.
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Occupational background, additional risk factors
(including IDU), PEP awareness and Gay community
connectedness were also noted and all data will be
graphed or described on the poster.
The study has implications for education and prevention
messages and is informing a planned Syphilis Testing
month in Cairns during June 2008.
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MODELLING THE EMERGENCE OF DRUGRESISTANT HIV IN BANGKOK
Hoare A, Kerr S, Wilson DP
National Centre in HIV Epidemiology and Clinical
Research, Faculty of Medicine, University of New South
Wales, Sydney, Australia
Thailand has been successful in scaling up access to
antiretroviral therapy (ART). However, second-line and
third-line therapy options are relatively scarce, limiting
options once a patient experiences treatment failure.
Continued use of a failed regime may select for drugresistant strains of HIV and these resistant strains may
be transmitted to susceptible individuals. The potential
emergence of transmitted drug-resistant HIV in Thailand
is of considerable concern.
We have investigated ART scale-up plans in Thailand in
order to predict the degree of acquisition and transmission
of drug resistant HIV. We also forecasted the impact of
treatment plans on future HIV incidence. We address
this issue through the development of a mathematical
model, calibrated to match the HIV epidemic in Bangkok
and the planned scale-up of therapy. The model tracks
transmission of susceptible individuals through the
stratification of seven different population groups across
thirteen different disease stages. This allows the model
to track the number of individuals that acquire drug
resistance through treatment failure, and those who
become newly infected with drug-resistant virus.
We show that high levels of treatment over a sustained
number of years without alternative treatment options,
has the potential to lead to large rates of transmitted
resistance. We predict low-to-moderate levels in the short
term, of ~5% transmitted drug resistance after 5 years, but
sustained treatment rates could lead to very high levels of
drug resistance in the longer term (of over 10% within 10
years). This work highlights the great need for accessibility
to second- and third-line antiretroviral therapies and drug
resistance monitoring in the region.
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Renewing the Seroconversion Study 
Jin F1, Bradley J1, Slavin S2, Ellard J3, Grulich A1, Prestage
G1,2
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW
2
Australian Research Centre in Sex Health and Society, La
Trobe University
3
National Centre in HIV Social Research, UNSW
The previous two waves of the Seroconversion Study
provided crucial information on circumstances that might
put gay men at higher risk of HIV infection in Australia, and
helped enormously in framing HIV prevention campaigns.
The last few years have seen a significant increase in HIV
notifications in homosexual men in some states and
changes in the forms of risk behaviour among gay men.
We have re-developed the Seroconversion Study to
continue monitoring risk factors for HIV infection.
To achieve optimal participation and expand recruitment
options beyond high-caseload clinics, the study
now allows enrolment through community-based
organisations as well as clinics in other settings. Further,
the reliance on clinic-based interviews has been reduced
by allowing for participants’ online enrolment and selfcompletion of the questionnaire.
Through to April 2008, 22 participants were recruited
through this new scheme. The questionnaire was
administered by interviewers in 16 men, and 6 men
completed the survey online. The mean age of the
participants was 35 years, and over 90% were gay/
homosexual self-identified. A quarter (26%) completed
a tertiary or higher degree and the majority (73%) were
recruited from Queensland. A high risk event (HRE)
which they thought had led to their HIV seroconversion
was identified by 19 (86%), and in 15 (79%) the source
person was reported as a casual partner. Among these
casual partners, 10 (67%) were previously known to the
participants, including 3 whom participants reported
having sex with before the HRE. Nearly 40% reported
that they met the source partner through the internet.
At the HRE, receptive unprotected anal intercourse
was reported by 15 (79%). Drug and alcohol use was
common at the high risk event. Four men (21%) reported
having more than 5 drinks of alcohol and amyl was the
most frequently reported recreational drug used (21%),
followed by crystal/meth (16%).
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The new wave of the seroconversion is up and running.
Preliminary results have indicated that participants
recruited under the new scheme are similar to those who
were recruited from clinics in the previous rounds.

P169
UNDERTREATMENT OF PAIN IN HIV-POSITIVE
SOUTH AFRICANS
Mphahlele NR, Mitchell D, Kamerman PR
Brain Function Research Group, School of Physiology,
University of the Witwatersrand, Johannesburg, South
Africa
Pain is a common complication of HIV infection and its
treatment. However, most studies investigating HIVrelated pain and its treatment have taken place in firstworld countries, with predominantly male and white
patients. Because ethnic and cultural background may
affect pain perception, and female HIV-positive patients
have been shown to be more likely to receive inadequate
pain management, we have investigated the prevalence,
intensity and treatment of pain in HIV-positive patients in
a predominantly female, and black, cohort of patients in
South Africa.
We recruited 392 adult outpatients (298 black females, 94
black male), in the day wards of a hospital in Johannesburg,
South Africa. Patients completed the Wisconsin Brief
Pain Questionnaire to assess the prevalence, severity
and location of pain, and what medications were being
taken to alleviate pain. The adequacy of analgesia
achieved by patients was assessed by calculating the Pain
Management Index, which compares pain intensity to
the analgesic potency (based on the WHO Pain Ladder)
of the medications that patients took.
Three-hundred and two (77%) of the patients were in
pain (30% had mild pain, 36% had moderate pain, and
11% had severe pain). Sixty-eight percent of patients in
pain had pain at multiple sites, with the most common
sites of pain being the feet (30%), abdomen (10%)
and head (20%). Only paracetamol and nonsteroidal
anti-inflammatory drugs were taken for pain control,
irrespective of pain severity, with no patients in moderate
to severe pain achieving adequate pain control. Therefore,
there is a high prevalence of pain in South African HIVpositive outpatients, which is similar to the prevalence
reported in European and North American studies, and
it is poorly treated.
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Triple class experience in the 
Australian HIV Observational 
Database (AHOD)

P171
PROJECTION DEATHS FOLLOWING AIDS IN
AUSTRALIA TO THE END OF 2010 BY USING
PARAMETRIC SURVIVAL MODELS

Marashi Pour,S1, Petoumenos,K1, and Chuah,J2, on behalf
of the Australian HIV Observational Database
1. National Centre in HIV Epidemiology and Clinical
Research, University of NSW, Sydney, Australia
2. Gold Coast Sexual Health Clinic, Queensland, Australia

Nakhaee F1,2, Law M1, McDonald A1, Black D3
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, Australia.
2
School of Health, Kerman University of Medical Sciences,
Kerman, Iran.
3
School of Public Health and Community Medicine,
Faculty of Medicine, UNSW, Sydney, Australia.

The management of HIV disease for patients who become
triple class experienced (TCE), is an important and
ongoing challenge. The aim of this study is to describe
the characteristics of patients who become TCE in the
Australian HIV Observational Database (AHOD).
Patients recruited to AHOD up to March 2007 who
commenced combination antiretroviral treatment (cART)
from 1 January 1997, for more than 14 days, and were
experienced to the three major ARV classes were included
in these analyses. Patients were defined as TCE at the time
they stopped or changed the regimen the third class of
ARV was first introduced. Patient characteristics including
age, sex, prior AIDS, CD4 cell count, and viral load at the
time of becoming TCE, and mortality rates after becoming
TCE are summarised.
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A total of 2066 patients were recruited to AHOD by
March 2007. Of these, 1168 commenced cART, 737 (63%)
patients commenced cART between 1 January 1997 and
31 December 1999; and a further 431 (37 %) since January
2000. During follow-up 386 patients (33%) became TCE;
359 (93%) were male, mean age was 44 years (SD:10.2),
and 91 (23.6%) had a prior AIDs defining illness diagnosed.
272 patients had a viral load measure available at the time
of becoming TCE, with 68% having a undetectable viral
load (<=400 copies/mL). The mean CD4 was 555 (SD:
376). The median time on treatment from commencing
cART to becoming TCE was 2.8 years (IQR: 1.4-5.2). Among
patients with follow-up after becoming TCE (n=386), 27
patients died, yielding an overall crude mortality rate of
1.67 per 100 person years. More than half (55.6%) were
non-AIDS related deaths.
While the majority of patients in AHOD who become
TCE are stopping or changing treatments for various
reasons including toxicities, approximately one third of
patients continue to stop treatment due to virological
failure. Despite become TCE, the rate of death in these
patients is similar to that previously shown in AHOD
overall. These results illustrate the complexities of treating
experienced patients and the challenges faced in
developing appropriate treatment regimens for the longterm management of HIV positive patients, particularly
in the era of continuous therapy once treatment is
commenced.
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Information on AIDS mortality is needed for health care
planning and resource allocation in upcoming years.
There has been little work projecting mortality following
AIDS in Australia.
Parametric models including exponential, Weibull,
lognormal and log-logistic were used to model survival
following AIDS between 1980 and 2003. Likelihood based
goodness-of-fit criteria were used to select the best fitting
parametric model. In order to project mortality to the end
of 2010, AIDS diagnoses over the period from 2006 to
2010 were generated based on the average number of
AIDS diagnoses reported to the National AIDS Registry in
2005. Covariate values for additional dummy diagnoses
required for projecting mortality were generated based
on the average values of those covariates among AIDS
diagnoses from 2001 to 2005. Three scenarios for trends
in highly active antiretroviral therapy (HAART) use for the
period between 2006 and 2010 were considered; that
HAART remained stable at, increased from, or decreased
from 2005 levels. Predicted number of deaths was
estimated by calculation of cumulative risk of death for
each individual and then summing over all individuals by
calendar year from 2006 to 2010.
The Weibull model was found to be the best fitting model
for survival following AIDS and consequently was used
to project deaths into the future. The number of deaths
after AIDS is projected to increase from 175 in 2005 to 213
and 252 in 2010 if HAART remains stable at 2005 levels
or decreases respectively. Deaths after AIDS are projected
to decrease from 175 in 2005 to 171 if HAART usage
increases to 100% of all AIDS diagnoses by 2010.
Deaths after AIDS is projected to increase if HAART usage
remains stable or decreases and to decrease if HAART
usage increases to 100 percent of AIDS diagnoses.
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In a time of increasing blood borne infection prevalence
and global travelling, NCHDs are thus being exposed to
a greater number and wider variation of blood borne
infections. Needle stick injuries (NI) are possibly the
main route of acquiring such infections from a nonconsultant hospital doctors (NCHDs) perspective. This
study examines NCHDs experiences surrounding NI,
blood/needle handling training received, infection fears
and NCHDs demographics.
A cross-sectional self-administered anonymous
questionnaire survey was conducted on 185 NCHDs
working in 7 teaching hospitals. NI history along with
training, fears and demographics were examined. Ethical
approval was prospectively received.
A response rate of 85.4% (158/185) was achieved, with
58% of participants being medical NCHDs and 42%
surgical. The mean age was 27.7, with Interns (46%),
SHOs (33%) and Registrars (20%) taking part. 58% have
experienced a NI with a mean number of 2.77 accidents
(range:1-13). Venopuncture (47%) was the commonest
type of injury. Only 31% report wearing gloves when
dealing with needles or blood products. 37% have had
sharps handling training, while 37% have reported their
NI to the relevant departments. HIV (60%) followed by
HCV (28%) and HBV (11%) are the infections most feared.
As a consequence of this study we conclude that a NI
history is greater among the surgical NCHDs than the
medical NCHDs. The level of disposable glove usage
is worryingly poor. Training in sharps handling and in
dealing with a NI needs to be addressed. HIV is the blood
borne infection most fear of being contracting as a
consequence of a NI.
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O’Connor MB1, Hannon MJ2*, Cagney D3*, Harrington U4*,
O’Brien F5*, O’Connor R5*, Courtney K6*, O’Connor C7.
1
The Department of Surgery, Cork University Hospital, Cork,
Ireland; 2The Department of Medicine, Cork University
Hospital, Cork, Ireland; 3The Department of Surgery,
Mercy University Hospital, Cork, Ireland; 4The Department
of Surgery, South Infirmary – Victoria University Hospital,
Cork, Ireland; 5The Department of Surgery, Mid-Western
Regional Hospital, Limerick, Ireland; 6The Department
of Surgery, Bon Secours Hospital, Cork, Ireland; 7The
Department of GU/STD Medicine, Mid-Western Regional
Hospital, Limerick, Ireland.
* Joint second authors

P173
A COMPARATIVE STUDY OF HUMAN
IMMUNODEFICIENCY VIRUS ANTIBODY
POSITIVE PATIENTS IN IRELAND &
AUSTRALIA
O’Connor MB1, O’Connor C2, Saunders JA3, Sheehan C4,
Murphy E4, Horgan M1, 4, Carr A5, Cooper DA5, 6.
1
The School of Medicine, University College Cork, Cork,
Ireland. 2 Department of GU/STD Medicine, Mid Western
Regional Hospital, Limerick, Ireland. 3 Department of
Mathematics and Statistics, University of Limerick,
Limerick, Ireland. 4 Department of Infectious Diseases,
Cork University Hospital, Cork, Ireland. 5 HIV, Immunology
and Infectious Diseases Clinical Services Unit, St Vincent’s
Hospital, Sydney, Australia. 6 National Centre for HIV
Epidemiology and Clinical Research, University for New
South Wales, Sydney, Australia
Differences between HIV+ patients in developed and
third world countries are publicised. This study proposes
to compare patients demographically, medically and
therapeutically in Ireland & Australia.
A confidential cross-sectional self-administered
anonymous questionnaire survey of HIV antibody
positive patients attending HIV outpatient services in
both countries was carried out. Data was analysed for
variations within cohorts and between cohorts using
SPSS. Ethical approval was prospectively received in both
countries.
A response rate of 71%(93/131)[Ire] & 76%(148/194)[Aus]
was achieved, with a mean age of 36(20-67)[Ire] &
45(20-71)[Aus]. Mean time diagnosed was 4.5yrs[Ire] &
11.8yrs[Aus], with a reported diagnostic CD4 <200 in
35%[Ire] & 22%[Aus]. A total of 64%[Ire] & 85%[Aus] are
currently receiving HAART medications. Resistance in
patient started ART post-HAART is 0%[Ire] & 2%[Aus].
Statistically significant findings included: 1) having a
history of Gonorrhoea and Syphilis (a) in all subgroups
in both countries, (b) is more likely with CD4 <200 at
diagnosis(p=0.035). 2) Recreational drug use is higher
in (a) younger people(p=0.021), (b) males(p=0.007),
(c) homosexuals(p=0.05). 3) Alcohol use more likely in
males(p=0.03). 4) Patients with HIV+ partners are less
likely to use condoms(p=0.012). 5) Mean lifetime partner
numbers predictive of number in last 6 months. 6)
Doctor requesting a test is associated with no previous
test(p=0.038).
There were no factors associated with place of diagnosis,
being “ill” at diagnosis, currently receiving ART, having a
regular sexual partner, or sharing diagnosis with others.
As a consequence of this study we conclude that
resistance post-HAART is minimal. Improvements are
needed in STI prevention, doctors being proactive in
testing, condom use with HIV antibody positive partners,
addictive substance habits in younger male homosexuals,
and the number of sexual partners of HIV antibody
positive patients post-diagnosis.
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A STUDY OF NEEDLE STICK INJURIES
AMONG NON-CONSULTANT HOSPITAL
DOCTORS IN IRELAND
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P174
MEASURES OF COUNTRY AND SITE
RESOURCING PREDICT VIROLOGIC
SUPPRESSION, IMMUNOLOGIC RESPONSE
AND DISEASE PROGRESSION IN THE TREAT
ASIA HIV OBSERVATIONAL DATABASE
(TAHOD).
Oyomopito R
The study’s objective		
HIV viral load (VL) and CD4 diagnostics are not routinely
available in resource-limited settings despite improved
access to antiretrovirals (ARVs). We aim to determine
whether measures of country income, based on World
Bank criteria or site-reported frequency of diagnostic
testing, predicted post HAART treatment outcomes.
Methodology
Analyses were based on 2333(69.7%) eligible patients
starting HAART from 2000 onwards. Sites were categorized
by country income (high/low) and annual frequency of
VL(>=3/1-2/<1) or CD4(>=3/<3) testing. Endpoints were
VL suppression (<400copies/ml) and change in CD4 count
at 12months and time to AIDS/death. Demographics, CDC
classification, baseline VL/CD4, Hepatitis B/C coinfections
and HAART regimen were covariates.
Effects of the country income measures were adjusted
for significant baseline patient covariates. VL and CD4
endpoints were analysed using logistic and linear
regression, respectively. Time to AIDS/death was analysed
by proportional hazards models.
Summary of results
Patients from low income countries had lower CD4
counts, less asymptomatic infection and fewer hepatitis
B/C and VL results available at (p<0.001).
785(33.7%) patients were analysed for VL
suppression. Patients from sites with <1/year VL
testing (OR=0.30;p<0.001) and reporting “Other” HIV
source exposures including IDU and blood products
(OR=0.28;p<0.001) experienced reduced suppression.
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1120(48.2%) patients had change in CD4 data. Smaller
increases were associated with older age (p=0.001) and
“Other” exposure (p=0.033). Patients from high income
sites had lower increases in CD4 count (p=0.005). Patients
from sites with VL testing <1/year had higher increases
(p<0.001).
For time to AIDS/death analyses, Hepatitis C coinfection
(HR=1.7;p<0.02) and severely symptomatic HIV infection
(HR=1.4;p=0.008) increased disease progression. Female
gender (HR=0.8;p=0.03) and baseline CD4 count
>=100cells/μL were protective (p<0.001). VL testing <1/
year was associated with increased disease progression
(HR=1.4;p=0.032).
Conclusion
Measures of country income, including site-reported
availability of diagnostic testing, were associated with
virological and clinical outcomes following HAART.
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– 0830
ASHM - Oral Poster Session - Public 
Health And Epidemiology
Estimating hiv prevalence of HIV
among men who have sex with men 
(MSM); a reVIEW OF methodological 
options
Pedrana A1, 2, Stoovè M1, von Doussa H3, Guy R4, Hellard
H1
1
Centre for Epidemiology and Population Health Research,
Burnet Institute, Melbourne, Vic, Australia; 2Department of
Epidemiology and Preventive Medicine, Melbourne, Vic,
Australia; 3Australian Research Centre in Sex, Health and
Society; La Trobe University, Melbourne, Vic, Australia;
4
National Centre for Epidemiology and Clinical Research,
Sydney, NSW, Australia
HIV prevalence estimates are required to support the
planning of health services, monitor the long-term impact
of interventions and inform models of HIV transmission.
In Victoria, like most other parts of Australia, the HIV
epidemic has been concentrated among men who
have sex with men (MSM), suggesting that prevalence
estimates should initially be focussed in this population.
Estimating HIV prevalence requires determination of
the number of people with HIV infection (numerator)
in a representative sample of the population of interest
(denominator). In order to identify a repeatable and
accurate strategy for estimating HIV prevalence among
MSM in Victoria we considered four methodological
strategies, and compared them against the criteria of
repeatability, accuracy, cost and representativeness.
Passive surveillance is based on reports of new HIV
diagnoses and can serve as a numerator in prevalence
estimates, with the denominator being the number of
people tested. Although representative of diagnosis rates,
these data do not provide true prevalence estimates
because the population tested does not include those
previously diagnosed, those not undergoing testing, and
does not account for in or outward migration. A second
option is estimating prevalence through census type
surveys to provide numerators and denominators. This
approach is expensive and theoretically representative,
but may be subject to high degrees of underreporting
of both quantities. Another approach to deriving HIV
prevalence is to use self-reported HIV status reported in
surveys such as Gay Community Periodic Survey which
takes place annually at community events, venues and
bars. This approach is relatively cheap, but can not be
assumed to provide valid prevalence estimates because
of its dependence on self-report and an inability to
detect unrecognised infections. A related, fourth
approach is to incorporate HIV testing into these types
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Demographic characteristics of clients
accessing public sexual health clinics in
New South Wales
Ramanathan V2, Sarangapany J 1,3, Kang M 2
1. Albion Street Centre, NSW, Australia
2. University of Sydney, NSW, Australia
3. University of Wollongong, NSW, Australia
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of surveys, ideally using some form of minimally invasive
specimen collection, such as oral fluids. This approach
does not provide for greater representativeness, but is
more accurate than self-report while being simple and
repeatable. On the basis of the criteria, an oral fluid,
venue-based approach was selected for Victoria and will
be piloted in June 2008.

We aimed to describe the demographics of an adult
population accessing public sexual health clinics (PSHCs)
in New South Wales (NSW). Demographic data was
collected as part of a larger study determining accessibility
and acceptability of PSHCs
The study was a survey using a self-administered,
anonymous questionnaire and was conducted between
December 2005 and February 2006 in four PSHCs in
different geographical locations – Sydney city (SC),
Sydney suburban (SS), Sydney outer metropolitan (SOM)
and NSW rural areas (NSWRA). An accredited health
interpreter was offered for non-English speaking clients
who required assistance completing the questionnaire.

The demographics of clients attending PSHCs varied from
site to site. SC clients were more likely to be Caucasian,
male age between 26-50 years. In contrast SS clients
were more culturally and linguistically diverse. SOM and
NSWRA were similar to SC but had equal distribution of
male and female clients born predominantly in Australia.
This reflects local demographic variation to some extent,
but may also reflect the nature of the clinical services
provided at PHSCs.
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Three hundred and two adults (68% male, 32% female)
participated, a response rate of 89%.. Thirty six refused
participation for reasons of: time constraints 6 (17%),
no interest 18 (50 %), and 12 (33%) gave no reasons..
The Majority (82%) of the participants were from the SC
(n=110) and SS (n=139) clinics with 53 (18%) from SOM
and NSWRA. Pooled data found 26.5% were aged 18 – 25
years, 56% were aged 26-49 years and 17.5% were over 50
years. Eighty-two percent of the sample was Caucasian,
69% were born in Australia and 88% spoke English as their
main language. Ninety six percent of the participants had
at least a secondary education. Of these, 65% had a tertiary
level education. Only 38% reported full-time employment
with 28 % being unemployed or retired. Seventy nine
percent of the respondents reported multiple visits to the
clinics. No differences were found in educational status
or SHC users. However, significant differences were found
in age (p<0.001), gender (p<0.001), employment status
(p<0.001), ethnicity (p=0.023), country of birth (p=0.02),
and language spoken at home (p=0.007) between sites.
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Prevalence Toxoplasma in women 
pregnante in zanjan city ,IRAN 20062007
H.shoaei , Z.laghaei , M.jalalian , Z.afshar
Emam Hossein hospital Zanjan ,Iran.
Abstract
The aims of the present study were to determine the
prevalence of toxoplasmosis in pregnant women
.Prevalence toxoplasma was determine by ELISA
method.Serum samples belonge to women pregnant
refer to hospital. Five hundred and fourty woman
pregnant presented.Overall IgG seroprevalence rate of
toxoplasmosis was (47.5%) , only egith women (1.5%)
were found to have IgM antibodies. No significant
difference was between ,job,abort, meat,based of Chisquar test but a significant difference was between
educatin ,contact with cat,dog ,vegetable and water
(P<0.001).Intervention programs including health
education and environment sanitation are recommended.

P178
SHORT-TERM CLINICAL DISEASE
PROGRESSION IN HIV-1-POSITIVE PATIENTS
TAKING COMBINATION ANTIRETROVIRAL
THERAPY: TAHOD RESULTS
Srasuebkul P1, Lim PL2, Lee MP3, Kumarasamy N4, Zhou J1,
Law M1
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney, Australia 2 Tan Tock Seng Hospital,
Singapore, 3 Queen Elizabeth Hospital Hong Kong, China,
4
YRG Centre for AIDS Research and Education, Chennai,
India
The aim is to develop short-term predictive risk equations
of AIDS or death in Asian populations based on simple
clinical data.
Inclusion criteria were HAART initiation and completion
of required laboratory tests. Predictors for short term
clinical disease progression defined as AIDS or death,
were assessed. Poisson regression was used with three
different models: (1) clinical data only, (2) clinical data and
CD4 counts, and (3) clinical data and CD4 and viral load
(VL).
Body mass index (BMI) and anaemia were predictive in all
three models. Others were age and female, CD4 (Models2
and 3) and detectable VL (Model3). We separated patients
into patient risk groups; low(L), high(H) and very high(VH).
For Model1 patients with severe anaemia or BMI < 18 were
at very high risk, while patients with (age < 40 or male)
and mild anaemia were at high risk. For Model2, patients
with CD4 < 50 or severe anaemia or BMI < 18 were at very
high risk, patients at high risk were patients with (CD4 51
– 200 or Age < 40 or male) and mild anaemia. For Model3,
patients with CD4 < 50 or detectable viral load or severe
anaemia or BMI < 18 were at very high risk, and patients
with CD4 51 – 200 and mild anaemia were at high risk.

poster abstracts

The incidences from Model1 were 2.4%, 7.6% and 17.7
% from L, H and VH risk groups, respectively. The Model2
incidences were 1.0%, 3.8% and 18.6 % from L, H and VH
risk groups, respectively. Finally, the Model3 incidences
were 1.6%, 4.3% and 6.3 % from L, H and VH risk groups,
respectively
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These models are simple enough for widespread use
in busy clinics. These models should allow clinicians to
identify patients at highest risk of the outcome, with a
view if possible to intervention.
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COST-EFFECTIVENESS OF DARUNAVIR/
RITONAVIR 600/100 MG BID VERSUS
COMPARATOR PIS IN HIGHLY TREATMENT
EXPERIENCED, HIV-INFECTED ADULTS IN
AUSTRALIA
Warren E¹, Schrover R¹
¹Janssen-Cilag Pty Ltd
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Introduction:
We evaluated, from an Australian perspective, the costeffectiveness of ritonavir-boosted darunavir (DRV/r)
600/100 mg BID plus an optimised background regimen
(OBR) compared with investigator-selected control PIs
(CPIs) +OBR used in the DRV POWER 1&2 trials in highly
treatment experienced HIV-infected adults, in line with the
currently reimbursed indication for DRV/r in Australia. We
also examined the cost-effectiveness of DRV/r compared
to tipranavir/ritonavir (TPV/r), which recently received
Pharmaceutical Benefits Scheme reimbursement for this
patient group in Australia.
Methods:
We extracted mean CD4 count and viral load data for
DRV/r and CPI-based HAART from weeks 0-72 from the
POWER 1&2 studies. We projected viral load from week
73 onwards over a 10 year time horizon with exponential
regression curves for each treatment group. Using the
relationship between CD4 count and viral load reported
in the PLATO collaboration, we estimated the monthly
mean CD4 counts in each group over this time horizon
from these projected viral load data. We then used a
Markov model with monthly transition probabilities as
reported in the EuroSIDA Cohort to predict AIDS defining
events, deaths and related costs based upon monthly
CD4 counts over this horizon. We also performed a costeffectiveness analysis of DRV/r + OBR versus TPV/r + OBR
based upon an indirect comparison and data from the
POWER and RESIST studies. We assumed that patients
would switch to salvage therapy after virological failure
with DRV/r, CPIs or TPV/r-based HAART.
Results:
Our analysis of DRV/r + OBR versus CPIs + OBR in highly
treatment experienced patients found a discounted
Incremental Cost-Effectiveness Ratio (ICER) of AUD$36,776
per life year gained and a discounted cost per Quality
Adjusted Life Year (QALY) gained of AUD$39,019 for DRV/
r. Our analysis of DRV/r versus TPV/r found a discounted
ICER for DRV/r of AUD$40,595 per life year gained and
AUD$42,284 per QALY gained.
Conclusion:
DRV/r 600/100mg BID-based HAART is cost-effective
compared to both CPI and TPV/r based regimens in
highly treatment experienced, HIV-infected adults in
Australia. A lower, once daily dose of DRV/r (800/100 mg
QD) is currently being evaluated in treatment naïve and
early treatment experienced HIV-infected patients.
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PROMOTION OF HPV VACCINES TO
FACILITATE SEXUAL HEALTH EDUCATION
WITHIN A HOLISTIC HEALTH FRAMEWORK IN
ABORIGINAL COMMUNITIES
Stacey Donovan
Aboriginal Sexual Health Worker, Biripi Aboriginal Medical
Service, Taree NSW Australia
The occurrences of cervical cancer in Aboriginal women,
is 5 times greater then that of Non- Aboriginal women.
The role of the Human Papilloma Virus (HPV) and cervical
cancer are well established.
It has been identified that being infected with HPV is a
normal part of being sexually active, thus is of particular
concern for girls and young Women, in the Aboriginal
communities, due to sexual activity commencing at a
younger age.
In 2006, the Therapeutic Goods Administration, approved
Gardasil™ which is a vaccine that protects women by 90100%. The vaccine was made available and subsidised
by the Australian Government, targeting females aged
between 9-26 years of age. From 2007 this became a
school based Vaccination Program.
The role of an Aboriginal Sexual Health Worker is
promoting health, providing health education on safe sex
practices and raising awareness of sexually transmissible
infections (STI), and blood bourne viruses (BBV).
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The NSW HIV/AIDS, STI and Hepatitis C Strategies:
Implementation Plan for Aboriginal People 2006-2009
states that HIV/AIDS, STI and hepatitis C programs may
be more acceptable to Aboriginal people, and therefore
more accessible, when delivered within a holistic health
framework.
In line with the above NSW Plan and the National
Aboriginal and Torres Strait Islander Sexual Health
and BBV Strategy 2005-2008, the Aboriginal sexual
health worker at Biripi Aboriginal Medical Service (AMS)
promotes HPV Vaccine part of their sexual health role.
This ensures Aboriginal girls and women receive this
preventative treatment, in an effort to reduce the statistics
around cervical cancer in Aboriginal communities, while
at the same time facilitating HIV/AIDS, STI and hepatitis C
education within a holistic health framework.
The presentation will focus on the strategies implemented
undertaken at Biripi AMS, and their results.
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‘WE HAVE INFECTIONS ZAPPED!’
OFFERING TESTING FOR CHLAMYDIA
AND GONORRHOEA IN TARGETED YOUTH
SETTINGS
McGowan AC1, Shaw MJ1, Prihaswan P1
1HIV & Related Programs Health Promotion Team, Sydney
South West Area Health Service, Camperdown, New
South Wales, Australia
Chlamydia is the most common STI in Australia and
is particularly high in young people 15 to 30 years old.
Aboriginal young people in NSW are recognised as
suffering from a higher burden of sexually transmitted
infections (STIs) and blood-borne viruses than non–
Aboriginal young people and have been identified as a
priority population for Sexual Health Services across the
state by the NSW Department of Health.
Young people however, do not access health services as
extensively as adults and seldom discuss sexual health
issues when they do. Research has noted that barriers to
accessing health care include financial concerns, lack of
knowledge, lack of confidentiality and other emotional
concerns. Young people traditionally do not perceive
themselves at risk of STIs. This supports the need to
actively engage young people in settings where they feel
more comfortable and secure engaging with health care
staff.
In response to these issues, the HIV & Related Programs
(HARP) Health Promotion Team (SSWAHS) has initiated an
outreach testing program as a strategy to improve access
for young clients, particularly young Aboriginal clients,
to sexual health clinical services. In line with the NSW
Sexually Transmissible Infections Strategy 2006-2009, the
program will trial an active outreach approach to sexual
health clinical services and promote collection of urine
for chlamydia and gonorrhoea testing.
This program is being delivered as a collaboration
between the HARP Health Promotion Team and the RPA
Sexual Health Clinic team. Of particular importance is the
role of the Aboriginal Sexual Health Workers (ASHWs)
in maintaining relationships with services and working
directly with Aboriginal young people. STI testing is
offered by both ASHWs and nursing staff.
This paper will discuss the process of:
• selecting two local youth services as sites for outreach
testing
• developing and formalising partnerships with these
services
• developing a series of project resources, including an
information pamphlet and safe sex packs
• delivering the program and preliminary results
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ENHANCED PRIMARY CARE (EPC) AND
CARE CO-ORDINATION AS A CO-OPERATIVE
MODEL
Scott-Visser BR , Starkey RJ 
1 SHAIDS, Lismore, NSW, Australia
2 ACON, Lismore, NSW, Australia
The terms empowerment and self determination can
become clichéd. Case management means many things
to many people. How can these values and perspectives
effectively be implemented to produce positive outcomes
for positive people, especially those with complex needs
living in a rural setting?
In this presentation, we discuss our unique roles, the theory
behind our work (differentiating case management and
care co-ordination), why we use these models and how
we have developed an effective partnership model.
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The two presenters work in differing services in differing
roles, however they have developed a partnership
approach to initiate productive outcomes for positive
people, especially those with complex needs living in
rural Australia.
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POTENTIAL DIFFICULTIES AND CONFLICTS:
FINDINGS FROM A KNOWLEDGE, ATTITUDES
AND PRACTICE SURVEY OF HEALTH CARE
WORKERS IN PAPUA NEW GUINEA
Hill R1, Ryan B2, Sadler S1, Sarangapany J1, Begley K1,
Wyndham H1, Cousins
J2, Nicol K2, Kalinoe M2 and Miria R2
1Albion Street Centre, Surry Hills, NSW, Australia
2Anglicare StopAIDS, Port Moresby, Papua New Guinea
The social and cultural impact of twin HIV and STI epidemics
in Papua New Guinea (PNG) is widely acknowledged.
Responding to these diseases using a multi-sectorial
approach is a Government of PNG (GoPNG) priority. The
PNG and Australia Sexual Health Improvement Program
(PASHIP) is a partnership between the Australian and PNG
governments, and a number of local and international
organisations. The purpose of the program is to reduce
the prevalence of STIs through the provision of sexual
health services.
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The study was a questionnaire based survey of knowledge
and attitudes of Health Care Workers (HCWs) in a single
health care facility in Port Moresby. The survey was
divided into two sections: 1) knowledge and 2) attitudes,
with each section containing three separate sub-sections.
A total of 19 forms were returned, four from nursing staff
and fifteen from counselling staff. For the knowledge
section of the survey overall scores were higher among
the nursing participants than among counselling staff,
90% correct compared with 69% correct respectively.
Basic knowledge of transmission was similar between
both groups. There were differences in specific knowledge
about STI’s between nurses and counsellors, and this
accounted for differences in the overall knowledge score.
Despite the overall sound knowledge of the HCWs, three
reported that there was a cure for HIV with one person
witnessing a ‘faith healing’ that cured HIV. Attitudes
towards condom use had positive response from both
groups. The survey indicated a strong perception that
those most vulnerable to STI’s, such as men who have
sex with men (MSM) and commercial sex workers (CS)
deserved access to health care. However, more than half
(8/15) of the counsellors felt that knowing a colleagues
HIV positive status would give them a better chance to
protect themselves against HIV.
The study found that the overall level of knowledge
was high and there was a high level of commitment
and motivation to care for people living with HIV in this
PNG HCW cohort. There were, however some myths and
beliefs that could potentially be barriers to the delivery of
care which need to be addressed.

256 						
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NEW MARRIAGES, NEW PREGNANCYS AND
KNOWLEDGE OF SPOUSE HIV STATUS AT AN
HIV TREATMENT FACILITY IN CAMBODIA.
Roeun M1, Pouv S1, Phorn S1, Khem C 1, Keo S1, Song S1,
Taing S1, Eng L1, Huffam S1,2, Saphonn V1, Kaldor J2, Cooper
D A2, Mean CV1.
1
National Center for HIV/AIDS, Dermatology and STIs
(NCHADS) Ministry of Health Cambodia, 2 The National
Center in HIV Epidemiology and Clinical Research
(NCHECR), University of New South Wales, Sydney, NSW,
Australia.
The NCHADS Social Health Clinic (SHC) is an outpatient
facility providing care, including antiretroviral therapy
(ART), to people living with HIV in Phnom Penh,
Cambodia.
Patients’spouse status (single, married, divorced, widowed,
and HIV/ART status) are recorded by counsellors and
peer support workers at enrolment, and entered into an
observational clinic database. All current patients’ data
were reviewed and updated in early 2008, and compared
with baseline.
Of 1989 ever enrolled patients 1411 were current at
April 30th 2008, with a median time of enrolment of 22.8
months, and 1047/1411(75%) on ART. At enrolment
479/677(71%) men, and 419/734(57%) women were
married, and 27/677(4%) men and 116/734(16%) women
widowed. Spouse status was “missing” for 106/734(14%)
women and 30/677(4%) men. At review, spouse status
rates are similar to at enrolment except 213/734 women
(29%) were subsequently recorded as widowed, with
data missing data for only 2 women.
New marriages (or stable partnerships) occurred for
56(8%) male patients and 58(8%) women, including 14
patients who entered more than one marriage since
enrolment. After enrolment 39/734(5%) women became
pregnant including 8(14%) of the 58 women with a new
marriage.
HIV status was recorded as unknown for 181/524(35%)
spouses of male patients, and 179/492(36%) spouses of
female patients at enrolment. At review, HIV status are
recorded unknown for 116/540(21%) current spouses
of male patients, and 144/504(29%) spouses of female
patients, including 9/50(18%) spouses of men, and
16/50(32%) spouses of women in new marriages. Overall
260/1044(25%) patients’ current spouse’s HIV status are
recorded as unknown, 492/1044(47%) HIV +ve, (including
39/100(39%) newly married), and 292/1044(28%) HIV
–ve (including 36/100(36%) newly married). Of HIV +ve
spouses, 278/492(56%) are on ART.
These data give some insight into changes in marital
status, knowledge of spouse HIV status, and occurrence
of pregnancies in a cohort of PLHA over time. To prevent
20 HIV transmission, HIV clinics must acknowledge their
patients’ relationships and family life and encourage
and facilitate honest communication between couples,
disclosure of HIV status, HIV testing of partners, use of HIV
prevention methods, and ensure family planning and
sexual heath services are available to patients and their
partners.

17-20 september 2008 @ Perth Convention Centre, Western Australia

Community capacity enhancement (CCE) is an approach
developed by the United Nations Development
Programme to assist communities to address social,
cultural, and gender factors contributing to HIV
vulnerability. It utilises the ‘community conversation’
methodology pioneered by the Salvation Army and Hope
Worldwide. CCE can be categorised as a ‘social change
communication’ intervention, defined in November
2007 by the Joint United nations Programme on HIV and
AIDS (UNAIDS) Technical Consultation on Social Change
Communication as “…the strategic use of advocacy,
communication and social mobilization to systematically
facilitate and accelerate change in the underlying drivers
of HIV risk, vulnerability and Impact.”
As an international non-governmental organisation,
World Vision’s challenge is to identify evidenceinformed and theory-based HIV response approaches
that are viable for scale-up and yet flexible enough to
be adapted for a range of epidemiological and social
contexts. World Vision is moving toward incorporating
a CCE approach into a ‘core model’ for HIV prevention
in generalised epidemic settings in sub-Saharan Africa
with predominantly sexual transmission. In 2007 World
Vision Ethiopia commenced a four-year pilot project to
test the viability and effectiveness of a CCE approach in
the context of broad-based, long-term, multi-sectoral
community development programmes. The project
operates in one district in Tigray Region and three districts
in the Southern Nations and Nationalities People’s Region.
The CCE approach is employed in combination with other
behaviour change interventions: life-skills education in
schools, child peer education for in-school and out-ofschool youth, and the ‘Channels of Hope’ methodology
for mobilising faith communities. Baseline, mid-term and
final evaluations will employ a combination of qualitative
and quantitative methodologies to compare results
against comparison sites, which will use the same set of
interventions, excluding the community conversations
methodology.

Tomkins M, Gold J
The Albion Street Centre, Sydney, NSW, Australia
The World Health Organization (WHO) and International
Labour Organization (ILO) recently published Joint WHO/
ILO guidelines on post-exposure prophylaxis (PEP) to
prevent HIV infection. Personnel from the Albion Street
Centre were involved in drafting the document.
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Tadesse Z1, Afework S1, Claxton A2, Duffy SM3
1
World Vision Ethiopia, 2World Vision HIV and AIDS Hope
Initiative Africa Region, 3World Vision Australia

P186
IMPLEMENTATION ISSUES ARISING FROM
THE 2008 WHO/ILO POST EXPOSURE
PROPHYLAXIS GUIDELINES

The Guidelines include policy and clinical guidelines for
PEP for occupational exposure and non-occupational
exposure (primarily after sexual assault) and are intended
to be able to be used in any setting in any country.
Although the guidelines are designed to ensure equitable
and appropriate access to PEP in resource constrained
settings issues with implementation are forseen.
Key delivery issues include:
- Is the provision of PEP after occupational exposure or
sexual assault beneficial in terms of effectiveness and/
or cost?
- How can PEP be seen as a priority in the context of
inadequate treatment resources?
- How can PEP be provided without affecting resources
available for antiretroviral therapy or prevention?
- Is there a link between provision of PEP and subsequent
sexual, drug use and occupational practices?
- What are the minimum requirements (in terms of other
support services) needed to be able to offer PEP?
- Is there a reliable risk assessment algorithm that ensures
PEP is not given for low risk exposures?
- What is the role of source assessment? Should PEP only
be given if the source is known to be HIV antibody or
HBV antigen positive?
- Which drugs should be recommended?
- How can PEP accessibility be made equitable in all
settings?
The provision of international PEP guidelines raises
important concerns regarding implementation and
should include mechanisms for an evaluation of their
impact on HIV care delivery and prevention programs.
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P185
COMMUNITY CAPACITY ENHANCEMENT
FOR HIV RESILIENCE IN A GENERALISED
EPIDEMIC: A COMPARISON STUDY OF
A SOCIAL CHANGE COMMUNICATION
APPROACH IN RURAL ETHIOPIA

This presentation will discuss the project’s implementation
approach and research methodology, and present
relevant baseline findings.
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SHARP PRACTICE: THIRTEEN YEARS OF THE
NSW NEEDLESTICK INJURY HOTLINE

P189

withdrawn

Cherry R, Melling P, Wyndham H
Albion Street Centre, NSW, Australia
The New South Wales (NSW) Needlestick Injury Hotline
was launched in September 1995. The Hotline was
developed in response to a 1994 NSW Health Department
report which identified a crucial need for a coordinated
approach to the treatment of health care workers
sustaining needlestick injuries in NSW health care facilities.
The Hotline was designed to augment, not supplant,
local policies and protocols for managing exposures. The
objective was to provide immediate information, risk
assessment, support and referral to injured health care
workers and the emergency services (i.e. police, fire and
ambulance personnel), their supervisors and clinicians, 24
hours a day, 365 days a year.
In 2008 occupational exposures remain a common
cause for concern among health care workers. Exposures
continue to occur despite the introduction of new safety
equipment such as needle-less systems. Knowledge
deficits among health care professionals providing direct
management of needlestick injuries persist, and the
uptake of hepatitis B vaccination among some groups of
health care workers remains inconsistent.
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The Needlestick Hotline has established a database
capturing valuable information about trends in
needlestick injuries and occupational exposures. This
poster will identify key trends and provide an overview
of the service.
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VALIDATING A TWO-QUESTION DEPRESSION
SCREENING TOOL IN AN HIV-POSITIVE
POPULATION TO USE IN IMPROVING
NUTRITION OUTCOMES AND PROGNOSIS

nutrition counselling can be initiated in a timely fashion
to improve outcomes. Effective treatment can reduce
major depression in 80-90% of patients. Greater attention
to nutritional factors in mental health is warranted given
that nutrition interventions are inexpensive, safe and easy
to administer. The depression screening questions should
be incorporated into a larger nutrition screening criteria
to assist in detecting and treating comorbidities relating
to HIV-infection and treatment.
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Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, Young,
J. 1, 3, Purnomo, J. 1, Begley, K. 1
1
The Albion Street Centre, Prince of Wales Hospital,
Sydney, NSW, Australia.
2
The University of Sydney, Sydney, NSW, Australia.
3
The University of Wollongong, Wollongong, NSW,
Australia.
Depression is a treatable disorder which is prevalent
amongst people infected with HIV with rates as high as
20-32%. Concurrent depression can result in increased
symptoms and accelerated progression to AIDS. Studies
have found associations between nutrient intake
and depression. Poor diet quality and micronutrient
deficiencies, particularly folate and omega-3 fatty acids,
may propagate depressive symptoms. This study aims
to validate a two-question depression screen, previously
validated within a veteran’s population, in HIV-1 infected
patients. The overall goal is to incorporate the tool within
nutritional screening to improve nutritional outcomes and
prognosis through identifying and treating depression.

poster abstracts

A convenience sample of 32 participants (30 male, 2
female) was recruited for the study. The mean age of the
participants was 44 ± 10 years and the mean duration of
HIV-infection was 12 ± 7 years. Participants completed
the two-question depression screen and the Centre
for Epidemiologic Studies Depression Scale (CESD-10),
to assess the validity of the tool. The scoring system for
both the CESD-10 and two-question depression screen
remained the same as in the original study. Validity
testing was performed by bi-variate correlation analysis
using Spearman’s (rho) correlation coefficient. A strong
correlation was found between the two measures,
rho=0.78 (p<0.001). These results indicated that the
abridged screening tool was valid for detecting individuals
at risk of depression. The proportion of participants
classified as depressed by the CESD-10 was 9/32 (28%)
and with the abridged tool was 12/32 (38%). The abridged
questions overestimated depressed participants, which is
acceptable for a screening tool.
As screening tools improve potential case identification,
further confirmatory assessment and appropriate
interventions such as cognitive behaviour therapy and
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fat deposits or weight gain, and 17 (53%) reported weight
loss or muscle wasting.

ASHM - Oral Poster Session - Clinical,
Allied Health And Basic Science
VALIDATING AN ABRIDGED SYMPTOMS
DISTRESS QUESTIONNAIRE IN AN HIVPOSITIVE POPULATION TO FACILITATE
DIETETIC REFERRAL AND IMPROVE
NUTRITION OUTCOMES

Nutrition management is integral to the care of HIVinfected individuals as they may be at nutritional risk
at any point in their illness. Nutritional counselling can
assist in alleviating nutrition related symptoms, and
improve nutrition status, immune function and survival.
The abridged symptom distress questions should be
incorporated into a larger nutrition screening criteria to
assist in detecting and treating symptoms related to HIVinfection and treatment.

Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, Young,
J. 1, 3, Purnomo, J1.
1
The Albion Street Centre, Prince of Wales Hospital,
Sydney, NSW, Australia.
2
The University of Sydney, Sydney, NSW, Australia.
3
The University of Wollongong, Wollongong, NSW,
Australia.
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HIV infection, secondary infections and treatment with
antiretroviral (ARV) medications can result in complicated
health and nutritional issues for individuals. There is
increasing evidence to suggest that nutrition interventions
can influence future health outcomes and prognosis.
HIV infection and/or ARV treatment may induce various
side effects including nausea, vomiting, diarrhoea, taste
changes, weight loss and micronutrient deficiencies.
These symptoms may propagate more serious
comorbidities such as malnutrition, muscle wasting and
reduced functional status. Nutrition screening allows for
early detection of symptoms and encourages treatment
with nutritional counselling.
This study aims to validate an abridged symptoms
distress questionnaire in a HIV-1 infected sample against
the Symptoms Distress Module (NIAID Adults AIDS
Clinical Trials Group), a validated questionnaire used in
HIV clinical trials. The overall goal is to increase symptom
detection and improve nutrition outcomes through
appropriate dietetic referral. A convenience sample of
32 (30 male, 2 female) participants was recruited for the
study. The mean age of the participants was 44 ± 10
years and the mean duration of HIV-infection was 12 ±
7 years. Participants completed both the abridged and
complete symptoms distress questionnaires. Validity
testing was performed by bi-variate correlation analysis
using Spearman’s (rho) correlation coefficient. A strong
correlation was found between the two measures,
rho=0.86 (p<0.001), indicating the abridged questionnaire
was valid for detecting patients with a high symptoms
score. The questionnaire indicated that a dietetic referral
was required in 28 (87%) participants. A high frequency of
symptoms was observed in the sample; 28 (88%) reported
fatigue, 23 (73%) diarrhoea, 21 (66%) bloating, 18 (56%)
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Targeted nutrition screening provides a quick, reliable
and cost-effective alternative to complete assessment, to
identify individuals who have one or more indicators of
poor nutritional status or disease risk. Early identification
allows for timely intervention and management with
nutritional counselling, support and supplementation to
improve nutritional status.
There have been few nutrition screening tools used
in the screening of HIV-positive patients and most
do not incorporate risk factors for multiple nutritional
issues, nor do they consistently take into account the
chronic nature of the disease or long-term antiretroviral
therapy. Hence, a multi-parameter tool is indicated for
nutrition screening amongst people living with HIV. We
have identified evidence-based risk factors that would
contribute to diabetes and cardiovascular disease; and
nutritional deficiencies in this population, including;
symptoms, malnutrition, food insecurity, poor oral health
and depression.
The aim of this study was to develop and pilot a nutrition
screening criteria using validated questionnaires and
evidence-based risk factors for disease, and to test
the inter-rater reliability of the tool in a HIV-positive
population. A convenience sample of 32 participants (30
male, 2 female) was recruited for the study. The mean
age of the participants was 44 ± 10 years and the mean
duration of HIV-infection was 12 ± 7 years. Reliability of
referrals between two health practitioners was tested
using the kappa-test statistics. Two of either a medical
officer, registered nurse or dietitian scored the completed
screening criteria and indicated an appropriate referral to a
dietitian, dentist or psychologist. Referral to a dietitian was
concordant in 93%, a dentist in 76% (k=0.66, p<0.001), and
a psychologist in 86% (k=0.73, p<0.001) of cases. Of the
32 participants; 29 (91%) required a referral to a dietitian,
15 (47%) to a dentist and 16 (41%) to a psychologist.
The screening criteria developed were found to be reliable
between examiners, and further testing is undertaken to
validate the tool and assess sensitivity and specificity. A
panel of experts within the centre concluded that the
tool was adequate and reliable for a referral pathway.

Complex Psychological Factors 
Contributing to Sexual Risk Behaviour 
Among HIV Negative Men Who Have Sex
With Men (MSM): Informing Sexual Riskreduction Initiatives for the Future.    
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Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, Young,
J. 1, 3, Purnomo, J. 1, Begley, K. 1
1
The Albion Street Centre, Prince of Wales Hospital,
Sydney, NSW, Australia.
2
The University of Sydney, Sydney, NSW, Australia.
3
The University of Wollongong, Wollongong, NSW,
Australia.
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Earle, M, Hoy, J., Price, B.
Victorian HIV Service, The Alfred, Melbourne, Victoria,
Australia.
Predictors of sexual risk behaviour potentiating HIV or
STI infection among HIV negative Men who have Sex
with Men (MSM), have been extensively researched.
An illuminating body of literature has accumulated
describing the demographics and health status of MSM
engaging in sexual risk behaviour along with many social
and contextual variables surrounding it. Though some
contributing mental health conditions such as substance
abuse, depression or anxiety have also been studied,
comparatively less attention has been given to complex
psychological factors such as impulsivity, affect regulation
or interpersonal relating difficulties. Given these factors
have repeatedly been identified in the mental health
literature as contributing to other forms of risk-taking
behaviour such as binge-drinking, substance or gambling
addiction, they warrant closer attention.
In response to this need, the Psychology Unit within the
Victorian HIV Service began systematically collecting data
regarding these psychological factors from HIV negative
MSM attending the service for assistance reducing sexual
risk behaviour. Clients were referred from the Victorian Non
Occupational Post-Exposure Prophylaxis (NPEP) program
and from general practice clinics in the community, after
seeking medical help regarding a sexual risk event. Clients
completed the Sexual Sensation-Seeking and Sexual
Compulsivity Scales (Kalichman & Rompa, 1995) and
the Personality Assessment Inventory (PAI, Morey, 2007).
Both of these psychological assessment instruments are
valid and reliable measures of sexual excitement-seeking,
sexual compulsivity, depression and anxiety along with
propensities toward impulsivity, self-harming behaviour,
difficulties with affect regulation and negotiating
interpersonal relationships.
Trends in the data collected to date will be presented
and discussed in light of relevant research from within
the HIV Prevention and Mental Health fields. Applications
of this data will also be discussed, including it’s use as an
evidence-base for developing psychological interventions
aimed at helping HIV negative MSM engaging in sexual
risk behaviour increase their sexual safety, and ways it
might inform preventative education campaigns
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DEVELOPMENT AND RELIABILITY TESTING
OF NUTRITION SCREENING CRITERIA FOR
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NURSE ROLE IN PROVIDER-INITIATED
HIV TESTING AND COUNSELING IN RSIJ
HOSPITAL, JAKARTA
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Hari Atikasari1, Husna Ihsanil3, Sumiwi Riris1, Umayah Siti1,
Imran Darma2
1
Department of Nursing Jakarta Islamic Hospital (RSIJ);
2
Department of Neurology University of Indonesia; 3AIDS
Working Group Jakarta Islamic Hospital (RSIJ)
Nurse role as a counselor for human immunodeficiency
virus (HIV) suspected patients based on admission
symptom was very important to diagnose HIV. We
determined patient or family response to providerinitiated HIV testing and counseling by nurses in our
hospital. We conducted a cross sectional study from
August 23rd to May 10th 2008. Fifty four patients were
included and majority of patients were males 41 (76%).
The age of patients ranged from 20 to 44 years with mean
value 28 years. Marital status was 57% single, 30% married
and 13% widow. Eleven (20%) patients had education
degree lower than high school. Thirty two (59%) of the
patients employee and 41 % unemployee. HIV risk factor
was intravenous drug users (IDU) 61%, heterosexual 6%
and others 33%. Admission symptoms were prolonged
fever 54%, chronic diarrhea 13%, unconsciousness 11%
and others 22%. Fourty (74%) patients showed a positive
response attitude when nurse asked for HIV testing and
14 (26%) showed a negative response attitude. Marital
and job status had significant value to patients response
(p=0,037 and p=0,042). Almost all of the provider-initiated
HIV testing and counseling in our hospital by nurses had
positive response, and factors which influenced their
response was marital and job status.

P196
Understanding Domestic Violence 
and Same Sex Domestic Violence in a 
HIV ambulatory care setting 
Hennessy R
Domestic Violence (DV) and Same Sex Domestic Violence
(SSDV) has been recognised as a serious issue. Overseas
and anecdotal reporting suggests that DV in samegender relationships is comparable to the rates of DV
against heterosexual women. As in opposite-gendered
couples, the issue is presumably underreported. Being
afraid of revealing the nature of the sexual relationship, an
unsympathetic justice system and inadequate resources
for male victims are some of the barriers to reporting.
Purportedly HIV in an abusive relationship may add
to the complexity of concerns. Perpetrators of DV
ostensibly could use HIV status as a means of coercion or
intimidation in their relationships. Victims may fear that
their abusive partner may reveal their HIV status to others
and thus face HIV discrimination and potentially outing of
sexual orientation due to HIV’s association with sexuality
in Australia. Alternatively abusive HIV positive partners
may coerce partners to risk HIV infection and should
HIV transmission occur this sero-concordance itself may
make separation more difficult due to the fears previously
noted.
Currently within the SESIAHS sector data on DV and SSDV
is not uniformly collected. Understanding how HIV may
affect DV has rarely been considered. In addition to other
approaches the Albion Street Centre’s (ASC) Psychology
Unit acknowledged the need to develop a strategic plan
to address DV and SSDV service delivery. Promoting
awareness and improving our understanding of DV and
SSDV within our HIV positive client’s relationships were
identified as essential first steps.
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Information regarding client’s experiences of DV both
in current and past relationships will be collected over a
one month period. Identifying if HIV features in any abuse
experienced and what help or barriers to help, if any,
clients will be considered. Data on a planned recruitment
of 30 clients will be presented.
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Gaining an insight into the incidence and type of DV
issues facing clients will potentially enable psychosocial
based services to better assist people to leave an abusive
relationship. Such information can assist professional
providers, who may have inadequate levels of experience
and training to work with victims, to highlight what the
professional development and resource needs are to
improve service delivery.
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Previous studies have shown the incidence of psychiatric
and substance abuse disorders are generally higher in
people infected with HIV than in the general population.
It has also been shown that improving treatment in those
with both HIV and mental health disorders can improve
quality of life and treatment outcomes. In order to
improve the provision of mental health care amongst the
cohort of HIV patients attending Fremantle’s Infectious
diseases department, we performed an audit examining
mental health diagnoses and the care accessed by these
persons.
A retrospective case note review was performed.
Demographic data, risk factors for HIV transmission, CD4
count at HIV diagnosis, current mental health diagnoses
(MHD), previous MHD, HIV treatment outcomes, current
psychiatric treatment, and health services accessed were
recorded.
In February 2008, 90 HIV-positive patients (males N=
69, females N=21) were registered on the department’s
database. Of these 34% (38/90) were found to have a
current MHD, and another 13% (14/90) had a past history.
Men were more likely to have a MHD and present later
with advanced HIV disease. Of the 11 indigenous patients
attending the clinic, 9 had a current MHD.
Only 51% of those with a current MHD were accessing a
General practitioner (GP) and 23% Mental health services.
67% were recorded as being prescribed antidepressants,
19% antipsychotics, and 14% were on both medications.
Of these, 55% of patients had their psychiatric medications
prescribed by the Infectious diseases department.
Reassuringly all patients with a mental health diagnosis
who required HIV treatment were taking HAART (highly
active antiretroviral treatment), and the majority had
undetectable HIV viral loads.
We have subsequently secured funding for a psychiatric
outpatient’s session in our HIV clinic and are actively
seeking GP’s for patients who are not registered with
a general practice. We are also a developing a mental
health assessment tool to be used within our clinics, in
order to identify patients who require early intervention
and referral to specialist services.

Crock L1, Gellie K1, Moyer J1, Tomnay J1.
1. Australian & New Zealand Association of Nurses in
AIDS Care (ANZANAC) Victorian Branch Committee,
Melbourne, Victoria
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Libertino S1, Kerth J1, Wilson M1, McLellan D1, Marshall L1,
Dyer J1, Clark B1.
1
Department of Infectious Diseases, Fremantle Hospital,
Western Australia.

P199
ANZANAC VICTORIAN BRANCH: RESPECTING
OUR HISTORY, CAPTURING OUR EXPERTISE
AND LOOKING TO THE FUTURE.

ANZANAC (Victorian Branch) began as the Victorian AIDS
Nurses Resource Group in 1986 when a group of nurses
recognised the need to support and educate nurses
working in HIV/AIDS. Whilst the group has had name
changes over the years, its purpose and core functions
have been maintained, with a small but dedicated group
of active members. Now in its 22nd year, the group is
led by a volunteer committee. Although it receives no
funding, ANZANAC (Victorian Branch) produces a regular
journal and holds education and networking events for
members. It advocates and responds to issues relevant to
Victorian HIV nurses, and people living with HIV/AIDS.
A strong sense of the historical importance among group
members is balanced by recognition of how a dynamic
epidemic impacts on the needs of Victorian nurses. In
2007, ANZANAC (Victorian Branch) conducted a survey
of members to explore and document the diversity and
expertise within the group, to establish the current needs
of members, and to plan for the future.
An email requesting members to fill in an online survey
was sent in three waves. Also, non participating members
attending a subsequent education session were invited
to fill in a hard copy of the survey. Results were entered
into “Survey Monkey” and analysis performed.
86% (19/22) of members participated. 90% of participants
worked in public health, community nursing, research or
a public hospital. All participants (100%) had or did work
in an HIV related position. 70% (14/20) respondents had
a combined 204 years experience in HIV nursing. 94% of
respondents were Division 1 nurses, with 90% having
post graduate qualifications (52% graduate diploma, 32%
Masters, 11% PhD). 78% of respondents indicated that
ANZANAC’s education sessions, journal, peer support and
networking were good or very good. Members stated
that, in the future, ANZANAC (Victorian Branch) should
focus on increasing its profile among nurses in Victoria
and provide more educational opportunities such as
journal/book clubs, refresher courses on HIV, blood borne
viruses and sexually transmissible infections. ANZANAC
(Victorian Branch) also needed stronger networking
within Australia.
We conclude that ANZANAC (Victorian Branch) is meeting
the current membership needs.
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A study of factors affecting longterm adherence to enfuvirtide (ENF)
therapy in HIV-1 infected individuals
Norris R.1, Fraser H.2, Hales G.3
1St Vincent’s Hospital, HIV Ambulatory Care Unit, Sydney,
Australia, 2St Vincent’s Hospital, Research Office, Sydney,
Australia, 3Roche Products, Medical, Sydney, Australia
Text: Objective: To describe issues for patients related to
long term adherence to ENF and to identify strategies
that affect adherence to twice daily injections.
Methods: 17 subjects provided informed consent;
structured interviews were undertaken at an HIV
Ambulatory Care Clinic. The interviews were taperecorded and transcribed verbatim. Transcripts were
analyzed using an interpretative phenomenological
approach. Themes were identified which reflected
the subjects’ experience of self administrating ENF.
Results:
Demographics

N = 17

Mean Age (Years)

47

24

Mean CD4+ Cells/mm3

287

% HIV Viral Load <50

71

% Currently on ENF

82

poster abstracts

% Male
[Demographics]

94

The main findings were that adherence to ENF takes
self discipline, commitment and a sustainable routine
combined with an understanding of the process for self
administering a twice daily injection. Improved HIV clinical
surrogate markers were powerful motivators for long term
use. Lifestyle readjustment was also required for successful
long term use. High levels of satisfaction with training and
confidence in the ability to self inject were important for
adherence. Injection site reactions (ISR) posed significant
problems for many patient however choice in the delivery
method (27, 31 gauge needles and biojector) provided
patients with options to manage the impact of ISR.
Conclusion: Study participants recognized that taking
ENF required additional commitment to adherence
compared to oral ART. Patient education needs to focus
on ways to develop routines, management of ISRs and
identification of suitable injection sites. Patients taking
ENF long term would benefit from annual training
sessions, targeting ISR management and updated self
administration education.
Country of research:
Australia
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REDUCED ENERGY and increased 
saturated fat intake IN A COHORT OF
HIV POSITIVE CLIENTS IN SYDNEY
Purnomo J1, Young J1,2, Sarangapany J1,2, Houtzager L1,2, Di
Guilmi A1,3
1
Albion St Centre, Surry Hills, Sydney, NSW, Australia;
2
University of Wollongong, Wollongong, NSW, Australia;
3
University of Sydney, Sydney, NSW, Australia
Balanced nutrition is essential for people living with
HIV (PLHIV) as it helps in managing symptoms, reduce
toxicities associated with anti retroviral therapy, delay
disease progression and maintain immune responses
leading to a better quality of life.
Thirty two subjects (30 males, 2 females) participated in
the study to evaluate dietary intake among HIV-1 infected
patients. Dietary intake was analysed using Food Works
Nutrient Analysis Software Version 5. Comparisons were
made to current Recommended Dietary Intakes (RDI),
the Australian Guide to Healthy Eating (AGTHE), National
Cholesterol Education Program (NCEP) and National
Nutrition Survey (1995).

Mean time taking Anti Retroviral 13
Therapy (ART) (Years)
Mean time taking ENF (Months)
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Mean age was 44 ± 10 years and mean duration of HIVinfection was 12 ± 7 years. Mean actual energy intake was
9618.2 ± 4697.1 kJ/day which was -890.7 ± 3498.3 kJ/day
lower than estimated energy requirements (EER). The
majority of subjects (72%) did not meet EER. Macronutrient
breakdown was 20% protein, 45% carbohydrate and 34%
fat. Total fat included 44% saturated fat contributing to
13% of total energy intake. Mean fibre intake was 23.2
± 12.4 g/day and was inadequate in 24 (75%) subjects.
Mean intakes of magnesium and folate in 25 (78%)
subjects, and zinc in 19 (59%) were found to be lower
than the RDI. Twenty nine (91%) did not meet the AGTHE
recommendation for consumption of vegetables; 27
(84%) for fruits and; 21 (66%) for bread, cereal, rice and
pasta. Mean percentage energy from saturated fat in 27
(84%) and dietary cholesterol in 17 (53%) were higher
than the NCEP guidelines. Mean cholesterol and sugar
intake were 356.0 ± 190.9 mg/day and 123.7 ± 83.6 g/day
respectively which were higher than that reported in the
general population in New South Wales.
This study found that despite high sugar and saturated fat
intake, energy intake was still lower than recommended.
The pattern of food consumption in these patients was not
consistent with the AGTHE guidelines with participants
consuming food of low nutritional value resulting in low
energy intake. Clinicians need to be aware of nutritional
deficiencies and to consider nutritional referral and
intervention in the management HIV-1 infected patients.
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ASHM - Program Delivery   
                             
ENHANCING THE GP’S PRIMARY CARE:
ACON SYDNEY’S ENHANCED PRIMARY CARE
PROJECT

ARE WE MISSING AN OPPORTUNITY TO
IMPACT BMI’S IN PEOPLE WHO ARE HIV +VE?
Roney J1, Bryant M1, Downs C1, Giddings E1, Hoy J1,
Liddle R1, Rotty J1. 1Clinical Research Unit, Infectious
Diseases, The Alfred Hospital, Melbourne, VIC, Australia
Excess body weight contributes to risk for a variety of
conditions such as diabetes, cardiovascular disease (CVD),
osteoarthritis, hypertension, and dyslipidemia, (WHO
2003). The most recent National Health Survey taken in
2004-2005 reported an increased number of Australians
classified as overweight (BMI score 25 to 29.99) and obese
(Body Mass Index or BMI score > 30), over the last 15 years,
4.6 million in 1989/90 to 7.4 million in 2004-005.
In the pre HAART era, the average BMI in the HIV
positive population was lower than normal. However
with effective anti-retroviral treatment, the HIV-infected
population is now at risk of disease associated with higher
BMIs. In 2003, the D:A:D study analysis identified that 3.5%
of the study population were considered obese.
In April 2008, all HIV-infected patients attending
the Infectious Diseases Outpatient clinic (OP), were
approached to have their BMI calculated. 191 patients
agreed. The purpose of this cross-sectional survey was to
examine the prevalence of obesity, and to assess whether
this had previously been identified and appropriate
interventions had been put in place. The Alfred Hospital
has 1191 HIV-infected people regularly attending the OP
for HIV clinical care. Of these 1093 are male, with a mean
age 46 years (range 21.2 to 83.3) and 98 are female, with a
mean age of 40.9 years (range 19.6 to 72.9).
Of the patients assessed in April 2008, 183 were male
with an average age of 46.6 (range 23-79),). The mean
male BMI was 24.26 (range 16.44 to 38.96) with 4% (n=8)
underweight, 33% (n=61) being considered overweight
and 6% (n=11) obese. Only 8 women participated in the
survey therefore not providing a sufficient data set for
analysis
This data is similar to data collected on 159 males
presenting to OP and enrolled in a lipodystrophy
prevalence study. The mean BMI was 24.1 (range 18.1 to
34.6) in 1998.
However, 39% of patients assessed in the cross-sectional
study in 2008 had a BMI > 25. The paper will explore other
risk factors such as duration of HIV infection, duration and
type of ART, VL suppression and CD4 cell count (current
and changes over time).

Saloner KL¹
Barr NJ¹
¹ACON
ACON’s Enhanced Primary Care (EPC) Project is a model
that can be adopted by a number of non-government
organizations (NGOs) and GP offices for wider practice.
The aim of this paper is to showcase the model currently
being revitalized by ACON Sydney which is possibly
underutilized by services working with clients who could
benefit immensely from a more immediate and accessible
level of psycho-social intervention, particularly where a
relationship and high degree of trust already exists.
The EPC project sees social workers, who are employed
by ACON, work onsite at high HIV caseload GP surgeries
assisting the GPs’ care provision.
A unique aspect of service delivery through the EPC
method is the maintenance of two very different types
of relationships. The first is the relationship with a range
of time-restricted GPs who have often had a long-term
relationship with the client. The second is a client group
who frequently has a history of involvement with health
care services, often characterized by experiences of
homophobia for GLBT clients and/or clients with “anger
management issues”. For clients, the interface with
systems is one that they frequently do not feel equipped
to negotiate with ease. The EPC officer’s role is to create a
harmonious outcome for the client and the GP.
In the 2007-2008 fiscal year, EPC workers saw approximately
13 clients per month. The majority (approximately 80%)
of these clients receive care co-ordination, whilst the
remainder might only seek information. On average
each care co-ordinated client receives seven occasions of
service from the EPC worker.
Historically, EPC officers were required to be experts in
relation to Medicare’s system of developing Team Care
Arrangements and GP Management Plans. Today, 2 out
of 3 GP surgeries utilise social workers’ professional skills
and knowledge to provide key services such as shortterm interventions to help clients realize their goals and
potential with particular emphasis on whole-of-person
care. With the GP looking after the medical aspects, social
workers can look after the psycho-social aspects so that a
complementary relationship results.
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Smith M L
Division of Nursing Albion Street
NSW, Australia
Studies suggest that cervical Low and High Grade
Intraepithelial Lesions (LSIL/HSIL) are more common and
potentially progress to higher grade cellular changes
faster in HIV positive women .The National Cervical
Screening Program Guidelines recommend annual Pap
smears for immunosuppressed women, which includes
HIV positive women.
An audit of HIV positive women attending Albion Street
Centre for their HIV care was commenced in March
2008 to ascertain the rate of women who adhere to
this recommendation. Of the 39 files reviewed 11(28%)
women have had documented Pap smears here or at
their GPs in the last 12 months, with no abnormal cells
detected , 2 (5%) women have had hysterectomies and
will require no further Pap smears, and 2(5%) women
are transgender and do not require Pap smears. Of the
remaining women, 6 (15%)have had Pap smears attended
in the past 2 years and the remainder of the women will
require clarification to identify if they have had Pap smears
attended elsewhere.
This poster aims to provide an overview of the results of
this audit and a review of the centre’s recall system. It is
anticipated that the findings from this audit will highlight
the need for a proactive recall system for these client’s
and to identify client’s awareness of the need for their Pap
smears. The results of this audit will potentially assist other
services in improving their care for HIV positive women.
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VALIDATION OF AN ABRIDGED FOOD
SECURITY TOOL AND EVALUATION OF ORAL
HEALTH RISK IN A HIV-1 INFECTED COHORT
Young J1,2, Sarangapany J1,2, Houtzager L1,2, Di Guilmi A1,3
and Purnomo J1
1. Albion St Centre, Surry Hills, NSW, Australia
2. University of Wollongong,NSW, Australia
3. University of Sydney, NSW, Australia
Food security (FS) and oral Health (OH) screening tools
have been used in the general population. However this
is the first time OH and FS have been screened together in
people living with HIV (PLHIV). The FS nutrition screening
tool (NST) was developed using two questions from the
FS questionnaire (FSQ). The OH NST included a question
on mouth pain, dry mouth and time since last dental visit
as these were the main OH issues identified in a HIV-1
infected cohort. Each participant completed three forms:
FSQ vs. FS NST and OH NST.
Thirty two (30 male, 2 female) participated in the study.
The mean age of participants was 44 ± 10 years, with a
mean duration of HIV infection of 12 ± 7 years. A highly
significant correlation was found between the abridged
FS NST and the FSQ (rho = 0.845, p <0.001). The proportion
of PLHIV reporting food insecurity was 11 (34%) and 12
(37.5%) with the FS NST and FSQ respectively indicating
that the FS NST accurately detected food insecurity. From
the OH NST 15 (50%) PLHIV were identified as being at
high risk of OH issues. A significant correlation was also
found between the OH NST and FS NST (rho = 0.471, p
=0.007).
The strong relationships found between the FS NST
and the FSQ suggest that the NST adequately screens
PLHIV for FS issues. Therefore the abridged food security
tool (FS NST) could be incorporated into a NST for a
multidisciplinary approach to the nutrition management
of PLHIV. The OH NST requires further investigation to
determine the true extent of OH issues in a HIV-1 infected
cohort. A relationship exists between oral health and food
security but the true cause and effect requires further
research.
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KNOWLEDGE OF HIV/AIDS AMONG
‘PRIMARY HEALTH CARE PROVIDER’S AND
IMPACT OF TRAINING.’
Badhan S
Objective:
India is ill prepared for ‘Provider- Initiated Testing and
Counselling (PITC)’ as per UNAIDS guidelines for HIV
testing because of the lack of knowledge about various
aspects of HIV/AIDS among the primary health care
providers. Thus, objective of present study was to assess
the level of knowledge about HIV/AIDS among the private
practitioners who are supposed to identify suspected
cases of HIV/AIDS, counsel and refer them for testing.
Methods:
The study was conducted in North East Delhi from
15th Dec. 06 to 15th Feb. 2007 among primary health
care service providers. A pre-tested, semi-structured
questionnaire was used to collect the information about
sexually transmitted diseases, presence of HIV in human
body, categorization of some of the risk categories for
HIV transmission, modes of transmission and prevention
of HIV/AIDS and the conditions for initiating treatment.
This was followed by one day workshop for training
and education for risk reduction practices. A purposive
sample of 350 private practitioners was taken for time
constraints.
Results:
Out of 350 study subjects contacted 278 responded
(79.42 %). Majority of these were males (87.05%), aged
below 40 years (81.40%) having no recognized medical
degree (82.02 %). Surprisingly only 27.33% study subjects
could name all the four modes of transmission viz.
sexual intercourse, blood transfusion, parent to child
and I/V Injections, correctly and there was significant
improvement at the end of workshop. There was no
significant difference between males and females
except in relation to the window period where females
outnumbered the males
Conclusion:
The knowledge about the STD’s, HIV/AIDS among the
study subjects was found to be very poor which improved,
a bit but not significantly, after the workshop, highlighting
the need of vigorous awareness campaigning before
they take up the responsibility of PITC as per UNAIDS
guidelines.

Correctly
named
transmission
mode
4
3
2
1
Window
Period:
Yes
CD 4
– Count:
Yes

Female (%)
36 (12.94)

THE SUPPORT FOCUS IS ON INDEPENDENT
LIVING!
Crooks L, Chair, NSW HIV/AIDS Supported Accommodation
Plan Implementation Working Group
Over the last twenty years, the NSW AIDS Program
established a range of supported accommodation
services for people with HIV/AIDS. Originally the services
provided respite care and support in a context of acute
illness and limited life expectancy. A range of graded
services were later developed for people with AIDS
Dementia Complex and other complex support needs.
With improved HIV/AIDS treatments supported
accommodation needs have changed. In particular a
greater number of people with HIV/AIDS require longer
term support and commonly support that is complex
in its provision because of co morbidities such as drug
and alcohol problems, mental illness and cognitive or
intellectual disabilities. Factors arising from ageing have
also become a consideration.
In an environment where HIV/AIDS is now a chronic
illness and where congregate types of supported
accommodation arrangements are no longer considered
the most appropriate model for service delivery, NSW has
changed its approach to the supported accommodation
provided through the AIDS Program for the purpose of
improving the coordination of services, the prioritisation of
access, the focus on individual needs and the partnerships
between HIV/AIDS services and other agencies.
This paper focuses on the NSW changes to policies and
models of care and the essential involvement of service
providers and other stakeholders in a process that
supports a philosophy of independent living.
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43
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(31.81)
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(50.0)
13
(36.11)
5
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0
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8
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6
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(41.66)
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54
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7
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(33.33)
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(12.58)
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(23.74)
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GENERAL PRACTITIONER UNDERSTANDINGS
OF HOW DEPRESSION AFFECTS GAY AND
HIV POSITIVE MEN IN AUSTRALIA
Newman CE,1 Kippax SC,1 Mao L,1 Saltman D,2 Kidd MR3
1
National
Centre
in
HIV
Social
Research,
The University of New South Wales Sydney
2
NSW
Australia;
Institute
of
Postgraduate
Medicine, Brighton and Sussex Medical School
Brighton, United Kingdom; 3Discipline of General
Practice, Faculty of Medicine, The University of Sydney
Balmain NSW Australia
This paper explores how Australian general practitioners
(GPs) who are accredited to prescribe antiretroviral
medications understand the relationship between
depression, gender and sexuality in gay men, including
those living with HIV.
The Primary Health Care Project on HIV and Depression is
a three year multi-method study funded by the General
Practice Clinical Research Program of the National Health
and Medical Research Council (2006-2009). The research
team represents a unique collaboration between social
researchers, general practice researchers, GPs and
community partners. The study employs both qualitative
and quantitative methods to answer a range of research
questions including the prevalence and nature of
depression among gay men (both with and without HIV)
and heterosexually-identified men attending general
practice clinics, factors associated with depression in
these three groups, and the clinical and self-management
of depression by GPs and patients themselves, especially
those living with HIV.
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As part of the qualitative component, interviews were
conducted with 16 GPs representing three geographical
settings and 7 practices: Sydney (4 practices), Adelaide
(1) and a rural-coastal town in New South Wales (2).
Participants included 14 male GPs and two female GPs,
and the number of years each had been working in HIV
medicine ranged from two to 24. Semi-structured faceto-face interviews of around one hour in length explored
the diagnosis, treatment and management of depression,
aspects of depression related to HIV, gender and sexuality,
and reflections on practice.
This paper will present the results of a thematic analysis
that identifies recurrent themes in the understandings (eg.
perceptions, attitudes and beliefs) of GPs regarding how
depression affects the gay men they see in their practices,
in comparison with heterosexual men. Both the differences
(eg. ways of seeking help, attitudes to treatment) and
similarities (eg. forms of emotional expression, excessive
time spent on work) that they identified are understood
to directly shape the management of depression in these
populations. Broader social issues (eg. ageing, social
isolation, poverty) are understood to also complicate
and exacerbate individual experiences of depression. GPs
with less experience in treating gay and HIV positive men
can benefit from these insights to ensure that depression
is accurately detected and effectively treated in these
populations.
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a comparative study of syphilis & HIV
from a Melbourne General Practice 
perspective.
Roth N, Nicolson J
Prahran Market Clinic, South Yarra, Victoria, Australia.
Since ~2000, there has been a resurgence of syphilis,
particularly in homosexual men (MSM) and in HIV positive
men. With an apparent rise in the rate of new HIV infections
(particularly in Victoria) there has been speculation that
this signified a rise in risk-taking behaviour among MSM
and/or confirmation that syphilis-associated ulceration
and inflammation increases the risk of HIV acquisition.
Our clinic has a predominantly gay patient population,
with a significant HIV caseload. We conducted a
retrospective case review of all diagnoses of syphilis, with
the aim of describing the differences, if any, between HIV
positive and negative men in the presentation, treatment
response and follow-up of syphilis cases.
The clinic uses a computerised medical record system
(CMRS). All patients with positive syphilis serology were
identified. By manual review, cases of previous treated
syphilis were removed, focussing this study on de novo
syphilis cases. The CMRS was then reviewed for all
identified cases to identify the parameters of interest.
187 diagnoses of syphilis were identified: 86 in HIV negative
men, 101 in HIV positive men. Differences were found in
the presentation, treatment regime, occurrence of JarischHerxheimer reaction and adequacy of serological followup in the HIV positive vs. negative groups. Response to
treatment was the same in both groups. In 7 cases, a
possible relationship was observed between the syphilis
diagnosis and subsequent HIV seroconversion. Follow-up
serology was significantly more consistently performed
in HIV-positive patients.
The clinical presentation of syphilis in HIV positive men
is associated with more florid clinical symptoms and
signs and better clinical follow-up, but a similar treatment
response to HIV negative men. Better documentation of
a past history of syphilis in medical records is needed to
optimise follow-up.
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LOCAL HIV INFORMATION TESTING
AND SUPPORT (HITS) PILOT PROGRAM:
IMPROVING THE CAPACITY OF GENERAL
PRACTITIONERS.
Stoove M1, Jenkinson R1, Hellard M1
1
Centre for Epidemiology and Population Health Research,
The Burnet Institute, Melbourne, VIC, Australia.
In Victoria, around one third of the men who have sex
with men (MSM) diagnosed with HIV each year have
their testing and diagnosis preformed at “low case load”
GP clinics. These low case load clinics are responsible for
the diagnosis of less than three HIV cases per year. MSM
diagnosed by these GP clinics have been shown to have
lower CD4 counts compared to those diagnosed at high
case load clinics. Low CD4 counts are indicative of late
diagnostic presentations, suggesting that men attending
low case load GP clinics may have been infected with
HIV for longer. These patients have a greater potential to
transmit HIV infection to others by not being aware of
their infection and through potentially higher viral loads.
The purpose of the HITS pilot program is to improve the
capacity of GPs working in low case load clinics to discuss
issues of sexual health and sexual risk behaviour with
MSM, improve HIV/STI testing, management and referral,
and develop clinical practices that are MSM welcoming.
The program includes: a review of existing HIV/STI
information; interviews with GPs/practice nurses; a sexual
health update session; development of a sexual health
education package; implementation of a system for
distribution of educational material; and a consultation
service for GPs to access support, advice and/or referral
information.
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A process and impact evaluation will be conducted
to assess the objectives of this program, including preand post-program surveys and interviews with MSM.
Findings from the HITS pilot program and evaluation will
be presented.
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NPEP Repeat Presenters Model of Care
Armishaw J 1, Earle M 2, Pierce A 1 Wright EJ1
1. Victorian NPEP Service, Infectious Diseases Unit, Alfred
Hospital, Melbourne, Victoria, Australia
2. Sex Health and Wellbeing Service, Victorian HIV Service,
Infectious Diseases Unit, Alfred Hospital, Melbourne,
Victoria, Australia
Non-occupational post-exposure prophylaxis (NPEP) is a
course of antiretroviral medications commenced within
72 hours of exposure to HIV and taken for 28 days in order
to reduce the risk of acquiring HIV infection. NPEP has been
available at The Alfred Hospital in Melbourne since 2000.
The Victorian NPEP Service was established in August
2005 and NPEP availability has been rolled out into the
community, with NPEP now available at 9 metropolitan
centres and in 5 rural areas. Approval to maintain a
database of individuals presenting for NPEP was granted
by The Alfred Research and Ethics Committee. Consent
for coded information to be sent to the Victorian NPEP
Service for inclusion on the database is obtained.
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From 10 August 2005 to 31 Dec 2007 (28 months),
1022 patients have presented on 1207 occasions of
service, with 204 patients (20.0%) presenting on 383
occasions. Of the 204 patients who have had repeat NPEP
presentations, 116 patients (56.9%) presented twice, 46
(22.5%) presented 3 times and 22 (10.8%) had 4 or more
presentations. Repeat presentations made up 31.7% of all
consultations. Data from the Health in Men (HIM) Cohort
shows that those who presented for NPEP were 2.2 times
more likely to sero-convert to HIV. NPEP presentation is a
marker of HIV risk, which if not addressed, may lead to HIV
acquisition from future exposures.
The Repeat Presenter Model of Care was implemented
in February 2008 and targets those who have presented
for NPEP 3 or more times in the previous 2 years. The
model of care has 3 components. Patients are asked to
nominate a GP/clinic where they will attend for any future
NPEP presentations and to consent for a summary of their
NPEP history to be sent to the nominated GP/clinic. These
2 interventions aim to support a therapeutic relationship
between the patient and the doctor where risk reduction
can be approached from a more informed position. The
third intervention is for the patient to agree to a referral
to the Sex Health and Wellbeing Service, a psychology
service at The Alfred Hospital focussed on men’s sexual
health.
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Using financial incentives to increase 
hepatitis B immunisation completion 
in injecting drug users: A randomised 
controlled trial
Barnes K, van Beek I, Day C, Topp L, Shanahan M, Wand
H, Maher L (on behalf of the Hepatitis Acceptability and
Vaccine Incentives Trail (HAVIT) Group*)
Using financial incentives to increase hepatitis B
immunisation completion in injecting drug users: A
randomised controlled trial
While injecting drug users (IDUs) are at high risk of
hepatitis B virus (HBV) infection, studies have documented
low rates of immunisation uptake, completion and
vaccination-induced immunity. The HAVIT trial seeks to
identify strategies to improve HBV vaccine completion and
seroconversion. The study will also gather important data
on acceptability and IDU attitudes towards immunisation
which will inform preparedness for candidate HCV
vaccine trials.
The primary objective is to compare the proportion
of participants who complete the vaccine series in an
incentive payment arm relative to a standard care arm.
Secondary objectives are to assess the incremental cost
effectiveness of standard care compared to incentive
payments as methods of improving series completion;
identify the correlates of immune response (HBsAb≥10
mIU/ml) week 12; and determine the acceptability of
vaccines, barriers to immunisation uptake and willingness
to participate in vaccine trials.
Results have the potential to reduce the burden of disease
associated with HBV infection, and potentially, other
vaccine-preventable infections, in IDUs by providing data
on the efficacy and cost-effectiveness of contingency
management in this group. Results in relation to
acceptability, attitudes and willingness to participate will
inform preparedness for future HCV clinical trials.
* Lisa Maher, Ingrid van Beek, Carolyn Day, Libby Topp,
Marian Shanahan, Handan Wand, Craig Rodgers, Greg
Dore, Andrew Lloyd, Paul Haber, Nicholas Walsh.
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NETREACH: ONLINE PEER OUTREACH
TO VIRTUAL COMMUNITIES ACROSS
AUSTRALIA

SERO-SORTING: WHAT IS THE IMPACT ON
HIV TRANSMISSION IN GAY MEN AND HOW
DO WE REDUCE IT?

Brown G1, Keen P2, Maycock B1, Hyde Z1
1Western Australian Centre for Health Promotion
Research, Curtin University Perth, Australia
2Australian Federation of AIDS Organisations, Sydney,
Australia

Stevie Clayton, CEO, ACON (AIDS Council of NSW)
Dermot Ryan, Manager Education, ACON (AIDS Council
of NSW)

In essence peer volunteers and staff entered existing
commercial online chat rooms in a similar way to peer
outreach at social, community and sexual venues. The
program was implemented in a way that aimed to
respect and support the users of this virtual environment
and the online community they had created. During
the brief development and trial period there were 304
outreach shifts, with exposure to 27,672 people and 460
in depth online discussions. 18 months after the end of
the trial period AIDS Councils were interviewed to discuss
the sustainability of the program and why some had
maintained the interventions and why some had ceased
Internet outreach in this format.
The online environment may change significantly in
as little as six months, requiring the delivery of online
outreach programs to be modified. Planning, funding and
evaluation arrangements need to reflect this. Involving
participants from the online community in the project
was critical to maintain a level of cultural acceptance
and credibility, adapt to rapid changes inn culture
and technology, and to sustain a reflexive approach.
Feedback from AIDS Councils 18 months after the trial
period focused around the challenges of sustaining
outreach with limited numbers of participants or capacity
to track direct impact verses the need to be part of the
developing context of online communities.

Research among Sydney gay men conducted by Australia’s
National HIV Research Centres since 2001 shows an overall
decline in partner numbers and in UAIC, an increase in
disclosure of HIV status to sexual partners, and increased
reporting of partners of the same sero-status. Disclosure
of sero-status and negotiation around condom use often
occurs in a context of trust and familiarity between players
which could indicate an increase in sero-sorting or simply
a greater willingness to discuss HIV status.
Sero-sorting is the practice of consciously choosing sexual
partners of the same HIV status to facilitate unprotected
anal intercourse while minimizing HIV transmission.
Recent studies have shown an increase in sero-sorting
amongst both HIV positive and HIV negative Sydney gay
men.
With a population as highly educated about HIV as
Sydney gay men, provision of information about risk may
not be sufficient to effect behaviour change as there are
complex analyses of relative risk versus potential pleasure
being undertaken, which require greater understanding
of motivation for effective interventions.
Based on this evidence ACON developed a culturally
appropriate, multi-faceted campaign encouraging gay
men to reflect on assumptions and beliefs which influence
their decisions around condom use in the context of
their knowledge, or presumed knowledge, about the HIV
status of themselves and their partners.
This paper will examine the current research, reflect on
the campaign and consider the evaluation results.
poster abstracts

NetReach was a peer-based sexual health promotion
outreach program targeting Australian men who have
sex with men (MSM) via Internet chat rooms and profile
sites. It was a collaborative effort of the AIDS Councils of
Western Australia, South Australia, Victoria, Queensland
and Tasmania and the Australian Federation of AIDS
Organisations.
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Organisations looking at online outreach need to consider
their infrastructure, connections to online cultures, and
flexibility of funding requirements before embarking on
an investment into online outreach.
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AVOIDING HEPATITIS C INFECTION DESPITE
LONG TERM INJECTING: BEHAVIOURAL,
SOCIAL OR IMMUNOLOGICAL?
Peter Higgs 1, Campbell Aitken 2, Margaret Hellard 2 and
Lisa Maher 1
1
Viral Hepatitis Epidemiology & Prevention Program,
National Centre in HIV Epidemiology & Clinical Research,
UNSW ; 2Centre for Epidemiology & Population Health
Research, The Burnet
Abstract:
Transmission of hepatitis C (HCV) in injecting drug users
primarily occurs as a result of exposure to the virus during
injection. There is some evidence that previous infection
with HCV may be protective for future infection of the
same genotype but not against other genotypes. If this
is true and HCV infection occurs at similar or higher rate
in previously exposed compared to naïve individuals
this poses significant challenges for HCV vaccine
development.
The Networks II study is an ongoing cohort study of HCV
among injecting drug users (IDUs) being conducted in
Melbourne, Australia. Three hundred and ninety-five IDUs
were recruited between July 2005 and November 2007
and most were interviewed and tested for HCV markers
at least twice.  
Fifty IDUs remained HCV antibody and RNA negative at
their last test, and 10 people initially lacking evidence
of exposure to HCV tested RNA-positive during the
study.  Initial analyses indicate that people who reported
injecting with five or more others in the three months
prior to baseline were significantly more likely to be
infected with HCV at any time than people who reported
injecting with fewer than five others.  
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However, there may not be specific injecting risk
behaviours that markedly increase or decrease an IDU’s
risk of HCV exposure and infection. Some IDUs may
simply be lucky, others may unknowingly only inject or
share with other HCV negative IDUs; alternatively, some
individuals’ immune systems may protect them from
infection.

P219
COUNSELORS’ PERSPECTIVE AND QUALITY
OF COUNSELING IN VOLUNTARY HIV
COUNSELING AND TESTING CENTERS IN
DELHI
Kant S
Background: Confidential counseling process is a crucial
step towards providing prevention, care and support
services. It empowers the client to make informed choice
about getting tested to know their HIV sero-status. With
rapid scale of counseling and testing services in India,
ensuring quality of counseling becomes very important.
We have assessed quality of counseling provided and
satisfaction level of counselors working in Voluntary
Counseling and Testing Centers (VCTC) of Delhi.
Methods: A cross-sectional health-facility survey was
conducted in 10 randomly selected VCTC of Delhi.
The observations of counseling sessions were carried
out by investigator through personal presence during
counseling using checklist. Counselors were interviewed
using a semi-structured interview schedule that assessed
counselors’perception as HIV counselor, trainings received;
availability and need of support and supervision; their
job satisfaction in present set up. It’s a semi-structured
interview schedule administered to the counselors.
Qualitative analysis of statements was done by coding
of themes, domain identification and calculation of
frequencies.
Results: Ten out of 18 VCT centers were selected randomly
(3/6, 5/8 and 5/8 from teaching, non-teaching and
specialized hospitals respectively). Fifty-one counseling
sessions were observed and 17 counselors interviewed.
Six out of 17 counselors were Masters in Social Work.
Counselors demonstrated good interpersonal skills
but needed in-service training to further improve their
counseling skills. Majority (9/17) of counselors believed
a positive career prospect as counselor. Few (5/17) felt
insecure due to low salary structure and temporary nature
of the job. The counselors reported the need of in-service
training that should be practically oriented (10/17).
Conclusion: The quality of counseling was found to be at
par with other studies and the counselors were overall
satisfied with their job profile. The nature of training
being received by the counselors has to be reviewed with
particular emphasis on frequency of in-service training,
eligibility of trainers and practical orientation of courses.

The ability of some IDUs to escape or reject HCV infection
despite repeated and often long-term exposure has
been previously noted by ourselves and others, and is the
subject of an ongoing international collaboration.
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A Public access program of Sculptra®
polylactic therapy to treat people 
with facial lipoatrophy 
Knox D1, Carr A2, Conway D3, Edwards B 1, Flanagan G4,
Furner V5, Heslop J6, Honnor G4, Lake R4, McKellar-Stewart
N7, McMurchie M8 and Pollard A7.
1
HIV/AIDS & Related Programs (HARP) Unit, South Eastern
Sydney and Illawarra Area Health Service, Sydney, NSW,
Australia, 2 St Vincent’s Hospital, Sydney, 3 Australasian
Society for HIV Medicine, 4 Positive Life NSW (previously
PLWHA NSW), 5 Albion Street Centre SESIH, 6 HARP Unit
North Coast Area Health Service, 7 ACON, 8 East Sydney
Doctors (formerly 407 Doctors) East Sydney NSW.

with the patients, the referring prescribing doctors and
proceduralists.
187 clients received treatment, with 53 of these returning
the evaluation survey so far (28%). Clients were asked to
indicate ‘yes’ or ‘no’ to the question of satisfaction with
treatment, with 52 indicating they were satisfied, with 1
writing that they would ‘wait and see’.
Of the 12 proceduralists engaged, 10 saw clients as part
of the program and were sent evaluations. Of these 8
have returned completed surveys (80%), with 3 reporting
minor nodules or bruising.
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49 prescribers referred patients to the program and were
sent surveys. 26 surveys have been returned (53%), with
25 reported no adverse reactions and 1 noting ‘expected
local reactions’.

Around half of people living with HIV in Australian report
some degree of lipodystrophy, with most reporting
consequent stigmatisation and poor body image.
A number of cosmetic treatment options for facial
lipoatrophy are available through private clinics. In 2006
NAPWA negotiated with a major pharmaceutical company
to provide polylactic therapy as part of a compassionate
access scheme for the delivery of Sculptra® to a defined
number of HIV positive people in Australia for no charge.
In New South Wales, the HARP Unit of South Eastern
Sydney and Illawarra Area Health Service, in collaboration
with a multidisciplinary Steering Committee and with
funding from NSW Health, developed and implemented
a Sculptra® Program. The Program was for eligible HIVpositive adults in NSW to be assessed by their S100
prescribing doctors to receive therapy. Access was based
on severity and financial need.
NSW received Sculptra® for 205 individuals to receive 8
vials (4 treatments). Allocations of places into the program
were made to S100 Prescribers based on antiretroviral
prescription numbers per service.
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Plastic and cosmetic surgeons across the state who are
able to provide Sculptra® were contacted and 12 agreed
to be part of the Program. Prescribers referred clients to
these proceduralists.
205 individuals were enrolled into the program which
ran from April 2007 until June 2008. Clients were offered
up to four treatments, each about 2 weeks apart, and
a survey evaluation of the program was conducted
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CAUSES OF DEATH OF HIV _ INFECTED
PATIENTS RECEIVING HAART IN UGANDA
Author Waiswa Moses, John Muwanga.
The African child care and Mother Development: (ACMD)
Kampala- Uganda
Background: HAART has had a dramatic impact in the HIV
epidemic in Uganda. With a clear decline in morbidity
and mortality, although even in development countries,
with a wide spread use of effective treatment HIV- related
deaths are still occurring.
Methods: We review the charts of all Hiv - infected patients
who have died from march 2004 through August 2007.
we evaluate the basic epidemiologic data, immunologic
and virologic status, treatments received, and causes of
death of every patient.
Results: of the 865 patients of our cohort, a total of 50
(5.5%) have died in the study period. SD of age at the
time of death is 35_+ 6years, 40, (85%)are male, 36 (77%)
are women, medium of CD4 Cell count is 79permm, and
medium of HIV RNA is 4.9log: 6patients(13%)had never
received anti-retroviral therapy although they should
have received according to guidelines, and 20 patients
are receiving suboptimal treatment or no treatment at
all. Cirrhosis of the liver is the cause of death in 18 pati
ents(38%),progressive multifocal koencephalopathy in
6 (13%),wasting syndrome in 12(23%),and pneumonia
in 3(6%).compared with the rest of the cohort, patients
who have died are commonly men, are more commonly
HCV-infected, have lower CD4 count, and have higher
HIV RNA(all differences p<.0.1).
Conclusion: in the era of HAART, the first causes of death
in patients with Hiv infection is Cirrhosis of the liver, in
adequate treatment is common among patients who
die.

P223
AN EXAMINATION OF A NUMBER OF RECENT
HIGH-PROFILE AUSTRALIAN CRIMINAL
CASES, TO HIGHLIGHT THE COMPLEX 
RELATIONSHIP BETWEEN THE LEGAL
REGULATION OF HIV TRANSMISSION AND
EXPOSURE, AND EFFECTIVE PUBLIC HEALTH
OUTCOMES
David Scamell, Policy Manager, AIDS Council of NSW
Sally Cameron, Policy Consultant to Australian Federation
of AIDS Organisations
Description
There is a growing international trend towards the
employment of criminal law in relation to HIV transmission
and exposure despite a lack of evidence to demonstrate its
effectiveness in reducing the incidences of HIV infection.
The type of laws that are enacted and the manner in
which they are used present a number of considerable
challenges to established public health HIV prevention
practices based on individual responsibility, voluntary
testing, and access to treatment, care and support.
Recently a number of HIV-related prosecutions in Australia
have occurred, attracting significant political and media
attention. These cases have coincided with a rise in HIV
infections across the country. The confluence between
these cases and the rise in infections has resulted in
public and government debate about the role of law in
Australia’s response to the epidemic and the effectiveness
of the response more generally.
Lessons learned
While the debate to date has reinforced the broad public
health approach to HIV prevention, certain aspects
reinforced the need for HIV policy to be guided by
comprehensive evidence, particularly given the impact
criminal penalties for HIV transmission may have in
relation to increasing stigma and decreasing levels of
testing and willingness to access health services.
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Next steps
Further research is needed across multiple jurisdictions
and within differing epidemics (generalized or within
specific population groups) as to the impact and
effectiveness of criminalization on HIV prevention.
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MEN’S QUICK QUIZ: ANNUAL SNAPSHOT
OF STI KNOWLEDGE AT A GAY COMMUNITY
EVENT
Prihaswan P1, Shaw MJ1, Silveira M1.
1
HIV & Related Programs Health Promotion Team
(Inner West), Sydney South West Area Health Service,
Camperdown, New South Wales, Australia.
As the Sydney Mardi Gras Season’s biggest daytime event,
Mardi Gras Fair Day provides an opportunity to promote
local sexual health services to gay men and to check their
sexual health and service knowledge.
Since 2004, we have been coordinating the administration
of a ‘Quick Quiz’ to gay men attending Fair Day. The quiz
includes a series of questions on STIs which are revised
annually. Questions generally address the asymptomatic
nature of STIs, current STI testing recommendations and
treatment for STIs. The quiz also asks about access to
sexual health clinics and general practice for regular sexual
health check-ups. Information on age and postcodes are
also collected.
The quiz is also useful as a tool to engage respondents in
discussion about sexual health and is administered from
an information stall shared by metropolitan Area Health
Services.
Each year, about half of the respondents have
demonstrated good understanding of the asymptomatic
nature of STIs. The majority have also demonstrated good
knowledge of current STI testing recommendations and
were generally aware of treatment for STIs.
A smaller proportion of respondents reported accessing
GPs for sexual health care. For those men accessing GPs,
the majority reported visiting a GP in the Darlinghurst
area.
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This paper will focus on the results of respondents from
Sydney’s inner-west. A detailed analysis of the quiz results
from 2005 to 2008, including attendance at public sexual
health services and general practice, will be presented.
Recommendations for future STI campaigns and capacity
building programs for health care workers, including GPs,
will also be discussed.
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P226
SEXUAL BEHAVIOUR IN FIJI ISLANDS. A
RETROSPECTIVE K.A.P SURVEY ON SEXUAL
BEHAVIOUR IN FIJI
Chaudhary A
The Western Health Hub Centre in Fiji caters for around 250
000 people. Since the inception of the clinic in 2004, 5367
clients seeking STI and HIV related out-patient services
have been seen. History from clients is recorded in a set
template and upon seeking verbal consent, question on
personal sexual behaviour is asked and recorded. The
clients were also informed that the information will be
used to draw up statistics on sexual behaviour in Fiji and
also that their names would be kept confidential.
Of the 5367, 133 did not qualify and 82 declined to answer
personal question.
The records of the 5152 clients was analysed and a
comprehensive report on sexual behaviour [wich
included age of first sex, number of sexual partners,
use of condoms, and failure to use of condoms, sexual
orientation and knowledge and attitude towards sex]
Correlations between the ethnic groups, social status,
marital and education level with the sexual behaviour
was elicited.

P227
CAMP GOODTIME: CATERING FOR THE
DADS!
SOCIAL RESEARCH INTO THE
IMPLEMENTATION AND EVALUATION OF
SPECIFIC GROUP PROGRAMS FROM 20022007 AS PART OF A UNIQUE NATIONAL
SERVICE TO FAMILIES LIVING WITH HIV/AIDS
CoadyJF1
1
Short Street Clinic St George Hospital KOGARAH NSW
2217
Camp Goodtime is an annual four day camp facilitated
by the Paediatric HIV service at Sydney Children’s Hospital
providing support to children and families living with
HIV/AIDS. Operating since 1990, this unique service
provides medical management, psychological support,
consultation and education in framework aimed at
reducing isolation experienced by these families. Trained
volunteers are assigned to care for the children while two
social workers cater to the needs of the parents.
Social work input for parents had previously been on
an ad hoc basis, usually with a different worker each
year. The last five years however has seen a continuous
social work service to fathers allowing the development
of a formalised group program. This program focused
on developing connection, sharing experiences and
information, providing client support and nurturing peer
and self support. It was envisaged that this knowledge
and experience would benefit the fathers and their
families in self management strategies long after they left
the camp.
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Apart from annual evaluation reports garnered by the
service, there had been no research done as to the
efficacy of the range of benefits received from the group
programs by attending families, and in particular by
the fathers. A qualitative research project was initiated
in 2007 to provide and evaluate written and recorded
data to research the lived experience of this unique
client group over a five year period. A detailed analysis
of the specialized service was undertaken to ascertain
what impact it has made in the lives of these families.
Initial findings indicate the programs have been highly
desirable, with further details to be presented.
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Information provided from this research will assist social
workers and other allied health professionals involved in
HIV care to adapt their client centred approach to improve
outcomes in working with specific populations such as
these families from diverse parts of Australia.
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ASHM - Oral Poster Session - Clinical,
Allied Health And Basic Science
PHYSICAL AND SOCIAL BENEFITS OF
ANTIRETROVIRAL THERAPY (ART) ON THE
LIVES OF PEOPLE LIVING WITH HIV AND
AIDS (PLWHA) IN PAPUA NEW GUINEA (PNG)  

ART has provided physical and social benefits to PLWHA.
Their health and well-being has improved and their
capacity to engage with family and the community has
benefited. While these results don’t disprove any of the
real negative impacts of ART such as side effects, these
physical and social benefits are significant as ART rolls out
and the country monitors the success of ART in its sociocultural context.

Social Research
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ORAL POSTER SATURDAY 20 SEPTEMBER
0815 – 0820

Emori R1, Kelly A2, Akuani F1, Nosi S1, Peter B1, Kupul M1,
Walizopa L1, Mek A1 , Pirpir L1,Worth H2 and Siba P1.
1
PNG Institute of Medical Research, Goroka, Eastern
Highlands Province, Papua New Guinea; 2 National Centre
in HIV Social Research, University of New South Wales,
Sydney, Australia.
In the past three years, there has been an increase in efforts
to roll out ART in PNG. While there is some knowledge of
the clinical impact of ART in PNG in terms of morbidity,
little is known of the social impacts of these treatments.
In an effort to understand these social impacts, this study
has sought to explore these impacts of ART on PLWHA
in PNG.
This study used a multi-method approach to examine the
social impacts of ART for PLWHA. A total of 152 people
were surveyed and 28 participated in in-depth interviews.
Ethics approval was granted by the PNG Medical Research
Advisory Committee and University of New South Wales,
Australia.
Since taking ART, the majority of people reported that
their health status improved. 90.8% of participants’ rated
their physical health as good to excellent whereas before
ART only 8.5% participants had good health. In the last
month on treatment 94.1% of people rated their mental
health as good to excellent where in the month before
treatment only 15.7% rated their mental health as good.
Prior to commencing ART 44.1% indicated that their
quality of life was poor. On treatment 50.7% people
experienced an improvement in the quality of life.
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The qualitative data shows similar results with most
participants experiencing improvements in physical and
social aspects of their lives. These included regaining
strength and appetite; being able to work; tend to chores
and work in the gardens; and walk long distances again.
Other physical improvements included gaining of weight
and the re-growing of hair. The social benefits of these
physical consequences of ART were considered of high
importance because they meant that they were no
longer recognizable as someone with HIV.
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P229
VISUAL RESPRESENTATION OF PEOPLE
LIVING WITH HIV IN PAPUA NEW GUINEA

p230
Translation: Papua New Guinean 
Researcher’s Perspective

Mek A1, Kelly A2, Akuani F1, Kepa B1, Kupul M1, Emori R1,
Peter B1, Nosi S1, Pirpir L1 & Walizopa L1
1
Operational Research Unit, Papua New Guinea Institute
of Medical Research, Goroka, Eastern Highlands Province,
Papua New Guinea
2
National Centre for HIV Social Research, University of
New South Wales, Sydney, NSW, Australia

By Pirpir Lawrencia 1, Kelly Angela 2, Nosi Somu 1, Walizopa
Lucy 1, Mek1 Agnes, Emori Rebecca 1, Akuani Frances 1,
Kupul Martha 1, Peter Cangah Brenda 1, Kepa Barbara 1 &
Keleba Kritoe 1

Participatory visual methods are used in social research
to better understand people’s experiences of health,
illnesses, death and dying including the everyday lives of
people living with HIV. Such methods offer an alternative
to the spoken and written word, and the statistical
representation of life. The use of visual methods was
chosen to understand how people pictorially perceive
themselves living with HIV in Papua New Guinea (PNG)
and to pilot the use of such methods here. The data
analysis is based on these drawings of self-image of
the body at various stages in the lives of people living
with HIV and the shift from imminent death to a life on
antiretroviral therapy (ART).
The visual data is drawn from a larger mixed-methods
study on the social impacts of ART on PLWHA in 3
provinces of PNG. Of those who participated in the
qualitative interviews, eight participants illustrated on
paper their routine daily activities and the meanings of
HIV prior to and after treatment.
The images contrast the difference between suffering
bodies confronting imminent death (prior to ART) with
healing, healthy bodies (post-ART). Before going on ART,
people positioned HIV as inseparable from who they were.
In contrast, in drawing life after antiretroviral treatment
they displayed drastic bodily changes leading to social
interaction and a new relationship to death. People drew
themselves interacting with others; with healthy bodies;
with their hair growing; with flesh on skeletons, and; being
able to participate in life again. ART transformed people’s
lives from one of inevitable death to one of renewed life.

poster abstracts

For HIV-positive people, the images they drew are
powerful tools that offer researchers an alternative
method of grasping what it means to live with HIV and
a method that can be applied in contexts where visual
imagery has a particular importance - such as PNG.
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Papua New Guinea Institute of Medical Research
University of New South Wales National Centre for HIV
Social Research
1
2

The philosophy that underpins the Strengthening HIV
Social and Behavioural Research Cadetship Program at
the Papua New Guinea Institute of Medical Research is
one of ‘learning by doing’, carrying out ‘real life’ research
projects. After completing a study on the attitudes of
young people towards sex and HIV the issue of language
and translation became a real life scenario which the
cadets had to become skilled in.
In HIV social and behavioural research the role of language
is critical. How questions are asked can influence the way
a person responds. But more than this, in international
research, the role of translating one language into another
is pivotal. Simply knowing the words of a language is not
sufficient to translate that language into another.
This paper highlights how translation requires the careful
recreation of meaning from one language to another,
not a literal word for word exchange. Learning to capture
meaning in this way is a skill and one that requires capacity
building, as has been the experience of the HIV social and
behavioural research cadets in PNG.
We cannot expect that because someone is fluent in
their own language that they will be automatically able
to translate it. Translation is a complex skill that social
researchers need to develop. This entails understanding
local differences in the use of language, for example
the metaphor ‘kol kaukau’ in Tok Pisin literally means
‘cold sweet potato’. However, the meaning of this in its
speech context was that the introverted girls are those
who go around and have sex. Thus, an English translation,
metaphorically, could be ‘still waters run deep’.
The skill of translation needs to be seen as an important
priority in capacity building of social researchers who
work across languages in setting where training has been
limited.
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Background: HIV epidemic continues to pose a major
public health challenge. National strategy for HIV aims to
decrease the number of HIV through increased testing for
disadvantaged and hard to reach group i.e. sex between
men, sex between men and women and injecting drug
users. Fear of stigmatisation and lack of peer supports
found major barriers to attend sexual health and HIV
screening. In order to further de-stigmatised HIV testing,
a service for HIV has been offered and managed as part
of a general health screen where urine tested for raised
sugar and Chlamydia as well as blood pressure screening
and advice on maintaining a healthy life style. The
purpose of the present study was to examine the effects
of community testing for HIV.
Methods: Standard 2 steps HIV testing is limited by poor
return for results rates and misses high risk individuals
who do not access conventional testing facilities. We,
therefore, describe a community testing programme
among people who had difficultly in accessing and
utilising of government local heath care services due
to stigma and challenging socio-cultural circumstances
using Abbort Rapid Determine HIV-1/2 test among three
primary health centres in rural part of Nepal, in 2005/6.
Results: over 6 months, 200 adults were invited to
participate and 180 (90%) underwent testing. HIV
seroprevalence was 17.2% (31 of 180) overall and 3.9%
amongst hard to reach individuals reporting no previous
testing, a prior negative test of previous testing without
result disclosure. All 180 patients received their results. Of
15 newly diagnosed persons who received confirmatory
results, 7 (47%) reported at least one contact with a health
provider in four months following diagnosis. Individuals
who reluctant to use hospital services were also attended
for testing, which enabled them to access treatment
and care for long term health benefits. General and testspecific counselling, mobilising health care professionals,
found important in dealing with positive and negative
results.
Conclusion: limited evidence suggest that routine HIV
testing in hospital setting has a part to play in increasing
uptake of testing and thus preventing deaths. This study
concludes that community testing for HIV is feasible,
acceptable and effective based on the number of high
risk persons tested over a short period, the participation
rate, the prevalence of new infection the rate of result
disclosure and the proportion linked to care and support.
Increasing update of HIV testing will have both individuals
and public health benefits.

ASHM - Oral Poster Session - Public 
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ORAL POSTER FRIDAY 19 SEPTEMBER 0830
- 0835

THE EFFECT OF INTRODUCING SPECIALIST
BLOOD BORNE VIRUS (BBV) NURSES INTO
PRISON HEALTH CENTRES.
Connelly C 1, Patterson KL 1 , McNulty L 1 .
1
Department of Corrective Services, Hakea Prison, Perth,
WA, Australia
Socio economic challenges and psychiatric illness can
affect the physical health and well being of an individual
and inadvertently, access to adequate medical care. Many
prisoners report low employment rates, mental health
issues and substance abuse prior to imprisonment.
Imprisonment allows health care workers to take
advantage of the opportunity provided by incarceration
to offer health screening- including BBVs - and assessment
to individuals who do not otherwise access a medical
service.
Approximately half of all prisoners in Australia have a
history of injecting drug use. BBV screening has become
a priority for prison health services. Currently such
screening is not compulsory upon reception to WA
prisons though many prisoners have taken up the offer
of testing after routine admission. Specialist BBV nurses
conduct detailed screening of risk behaviour, Pre- and
Post-Test Counselling, provide ongoing education and
discuss treatment options. Currently the main focus is on
Hepatitis C.
The creation of the specialist BBV nurse role has allowed
significant health care benefits to patients in the custodial
setting including:
• Increased rates of BBV screening
• Access to support & harm reduction counselling and
treatments.
• More prisoners will have treatment for their BBV thus
reducing the public health burden of the disease.
Recent improvements in screening as a result of BBV
nurses have led to the following outcomes;
• Screening of an average of 22 new patients per week.
• A current register of 76 people who are Hepatitis C
antibody positive of whom 64 are also RNA positive.
• Of these 76 patients, eight were newly diagnosed
cases of Hepatitis C detected in the current intensive
screening program.
In conclusion, the introduction of specialist BBV nurses
has resulted in improved care being provided to prisoners
with, or at risk of contracting, Hepatitis C.
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does COMMUNITY testing for HIV prove 
effective?
[a cross-sectional study in Nepal]
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Regan DR1, Law MG1, Philp DJ2, Hocking JS3
1
National Centre in HIV Epidemiology and Clinical
Research, UNSW, Sydney: 2National Centre for
Epidemiology and Population Health, ANU, Canberra:
3
Key Centre for Women’s Health in Society, University of
Melbourne, Melbourne
HPV vaccination has been shown to be effective
in preventing cervical cancer in females. While
immunogenicity has been shown in males, trials are
underway to demonstrate HPV vaccination is clinically
effective.
Mathematical modeling of HPV transmission in Australia
suggested that for a vaccine with 100% effectiveness
and conferring lifelong immunity, then with coverage
over 80%, vaccinating 12-year old males in addition to
12-year old females had only a modest impact on HPV
incidence among females. Vaccinating 12-year olds only
was estimated to take long periods to take effect, with
an estimated 7 years to achieving 50% of the effect on
HPV incidence. A catch-up campaign, vaccinating 13-25
year old females, was estimated to decrease this time to
under 2 years. The models suggested that vaccination of
males and females would not eradicate HPV with realistic
vaccine coverage rates.
These models suggest that for a HPV vaccine of 100%
effectiveness and conferring lifelong immunity, there is at
most modest effect on cervical cancer risk in vaccinating
males in addition to females. Vaccinating 12-year old
males with such a vaccine would only be cost-effective if
this resulted in appreciable reductions in HPV-associated
disease in men, such as anal or penile warts, and anal or
head/neck cancer. Vaccinating 12-year old males may
be cost-effective in preventing cervical cancer among
females if herd-immunity effects become important in
the case that vaccination coverage rates are low, or that
the vaccines prove to be only partially effective or confer
limited duration of immunity. To answer these questions,
it is important that the current HPV vaccination schedule
in Australia is monitored, both in terms of coverage rates
and conferred immunity.

A Woman’s Personal Perspective and Experience of what
is missing in sexual health and society, The Vulva
Kath Mazzella
This presentation aims to bring life to the vulva, bringing
it out from the unknown or un-mentionable and giving it
the recognition and the status it deserves.
It will highlight the stigmas, misconceptions and taboos
that surround the vulva and ask how women, educator’s,
health professionals and society can break down these
barriers and move to a healthy and accurate knowledge
of this vital part of female genitalia. These questions will
be posed and related to you through the perspective of
one woman.

Sexual Health Plenary 5: A Mixed Bag of Jewels

SHOULD WE BE VACCINATING BOYS AS WELL
AS GIRLS WITH THE HPV VACCINE?

IS YOUR CLITORIS IN YOUR VAGINA OR THE
VULVA! WHAT IS A VULVA!  

A woman who’s experience of gynaecological cancer has
taken her on an inspiring journey. A woman who went
from knowing nothing about down there, to one who is
now an empowered, assertive, understanding individual.
The presenter will relate how her own experience altered
her to how women in the community suffer in silence
and of the need to give these women a voice.
She will take you through her quest to raise the profile of
this issue within Australia,
Her successes – which include the establishment of the
Gynaecological Awareness Information Network (GAIN),
National Gynaecological Awareness Day – the lessons
learned and the work that is yet to be done. She was
also involved with the Australian Senate Gynaecological
Cancer Enquiry. Key themes of the presentation include:
i.		 Giving women better knowledge of, and responsibility
for their sexual health
ii.		 Educators seeing it from a health consumers point of
		 view. Working together.
iii.		 Calling a spade a spade, a vagina a vagina, and a vulva
a vulva. How by not speaking about or acknowledging
this part of the body can suppress emotions, disempower women and cause significant psychological
and physical health problems.
iv.		 Encouraging women to be proud of their vulva
instead of calling it something it is not: a vagina. Come
and get inVULed!
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Sexual Health Plenary 6: Drugs and Sex
wednesday 17 september 2008: 11.00am – 12.30pm

Sexual Health Plenary 6: Drugs and Sex
11.00am – 12.30pm
NATURAL HISTORY OF HPV IN THE ANAL
CANAL: EVERYONE’S GETTING INTO THE ACT
Palefsky JM1
1
Department of Medicine, University of California, San
Francisco, San Francisco CA USA 94143
A high proportion of anal cancers are associated with
human papillomavirus (HPV), most commonly HPV16.
The incidence of anal cancer is increasing annually in the
general population among both men and women but
has increased most dramatically among HIV-positive men
and women.
Among HIV-negative men who have sex with men (MSM),
the epidemiology of anal HPV infection resembles that of
penile infection more than that of cervical infection with
approximately 60% having anal HPV infection throughout
a wide age range. In contrast nearly all HIV-positive MSM
have anal HPV infection. Other high-risk groups include
HIV-positive women and high-risk HIV-negative women,
in whom anal HPV infection is more common than cervical
infection. Anal HPV infection may also be as common or
more common than cervical HPV infection in sexually
active but healthy, lower risk women. Finally, more than
20% of heterosexual men have anal HPV infection.
The key consequence of anal HPV infection is anal cancersome but not all individuals with anal HPV infection will
develop anal intrraepithelial neoplasia (AIN) and fewer
still will develop anal cancer. The main risk factors for
progression to high-grade AIN (HGAIN) are HIV-positivity
with lower CD4+ level and oncogenic anal infection but
risk factors for progression from HGAIN to anal cancer
are not understood. ART has not reduced the incidence
of HGAIN nor of anal cancer implying that the immune
response plays a less prominent role in progression to
anal cancer than in development of HGAIN. The data
suggest that the incidence of anal cancer will continue
to grow in the future, raising questions about whether atrisk individuals should be screened for HGAIN and/or anal
HPV infection. Additional questions relate to the effect of
anal HPV in women on the biology and natural history of
cervical cancer and its precursors.

284 						

17-20 september 2008 @ Perth Convention Centre, Western Australia

Sexual Health Plenary 7: Out of Sight Out of Mind

Sexual Health Plenary 7:
Out of Sight Out of Mind
1.30pm – 3.00pm
Anal Dysplasia and Cancer. An 
Australian Experience
Richard Hillman
Australian rates of anal cancer are rising in both males and
females, with approximately 260 new cases being reported
annually. Precursor lesions are typically asymptomatic,
leading to frequent late-stage presentation and poor
five year survival rates (typically 60 -70%). Furthermore,
symptoms of anal cancer & associated treatments are
often extremely unpleasant.
Anal cancer occurs as a consequence of sexually
transmitted infection and has an unusual epidemiology.
Overall, rates in women are generally slightly higher than
in men. However, within the two sexes, the distribution
varies markedly. In women, anal cancer typically presents
over the age of 60 years, in smokers, and in those with
a history of cervical cancer & receptive anal intercourse.
In men, it presents at a younger age, in men who have
sex with men, and in the HIV-infected. Indeed, rates in the
latter group are approximately 100 times higher than in
the general population.

wednesday 17 september 2008: 1.30pm –3.00pm

This presentation will review what we know of the
epidemiology of anal cancer & precancerous lesions in
Australia, the potential value of screening programs and
the possible public health impacts of HPV prophylactic
vaccination.
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It’s only a cold sore, Love…
B Donovan.
National Centre in HIV Epidemiology and Clinical Research,
University of New South Wales, Level 2, 376 Victoria Street,
Darlinghurst NSW 2010, Australia; and Sydney Sexual
Health Centre, Sydney Hospital.
Over recent generations oral sexual practices have grown
in incidence while re-positioning themselves in our
society, with variations within different sub-populations.
For many teenagers, oral sex is the new abstinence (in
the Clintonesque sense), and its contraceptive effect is
a bonus. For men who have sex with men (MSM), the
near-universal practice of fellatio is a pretty effective HIV
prevention strategy. Indeed, sexual safety codes within
MSM relationships are often seen as being honoured if
oral sex is the only sex that takes place with third parties.
Oro-anal sex (‘rimming’) with casual partners has gone
from being a minority practice among MSM in Australia
in the 1980s to a majority practice by the 2000s.

wednesday 17 september 2008: 1.30Pm – 3.00pm

Oral sex brings with it advantages and dangers. Certainly,
among MSM only anal sex and oral sex rate as ‘highly
valued’ as a source of pleasure, with the widespread use of
oral sex probably reducing the individual- and populationlevel risk of HIV transmission. And oral sex is one of the
most efficacious and use-effective contraceptives.
On the public health down-side, oral sex is logistically
easier to organise than anal or vaginal sex so it enables
rapid and furtive sexual encounters. Only in commercial
contexts is oral sex protected with a condom. Promoted
since the 1980s, everyone talks about dental dams for
cunnilingus and rimming, but hardly anybody has ever
used one. Some of the diseases that have been linked to
oral sex include ano-genital HSV-1 infection, gonorrhoea,
syphilis, hepatitis A, shigellosis, giardiasis, amoebiasis,
and ocular and oro-pharyngeal cancers. While unusual,
there are occasional traumatic consequences to oral sex,
though these are rarely fatal.
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Conclusions: The demographic differences between the
sex industries in the 3 cities may be partially explained
by their legal frameworks. The policy of compulsory
monthly STI screening of sex workers in Victoria should
be reviewed.

THE LAW AND SEXWORKER HEALTH (LASH)
PROJECT
Donovan B1,2, O’Connor JL1, Harcourt C1,2, Egger S3,
Wand H1, Chen MY4,5, Tabrizi S6, Marshall L7, Kaldor JM1,
Fairley CK4,5
1
National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney NSW;
2
Sydney Sexual Health Centre, Sydney Hospital NSW;
3
Faculty of Law, UNSW; 4School of Population Health,
University of Melbourne VIC; 5Melbourne Sexual Health
Centre, The Alfred Hospital, Melbourne VIC; 6Microbiology
Department, Royal Women’s Hospital, Melbourne
VIC; 7Fremantle Sexual Health Centre, Fremantle WA,
AUSTRALIA.

Sexual Health Conference Closing

Sexual Health Conference Closing
3.30pm – 5.00pm

Objective: Based on the hypothesis that restrictive or
punitive laws could have adverse consequences, we
explored the impact of various prostitution laws on the
health and welfare of the sex workers working in three
jurisdictions.
Methods: Key informants, searches of advertisements,
agency lists, and site visits enabled us to map the female
brothel-based sex industries in Perth (where all forms of
sex work were criminalised), Melbourne (decriminalised,
but regulated), and Sydney (decriminalised and
deregulated). Representative samples of sex workers
were invited to self-complete a questionnaire (available in
5 languages) and to provide a vaginal tampon for testing
for chlamydia, gonorrhoea, Mycoplasma genitalium, and
Trichomonas vaginalis by multiplex PCR.
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Results: All 3 cities had thriving and diverse sex industries,
though the unregistered premises in Melbourne
proved to be the most difficult to access. Questionnaire
participation rates were high (>80%) when access was
gained: 175 women in Perth, 229 in Melbourne, and 201
in Sydney. The Melbourne women were a median of 4
years older and had been working 2-3 times longer. Only
27% of the Sydney women had been born in Australia (cf
51% in Perth and 67% in Melbourne, p<0.001), while more
Perth women had injected drugs (14%) in the last 12m (cf
2% in Sydney and 10% in Melbourne, p<0.001). There was
no significant difference in mental health scores (K10)
between the women in the 3 cities. Despite vastly more
frequent screening of the Melbourne women as required
by the law (72% monthly cf 12% in Sydney and 15% in
Perth, p<0.001) STI prevalences were similarly low in each
city. However, the under-sampling of unregulated sex
workers in Melbourne limited the interpretation of these
findings.
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